

Sources

Title

Find sources

Title: Pharmaceuticals x

Improved Citescore

We have updated the CiteScore methodology to ensure a more robust, stable and comprehensive metric which provides an indication of research impact, earlier. The updated methodology will be applied to the calculation of CiteScore, as well as retroactively for all previous CiteScore years (ie. 2018, 2017, 2016...). The previous CiteScore values have been removed and are no longer available.

[View CiteScore methodology.](#)

Filter refine list

Apply Clear filters

Display options

Display only Open Access journals

Counts for 4-year timeframe

No minimum selected

Minimum citations

Minimum documents

Citescore highest quartile

Show only titles in top 10 percent

1st quartile

2nd quartile

3rd quartile

4th quartile

Source type

Journals

Book Series

Conference Proceedings

Trade Publications

Apply Clear filters

1 result

[Download Scopus Source List](#) [Learn more about Scopus Source List](#)

<input type="checkbox"/> All <input type="button" value="Export to Excel"/> <input type="button" value="Save to source list"/>		View metrics for year: 2022			
Source title ↓	CiteScore ↓	Highest percentile ↓	Citations 2019-22 ↓	Documents 2019-22 ↓	% Cited ↓
<input type="checkbox"/> 1 Pharmaceuticals <i>Open Access</i>	4.7	59% 69/171 Pharmaceutical Science	16,911	3,568	70

^ Top of page



Source details

Pharmaceuticals

Open Access ⓘ

Scopus coverage years: 2004, from 2009 to 2023

Publisher: Multidisciplinary Digital Publishing Institute (MDPI)

ISSN: 1424-8247 E-ISSN: 1424-8247

- Subject area:
- Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science
 - Pharmacology, Toxicology and Pharmaceutics: Drug Discovery
 - Biochemistry, Genetics and Molecular Biology: Molecular Medicine

Source type: Journal

- [View all documents >](#)
[Set document alert](#)
[Save to source list](#)

CiteScore 2022 **4.7** ⓘ

SJR 2022 **0.799** ⓘ

SNIP 2022 **1.020** ⓘ

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology ✕

CiteScore 2022 counts the citations received in 2019-2022 to articles, reviews, conference papers, book chapters and data papers published in 2019-2022, and divides this by the number of publications published in 2019-2022. [Learn more >](#)

CiteScore 2022 ▼

4.7 = $\frac{16,911 \text{ Citations } 2019 - 2022}{3,568 \text{ Documents } 2019 - 2022}$

Calculated on 05 May, 2023

CiteScoreTracker 2023 ⓘ

5.9 = $\frac{30,237 \text{ Citations to date}}{5,086 \text{ Documents to date}}$

Last updated on 05 January, 2024 • Updated monthly

CiteScore rank 2022 ⓘ

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#69/171	59th
Pharmaceutical Science		
Pharmacology, Toxicology and Pharmaceutics	#84/156	46th
Drug Discovery		

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site ↗](#)

About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

ELSEVIER

[Terms and conditions ↗](#) [Privacy policy ↗](#)

All content on this site: Copyright © 2024 Elsevier B.V. ↗, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.





an Open Access Journal by MDPI

Impact Factor 4.3

CiteScore 6.1

Indexed in PubMed

Pharmaceuticals

A vertical strip on the left side of the page shows a microscopic image of a textured surface, possibly a pill or a biological structure, with a purple overlay.



[mdpi.com/
journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



MDPI

issue

Go

 (toggle desktop layout cookie)  

> [Forthcoming issue \(/1424-8247/17/2\)](#)

> [Current issue \(/1424-8247/17/1\)](#)

[Vol. 17 \(2024\) \(/1424-8247/17\)](#)

[Vol. 16 \(2023\) \(/1424-8247/16\)](#)

[Vol. 15 \(2022\) \(/1424-8247/15\)](#)

[Vol. 14 \(2021\) \(/1424-8247/14\)](#)

[Vol. 13 \(2020\) \(/1424-8247/13\)](#)

[Vol. 12 \(2019\) \(/1424-8247/12\)](#)

[Vol. 11 \(2018\) \(/1424-8247/11\)](#)

[Vol. 10 \(2017\) \(/1424-8247/10\)](#)

[Vol. 9 \(2016\) \(/1424-8247/9\)](#)

[Vol. 8 \(2015\) \(/1424-8247/8\)](#)

[Vol. 7 \(2014\) \(/1424-8247/7\)](#)

[Vol. 6 \(2013\) \(/1424-8247/6\)](#)

[Vol. 5 \(2012\) \(/1424-8247/5\)](#)

[Vol. 4 \(2011\) \(/1424-8247/4\)](#)

[Vol. 3 \(2010\) \(/1424-8247/3\)](#)

[Vol. 2 \(2009\) \(/1424-8247/2\)](#)

[Vol. 1 \(2004\) \(/1424-8247/1\)](#)



Affiliated Society:



https://serve.mdpi.com/www/my_files/cliik.php?oaparams=0bannerid=7061zoneid=4cb=d5863f0b9boadest=ht

Editorial Board


- [Medicinal Chemistry Section \(/journal/pharmaceuticals/sectioneditors/pharm_medicinal_chemistry\)](#)
- [Biopharmaceuticals Section \(/journal/pharmaceuticals/sectioneditors/biopharmaceuticals\)](#)
- [Natural Products Section \(/journal/pharmaceuticals/sectioneditors/natural_products\)](#)
- [Radiopharmaceutical Sciences Section \(/journal/pharmaceuticals/sectioneditors/radiopharmaceutical_sciences\)](#)



- [Pharmacology Section \(/journal/pharmaceuticals/sectioneditors/pharm-pharmacology\)](#)
- [Pharmaceutical Technology Section \(/journal/pharmaceuticals/sectioneditors/pharmaceutical_technology\)](#)

Please note that the order in which the Editors appear on this page is alphabetical, and follows the structure of the editorial board presented on the MDPI website under information for editors: [editorial board responsibilities \(/editors#Editorial Board Responsibilities\)](#).


Members

 **Amélia Pilar Rauter** (https://sciprofiles.com/profile/266604?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
<https://webpages.ciencias.ulisboa.pt/~aprauter/>)
Editor-in-Chief

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Interests: carbohydrate small molecule synthesis; organic and biomolecular chemistry developments towards new therapeutic approaches for diabetes; Alzheimer's disease and other amyloid diseases and carbohydrate-based antibiotics


[Special Issues, Collections and Topics in MDPI journals](#)

 **Pedro Berzal-Herranz** (https://sciprofiles.com/profile/19235?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
https://www.ipb.csic.es/departamentos/aberalzh_ingles.html?depto=MolecularBiologyDepartment)
Section Editor-in-Chief

Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), PTS Granada, Av del Conocimiento 17, 18016 Granada, Spain

Interests: antiviral nucleic acids; therapeutic RNA; aptamers; RNA inhibitors; structure/function of RNA; RNA viruses


[Special Issues, Collections and Topics in MDPI journals](#)

 **Daniela De Vita** (https://sciprofiles.com/profile/924933?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
https://phd.uniroma1.it/web/DE-VITA-DANIELA_nC2550.aspx)
Section Editor-in-Chief

Department of Environmental Biology, Sapienza University of Rome, Rome, Italy

Interests: medicinal plants; alkaloids; phytochemistry; HPLC; LC-MS; antiviral agents; antifungal agents; anticancer agents; Alzheimer's disease; cholinesterases


[Special Issues, Collections and Topics in MDPI journals](#)

 **Gill Diamond** (https://sciprofiles.com/profile/66473?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
<https://louisville.edu/dentistry/departments/oralhealth/faculty/gill-diamond-phd>)
Section Editor-in-Chief

Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville, KY 40292, USA

Interests: regulation of innate immunity; antimicrobial peptides; antifungal peptides; defensins; cathelicidins; novel antiviral compounds

[Special Issues, Collections and Topics in MDPI journals](#)

 **Mary J. Meegan** (https://sciprofiles.com/profile/162157?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
<https://people.tcd.ie/Profile?Username=mmeegan>)
Section Editor-in-Chief

Trinity Biomedical Sciences Institute, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, 152–160 Pearse Street, Dublin 2 D02 R590, Ireland

Interests: anticancer drug design; breast cancer; novel antioestrogens; tubulin targeting agents; azetidinones; antioestrogen–drug conjugates; oestrogen receptor; Burkitt's lymphoma; chronic lymphocytic leukaemia


[Special Issues, Collections and Topics in MDPI journals](#)

 **Serge Mordon** (https://sciprofiles.com/profile/583847?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
<http://www.biotis-bordeaux.com/>) [Website2 \(http://www.oncothai.fr/\)](http://www.oncothai.fr/)
Section Editor-in-Chief

INSERM (French National Institute of Health and Medical Research) U1026, The Laboratory of the Bioengineering of Tissues (BioTis), University of Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France

Interests: photodynamic therapy; cancer; clinical evaluation; photosensitizer; dosimetry; fluoroscencer; Dosimetry; fluorescence

[Special Issues, Collections and Topics in MDPI journals](#)




 **Gary J. Stephens** (https://sciprofiles.com/profile/43946?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
<https://www.reading.ac.uk/pharmacy/staff/professor-gary-stephens>)


 **Section Editor-in-Chief**

School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AJ, UK

Interests: electrophysiology; voltage-gated calcium channels; cannabinoids; ion channels; GPCRs; pain; ataxia

[Special Issues, Collections and Topics in MDPI journals](#)

 (toggle desktop layout cookie)  


 **Velikyan** (https://sciprofiles.com/profile/113591?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
te (<https://katalog.uu.se/profile/?id=N1-184>)

Section Editor-in-Chief

Department of Surgical Science, Uppsala University, 751 85 Uppsala, Sweden

Interests: nuclear medicine; radiochemistry; positron emission tomography; molecular imaging; radiopharmaceutical sciences; cancer; diabetes; fibrosis; drug development; inflammation

[Special Issues, Collections and Topics in MDPI journals](#)

 **Emília De Sousa** (https://sciprofiles.com/profile/148085?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
te1 (<http://www.ff.up.pt/esousa>) **Website2** (<https://orcid.org/0000-0002-5397-4672>)


Associate Editor

1. Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), 4450-208 Porto, Portugal

2. Laboratory of Organic and Pharmaceutical Chemistry, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

Interests: medicinal chemistry; organic synthesis; heterocycles; P-glycoprotein; anticancer; antimicrobials; chiral drugs; marine natural products

[Special Issues, Collections and Topics in MDPI journals](#)


 **Thomas Efferth** (https://sciprofiles.com/profile/9530?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
te (<https://www.cinema.uni-mainz.de/prof-dr-thomas-efferth/>)

Associate Editor

Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany

Interests: natural products; molecular pharmacology; cancer; drug resistance; genome-wide profiling

[Special Issues, Collections and Topics in MDPI journals](#)

 **Joachim Jose** (https://sciprofiles.com/profile/123628?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
te (<https://www.uni-muenster.de/Chemie.pz/forschen/ag/jose/index.html>)

Associate Editor

PharmaCampus Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Corrensstr. 48, 48149 Muenster, Germany

Interests: autodisplay; assay development and inhibitor testing; whole cell biocatalysts for synthesis of drugs and building blocks; directed evolution of enzyme inhibitors and biocatalysts; biosensor development and diagnostic tools

[Special Issues, Collections and Topics in MDPI journals](#)


 **Klaus Kopka** (https://sciprofiles.com/profile/907163?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
te (<https://www.hzdr.de/db/Cms?pNid=130>)

Associate Editor

Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany

Interests: radiopharmaceutical drug development; radiopharmaceutical sciences; medicinal radiochemistry; radionuclide theranostics; targeted endoradiotherapy; noninvasive molecular imaging; PET; SPECT


[Special Issues, Collections and Topics in MDPI journals](#)

 **Lin Ling** (https://sciprofiles.com/profile/962574?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
te (<https://life.fudan.edu.cn/66/cb/c31279a353995/page.htm>)

Associate Editor

State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology (Ministry of Education), School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai 200438, China

Interests: cancer therapeutics; mRNA translation; gene therapy; virology

 **Guangshun Wang** (https://sciprofiles.com/profile/47472?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
te (<https://www.unmc.edu/pathology/faculty/bios/wang.html>)

Associate Editor

Department of Pathology & Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-5900, USA

Interests: host defense antimicrobial peptides; structural bioinformatics; biomolecular NMR

[Special Issues, Collections and Topics in MDPI journals](#)

 **Mayence** (https://sciprofiles.com/profile/468756?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)



<https://orcid.org/0000-0003-2509-7593>

Advisory Board Member

Formerly professor at the Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium

Interests: medicinal chemistry; organic synthesis; parasitic diseases; orphan drugs

 (toggle desktop layout cookie)  

[Special Issues, Collections and Topics in MDPI journals](#)



Jacques Vanden Eynde (https://sciprofiles.com/profile/93338?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

<https://orcid.org/0000-0003-4770-4104> [Website2 \(https://publons.com/researcher/1447855/jean-jacques-vanden-eynde\)](https://publons.com/researcher/1447855/jean-jacques-vanden-eynde)

Advisory Board Member

Formerly Head of the Department of Organic Chemistry (FS), University of Mons-UMONS, 7000 Mons, Belgium

Interests: heterocycles; medicinal chemistry; green chemistry; microwave-induced synthesis

[Special Issues, Collections and Topics in MDPI journals](#)



Carlos Alonso-Moreno (https://sciprofiles.com/profile/780129?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

<https://www.researchgate.net/profile/C-Alonso-moreno>

Editorial Board Member

Departamento de Química Inorgánica, Orgánica y Bioquímica, Universidad de Castilla-La Mancha, Facultad de Farmacia, Campus Universitario de Albacete, 02071 Albacete, Spain

Interests: polymeric nanoparticles; antibody conjugate nanoparticles; breast cancer; biodegradable polymers; metallodrugs

[Special Issues, Collections and Topics in MDPI journals](#)

Dr. Cristina Amaral

[Website \(https://ucibio.pt/people/cristina-amaral\)](https://ucibio.pt/people/cristina-amaral)

Editorial Board Member

UCIBIO.REQUIMTE, Laboratory of Biochemistry, Faculty of Pharmacy, University of Porto, Porto, Portugal

Interests: breast cancer; endocrine/acquired resistance; anti-cancer drugs; targeted therapy; aromatase inhibitors; estrogen receptor modulators; multi-target compounds; cannabinoids



Sandra Ammazalorso (https://sciprofiles.com/profile/612587?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

<https://www.unich.it/ugov/person/624>

Editorial Board Member

Department of Pharmacy, G. d'Annunzio University, 66100 Chieti, Italy

Interests: medicinal chemistry; drug discovery; aromatase inhibitors; PPAR ligands; anticancer agents

[Special Issues, Collections and Topics in MDPI journals](#)



Salvatore Annunziata (https://sciprofiles.com/profile/1966067?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

<https://orcid.org/0000-0003-3241-1501>

Editorial Board Member

Unità di Medicina Nucleare, TracerGLab, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico A. Gemelli IRCCS, 00168 Roma, Italy

Interests: PET; radiomics; AI; lymphoma; radiopharmaceuticals

[Special Issues, Collections and Topics in MDPI journals](#)



Paolo Arosio (https://sciprofiles.com/profile/149345?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

<https://orcid.org/0000-0002-5343-8992>

Editorial Board Member

Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy

Interests: iron metabolism; ferritin; iron storage

[Special Issues, Collections and Topics in MDPI journals](#)



Anna Artese (https://sciprofiles.com/profile/27411?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

<https://dss.unicz.it/personale/docente/annaartese>

Editorial Board Member

Dipartimento di Scienze della Salute, Università "Magna Graecia" di Catanzaro, Campus "Salvatore Venuta", Viale Europa, 88100 Catanzaro, Italy

Interests: drug design; molecular modeling; molecular dynamics; virtual screening; pharmacophore modeling; drug repurposing; natural products

[Special Issues, Collections and Topics in MDPI journals](#)



Atanas G. Atanasov (https://sciprofiles.com/profile/1611726?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)




<https://recognition.webofscience.com/awards/highly-cited/2021/> [Website \(https://inpst.net/contact/\)](https://inpst.net/contact/)

Editorial Board Member

1. Ludwig Boltzmann Institute for Digital Health and Patient Safety, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria
2. Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences, Jastrzebiec, 05-552 Magdalenka, Poland

Interests: molecular medicine; biotechnology; digital health; open innovation; natural products

Special Issues, Collections and Topics in MDPI journals

 (toggle desktop layout cookie)  

 **Jong-Sup Bae** (https://sciprofiles.com/profile/845300?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
<https://pharmacye.knu.ac.kr/>

Editorial Board Member

College of Pharmacy, Kyungpook National University, Daegu, Korea

Interests: molecular biology; cell biology; natural products

Dr. Nektarios Barabutis (https://sciprofiles.com/profile/867285?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
[Website \(https://webservices.ulm.edu/facultyactivities/profile/barabutis\)](https://webservices.ulm.edu/facultyactivities/profile/barabutis)

Editorial Board Member

College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA

Interests: pathophysiology of acute lung injury and acute respiratory distress syndrome; P53 in the lung endothelium; unfolded protein response in the regulation of endothelial permeability; endoplasmic reticulum stress in the context of the lung microvasculature; heat shock proteins; extra hypothalamic effects of growth hormone-releasing hormone; endocrine-related cancer; reactive oxygen species; vascular biology


Special Issues, Collections and Topics in MDPI journals

 **Valentina Bassareo**
<https://www.researchgate.net/profile/Valentina-Bassareo>

Editorial Board Member

Department of Biomedical Science, Università degli Studi di Cagliari, Cagliari, Italy

Interests: dopamine; mesocorticolimbic system; drug addiction; ethanol; food reward; microdialysis


 **Jean-Pierre Bazureau** (https://sciprofiles.com/profile/14544?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
<https://iscr.univ-rennes1.fr/jean-pierre-bazureau>

Editorial Board Member

Institut des Sciences Chimiques de Rennes (ISCR), UMR CNRS 6226, Groupe CORINT, Université de Rennes 1 (UR1), Campus de Beaulieu, Bât. 10A, 263 Avenue du Général Leclerc, CS 74205, 35042 Rennes CEDEX, France

Interests: microwave-assisted organic chemistry and scale-up; "Store Operated Calcium Entry" inhibitors (Orai1) for cancer via Délikine program inhibitors; mitochondrial ion channel inhibitors for cancer; protein kinase (PKs) inhibitors for CNS (Alzheimer's disease and Down syndrome) via Leucettine program inhibitors; fluorescence probes for studies of molecular mechanisms in cancer biology

Special Issues, Collections and Topics in MDPI journals


 **Martina Benešová-Schäfer** (https://sciprofiles.com/profile/720157?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
<https://www.dkfz.de/en/molekularbiologie-systemischer-radiotherapie/index.php>

Editorial Board Member

Research Group Molecular Biology of Systemic Radiotherapy, Research Program Imaging and Radiooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 223, 69120 Heidelberg, Germany

Interests: theranostic radioligands; targeted radionuclide therapies; targeted alpha therapies; combination therapies; molecular imaging; pharmaceutical radiochemistry; coordination and bioinorganic chemistry; radionuclide production and separation methods

Special Issues, Collections and Topics in MDPI journals


 **Thierry Besson** (https://sciprofiles.com/profile/84052?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
<https://www.researchgate.net/profile/Thierry-Besson>

Editorial Board Member

INSA Rouen Normandie, Univ. Rouen Normandie, CNRS UMR 6014 COBRA, FR 3038, F-76000 Rouen, France

Interests: chemistry of heterocyclic compounds; microwave-assisted chemistry; sustainable methodologies; green chemistry applied to bioactive compounds; kinase inhibitors; Alzheimer's disease; down syndrome; cancer

Special Issues, Collections and Topics in MDPI journals

 **Giuseppe Biagini** (https://sciprofiles.com/profile/258520?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
<https://personale.unimore.it/rubrica/dettaglio/gbiagini>

Editorial Board Member

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy

Interests: neuroscience; peptides; steroids

Special Issues, Collections and Topics in MDPI journals

Displaying Editorial board member 1-30 on page 1 of 8.



Go to page [1](#) [2](#) (/journal/pharmaceuticals/editors?page_no=2) [3](#) (/journal/pharmaceuticals/editors?page_no=3) [4](#) (/journal/pharmaceuticals/editors?page_no=4) [5](#) (/journal/pharmaceuticals/editors?page_no=5) > /journal/pharmaceuticals/editors?page_no=2) > /journal/pharmaceuticals/editors?page_no=8

Pharmaceuticals (</journal/pharmaceuticals>), EISSN 1424-8247, Published by MDPI

[RSS \(/rss/journal/pharmaceuticals\)](/rss/journal/pharmaceuticals) [Content Alert \(/journal/pharmaceuticals/toc-alert\)](/journal/pharmaceuticals/toc-alert)

Further Information

[Article Processing Charges \(/apc\)](#)

[Pay an Invoice \(/about/payment\)](#)

[Open Access Policy \(/openaccess\)](#)

[Contact MDPI \(/about/contact\)](#)

[Jobs at MDPI \(https://careers.mdpi.com\)](https://careers.mdpi.com)

Guidelines

[For Authors \(/authors\)](#)

[For Reviewers \(/reviewers\)](#)

[For Editors \(/editors\)](#)

[For Librarians \(/librarians\)](#)

[For Publishers \(/publishing_services\)](#)

[For Societies \(/societies\)](#)

[For Conference Organizers \(/conference_organizers\)](#)

MDPI Initiatives

[Sciforum \(https://sciforum.net\)](https://sciforum.net)

[MDPI Books \(https://www.mdpi.com/books\)](https://www.mdpi.com/books)

[Preprints.org \(https://www.preprints.org\)](https://www.preprints.org)

[Scilit \(https://www.scilit.net\)](https://www.scilit.net)

[SciProfiles \(https://sciprofiles.com?utm_source=mpdi.com&utm_medium=bottom_menu&utm_campaign=initiative\)](https://sciprofiles.com?utm_source=mpdi.com&utm_medium=bottom_menu&utm_campaign=initiative)

[Encyclopedia \(https://encyclopedia.pub\)](https://encyclopedia.pub)

[JAMS \(https://jams.pub\)](https://jams.pub)

[Proceedings Series \(/about/proceedings\)](#)

Follow MDPI

[LinkedIn \(https://www.linkedin.com/company/mdpi\)](https://www.linkedin.com/company/mdpi)

[Facebook \(https://www.facebook.com/MDPIOpenAccessPublishing\)](https://www.facebook.com/MDPIOpenAccessPublishing)

[Twitter \(https://twitter.com/MDPIOpenAccess\)](https://twitter.com/MDPIOpenAccess)



Subscribe to receive issue release notifications and newsletters from MDPI journals

Select options

Enter your email address...

Subscribe

© 1996-2024 MDPI (Basel, Switzerland) unless otherwise stated

[Disclaimer](#)

[Terms and Conditions \(/about/terms-and-conditions\)](/about/terms-and-conditions)

[Privacy Policy \(/about/privacy\)](/about/privacy)





Journals (about/journals) Topics (topics) Information (/authors) Author Services (/authors/enolist) Initiatives (/about/initiatives) Desktop Alerts (/ebooks) Q

Sign In / Sign Up (/user/login)

Submit (https://susy.mdpi.com/user/manuscripts/upload?journal=pharmaceuticals)

Search for Articles:

Search form with fields for Title / Keyword, Author / Affiliation / Email, and a Search button.

Advanced Search

Journals (about/journals) / Pharmaceuticals (journal/pharmaceuticals) / Volume 17 (1424-8247/17) / Issue 1 /



Indexed in: PubMed

CITESCORE

4.7

(https://www.scopus.com/sourceid/17700156714)

IMPACT FACTOR

4.6

(journal/pharmaceuticals/stats)

Journal Menu

Journal Menu

- Pharmaceuticals Home (/journal/pharmaceuticals)
Aims & Scope (/journal/pharmaceuticals/about)
Editorial Board (/journal/pharmaceuticals/editors)
Reviewer Board (/journal/pharmaceuticals/submission_reviewers)
Topical Advisory Panel (/journal/pharmaceuticals/topical_advisory_panel)
Instructions for Authors (/journal/pharmaceuticals/instructions)
Special Issues (/journal/pharmaceuticals/special_issues)
Topics (/topics?journal=pharmaceuticals)
Sections & Collections (/journal/pharmaceuticals/sections)
Article Processing Charge (/journal/pharmaceuticals/apc)
Indexing & Archiving (/journal/pharmaceuticals/indexing)
Editor's Choice Articles (/journal/pharmaceuticals/editors_choice)
Most Cited & Viewed (/journal/pharmaceuticals/most_cited)
Journal Statistics (/journal/pharmaceuticals/stats)
Journal History (/journal/pharmaceuticals/history)
Journal Awards (/journal/pharmaceuticals/awards)
Society Collaborations (/journal/pharmaceuticals/societies)
Conferences (/journal/pharmaceuticals/events)
Editorial Office (/journal/pharmaceuticals/editorial_office)

Journal Browser

Journal Browser

Journal browser form with volume and issue input fields and a Go button.

- Forthcoming issue (/1424-8247/17/2)
Current issue (/1424-8247/17/1)

- Vol. 17 (2024) (/1424-8247/17)
Vol. 16 (2023) (/1424-8247/16)
Vol. 15 (2022) (/1424-8247/15)
Vol. 14 (2021) (/1424-8247/14)
Vol. 13 (2020) (/1424-8247/13)
Vol. 12 (2019) (/1424-8247/12)
Vol. 11 (2018) (/1424-8247/11)
Vol. 10 (2017) (/1424-8247/10)
Vol. 9 (2016) (/1424-8247/9)
Vol. 8 (2015) (/1424-8247/8)
Vol. 7 (2014) (/1424-8247/7)
Vol. 6 (2013) (/1424-8247/6)
Vol. 5 (2012) (/1424-8247/5)
Vol. 4 (2011) (/1424-8247/4)
Vol. 3 (2010) (/1424-8247/3)
Vol. 2 (2009) (/1424-8247/2)
Vol. 1 (2004) (/1424-8247/1)

Member Society



(https://serve.mdpi.com/www/my_files/cliik.php?oaparams=0&bannerid=7061&zoneid=4cb-be1b19c391&oadest=https%3A%2F%2F

Pharmaceuticals, Volume 17, Issue 1 (January 2024) – 143 articles



Cover Story (view full-size image (/files/uploaded/covers/pharmaceuticals/big_cover-pharmaceuticals-v17-i1.png)): The advent of CRISPR/Cas technologies has enabled us to manipulate the genetic code with various possibilities. However, controlling the dose, time, and location of action remains a significant challenge in the application of said technologies. Small molecules offer a simple and cost-effective way to regulate biological processes. This review explores the various mechanisms by which the CRISPR/Cas9 machinery can be influenced with the help of small molecules. While the indirect influence on the machinery by small molecules is discussed, the primary focus is on direct interactions between small molecules and (engineered) Cas9 or sgRNA. These findings highlight the promise of small-molecule-mediated control of CRISPR/Cas9 activity for developing more precise, efficient, and controllable genome-editing strategies. View this paper (https://www.mdpi.com/1424-8247/17/1/41)

(https://www.mdpi.com/1424-8247/17/1/41) are recorded as officially published after their release is announced to the table of contents alert mailing list (/journal/pharmaceuticals/toc-alert).

1424-8247/17/1/41) for e-mail alerts (/journal/pharmaceuticals/toc-alert) to receive table of contents of newly released issues.

- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader (http://www.adobe.com) to open them.

Order results

Order results form with fields for Publication Date, Result details, Normal, Section, and All Sections.

MDPI **Short options**

Open Access Article

14 pages, 1653 KiB (1424-8247/17/1/143/pdf?version=1705983683) (toggle desktop layout cookie) Q

Association between Prescribing and Intoxication Rates for Selected Psychotropic Drugs: A Longitudinal Observational Study (1424-8247/17/1/143)

by Matej Dobravc Verbič (https://sciprofiles.com/profile/3315359?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Iztok Grabnar (https://sciprofiles.com/profile/172906?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Miran Brvar (https://sciprofiles.com/profile/186653?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) *Pharmaceuticals* 2024, 17(1), 143; https://doi.org/10.3390/ph17010143 (https://doi.org/10.3390/ph17010143) - 22 Jan 2024

Viewed by 413

Abstract Psychotropic prescription drugs are commonly involved in intoxication events. The study's aim was to determine a comparative risk for intoxication in relation to prescribing rates for individual drugs. This was a nationwide observational study in Slovenian adults between 2015 and 2021. Intoxication events [...] [Read more](#). (This article belongs to the Special Issue **Therapeutic Drug Monitoring and Adverse Drug Reactions** (Journal/pharmaceuticals/special_issues/Q4B8E1FM23))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00143/article_deploy/html/images/pharmaceuticals-17-00143-g001-550.jpg?1705983684) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00143/article_deploy/html/images/pharmaceuticals-17-00143-g002-550.jpg?1705983685) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00143/article_deploy/html/images/pharmaceuticals-17-00143-g003-550.jpg?1705983687)

Open Access Review

27 pages, 2723 KiB (1424-8247/17/1/142/pdf?version=1705935764)

Moringa oleifera: A Review of the Pharmacology, Chemical Constituents, and Application for Dental Health (1424-8247/17/1/142)

by Meiny Faudah Amin (https://sciprofiles.com/profile/3260403?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Taufiq Ariwibowo (https://sciprofiles.com/profile/author/RVRVTVWhOQTR3SUNzKtFeEwTGRWYdRdY0WQ3dmY1JpWGFYaXZrZJpND0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Salsabila Anila Putri (https://sciprofiles.com/profile/2492508?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Dikdik Kurnia (https://sciprofiles.com/profile/135727?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) *Pharmaceuticals* 2024, 17(1), 142; https://doi.org/10.3390/ph17010142 (https://doi.org/10.3390/ph17010142) - 22 Jan 2024

Viewed by 436

Abstract *Moringa oleifera* L., commonly known as Kelor in Indonesia and miracle tree in English, has a rich history of utilization for medicinal, nutritional, and water treatment purposes dating back to ancient times. The plant is renowned for its abundance of vitamins, minerals, and [...] [Read more](#). (This article belongs to the Section **Natural Products** (Journal/pharmaceuticals/sections/natural_products))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g001a-550.jpg?1705935835) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g001b-550.jpg?1705935837) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g002-550.jpg?1705935838) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g003-550.jpg?1705935843) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g004-550.jpg?1705935845) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g005a-550.jpg?1705935851) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g005b-550.jpg?1705935854) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g006a-550.jpg?1705935856) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g006b-550.jpg?1705935857) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g007-550.jpg?1705935859) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g008-550.jpg?1705935863) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g009-550.jpg?1705935866) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g010-550.jpg?1705935868) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g011a-550.jpg?1705935872) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00142/article_deploy/html/images/pharmaceuticals-17-00142-g011b-550.jpg?1705935878)

Open Access Article

14 pages, 1902 KiB (1424-8247/17/1/141/pdf?version=1705914697)

Toxicity and Toxicokinetics of a Four-Week Repeated Gavage of Levamisole in Male Beagle Dogs: A Good Laboratory Practice Study (1424-8247/17/1/141)

by Jiahui Zhang (https://sciprofiles.com/profile/3315481?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Junxiang Wang (https://sciprofiles.com/profile/author/Ymxtb2VhVjdHQMdQIdMVTZ0UFWcE9cFUSZr2rDdRWa0g1MHA0ZGVvaz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Lingfan Chen (https://sciprofiles.com/profile/author/SzjZY3dsTudmRzFTa29ORnFZZmxQbTB0Unp4dJWTFa1d4T3VkcitQST0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Xiangbin Yu (https://sciprofiles.com/profile/3315687?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Shuihua Zhang (https://sciprofiles.com/profile/author/T080VDAU0jPmzc2SFBjNEKWFENR5Gpc29xZ25kzNT0E5TR3dTVWhoYz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Yue Yu (https://sciprofiles.com/profile/929025?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) *Pharmaceuticals* 2024, 17(1), 141; https://doi.org/10.3390/ph17010141 (https://doi.org/10.3390/ph17010141) - 22 Jan 2024

Viewed by 401

Abstract Levamisole (LVM) is considered an immunomodulatory agent that has the potential to treat various cancer and inflammation diseases. However, there is still much debate surrounding the toxicokinetic and toxicological information of LVM. Therefore, it is crucial to assess its toxicity to provide useful [...] [Read more](#). (This article belongs to the Section **Pharmacology** (Journal/pharmaceuticals/sections/pharm-pharmacology))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00141/article_deploy/html/images/pharmaceuticals-17-00141-g001-550.jpg?1705914781) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00141/article_deploy/html/images/pharmaceuticals-17-00141-g002-550.jpg?1705914784) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00141/article_deploy/html/images/pharmaceuticals-17-00141-g003-550.jpg?1705914785) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00141/article_deploy/html/images/pharmaceuticals-17-00141-g004-550.jpg?1705914786)

Open Access Article

12 pages, 618 KiB (1424-8247/17/1/140/pdf?version=1705914438)

A Comparison of the Anxiolytic Properties of Tofisopam and Diazepam: A Double-Blind, Randomized, Crossover, Placebo-Controlled Pilot Study (1424-8247/17/1/140)

by Andrzej Kokoszka (https://sciprofiles.com/profile/1743233?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) *Pharmaceuticals* 2024, 17(1), 140; https://doi.org/10.3390/ph17010140 (https://doi.org/10.3390/ph17010140) - 22 Jan 2024

Viewed by 344

Abstract New clinical reports have recently been published on tofisopam—an anxiolytic drug currently registered as a benzodiazepine—after a long break in this research area. Neurobiological studies concerning its properties, which differ from those of benzodiazepines, are underway. The analyses presented in this study aimed [...] [Read more](#). (This article belongs to the Special Issue **Advances in Behavioral Psychopharmacology** (Journal/pharmaceuticals/special_issues/behavioral_psychopharmacology))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00140/article_deploy/html/images/pharmaceuticals-17-00140-g001-550.jpg?1705914525) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00140/article_deploy/html/images/pharmaceuticals-17-00140-sch001-550.jpg?1705914526)

Open Access Review

16 pages, 3303 KiB (1424-8247/17/1/139/pdf?version=1705913007)

Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects (1424-8247/17/1/139)

by Zhaozhao Chen (https://sciprofiles.com/profile/author/ZTdHskNjcxRGSIR5WDDic1J1QrJFWUVZVYB0N2c3cEi6WU1CUK1RM0RzWT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Yu Hu (https://sciprofiles.com/profile/3075330?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Heng Mei (https://sciprofiles.com/profile/1073975?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) *Pharmaceuticals* 2024, 17(1), 139; https://doi.org/10.3390/ph17010139 (https://doi.org/10.3390/ph17010139) - 22 Jan 2024

Viewed by 435

Abstract Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a groundbreaking approach in cancer treatment, showcasing remarkable efficacy. However, the formidable challenge lies in taming the formidable side effects associated with this innovative therapy, among which cytokine release syndrome (CRS), immune effector [...] [Read more](#). (This article belongs to the Section **Biopharmaceuticals** (Journal/pharmaceuticals/sections/biopharmaceuticals))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00139/article_deploy/html/images/pharmaceuticals-17-00139-ag-550.jpg?1705913125) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00139/article_deploy/html/images/pharmaceuticals-17-00139-sch001-550.jpg?1705913096) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00139/article_deploy/html/images/pharmaceuticals-17-00139-sch002-550.jpg?1705913098) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00139/article_deploy/html/images/pharmaceuticals-17-00139-sch003-550.jpg?1705913100) (https://pub.mdpi-res.com/

https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00139/article_deploy/html/images/pharmaceuticals-17-00139-sch004-550.jpg (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00139/article_deploy/html/images/pharmaceuticals-17-00139-sch005-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00139/article_deploy/html/images/pharmaceuticals-17-00139-sch006-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00139/article_deploy/html/images/pharmaceuticals-17-00139-sch007-550.jpg)

Open Access Review 13 pages, 2464 KB (1424-8247/17/1/138/pdf/version=1705900980)

Microbial Biosurfactants: Antimicrobial Activity and Potential Biomedical and Therapeutic Exploits (1424-8247/17/1/138)
 by Patricia Puyol McKenna (https://sciprofiles.com/profile/3289981?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Patrick J. Naughton (https://sciprofiles.com/profile/1163342?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), James S. G. Dooley (https://sciprofiles.com/profile/222373?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Nigel G. Ternan (https://sciprofiles.com/profile/1865711?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Patrick Lemoine (https://sciprofiles.com/profile/1498492?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Ibrahim M. Banat (https://sciprofiles.com/profile/488066?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 138; https://doi.org/10.3390/ph17010138 (https://doi.org/10.3390/ph17010138) - 22 Jan 2024
 Viewed by 639

Abstract The rapid emergence of multidrug-resistant pathogens worldwide has raised concerns regarding the effectiveness of conventional antibiotics. This can be observed in ESKAPE pathogens, among others, whose multiple resistance mechanisms have led to a reduction in effective treatment options. Innovative strategies aimed at mitigating [...] **Read more.**
 (This article belongs to the Section [Biopharmaceuticals](#) ([journal/pharmaceuticals/sections/biopharmaceuticals](#)))

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00138/article_deploy/html/images/pharmaceuticals-17-00138-ag-550.jpg (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00138/article_deploy/html/images/pharmaceuticals-17-00138-g001-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00138/article_deploy/html/images/pharmaceuticals-17-00138-g002-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00138/article_deploy/html/images/pharmaceuticals-17-00138-g003-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00138/article_deploy/html/images/pharmaceuticals-17-00138-g004-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00138/article_deploy/html/images/pharmaceuticals-17-00138-g005-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00138/article_deploy/html/images/pharmaceuticals-17-00138-g006-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00138/article_deploy/html/images/pharmaceuticals-17-00138-g007-550.jpg)

Open Access Review 19 pages, 1459 KB (1424-8247/17/1/137/pdf/version=1705742713)

Investigation of Potential Drug Targets Involved in Inflammation Contributing to Alzheimer's Disease Progression (1424-8247/17/1/137)
 by Catherine Sharo (https://sciprofiles.com/profile/3022415?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Tianhua Zhai (https://sciprofiles.com/profile/author/cWFYMDc1ZlphNR2lMUHFzeTRYbZoNGx1ZWNGTEhLCk4MU9GeVdnSlUCbz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Zuyi Huang (https://sciprofiles.com/profile/851207?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 137; https://doi.org/10.3390/ph17010137 (https://doi.org/10.3390/ph17010137) - 20 Jan 2024
 Viewed by 637

Abstract Alzheimer's disease has become a major public health issue. While extensive research has been conducted in the last few decades, few drugs have been approved by the FDA to treat Alzheimer's disease. There is still an urgent need for understanding the disease pathogenesis. [...] **Read more.**
 (This article belongs to the Section [Pharmacology](#) ([journal/pharmaceuticals/sections/pharm-pharmacology](#)))

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00137/article_deploy/html/images/pharmaceuticals-17-00137-g001-550.jpg (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00137/article_deploy/html/images/pharmaceuticals-17-00137-g002-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00137/article_deploy/html/images/pharmaceuticals-17-00137-g003-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00137/article_deploy/html/images/pharmaceuticals-17-00137-g004-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00137/article_deploy/html/images/pharmaceuticals-17-00137-g005-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00137/article_deploy/html/images/pharmaceuticals-17-00137-g006-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00137/article_deploy/html/images/pharmaceuticals-17-00137-g007-550.jpg)

Open Access Article 17 pages, 444 KB (1424-8247/17/1/136/pdf/version=1705738886)

Natural Products for Cancer Prevention and Interception: Preclinical and Clinical Studies and Funding Opportunities (1424-8247/17/1/136)
 by Edward R. Sauter (https://sciprofiles.com/profile/1566536?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Afaf Mohammed (https://sciprofiles.com/profile/635525?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 136; https://doi.org/10.3390/ph17010136 (https://doi.org/10.3390/ph17010136) - 20 Jan 2024
 Viewed by 1138

Abstract Multiple agents derived from natural products (NPs) have been evaluated for cancer prevention and interception, either alone or in combination. The National Cancer Institute (NCI) is very interested in advancing research to identify additional agents that, alone or in combination, may prove useful [...] **Read more.**
 (This article belongs to the Special Issue [Naturally-Occurring Dietary Compounds for Cancer Prevention and Therapy](#) ([journal/pharmaceuticals/special_issues/80180976B8](#)))

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00136/article_deploy/html/images/pharmaceuticals-17-00136-g001-550.jpg (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00136/article_deploy/html/images/pharmaceuticals-17-00136-g002-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00136/article_deploy/html/images/pharmaceuticals-17-00136-g003-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00136/article_deploy/html/images/pharmaceuticals-17-00136-g004-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00136/article_deploy/html/images/pharmaceuticals-17-00136-g005-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00136/article_deploy/html/images/pharmaceuticals-17-00136-g006-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00136/article_deploy/html/images/pharmaceuticals-17-00136-g007-550.jpg)

Open Access Article 17 pages, 4591 KB (1424-8247/17/1/135/pdf/version=1705664309)

Harmaline to Human Mitochondrial Caseinolytic Serine Protease Activation for Pediatric Diffuse Intrinsic Pontine Glioma Treatment (1424-8247/17/1/135)
 by Morena Micciaccia (https://sciprofiles.com/profile/1163035?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Francesca Rizzo (https://sciprofiles.com/profile/1445589?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Antonella Centonze (https://sciprofiles.com/profile/1330874?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Gianfranco Cavallaro (https://sciprofiles.com/profile/2847679?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Mariassandra Contino (https://sciprofiles.com/profile/47984?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Domenico Armenise (https://sciprofiles.com/profile/author/Ykc4Z3pDU9hY09EZOILbVqrdVFCcR0VKhEm04ZHnNVUFEZFufU3F0ST0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Olga Maria Baldelli (https://sciprofiles.com/profile/author/TWFpTXdwRHRvN0REWIZNlVg2QWR6b01KeTnChGRDTmZzC2ZktvWU5mOD0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Roberta Solidoro (https://sciprofiles.com/profile/author/Q20xSHjBdXgybWcwZFB1bX00XFjNdaNm12NmXZ0FvqUXi0emNOVEZIWT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Savina Ferorelli (https://sciprofiles.com/profile/author/UUZXdnRSdmI5S1cmdGZWN0aW50Q3NkZWJ6QktVzK1jYdVdkVWY5bExkYz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Pasquale Scarcia (https://sciprofiles.com/profile/1031841?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Gennaro Agrimi (https://sciprofiles.com/profile/232265?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Veronica Zingales (https://sciprofiles.com/profile/1521615?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Elisa Cimetta (https://sciprofiles.com/profile/405519?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Simone Ronnisvalle (https://sciprofiles.com/profile/183662?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Federica Maria Sipala (https://sciprofiles.com/profile/2558740?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Paola Loggerico Polosa (https://sciprofiles.com/profile/1445352?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Cosimo Grazia Fortuna (https://sciprofiles.com/profile/author/RkU0bXRBC2R1dEFQREkxc0g4L0VnQJowbWx6RGlmMW1CM10ZTE1eW5lT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Maria Gianlu Perrone (https://sciprofiles.com/profile/866711?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Antonio Scilimati (https://sciprofiles.com/profile/612056?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 135; https://doi.org/10.3390/ph17010135 (https://doi.org/10.3390/ph17010135) - 19 Jan 2024
 Viewed by 565

Abstract Diffuse intrinsic pontine glioma (DIPG), affecting children aged 4–7 years, is a rare, aggressive tumor that originates in the pons and then spreads to nearby tissue. DIPG is the leading cause of death for pediatric brain tumors due to its infiltrative nature and [...] **Read more.**
 (This article belongs to the Special Issue [Development of Medicines for Rare Pediatric Diseases II](#) ([journal/pharmaceuticals/special_issues/1S81n2C0S](#)))

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-ag-550.jpg (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g001-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g002-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g003-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g004-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g005-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g006-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g007-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g008-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g009-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g010-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g011-550.jpg)

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-ag-550.jpg (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g001-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g002-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g003-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g004-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g005-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g006-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g007-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g008-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g009-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g010-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g011-550.jpg)

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-ag-550.jpg (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g001-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g002-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g003-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g004-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g005-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g006-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g007-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g008-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g009-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g010-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g011-550.jpg)

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-ag-550.jpg (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g001-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g002-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g003-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g004-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g005-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g006-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g007-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g008-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g009-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g010-550.jpg) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00135/article_deploy/html/images/pharmaceuticals-17-00135-g011-550.jpg)

Open Access Article 20 pages, 6972 KiB (1424-8247/17/1/134/pdf2version=1705663913)

Exploring *Potentilla nepalensis* Phytoconstituents: Integrated Strategies of Network Pharmacology, Molecular Docking, Dynamic Simulations, and MMGBSA Analysis for Cancer Therapeutic Targets Discovery (1424-8247/17/1/134)

by Mallari Praveen (https://sciprofiles.com/profile/3185209?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Ihsan Ullah (https://sciprofiles.com/profile/author/T2VIK0xyMDNkK1BraDQ5Z2lpUFg0eXVsb1NQZzJlVTRyUUM4SWFYVWx6bz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Ricardo Ullah (https://sciprofiles.com/profile/author/ME8xcUJybE54QUFH7VQWU51eGJaZGxkSWxibFFEWGIDZGNZGFzY0lUT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Imran Ahmad Khan (https://sciprofiles.com/profile/2385478?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Mian Gul Sayed (https://sciprofiles.com/profile/1808960?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Rahmul Kabir (https://sciprofiles.com/profile/3362080?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Mashood Ahmad Bhat (https://sciprofiles.com/profile/385348?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Muhammad Yaseen (https://sciprofiles.com/profile/2821533?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 134; https://doi.org/10.3390/ph17010134 (https://doi.org/10.3390/ph17010134) - 19 Jan 2024

Viewed by 533

Abstract Potentilla nepalensis belongs to the Rosaceae family and has numerous therapeutic applications as potent plant-based medicine. Forty phytoconstituents (PCs) from the root and stem through n-hexane (NR and NS) and methanolic (MR and MS) extracts were identified in earlier studies. However, the PCs [...] Read more. (This article belongs to the Special Issue Computer-Aided Drug Design and Drug Discovery. (journal/pharmaceuticals/special_issues/CDY0D8W0CQ))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00134/article_deploy/html/images/pharmaceuticals-17-00134-g001-550.jpg?1705663982) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00134/article_deploy/html/images/pharmaceuticals-17-00134-g002-550.jpg?1705663985) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00134/article_deploy/html/images/pharmaceuticals-17-00134-g003-550.jpg?1705663988) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00134/article_deploy/html/images/pharmaceuticals-17-00134-g004-550.jpg?1705663991) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00134/article_deploy/html/images/pharmaceuticals-17-00134-g005-550.jpg?1705663994) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00134/article_deploy/html/images/pharmaceuticals-17-00134-g006-550.jpg?1705663997) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00134/article_deploy/html/images/pharmaceuticals-17-00134-g007-550.jpg?1705663999) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00134/article_deploy/html/images/pharmaceuticals-17-00134-g008-550.jpg?1705664001) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00134/article_deploy/html/images/pharmaceuticals-17-00134-g009-550.jpg?1705664003) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00134/article_deploy/html/images/pharmaceuticals-17-00134-g010-550.jpg?1705664004)

Open Access Article 18 pages, 6800 KiB (1424-8247/17/1/133/pdf2version=1705907294)

Combination Treatment with Liposomal Doxorubicin and Inductive Moderate Hyperthermia for Sarcoma Saos-2 Cells (1424-8247/17/1/133)

by Valerii E. Orel (https://sciprofiles.com/profile/862733?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Anatoly G. Diedkov (https://sciprofiles.com/profile/3291914?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Vasyly V. Ostafichuk (https://sciprofiles.com/profile/3375140?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Oleksandra O. Lykhova (https://sciprofiles.com/profile/author/VWMrYkVpYkN3UzVlWFbmcHFT0w0TE9pWStUdVHN3Zpd0xmZ0VB1F5MD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Denys L. Kolesnyk (https://sciprofiles.com/profile/author/MVMrYjhiM0N2aWtCwWydE5PqX3k0zVUJqN1FhS21HMzyzNXyZ1ZiZ0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Valerii B. Orel (https://sciprofiles.com/profile/3371740?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Oлга Yo. Dasylkevich (https://sciprofiles.com/profile/author/YfW6TlxQUF2OEFZTV1a3drRGc0UHGmY9CaGc3ZX01ekV1VONXczB5RTO=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Oleksandr Yu. Rykhalskiy (https://sciprofiles.com/profile/1440301?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Serhiy A. Diedkov (https://sciprofiles.com/profile/3371868?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Anna B. Prosvietova (https://sciprofiles.com/profile/author/emRYTbVl2R5cQMgPaD0kMgpxz0FGVGTvMq3V1hYzLzFoN2d1SVV2MD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 133; https://doi.org/10.3390/ph17010133 (https://doi.org/10.3390/ph17010133) - 19 Jan 2024

Viewed by 524

Abstract Despite efforts in osteosarcoma (OS) research, the role of inductive moderate hyperthermia (IMH) in delivering and enhancing the antitumor effect of liposomal doxorubicin formulations (LDOX) remains unresolved. This study investigated the effect of a combination treatment with LDOX and IMH on Saos-2 human [...] Read more. (This article belongs to the Special Issue Molecular Systems for the Delivery of Drugs and Contrast Agents. (journal/pharmaceuticals/special_issues/ZL3P7V1IA))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00133/article_deploy/html/images/pharmaceuticals-17-00133-g001-550.jpg?1705907377) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00133/article_deploy/html/images/pharmaceuticals-17-00133-g002-550.jpg?1705907378) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00133/article_deploy/html/images/pharmaceuticals-17-00133-g003-550.jpg?1705907381) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00133/article_deploy/html/images/pharmaceuticals-17-00133-g004-550.jpg?1705907383) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00133/article_deploy/html/images/pharmaceuticals-17-00133-g005-550.jpg?1705907384) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00133/article_deploy/html/images/pharmaceuticals-17-00133-g006-550.jpg?1705907387) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00133/article_deploy/html/images/pharmaceuticals-17-00133-g007-550.jpg?1705907389) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00133/article_deploy/html/images/pharmaceuticals-17-00133-g008-550.jpg?1705907391) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00133/article_deploy/html/images/pharmaceuticals-17-00133-g009-550.jpg?1705907394) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00133/article_deploy/html/images/pharmaceuticals-17-00133-g010-550.jpg?1705907395) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00133/article_deploy/html/images/pharmaceuticals-17-00133-g011-550.jpg?1705907396)

Open Access Article 23 pages, 3803 KiB (1424-8247/17/1/132/pdf2version=1705647709)

Combination Therapy of Cuban Policosanol (Raydel®, 20 mg) and Intensive Exercise for 12 Weeks Resulted in Improvements in Obesity, Hypertension, and Dyslipidemia without a Decrease in Serum Coenzyme Q₁₀: Enhancement of Lipoproteins Quality and Antioxidant Functionality in Obese Participants (1424-8247/17/1/132)

by Kyung-Hyun Cho (https://sciprofiles.com/profile/623875?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Hyo-Seon Nam (https://sciprofiles.com/profile/author/R215TzE0UFpXbUK420Vvblk3SEVVZkhBm3jdZK2R3UWxRl0hMQiUXND0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Na-Young Kim (https://sciprofiles.com/profile/author/VihVMhROFhYm3lqYmUv0dGalV5ZYMEJiK0FSNEkUEt1SFfDlWVMD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Myeong-Sung Lee (https://sciprofiles.com/profile/author/bGNpYkR0b0Q4T1U3UE13eWJlC0VdnRCWmZkYsSeVArL0JhYi85QJ3az0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Dae-Jin Kang (https://sciprofiles.com/profile/author/dGxUjzRmd2UWZFSUzUrYtZQZmtMOE1SaXZvZUJFT0ZncKBUUDyzaGZyWt0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 132; https://doi.org/10.3390/ph17010132 (https://doi.org/10.3390/ph17010132) - 19 Jan 2024

Viewed by 1177

Abstract Obesity and overweight, frequently caused by a lack of exercise, are associated with many metabolic diseases, such as hypertension, diabetes, and dyslipidemia. Aerobic exercise effectively increases the high-density lipoproteins-cholesterol (HDL-C) levels and alleviates the triglyceride (TG) levels. The consumption of Cuban policosanol (Raydel [...]) Read more. (This article belongs to the Special Issue Bioactive Substances, Oxidative Stress, and Inflammation. (journal/pharmaceuticals/special_issues/90C66403U))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00132/article_deploy/html/images/pharmaceuticals-17-00132-g001-550.jpg?1705647804) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00132/article_deploy/html/images/pharmaceuticals-17-00132-g002-550.jpg?1705647805) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00132/article_deploy/html/images/pharmaceuticals-17-00132-g003a-550.jpg?1705647807) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00132/article_deploy/html/images/pharmaceuticals-17-00132-g003b-550.jpg?1705647808) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00132/article_deploy/html/images/pharmaceuticals-17-00132-g004-550.jpg?1705647810) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00132/article_deploy/html/images/pharmaceuticals-17-00132-g005-550.jpg?1705647812) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00132/article_deploy/html/images/pharmaceuticals-17-00132-g006a-550.jpg?1705647815) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00132/article_deploy/html/images/pharmaceuticals-17-00132-g006b-550.jpg?1705647815)

Open Access Article 15 pages, 6203 KiB (1424-8247/17/1/131/pdf2version=1705644200)

Rapamycin as a Potential Alternative Drug for Squamous Cell Gingiva Carcinoma (Ca9-22): A Focus on Cell Cycle, Apoptosis and Autophagy Genetic Profile (1424-8247/17/1/131)

by Sofia Papadokos (https://sciprofiles.com/profile/3305790?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Hawraa Issa (https://sciprofiles.com/profile/author/czhaGcxUEp5b2pOnk96HqQWnpuMmZiWGHWODkVnJ5VmsrN25Y3psTT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Abdullah Alami (https://sciprofiles.com/profile/2248529?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Abdullah Alami (https://sciprofiles.com/profile/3249193?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Abdelhabib Semlali (https://sciprofiles.com/profile/193117?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 131; https://doi.org/10.3390/ph17010131 (https://doi.org/10.3390/ph17010131) - 19 Jan 2024

pharmaceuticals/pharmaceuticals-17-00127/article_deploy/html/images/pharmaceuticals-17-00127-g004-550.jpg?1705581722) (https://pub.mdpi-res.com/
 pharmaceuticals/pharmaceuticals-17-00127/article_deploy/html/images/pharmaceuticals-17-00127-g005-550.jpg?1705581724)

Open Access Review

38 pages, 6279 KiB (1424-8247/17/1/125/pdf?version=1705589028)

Recent Developments in Nanoparticle Formulations for Resveratrol Encapsulation as an Anticancer Agent (1424-8247/17/1/126)

by **Muhammad Ali** (https://sciprofiles.com/profile/27414657?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- **Viviana Benifante** (https://sciprofiles.com/profile/21038997?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Domenico Di Raimondo** (https://sciprofiles.com/profile/818711?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Giuseppe Salvaggio** (https://sciprofiles.com/profile/13478977?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Antonino Tuttolomondo** (https://sciprofiles.com/profile/784741?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- **Albert Comelli** (https://sciprofiles.com/profile/977776?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 126; https://doi.org/10.3390/ph17010126 (https://doi.org/10.3390/ph17010126) - 18 Jan 2024

Viewed by 746

Abstract: Resveratrol is a polyphenolic compound that has gained considerable attention in the past decade due to its multifaceted therapeutic potential, including anti-inflammatory and anticancer properties. However, its anticancer efficacy is impeded by low water solubility, dose-limiting toxicity, low bioavailability, and rapid hepatic metabolism.

[...] [Read more](#).

(This article belongs to the Section [Natural Products](#) ([Journal/pharmaceuticals/sections/natural_products](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-ag-550.jpg?1705585149) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g001-550.jpg?1705585100) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g002-550.jpg?1705585102) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g003-550.jpg?1705585105) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g004-550.jpg?1705585106) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g005-550.jpg?1705585109) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g006-550.jpg?1705585111) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g007-550.jpg?1705585114) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g008-550.jpg?1705585117) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g009-550.jpg?1705585120) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g010-550.jpg?1705585123) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g011-550.jpg?1705585125) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g012-550.jpg?1705585127) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g013-550.jpg?1705585131) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g014-550.jpg?1705585134) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g015-550.jpg?1705585136) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g016-550.jpg?1705585139) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g017-550.jpg?1705585142) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g018-550.jpg?1705585145) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g019-550.jpg?1705585146) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00126/article_deploy/html/images/pharmaceuticals-17-00126-g020-550.jpg?1705585149)

Open Access Article

14 pages, 1659 KiB (1424-8247/17/1/125/pdf?version=1705576499)

Promising Effects of Montelukast for Critically Ill Asthma Patients via a Reduction in Delirium (1424-8247/17/1/125)

by

- **Yuan Li** (https://sciprofiles.com/profile/author/NllkQmJsZpE1VfncEdSQmZrN0ZqdWcWtIAyb1NaZdnnU9hNzc2NwHDND0s?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Mellin Zhang** (https://sciprofiles.com/profile/author/dU1FSGN1QUFYMGFYSDYzOWICRC9obGoxaERuYkFXMFSZWhMU0pQmdMZz0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Shengnan Zhang** (https://sciprofiles.com/profile/author/SVJR130VRRkJYSUcxZGdmK2Fta1JK005dExjS0hBSzY5ZkvHm05QOD0s?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- **Guoping Yang** (https://sciprofiles.com/profile/755334?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 125; https://doi.org/10.3390/ph17010125 (https://doi.org/10.3390/ph17010125) - 18 Jan 2024

Viewed by 453

Abstract Background: Montelukast (MTK), a potent antagonist of cysteinyl leukotriene receptor 1, has shown therapeutic promise for the treatment of neuropsychiatric disorders. Delirium, a common complication in critically ill patients, lacks effective treatment. This study aims to explore the impact of pre-intensive care unit [...] [Read more](#).

(This article belongs to the Section [Pharmacology](#) ([Journal/pharmaceuticals/sections/pharm-pharmacology](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00125/article_deploy/html/images/pharmaceuticals-17-00125-ag-550.jpg?1705576589) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00125/article_deploy/html/images/pharmaceuticals-17-00125-g001-550.jpg?1705576585) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00125/article_deploy/html/images/pharmaceuticals-17-00125-g002-550.jpg?1705576586) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00125/article_deploy/html/images/pharmaceuticals-17-00125-g003-550.jpg?1705576587)

Open Access Review

28 pages, 2573 KiB (1424-8247/17/1/124/pdf?version=1705558879)

A Comprehensive Review on Deep Eutectic Solvents and Its Use to Extract Bioactive Compounds of Pharmaceutical Interest (1424-8247/17/1/124)

by **Cátia Ferreira** (https://sciprofiles.com/profile/3200306?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

- **Mafalda Sarragaça** (https://sciprofiles.com/profile/2973687?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 124; https://doi.org/10.3390/ph17010124 (https://doi.org/10.3390/ph17010124) - 18 Jan 2024

Viewed by 603

Abstract: The extraction of bioactive compounds of pharmaceutical interest from natural sources has been significantly explored in recent decades. However, the extraction techniques used were not very efficient in terms of time and energy consumption; additionally, the solvents used for the extraction were harmful [...] [Read more](#).

(This article belongs to the Special Issue [20th Anniversary of Pharmaceuticals—Green Techniques for Organic and Organometallic/Coordination Synthesis and Medicinal Chemistry](#) ([Journal/pharmaceuticals/special_issues/XAE5626XPG](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00124/article_deploy/html/images/pharmaceuticals-17-00124-g001-550.jpg?1705559025) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00124/article_deploy/html/images/pharmaceuticals-17-00124-g002-550.jpg?1705559026) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00124/article_deploy/html/images/pharmaceuticals-17-00124-g003-550.jpg?1705559027) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00124/article_deploy/html/images/pharmaceuticals-17-00124-g004-550.jpg?1705559028) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00124/article_deploy/html/images/pharmaceuticals-17-00124-g005-550.jpg?1705559028) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00124/article_deploy/html/images/pharmaceuticals-17-00124-g006-550.jpg?1705559029) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00124/article_deploy/html/images/pharmaceuticals-17-00124-g007-550.jpg?1705559029)

Open Access Article

14 pages, 1798 KiB (1424-8247/17/1/123/pdf?version=1705492082)

Pharmacology of *Veratrum californicum* Alkaloids as Hedgehog Pathway Antagonists (1424-8247/17/1/123)

by **Madison L. Dirks** (https://sciprofiles.com/profile/1736123?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

- **Owen M. McDougal** (https://sciprofiles.com/profile/216715?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 123; https://doi.org/10.3390/ph17010123 (https://doi.org/10.3390/ph17010123) - 17 Jan 2024

Viewed by 451

Abstract: *Veratrum californicum* contains steroidal alkaloids that function as inhibitors of hedgehog (Hh) signaling, a pathway involved in the growth and differentiation of cells and normal tissue development. This same Hh pathway is abnormally active for cell proliferation in more than 20 types of [...] [Read more](#).

(This article belongs to the Section [Natural Products](#) ([Journal/pharmaceuticals/sections/natural_products](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00123/article_deploy/html/images/pharmaceuticals-17-00123-g001-550.jpg?1705492153) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00123/article_deploy/html/images/pharmaceuticals-17-00123-g002-550.jpg?1705492156) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00123/article_deploy/html/images/pharmaceuticals-17-00123-g003-550.jpg?1705492157) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00123/article_deploy/html/images/pharmaceuticals-17-00123-g004-550.jpg?1705492158) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00123/article_deploy/html/images/pharmaceuticals-17-00123-g005-550.jpg?1705492160)

Open Access Article

15 pages, 3490 KiB (1424-8247/17/1/122/pdf?version=1705489589)

Humoral and Cellular Immune Response after Three Doses of Sinopharm [Vero Cell]-Inactivated COVID-19 Vaccine in Combination with SARS-CoV-2 Infection Leads to Immunity (1424-8247/171/1122)

by Marja Vukčević... Katarina Šerović... Mateja Despot... Aleksandra Nikolić-Kokić... Aleksandra Vujičić... Milan Nikolić... Duško Blagojević... Tanja Jovanović... Dragana Despot... Pharmaceutics 2024, 17(1), 122; https://doi.org/10.3390/ph17010122

Abstract Background: Several vaccines against COVID-19 have been developed and licensed to enhance the immune response against SARS-CoV-2. Similarly, previous infection with SARS-CoV-2 has been shown to provide significant protection against severe infection and hospitalization. Methods: We investigated the effect of three doses of [...] Read more.

(This article belongs to the Section Biopharmaceuticals (/journal/pharmaceuticals/sections/biopharmaceuticals))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00122/article_deploy/html/images/pharmaceuticals-17-00122-g001-550.jpg?1705489655)

Open Access Article 20 pages, 1033 KB (1424-8247/171/1122/pdf?version=1705489655)

Chemical Composition, Antioxidant, Anticancer, and Antibacterial Activities of Roots and Seeds of Ammi visnaga L. Methanol Extract (1424-8247/171/1121)

by Ibrahim M. Aziz... Rawan M. Alshalan... Humaira Rizwana... Fatoon Alkhalwai... Abdulaziz M. Almugrin... Reem M. Aljowaini... Neorah A. Alkubaisi... Pharmaceutics 2024, 17(1), 121; https://doi.org/10.3390/ph17010121

Abstract For centuries, plants and their components have been harnessed for therapeutic purposes, with Ammi visnaga L. (Khella) being no exception to this rich tradition. While existing studies have shed light on the cytotoxic and antimicrobial properties of seed extracts, there remains a noticeable [...] Read more.

(This article belongs to the Special Issue Therapeutic Potential of Natural Products in Internal Diseases (/journal/pharmaceuticals/special_issues/9NUU2R8ISI))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00121/article_deploy/html/images/pharmaceuticals-17-00121-g001-550.jpg?1705485417)

Open Access Article 11 pages, 437 KB (1424-8247/171/1121/pdf?version=1705485416)

In Vitro Evaluation of Drug-Drug Interaction Potential of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor (1424-8247/171/1120)

by Afshin Shafiei... Sanjay Chandra... Abstract Epetraborole (EBO) is a boron-containing inhibitor of bacterial leucyl-tRNA synthetase, with potent activity against nontuberculous mycobacteria (NTM) and Gram-negative bacteria, including Burkholderia pseudomallei. EBO is being developed for the treatment of NTM lung disease and melioidosis, administered in combination with other therapeutic [...] Read more.

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00120/article_deploy/html/images/pharmaceuticals-17-00120-fig-550.jpg?1705484592)

Open Access Article 11 pages, 726 KB (1424-8247/171/1120/pdf?version=1705484592)

Functional Regression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study (1424-8247/171/1119)

by Barbara Ruaro... Andrea Salotti... Nicolo' Reccardinì... Stefano Kette... Beatrice Da Re... Salvatore Nicolosi... Umberto Zuccon... Marco Confalonieri... Lucrezia Mondini... Riccardo Pozzan... Michael Hughes... Paola Confalonieri... Francesco Salton... Pharmaceutics 2024, 17(1), 119; https://doi.org/10.3390/ph17010119

Abstract Background. Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with rapidly progressive evolution and an unfavorable outcome. Nintedanib (NTD) is an antifibrotic drug that has been shown to be effective in slowing down the progression of the disease. The aim of [...] Read more.

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00119/article_deploy/html/images/pharmaceuticals-17-00119-g001-550.jpg?1705477654)

Open Access Article 15 pages, 2814 KB (1424-8247/171/1119/pdf?version=1705406061)

Anti-Inflammatory Activity of APPA (Apocynin and Paenon) in Human Articular Chondrocytes (1424-8247/171/1118)

by Mercedes Fernández-Moreno... Tamara Hermedia-Gómez... Nicholas Larkins... Alan Reynolds... Pharmaceutics 2024, 17(1), 118; https://doi.org/10.3390/ph17010118

Francisco J. Blanco (https://sciprofiles.com/profile/990306?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 118; https://doi.org/10.3390/ph17010118 (https://doi.org/10.3390/ph17010118) - 16 Jan 2024

Viewed by 526

Abstract Osteoarthritis (OA) is a chronic joint disease leading to cartilage loss and reduction in the joint space which results in pain. The current pharmacological treatment is inadequate and pharmacological interventions focus on symptom management. APPA, a combination of apocynin (AP) and [..] Read more.
(This article belongs to the Section Pharmacology (Journal/pharmaceuticals/sections/pharm-pharmacology))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00118/article_deploy/html/images/pharmaceuticals-17-00118-g001-550.jpg?1705406138) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00118/article_deploy/html/images/pharmaceuticals-17-00118-g002-550.jpg?1705406140) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00118/article_deploy/html/images/pharmaceuticals-17-00118-g003-550.jpg?1705406141) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00118/article_deploy/html/images/pharmaceuticals-17-00118-g004-550.jpg?1705406142) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00118/article_deploy/html/images/pharmaceuticals-17-00118-g005-550.jpg?1705406143) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00118/article_deploy/html/images/pharmaceuticals-17-00118-g006-550.jpg?1705406145) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00118/article_deploy/html/images/pharmaceuticals-17-00118-g007-550.jpg?1705406146)

Open Access Article

14 pages, 3062 KIB (1424-8247/17/1/117/pdf?version=1705387902) ©

Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients (1424-8247/17/1/117)

by Francesca Barei (https://sciprofiles.com/profile/3306546?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Martina Zussino (https://sciprofiles.com/profile/author/V0swRVJHSmk0RGpORndiRkKhNnR3ZUFxMw5RYIRiQRk1PktDZTWEY1WGZBQxYVWZPYW1yUkZYT3IGMnZvZQ==?utm_source=mdpi.com&utm_medium=)

Simona Tavecchio (https://sciprofiles.com/profile/author/WV13V2RNOUNJRyCZ0RpUJUVSWIR2J4Bd3VoYXpjW8vTndTOEM3Y3BNWTO=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Luisa Angileri (https://sciprofiles.com/profile/author/Sm4vSUNYVHYR1ZYWFB6cizUaFh0V2EMjlmUkdmK9qQZ5T0Vmam95ellitU0vKMWtuWXZCTHFFOTR1SmhxeQ==?utm_source=mdpi.com&utm_medium=websit)

Arianna Rizzo (https://sciprofiles.com/profile/author/RytUQ3VnckoxaTBkE10K1lrSEN0RDM2N9URGHxVGzUVdyaUcCeGNBQT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Paolo Calzari (https://sciprofiles.com/profile/author/dVQ4R2xvRTVYic3Ymp1Vmw5amFyeDbQfJbJlRpdh6dUpJzmwyTfBSMD0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Angelo V. Marzano (https://sciprofiles.com/profile/author/OFIYaJST3psSDZhVFBQcVNIQTJVVVYwM3puKfTmtSN0JadDZMVHgj1az0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Silvia Ferrucci (https://sciprofiles.com/profile/1206472?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 117; https://doi.org/10.3390/ph17010117 (https://doi.org/10.3390/ph17010117) - 16 Jan 2024

Viewed by 485

Abstract Background: The main objective was to analyze patient-reported outcomes (PRO) trends over a four-year period in severe atopic dermatitis (AD) patients treated with dupilumab. Methods: data from 126 severe patients receiving dupilumab for at least 48 months were collected. The clinical scores assessed [..] Read more.
(This article belongs to the Topic Research in Pharmacological Therapies (topics/99X64ZT450))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00117/article_deploy/html/images/pharmaceuticals-17-00117-g001-550.jpg?1705388030) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00117/article_deploy/html/images/pharmaceuticals-17-00117-g002-550.jpg?1705388032) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00117/article_deploy/html/images/pharmaceuticals-17-00117-g003-550.jpg?1705388034) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00117/article_deploy/html/images/pharmaceuticals-17-00117-g004-550.jpg?1705388035) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00117/article_deploy/html/images/pharmaceuticals-17-00117-g005-550.jpg?1705388036) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00117/article_deploy/html/images/pharmaceuticals-17-00117-g006-550.jpg?1705388037) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00117/article_deploy/html/images/pharmaceuticals-17-00117-g007-550.jpg?1705388037) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00117/article_deploy/html/images/pharmaceuticals-17-00117-g008-550.jpg?1705388039)

Open Access Article

11 pages, 222 KIB (1424-8247/17/1/116/pdf?version=1705392145)

Regular and Irregular Use and Reasons for Discontinuation of Solifenacin Therapy in Patients with Overactive Bladder Managed by Urologists (1424-8247/17/1/116)

by

Mateusz Malkowski (https://sciprofiles.com/profile/author/ZnJtdlZmcGF0eH0kzRI0QpSlqgODREMUc1NEdSRStEbXhKb1UwalfR3az0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Agnieszka Almgren-Rachtan (https://sciprofiles.com/profile/3293136?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Magdalenia Olszanecka-Glinianowicz (https://sciprofiles.com/profile/562312?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Jerzy Chudek (https://sciprofiles.com/profile/513528?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Piotr Chłosta (https://sciprofiles.com/profile/1399473?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 116; https://doi.org/10.3390/ph17010116 (https://doi.org/10.3390/ph17010116) - 16 Jan 2024

Viewed by 443

Abstract Solifenacin, a selective muscarinic receptor antagonist, is one of the best-tolerated and most effective medicines that relieve storage symptoms in patients with an overactive bladder (OAB). However, the persistence of solifenacin in daily clinical practice remains far below that reported in clinical trials. [..] Read more.
(This article belongs to the Section Pharmacology (Journal/pharmaceuticals/sections/pharm-pharmacology))

Open Access Article

13 pages, 1653 KIB (1424-8247/17/1/115/pdf?version=1705372744)

Retrospective Study on Genetic Diversity and Drug Resistance among People Living with HIV at an AIDS Clinic in Beijing (1424-8247/17/1/115)

by

Yan-Ze Shi (https://sciprofiles.com/profile/author/emdFVjNhek1uLAvaz2KRGiITDvd3V2c1E1WndXS0FsZ2Nybm80ZVBVCND0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Hui-Huang Huang (https://sciprofiles.com/profile/3242544?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Xin-Hua Wang (https://sciprofiles.com/profile/author/WJ3aUdDcDFTTEnWFK1QSS5b3Q5VUYxVEVPTVU0QXExcV0VOU5oY3A5VT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Bing Song (https://sciprofiles.com/profile/author/K3JaMmR4EVRa3BifR3d3bJhV0M2dz09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Tian-Jun Jiang (https://sciprofiles.com/profile/3308605?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Min-Rui Yu (https://sciprofiles.com/profile/author/YfZeDjHMGpWRW9Ybkozdzkz\$JRMjllV8rN3FHYmgSS3JBeEJnJUR5az0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Zo-Rui Wang (https://sciprofiles.com/profile/author/L2JnUmNNSHZPL0hNR201cG1YWmpRNFNV0pKZk9hR0VFWm4ZG9jYncwdz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Rui-Ting Li (https://sciprofiles.com/profile/author/RXFGNjRG70M4hNaejg3YkrlL0Nw50hDanMwSmU0bndITkdJrVhZKzIIWTO=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Yan-Mei Jiao (https://sciprofiles.com/profile/2743865?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Xin Su (https://sciprofiles.com/profile/3064462?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Fu-Sheng Wang (https://sciprofiles.com/profile/author/T3pvb0pjeTQ0K0R3Mzc1Ax04TGJd0Zsa3pvUEhRbXlYa2U2zRORGHoc20=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 115; https://doi.org/10.3390/ph17010115 (https://doi.org/10.3390/ph17010115) - 16 Jan 2024

Viewed by 538

Abstract (1) Background: The objective of this study was to investigate the prevalence of genetic diversity and drug resistance mutations among people living with HIV (PLWH) attending clinics in Beijing. (2) Methods: A retrospective analysis was conducted on PLWH admitted to the Fifth Medical [..] Read more.
(This article belongs to the Section Pharmacology (Journal/pharmaceuticals/sections/pharm-pharmacology))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00115/article_deploy/html/images/pharmaceuticals-17-00115-g001-550.jpg?1705372859) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00115/article_deploy/html/images/pharmaceuticals-17-00115-g002-550.jpg?1705372860) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00115/article_deploy/html/images/pharmaceuticals-17-00115-g003-550.jpg?1705372862) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00115/article_deploy/html/images/pharmaceuticals-17-00115-g004-550.jpg?1705372865)

Open Access Article

19 pages, 7083 KIB (1424-8247/17/1/114/pdf?version=1705372522) ©

Coflin Inhibitor Improves Neurological and Cognitive Functions after Intracerebral Hemorrhage by Suppressing Endoplasmic Reticulum Stress Related-Neuroinflammation (1424-8247/17/1/114)

by Daniyah A. Almarghalani (https://sciprofiles.com/profile/3274231?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Ghaith A. Bahader (https://sciprofiles.com/profile/2812990?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Mohammad Al1 (https://sciprofiles.com/profile/author/MkRnUTFTCXZ1Y1FqTEhZUWURTW5ScFFJSHN0WvHxbkktkeHBSWORzOXduJd3MONUpl1GdFdGrjsjaakFWG3ag=?utm_source=mdpi.com&utm_medium=web)

L. M. Viranga Tillekeratne (https://sciprofiles.com/profile/630683?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Zahoor A. Shah (https://sciprofiles.com/profile/278438?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 114; https://doi.org/10.3390/ph17010114 (https://doi.org/10.3390/ph17010114) - 15 Jan 2024

Viewed by 552

Abstract Neuroinflammation after intracerebral hemorrhage (ICH) is a crucial factor that determines the extent of the injury. Cofilin is a cytoskeleton-associated protein that drives... (This article belongs to the Special Issue *Microglia and Astrocytes as Drug Targets* (/journal/pharmaceuticals/special_issues/6LOA03571G1))

► Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00114/article_deploy/html/images/pharmaceuticals-17-00114-g001-550.jpg?1705372684) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00114/article_deploy/html/images/pharmaceuticals-17-00114-g002-550.jpg?1705372686) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00114/article_deploy/html/images/pharmaceuticals-17-00114-g003a-550.jpg?1705372690) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00114/article_deploy/html/images/pharmaceuticals-17-00114-g003b-550.jpg?1705372694) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00114/article_deploy/html/images/pharmaceuticals-17-00114-g004-550.jpg?1705372695) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00114/article_deploy/html/images/pharmaceuticals-17-00114-g005-550.jpg?1705372697) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00114/article_deploy/html/images/pharmaceuticals-17-00114-g006-550.jpg?1705372698) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00114/article_deploy/html/images/pharmaceuticals-17-00114-g007-550.jpg?1705372701)

Open Access Article 21 pages, 22514 KiB (1424-8247/17/1/113/pdf?version=1705309213)

Zinc Oxide and Magnesium-Doped Zinc Oxide Nanoparticles Ameliorate Murine Chronic Toxoplasmosis (1424-8247/17/1/113)

by [Shahad H. Sarhan](https://sciprofiles.com/profile/3258821?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3258821?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Mothaga G. Felemban](https://sciprofiles.com/profile/1136124?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1136124?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Walla Abelwan](https://sciprofiles.com/profile/3323003?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3323003?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Hesam M. Sharaf](https://sciprofiles.com/profile/author/cIBTWHZRCUZRlRptczMySDFaQp5ZGJTzXlKMc5ERzKURUeHh3c1YrVT0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/cIBTWHZRCUZRlRptczMySDFaQp5ZGJTzXlKMc5ERzKURUeHh3c1YrVT0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Yasmin A. Abd EL-Atif](https://sciprofiles.com/profile/3307769?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3307769?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Elsayed Elgazzar](https://sciprofiles.com/profile/author/cXRIMW54NGJEzcc2WH5Q2w3UDZFSGNXL2Nhd015RTbVtMFrVz5MGEYnNuSIFPNTZQOQVEWUVNvNocXNzWw=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/cXRIMW54NGJEzcc2WH5Q2w3UDZFSGNXL2Nhd015RTbVtMFrVz5MGEYnNuSIFPNTZQOQVEWUVNvNocXNzWw=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Ahmad M. Kandil](https://sciprofiles.com/profile/author/U3dbVhQdmVnVmVzMXhORkxQZfEaUFRSIFhL2NaKzAvSm5EbZKbZ0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/U3dbVhQdmVnVmVzMXhORkxQZfEaUFRSIFhL2NaKzAvSm5EbZKbZ0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Guillermo Tellez-Isaias](https://sciprofiles.com/profile/308957?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/308957?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Aya A. Mohamed](https://sciprofiles.com/profile/author/ZGdUeH8ZY3B4dmmYTvhT2RVdis3RnJZmZuWG41cWYy2hmQ3FmK05VIT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/ZGdUeH8ZY3B4dmmYTvhT2RVdis3RnJZmZuWG41cWYy2hmQ3FmK05VIT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 113; <https://doi.org/10.3390/ph17010113> (https://doi.org/10.3390/ph17010113) - 15 Jan 2024
Viewed by 597

Abstract *Toxoplasma gondii* causes a global parasitic disease. Therapeutic options for eradicating toxoplasmosis are limited. In this study, ZnO and Mg-doped ZnO NPs were prepared, and their structural and morphological characteristics were investigated. The XRD pattern revealed that Mg-doped ZnO NPs have weak crystallinity [...]. **Read more.** (This article belongs to the Special Issue *Recent Efforts in Drug Discovery and Development for the Treatment of Parasitic Infections* (/journal/pharmaceuticals/special_issues/07F872NOJY))

► Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00113/article_deploy/html/images/pharmaceuticals-17-00113-g001-550.jpg?1705309294) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00113/article_deploy/html/images/pharmaceuticals-17-00113-g002-550.jpg?1705309297) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00113/article_deploy/html/images/pharmaceuticals-17-00113-g003-550.jpg?1705309303) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00113/article_deploy/html/images/pharmaceuticals-17-00113-g004a-550.jpg?1705309305) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00113/article_deploy/html/images/pharmaceuticals-17-00113-g004b-550.jpg?1705309307) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00113/article_deploy/html/images/pharmaceuticals-17-00113-g005-550.jpg?1705309309) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00113/article_deploy/html/images/pharmaceuticals-17-00113-g006a-550.jpg?1705309310) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00113/article_deploy/html/images/pharmaceuticals-17-00113-g006b-550.jpg?1705309312) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00113/article_deploy/html/images/pharmaceuticals-17-00113-g007-550.jpg?1705309315) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00113/article_deploy/html/images/pharmaceuticals-17-00113-g008-550.jpg?1705309318)

Open Access Review 16 pages, 1326 KiB (1424-8247/17/1/112/pdf?version=1705140406)

Microbiome and Prostate Cancer: Emerging Diagnostic and Therapeutic Opportunities (1424-8247/17/1/112)

by [Sung Jin Kim](https://sciprofiles.com/profile/3284523?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3284523?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Myungchan Park](https://sciprofiles.com/profile/author/WGpiUHNCFTVTdXVTTWiWjBkUkFEZWM5WURNDIKLzq5NrnNaDyRGR1WT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/WGpiUHNCFTVTdXVTTWiWjBkUkFEZWM5WURNDIKLzq5NrnNaDyRGR1WT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Ahnryul Choi](https://sciprofiles.com/profile/1274419?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1274419?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Sangjun Yoo](https://sciprofiles.com/profile/3307352?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3307352?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 112; <https://doi.org/10.3390/ph17010112> (https://doi.org/10.3390/ph17010112) - 13 Jan 2024
Viewed by 741

Abstract This review systematically addresses the correlation between the microbiome and prostate cancer and explores its diagnostic and therapeutic implications. Recent research has indicated an association between the urinary and gut microbiome composition and prostate cancer incidence and progression. Specifically, the urinary microbiome is [...]. **Read more.** (This article belongs to the Section *Pharmaceutical Technology* (/journal/pharmaceuticals/sections/pharmaceutical_technology))

► Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00112/article_deploy/html/images/pharmaceuticals-17-00112-g001-550.jpg?1705140479)

Open Access Article 11 pages, 631 KiB (1424-8247/17/1/111/pdf?version=1705138645)

Ocular and Plasma Pharmacokinetics of Enavogliflozin Ophthalmic Solution in Preclinical Species (1424-8247/17/1/111)

by [Mingui Jang](https://sciprofiles.com/profile/author/QTVmSlidLOVvJNiL3pPWEU4Q045aG4ycEwya3RCUMVTZG90ldzSFTaz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/QTVmSlidLOVvJNiL3pPWEU4Q045aG4ycEwya3RCUMVTZG90ldzSFTaz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Minsung Kang](https://sciprofiles.com/profile/author/TIVhd0xmbDuaFB5ZGkyWVNFdWdN3F2OFBPyQzRnMzJyNUx5UmdxZz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/TIVhd0xmbDuaFB5ZGkyWVNFdWdN3F2OFBPyQzRnMzJyNUx5UmdxZz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Eunseok Lee](https://sciprofiles.com/profile/3359347?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3359347?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Dongseong Shin](https://sciprofiles.com/profile/3290311?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3290311?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 111; <https://doi.org/10.3390/ph17010111> (https://doi.org/10.3390/ph17010111) - 13 Jan 2024
Viewed by 582

Abstract An enavogliflozin ophthalmic solution (DWRX2008) is being developed to treat diabetic retinopathy and macular edema. This study evaluated the ocular distribution and plasma pharmacokinetics (PKs) of enavogliflozin in animal species. A sample of [¹⁴C] enavogliflozin was ocularly administered to two rabbits [...]. **Read more.** (This article belongs to the Section *Pharmacology* (/journal/pharmaceuticals/sections/pharm-pharmacology))

► Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00111/article_deploy/html/images/pharmaceuticals-17-00111-g001-550.jpg?1705138716) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00111/article_deploy/html/images/pharmaceuticals-17-00111-g002-550.jpg?1705138718)

Open Access Article 22 pages, 2461 KiB (1424-8247/17/1/110/pdf?version=1705137222)

Can Pharmacological Conditioning as an Add-On Treatment Optimize Standard Pharmacological Treatment in Patients with Recent-Onset Rheumatoid Arthritis? A Proof-of-Principle Randomized Clinical Trial (1424-8247/17/1/110)

by [Meriem Manai](https://sciprofiles.com/profile/author/d3VPazlxU291NWZlZw51cGU5Q04xbk1rbDAwKw0R3V5eIBNeHzNjNOcz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/d3VPazlxU291NWZlZw51cGU5Q04xbk1rbDAwKw0R3V5eIBNeHzNjNOcz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Henriët van Middendorp](https://sciprofiles.com/profile/author/ZnFTYkNsRTZz3IpaDv0REUVvVdGTjNYkFuE4rUCiEpnUGpBWFpCc2xROG9BVU4rUGJk1JxWHR6ZndkOQ==7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/ZnFTYkNsRTZz3IpaDv0REUVvVdGTjNYkFuE4rUCiEpnUGpBWFpCc2xROG9BVU4rUGJk1JxWHR6ZndkOQ==7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Joy A. van der Pol](https://sciprofiles.com/profile/3236726?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3236726?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Cornelia F. Allaart](https://sciprofiles.com/profile/author/WEVjNovR1dpKzpmM2Y5aHdQUIVm0wrTmRGnzFuWVvFvdBJd0lWFIUaz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/WEVjNovR1dpKzpmM2Y5aHdQUIVm0wrTmRGnzFuWVvFvdBJd0lWFIUaz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Elise Dusseldorp](https://sciprofiles.com/profile/author/ODZRVWFGa0Zza0JZbWtkeUFJ0EJFWMC90cHVxepQm9GSW0vTzBHK3nyeU4zRitxzcBRUMFvMElQbittd3Vseg=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/ODZRVWFGa0Zza0JZbWtkeUFJ0EJFWMC90cHVxepQm9GSW0vTzBHK3nyeU4zRitxzcBRUMFvMElQbittd3Vseg=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Dieuwke S. Veldhuijzen](https://sciprofiles.com/profile/author/OkRPIYUJUHd5YUsrNEhna2RBAxhucEpl_b2dpTzZzBjDGGVpRb0pHlur2bGdDNVJYnk2KzhXZnWY0Zy2lTWg9=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/OkRPIYUJUHd5YUsrNEhna2RBAxhucEpl_b2dpTzZzBjDGGVpRb0pHlur2bGdDNVJYnk2KzhXZnWY0Zy2lTWg9=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Tom W. J. Huizinga](https://sciprofiles.com/profile/author/azc2S1F1a3ZBWU1VZXpPMWNMHNN22F2alB2bGswXZA1MU5HdGEvMHQwaz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/azc2S1F1a3ZBWU1VZXpPMWNMHNN22F2alB2bGswXZA1MU5HdGEvMHQwaz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Andrea W. M. Evers](https://sciprofiles.com/profile/3075207?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3075207?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 110; <https://doi.org/10.3390/ph17010110> (https://doi.org/10.3390/ph17010110) - 13 Jan 2024
Viewed by 469

Abstract Medication regimens using conditioning via variable reinforcement have shown similar or improved therapeutic effects as full pharmacological treatment, but evidence in patient populations is scarce. This proof-of-principle double-blind randomized clinical trial examined whether treatment effects in recent-onset rheumatoid arthritis (RA) can be optimized [...]. **Read more.** (This article belongs to the Special Issue *Rheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations 2023* (/journal/))

Pharmaceuticals/special_issues/P8RCX06587)

MDPI

Show Figures

- (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00110/article_deploy/html/images/pharmaceuticals-17-00110-ag-550.jpg?1705337327) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00110/article_deploy/html/images/pharmaceuticals-17-00110-g001-550.jpg?1705337305) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00110/article_deploy/html/images/pharmaceuticals-17-00110-g002a-550.jpg?1705337309) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00110/article_deploy/html/images/pharmaceuticals-17-00110-g002b-550.jpg?1705337313) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00110/article_deploy/html/images/pharmaceuticals-17-00110-g002c-550.jpg?1705337316) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00110/article_deploy/html/images/pharmaceuticals-17-00110-g003-550.jpg?1705337319) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00110/article_deploy/html/images/pharmaceuticals-17-00110-g004-550.jpg?1705337326)

Open Access Review

22 pages, 7188 KIB (1424-8247/17/1/109/pdf?version=1705133692)

Interleukins in Platelet Biology: Unraveling the Complex Regulatory Network (1424-8247/17/1/109)

by Miao Huang (https://sciprofiles.com/profile/3338910?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Long Wang (https://sciprofiles.com/profile/1723343?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Qianhui Zhang (https://sciprofiles.com/profile/author/VfIkbHA11ko2VHhFctHRdsbHBOqZqaGpov2pmbkdNbUFZTUxGZEJDUt0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Ling Zhou (https://sciprofiles.com/profile/author/N1ppUj9d1TDhOQUXeWhudmpFNEhZfXNFvZWthQz2a2UNEPmaz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Rui Liao (https://sciprofiles.com/profile/author/QWdlMStnamZpY2NZVGyYeExGNVg0L0NcF11Y0piODVJRIBYcJHNNKRTST0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Anguo Wu (https://sciprofiles.com/profile/430407?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Xinle Wang (https://sciprofiles.com/profile/author/anJ6Y3NQCUpbXRRL2pmaVIUSmJsdz09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Jiesi Luo (https://sciprofiles.com/profile/1238767?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Feihong Huang (https://sciprofiles.com/profile/author/a29LeDIHeXN1aXU3TEZ4L3g1dmjjsk1RSVRnSFoxZINGSk9DK2JONWthdz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Wenjun Zou (https://sciprofiles.com/profile/2615636?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Jianmin Wu (https://sciprofiles.com/profile/71307?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 109; https://doi.org/10.3390/ph17010109 (https://doi.org/10.3390/ph17010109) · 13 Jan 2024

Viewed by 494

Abstract Interleukins, a diverse family of cytokines produced by various cells, play crucial roles in immune responses, immunoregulation, and a wide range of physiological and pathological processes. In the context of megakaryopoiesis, thrombopoiesis, and platelet function, interleukins have emerged as key regulators, exerting significant [...] Read more.

(This article belongs to the Special Issue Inflammatory Cytokines as New Therapeutic Targets (Journal/pharmaceuticals/special_issues/V18KNT37HL))

Show Figures

- (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00109/article_deploy/html/images/pharmaceuticals-17-00109-g001-550.jpg?1705133787) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00109/article_deploy/html/images/pharmaceuticals-17-00109-g002-550.jpg?1705133789) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00109/article_deploy/html/images/pharmaceuticals-17-00109-g003-550.jpg?1705133791) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00109/article_deploy/html/images/pharmaceuticals-17-00109-g004-550.jpg?1705133792) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00109/article_deploy/html/images/pharmaceuticals-17-00109-g005-550.jpg?1705133793) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00109/article_deploy/html/images/pharmaceuticals-17-00109-g006-550.jpg?1705133797)

Open Access Article

16 pages, 3259 KIB (1424-8247/17/1/108/pdf?version=1705371224)

Cathin-6-One Inhibits Developmental and Tumour-Associated Angiogenesis in Zebrafish (1424-8247/17/1/108)

by Mei Fong Ng (https://sciprofiles.com/profile/2105262?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Juliana Da Silva Viana (https://sciprofiles.com/profile/author/SWZCbJJSIBBaAVvth2TUJWZm1ERkp0cUweEU2TTVYQzZ0VDJONE1Wb082dkFINOE5Y1INM1VTRGStnNFkw==2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pei Jean Tan (https://sciprofiles.com/profile/author/UnNsWthXOEVDWG0ZmwwGk4d1BhOXnSFN101adWXOGVDGjdCRk4d4z0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Denver D. Brito (https://sciprofiles.com/profile/author/NIVlvVphSIVycXNuMFM1UUJL3hsKzh4UXRY12wJnWbKvS3FBby8xST0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Sy Bing Choi (https://sciprofiles.com/profile/author/aERsd3pvbnNZWTZCQTfPjYUjTQVubpIBLbUdLYWY2a2pFYQ5c1dFcnZkbz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Sakurako Kobayashi (https://sciprofiles.com/profile/author/TDJOwGKtWNMTGczbU1TUp3a1gybVWIIWEbEg1Z3BRZ0p2cWtxRm95U0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Norazwana Samat (https://sciprofiles.com/profile/author/eEFIMGw2chZONDIUb0Z3TThmckN4V0F5T1VUkXhZQ2eXd3cG8zRVZ3Z0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Dedrick Soon Seng Song (https://sciprofiles.com/profile/author/UEIWMVICZDJPV0VCaEZMeU0RvD2L3ZTQJfW5N5b1pKNHtcEdod3dSZz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Satoshi Ogawa (https://sciprofiles.com/profile/847155?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Ishwar S. Parhar (https://sciprofiles.com/profile/3335910?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Jonathan W. Astin (https://sciprofiles.com/profile/1160957?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Benjamin M. Hogan (https://sciprofiles.com/profile/author/M0ZQaTlveXc3QkM0djk5RCsrdGN0V0G1ekh30EPnXpQR0xxaUJ5T3JUbz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Vyomesh Patel (https://sciprofiles.com/profile/author/eVBelV3TGJzCzEeJKNkNubN0b21XbWhadndOYTNzOGpmaUpJcJrXRT0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Kazuhide S. Okuda (https://sciprofiles.com/profile/810504?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 108; https://doi.org/10.3390/ph17010108 (https://doi.org/10.3390/ph17010108) · 12 Jan 2024

Viewed by 676

Abstract Tumour-associated angiogenesis play key roles in tumour growth and cancer metastasis. Consequently, several anti-angiogenic drugs such as sunitinib and axitinib have been approved for use as anti-cancer therapies. However, the majority of these drugs target the vascular endothelial growth factor A (VEGFA)/VEGF receptor [...] Read more.

(This article belongs to the Special Issue Zebrafish as a Powerful Tool for Drug Discovery 2023 (Journal/pharmaceuticals/special_issues/zebrafish_drug_3))

Show Figures

- (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00108/article_deploy/html/images/pharmaceuticals-17-00108-g001-550.jpg?1705371337) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00108/article_deploy/html/images/pharmaceuticals-17-00108-g002-550.jpg?1705371341) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00108/article_deploy/html/images/pharmaceuticals-17-00108-g003-550.jpg?1705371344) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00108/article_deploy/html/images/pharmaceuticals-17-00108-g004-550.jpg?1705371346) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00108/article_deploy/html/images/pharmaceuticals-17-00108-g005-550.jpg?1705371349)

Open Access Article

20 pages, 4248 KIB (1424-8247/17/1/107/pdf?version=1705049179)

Chrysin Directing an Enhanced Solubility through the Formation of a Supramolecular Cyclodextrin–Calixarene Drug Delivery System: A Potential Strategy in Antifibrotic Diabetes Therapeutics (1424-8247/17/1/107)

by Anca Hermenean (https://sciprofiles.com/profile/26486?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Fletheria Doasi (https://sciprofiles.com/profile/3285245?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Alex Hamilton (https://sciprofiles.com/profile/author/MGVGRHREBqZUa3Q1L21vbkNGzh2L29ObWNoY21CdUJ3aWc4Szkzd3Jaz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Maria Consiglia Trotta (https://sciprofiles.com/profile/1904337?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Marina Russo (https://sciprofiles.com/profile/2690083?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Caterina Claudia Lepre (https://sciprofiles.com/profile/author/NkkwdWQxdWs1cB1RnWEN2VngWwraXBmbTZV1ZMcWUuKvKdHNSU0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Cailla Saitos (https://sciprofiles.com/profile/3372676?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Ágnes Rusznyák (https://sciprofiles.com/profile/1053510?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Judit Váradi (https://sciprofiles.com/profile/219530?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Ildikó Bácskay (https://sciprofiles.com/profile/115535?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

István Budai (https://sciprofiles.com/profile/1151650?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Ferenc D'Amico (https://sciprofiles.com/profile/291314?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Mirela Fenyo (https://sciprofiles.com/profile/121282?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 107; https://doi.org/10.3390/ph17010107 (https://doi.org/10.3390/ph17010107) · 12 Jan 2024

Viewed by 500

Abstract Calixarene 0118 (OTX008) and chrysin (CHR) are promising molecules for the treatment of fibrosis and diabetes complications but require an effective delivery system to overcome their low solubility and bioavailability. Sulfobutylated β -cyclodextrin (SBECD) was evaluated for its ability to increase the solubility of [...] Read more.

(This article belongs to the Special Issue Cyclodextrin-Based Drug Delivery System and Its Pharmaceutical and Biomedical Application 2024 (Journal/pharmaceuticals/special_issues/15K6482FY))

Show Figures
MDPI
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00107/article_deploy/html/images/pharmaceuticals-17-00107-g001-550.jpg?1705049259)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00107/article_deploy/html/images/pharmaceuticals-17-00107-g002-550.jpg?1705049260)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00107/article_deploy/html/images/pharmaceuticals-17-00107-g003-550.jpg?1705049265)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00107/article_deploy/html/images/pharmaceuticals-17-00107-g004-550.jpg?1705049266)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00107/article_deploy/html/images/pharmaceuticals-17-00107-g005-550.jpg?1705049269)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00107/article_deploy/html/images/pharmaceuticals-17-00107-g006-550.jpg?1705049272)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00107/article_deploy/html/images/pharmaceuticals-17-00107-g007-550.jpg?1705049273)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00107/article_deploy/html/images/pharmaceuticals-17-00107-g008-550.jpg?1705049275)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00107/article_deploy/html/images/pharmaceuticals-17-00107-g009-550.jpg?1705049278)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00107/article_deploy/html/images/pharmaceuticals-17-00107-g010-550.jpg?1705049282)

Open Access Article 14 pages, 252 KB (1424-8247/17/1/106/pdf?version=1705044433)

Improving Drug Safety in Pediatric and Young Adult Patients with Hemato-Oncological Diseases: A Prospective Study of Active Pharmacovigilance (1424-8247/17/1/106)

- by Anna Parzianello (https://sciprofiles.com/profile/author/azFZMEoUUVUkdmWmVvDEt2wxMm9nOGsOakFZRTYQEHYRFRNaXFfbTFqbmITVmjJbJn1cS9Gc2luZGINQw==?utm_source=mdpi.com&utm_medium=we...)
Giulia Fornasier (https://sciprofiles.com/profile/3291816?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Valentina Kiren (https://sciprofiles.com/profile/author/dmj3SU4vStKk3JQUDRsdE9ybnBhQWR0bmtWTFNmS3QWk5FUDJMaKdvTktkZW9Yl3o4K4y3mMwkh9SVV6c9==?utm_source=mdpi.com&utm_medium=web...)
Federico Pigato (https://sciprofiles.com/profile/author/RIBWQStvejc1Nj3cy9FcGIVczNLQIZBzbBQZkMrOG9Rb2lUj1pKbDZaZEhoSERKcWN4bmNoZzhN280Vc2dw==?utm_source=mdpi.com&utm_medium=website&)
Sabrina Orzetti (https://sciprofiles.com/profile/3241337?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Giulia Zamagni (https://sciprofiles.com/profile/1812667?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Anna Arbo (https://sciprofiles.com/profile/1302067?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Paolo Baldo (https://sciprofiles.com/profile/1818774?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Paola Rossi (https://sciprofiles.com/profile/author/bzJlUkV0ej4SDJpNnMUo01RJR0dMwMTZJcGNQem90NEdb0VRUkWT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Marco Rabusin (https://sciprofiles.com/profile/author/NFVFZ0dheHA2bXo1MTBkZDR3VCiqN1gr0RVMDVzVVRUCnBNY1B2RIBSST0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Maurizio Mascarin (https://sciprofiles.com/profile/10382?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Marta Paulina Trojank (https://sciprofiles.com/profile/3269909?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 106; https://doi.org/10.3390/ph17010106 (https://doi.org/10.3390/ph17010106) - 12 Jan 2024

Viewed by 499

Abstract The acquisition of relevant pediatric clinical safety data is essential to ensure tolerable drug therapies. Comparing the real number of Adverse Drug Reaction (ADR) reports in clinical practice with the literature, the idea of ADR underreporting emerges. An active pharmacovigilance observational prospective study [...] Read more. (This article belongs to the Special Issue Pharmacology of Pediatric Medicines (/journal/pharmaceuticals/special_issues/Pediatric_Medicines))

Open Access Editorial 8 pages, 262 KB (1424-8247/17/1/105/pdf?version=1705030568)

Aptamers' Potential to Fill Therapeutic and Diagnostic Gaps (1424-8247/17/1/105)

- by Alfredo Berzal-Herranz (https://sciprofiles.com/profile/19235?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Cristina Romero-López (https://sciprofiles.com/profile/180902?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 105; https://doi.org/10.3390/ph17010105 (https://doi.org/10.3390/ph17010105) - 12 Jan 2024

Viewed by 573

Abstract More than 30 years ago, in 1990, three independent research groups published several papers demonstrating that genetics could be performed in vitro in the absence of living organisms or cells [...] Full article (1424-8247/17/1/105)

(This article belongs to the Special Issue Potential of the Aptamers to Fill Therapeutic and Diagnostic Gaps (/journal/pharmaceuticals/special_issues/pharm_aptamers))

Open Access Article 19 pages, 1927 KB (1424-8247/17/1/99/pdf?version=1704962335)

Liuwei Dihuang Pills Enhance Osteogenic Differentiation in MC3T3-E1 Cells through the Activation of the Wnt/ β -Catenin Signaling Pathway (1424-8247/17/1/99)

- by Jinlong Zhao (https://sciprofiles.com/profile/3360530?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Guihong Lian (https://sciprofiles.com/profile/3140967?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Junzheng Yang (https://sciprofiles.com/profile/author/Q2EzVtBURFZvcDRSKzY3RWs4V0V1TFoUVZMCLjZTVhUjNFBnFPBm80VTO=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Hetao Huang (https://sciprofiles.com/profile/author/NjhsSGNBNEkKa0d4d2EycVmdzRySGhRaUpyREJaNFVdDILNjZnXcz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Abstract Objective: The therapeutic efficacy and molecular mechanisms of traditional Chinese medicines (TCMs), such as Liuwei Dihuang pills (LWDH pills), in treating osteoporosis (OP) remain an area of active research and interest in modern medicine. This study investigated the mechanistic underpinnings of LWDH pills [...] Read more.

(This article belongs to the Section Pharmacology (/journal/pharmaceuticals/sections/pharm-pharmacology))

- by Jun Liu (https://sciprofiles.com/profile/3140953?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Lingfeng Zeng (https://sciprofiles.com/profile/607287?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Weiwei Yang (https://sciprofiles.com/profile/author/em5CMjJzcW5NLOFLUnYvSWpZDdocGJYkzAwdm1TSVYVOS9YmK5ONWJwbz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 99; https://doi.org/10.3390/ph17010099 (https://doi.org/10.3390/ph17010099) - 11 Jan 2024

Viewed by 641

Abstract Objective: The therapeutic efficacy and molecular mechanisms of traditional Chinese medicines (TCMs), such as Liuwei Dihuang pills (LWDH pills), in treating osteoporosis (OP) remain an area of active research and interest in modern medicine. This study investigated the mechanistic underpinnings of LWDH pills [...] Read more. (This article belongs to the Section Pharmacology (/journal/pharmaceuticals/sections/pharm-pharmacology))

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g001-550.jpg?1704962430)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g002-550.jpg?1704962433)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g003-550.jpg?1704962436)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g004-550.jpg?1704962439)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g005-550.jpg?1704962443)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g006-550.jpg?1704962445)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g007-550.jpg?1704962448)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g008-550.jpg?1704962451)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g009-550.jpg?1704962453)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g010-550.jpg?1704962455)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g011-550.jpg?1704962456)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g012-550.jpg?1704962458)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00099/article_deploy/html/images/pharmaceuticals-17-00099-g013-550.jpg?1704962461)

Open Access Article 19 pages, 3273 KB (1424-8247/17/1/98/pdf?version=1704953141)

The Study on Timolol and Its Potential Phototoxicity Using Chemical, In Silico and In Vitro Methods (1424-8247/17/1/98)

- by Karolina Lejwoda (https://sciprofiles.com/profile/1829385?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Anna Gumieniczek (https://sciprofiles.com/profile/306161?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Agata Filip (https://sciprofiles.com/profile/1551633?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Beata Naumczuk (https://sciprofiles.com/profile/1106827?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 98; https://doi.org/10.3390/ph17010098 (https://doi.org/10.3390/ph17010098) - 11 Jan 2024

Viewed by 486

Abstract Timolol (TIM) is a non-selective β -adrenergic receptor antagonist used orally for the treatment of hypertension and heart attacks, and topically for treating glaucoma; lately, it has also been used in some specific dermatological problems. In the present study, its photodegradation and potential risk [...] Read more. (This article belongs to the Special Issue Advances in Drug Analysis and Drug Development (/journal/pharmaceuticals/special_issues/1QF90ZP65X))

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g001-550.jpg?1704953217)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g002-550.jpg?1704953218)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g003-550.jpg?1704953219)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g004-550.jpg?1704953220)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g005-550.jpg?1704953221)
https://pub.mdpi-res.com/

[pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g006-550.jpg?1704953222](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g006-550.jpg?1704953222) (https://pub.mdpi-res.com/
[pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g007-550.jpg?1704953224](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g007-550.jpg?1704953224)) (https://pub.mdpi-res.com/
[pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g008-550.jpg?1704953226](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g008-550.jpg?1704953226)) (https://pub.mdpi-res.com/
[pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g009-550.jpg?1704953227](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g009-550.jpg?1704953227)) (https://pub.mdpi-res.com/
[pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g010-550.jpg?1704953229](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g010-550.jpg?1704953229)) (https://pub.mdpi-res.com/
[pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g011-550.jpg?1704953230](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g011-550.jpg?1704953230)) (https://pub.mdpi-res.com/
[pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g012-550.jpg?1704953231](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g012-550.jpg?1704953231)) (https://pub.mdpi-res.com/
[pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g013-550.jpg?1704953234](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g013-550.jpg?1704953234)) (https://pub.mdpi-res.com/
[pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g014-550.jpg?1704953236](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g014-550.jpg?1704953236)) (https://pub.mdpi-res.com/
[pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g015-550.jpg?1704953238](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00098/article_deploy/html/images/pharmaceuticals-17-00098-g015-550.jpg?1704953238))

Open Access Editorial 2 pages, 153 KB (1424-8247/17/1/97/pdf?version=1704949472)

Immune Diseases: Challenges, Hopes and Recent Achievements (1424-8247/17/1/97)

by [François Dufrasne](https://sciprofiles.com/profile/121564?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/121564?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 97; <https://doi.org/10.3390/ph17010097> (https://doi.org/10.3390/ph17010097) - 11 Jan 2024

Viewed by 433

Abstract Although they have been greatly described for about 50 years, we have gained a much greater understanding of immune diseases since the beginning of this millennium [...]. [Full article \(1424-8247/17/1/97\)](#)

(This article belongs to the Special Issue [Drug Candidates for the Treatment of Immune Disease 2023 \(/journal/pharmaceuticals/special_issues/YL49G89Y51\)](#))

Open Access Review 50 pages, 11795 KB (1424-8247/17/1/104/pdf?version=1705053114)

Recent Advances in Pyrimidine-Based Drugs (1424-8247/17/1/104)

by [Baskar Nammalwar](https://sciprofiles.com/profile/5288930?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/5288930?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

[Richard A. Bunce](https://sciprofiles.com/profile/63392?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/63392?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 104; <https://doi.org/10.3390/ph17010104> (https://doi.org/10.3390/ph17010104) - 11 Jan 2024

Viewed by 935

Abstract Pyrimidines have become an increasingly important core structure in many drug molecules over the past 60 years. This article surveys recent areas in which pyrimidines have had a major impact in drug discovery therapeutics, including anti-infectives, anticancer, immunology, immuno-oncology, neurological disorders, chronic pain, [...].

[Read more.](#)

(This article belongs to the Special Issue [Heterocyclic Compounds in Medicinal Chemistry \(/journal/pharmaceuticals/special_issues/GC66SF595K\)](#))

Show Figures

- https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-g001-550.jpg?1705053189) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-g002-550.jpg?1705053192) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-g003-550.jpg?1705053193) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-g004-550.jpg?1705053195) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-g005-550.jpg?1705053195) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch001-550.jpg?1705053197) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch002-550.jpg?1705053198) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch003-550.jpg?1705053200) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch004-550.jpg?1705053201) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch005-550.jpg?1705053202) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch006-550.jpg?1705053203) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch007-550.jpg?1705053205) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch008-550.jpg?1705053207) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch009-550.jpg?1705053208) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch010-550.jpg?1705053210) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch011-550.jpg?1705053211) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch012-550.jpg?1705053213) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch013-550.jpg?1705053214) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch014-550.jpg?1705053215) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch015-550.jpg?1705053216) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch016-550.jpg?1705053217) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch017-550.jpg?1705053218) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch018-550.jpg?1705053219) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch019-550.jpg?1705053220) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch020-550.jpg?1705053221) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch021-550.jpg?1705053223) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch022-550.jpg?1705053224) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch023-550.jpg?1705053225) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch024-550.jpg?1705053226) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch025-550.jpg?1705053227) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch026-550.jpg?1705053228) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch027-550.jpg?1705053231) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch028-550.jpg?1705053232) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch029-550.jpg?1705053233) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch030-550.jpg?1705053234) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch031-550.jpg?1705053236) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch032-550.jpg?1705053238) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch033-550.jpg?1705053240) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch034-550.jpg?1705053241) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch035-550.jpg?1705053243) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch036-550.jpg?1705053245) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch037-550.jpg?1705053247) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch038-550.jpg?1705053248) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch039-550.jpg?1705053249) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch040-550.jpg?1705053250) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch041-550.jpg?1705053251) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch042-550.jpg?1705053252) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00104/article_deploy/html/images/pharmaceuticals-17-00104-sch043-550.jpg?1705053253)

Open Access Article 40 pages, 8102 KB (1424-8247/17/1/103/pdf?version=1704983393)

Comprehensive Tools of Alkaloid/Volatile Compounds—Metabolomics and DNA Profiles: Bioassay-Role-Guided Differentiation Process of Six *Annona* sp. Grown in Egypt as Anticancer Therapy (1424-8247/17/1/103)

by [Mona A. Mohammed](https://sciprofiles.com/profile/1623439?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1623439?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Nahia Elzefzafy](https://sciprofiles.com/profile/author/RWxZRGnXZzhKdWuUnZnYkx3WksvdVpZOUF6UinNG83TzJhSy9sQWx5MD0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/RWxZRGnXZzhKdWuUnZnYkx3WksvdVpZOUF6UinNG83TzJhSy9sQWx5MD0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Manal F. El-Khadragy](https://sciprofiles.com/profile/2162764?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/2162764?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Abduhakeem Alzahrani](https://sciprofiles.com/profile/1447633?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1447633?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Hany Mohamed Yehia](https://sciprofiles.com/profile/278657?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/278657?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

[Piotr Kachlicki](https://sciprofiles.com/profile/295449?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/295449?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 103; <https://doi.org/10.3390/ph17010103> (https://doi.org/10.3390/ph17010103) - 11 Jan 2024

Viewed by 654

Abstract Trees of the *Annona* species that grow in the tropics and subtropics contain compounds that are highly valuable for pharmacological research and medication development and have anticancer, antioxidant, and migratory properties. Metabolomics was used to functionally characterize natural products and to distinguish differences [...] **Read more**.
(This article belongs to the Special Issue **Bioactive Compounds and Their Optimized Structural Derivatives of Natural Products** ([/journal/pharmaceuticals/special_issues/I9DU8C792](https://pub.mdpi-res.com/special_issues/I9DU8C792)))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-01-550.jpg?1705283530) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0001-550.jpg?1705283468) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0002-550.jpg?1705283471) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0003-550.jpg?1705283473) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0004-550.jpg?1705283474) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0005-550.jpg?1705283476) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0006-550.jpg?1705283477) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0007-550.jpg?1705283478) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0008-550.jpg?1705283479) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0009-550.jpg?1705283483) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0010-550.jpg?1705283485) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0011-550.jpg?1705283487) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0012-550.jpg?1705283488) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0013-550.jpg?1705283489) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0014-550.jpg?1705283492) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0015a-550.jpg?1705283493) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0015b-550.jpg?1705283494) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0016-550.jpg?1705283497) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0017-550.jpg?1705283501) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00103/article_deploy/html/images/pharmaceuticals-17-00103-0018-550.jpg?1705283503)

Open Access Article 15 pages, 16823 KIB (1424-8247/17/1/102/pdf?version=1704975578)

An Integrated Computational and Experimental Approach to Formulate Tamanu Oil Bigels as Anti-Scarring Agent (1424-8247/17/1/102)

- by
- Megha Krishnappa ([https://sciprofiles.com/profile/author/NTRLUDJubTY2NHV5VxGYkFYbDVqSTREVERSSm5nTBWbE5JUDRLaENoSt0=](https://sciprofiles.com/profile/author/NTRLUDJubTY2NHV5VxGYkFYbDVqSTREVERSSm5nTBWbE5JUDRLaENoSt0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Sindhu Abraham (https://sciprofiles.com/profile/3102654?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Sharon Caroline Furtado ([https://sciprofiles.com/profile/author/Z3hvbklFYjk5M2x6SW8rZmN5ZnZsMVBRbHpoZSfrSFYVVRbE44dVd0Zz0=](https://sciprofiles.com/profile/author/Z3hvbklFYjk5M2x6SW8rZmN5ZnZsMVBRbHpoZSfrSFYVVRbE44dVd0Zz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Shwetha Krishnamurthy ([https://sciprofiles.com/profile/author/AJDNFWG5oNWVJWJUJZDFyNEJnSWDFRWNbnmZTUQUBiU3nU0ZVK1dnZz0=](https://sciprofiles.com/profile/author/AJDNFWG5oNWVJWJUJZDFyNEJnSWDFRWNbnmZTUQUBiU3nU0ZVK1dnZz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Aynul Rifaya ([https://sciprofiles.com/profile/author/RVJxWtPpRHNWVhCbU9rYTiVuo2d126hdZ5VjUISFMfY0dVYmo0SVRUQT0=](https://sciprofiles.com/profile/author/RVJxWtPpRHNWVhCbU9rYTiVuo2d126hdZ5VjUISFMfY0dVYmo0SVRUQT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Yahya I. Asiri (https://sciprofiles.com/profile/964376?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Kumarapann Chidambaram (https://sciprofiles.com/profile/1170631?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
 - Parasuraman Pavadai (https://sciprofiles.com/profile/2287540?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Pharmaceuticals* 2024, 17(1), 102; <https://doi.org/10.3390/ph17010102> (<https://doi.org/10.3390/ph17010102>) · 11 Jan 2024

Viewed by 533

Abstract Tamanu oil has traditionally been used to treat various skin problems. The oil has wound-healing and skin-regenerating capabilities and encourages the growth of new skin cells, all of which are helpful for fading scars and hyperpigmentation, as well as promoting an all-around glow. [...] **Read more**.
(This article belongs to the Special Issue **Structural and Computational-Driven Molecule Design in Drug Discovery** ([/journal/pharmaceuticals/special_issues/6GZOS8951](https://journal/pharmaceuticals/special_issues/6GZOS8951)))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00102/article_deploy/html/images/pharmaceuticals-17-00102-01-550.jpg?1704975673) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00102/article_deploy/html/images/pharmaceuticals-17-00102-0001-550.jpg?1704975656) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00102/article_deploy/html/images/pharmaceuticals-17-00102-0002-550.jpg?1704975661) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00102/article_deploy/html/images/pharmaceuticals-17-00102-0003-550.jpg?1704975665) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00102/article_deploy/html/images/pharmaceuticals-17-00102-0004-550.jpg?1704975670) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00102/article_deploy/html/images/pharmaceuticals-17-00102-0005-550.jpg?1704975672)

Open Access Article 12 pages, 1072 KIB (1424-8247/17/1/101/pdf?version=1704962943)

Safety and Efficacy of Selective Internal Radionuclide Therapy with ⁹⁰Y Glass Microspheres in Patients with Progressive Hepatocellular Carcinoma after the Failure of Repeated Transarterial Chemoembolization (1424-8247/17/1/101)

- by
- Alexander Bellendorf ([https://sciprofiles.com/profile/author/RVkhzQGZmZyvakFTUhuKVC14b0NZVnNAXkRGLTtdWSJYwbU1HZNhZODNJQJIM3hPM3d0Zm1FZmVWFVQ9=](https://sciprofiles.com/profile/author/RVkhzQGZmZyvakFTUhuKVC14b0NZVnNAXkRGLTtdWSJYwbU1HZNhZODNJQJIM3hPM3d0Zm1FZmVWFVQ9=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Nicolai Mader ([https://sciprofiles.com/profile/author/aUIMbV14QmxER20eTYzYjN4bWo4cRaOXp0UzYbC90MGs5K1Npb0laZz0=](https://sciprofiles.com/profile/author/aUIMbV14QmxER20eTYzYjN4bWo4cRaOXp0UzYbC90MGs5K1Npb0laZz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Stefan P. Mueller ([https://sciprofiles.com/profile/author/WJj2WU10SWxJMXV4K1J2vTJa2ZTeHd3cWRwZfHGaVnMmK0rMHHzbFBQOD0=](https://sciprofiles.com/profile/author/WJj2WU10SWxJMXV4K1J2vTJa2ZTeHd3cWRwZfHGaVnMmK0rMHHzbFBQOD0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Samer Ezziddin (https://sciprofiles.com/profile/1465121?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Andreas Bockisch ([https://sciprofiles.com/profile/author/ZTFpQLjpbZxMwJhNThsWnNzlhQUJfowN9xhZNNZcydi0EJfUfKxbz0=](https://sciprofiles.com/profile/author/ZTFpQLjpbZxMwJhNThsWnNzlhQUJfowN9xhZNNZcydi0EJfUfKxbz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Hong Grafe (https://sciprofiles.com/profile/2201128?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Jan Best (https://sciprofiles.com/profile/1658139?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Juliane Goebel ([https://sciprofiles.com/profile/author/WIE5YNUVvE5pb3NIWDIXc1CRmIQm9NSW1RRUcSDNOc0YvVkJzMnZWST0=](https://sciprofiles.com/profile/author/WIE5YNUVvE5pb3NIWDIXc1CRmIQm9NSW1RRUcSDNOc0YvVkJzMnZWST0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Thorsten D. Pöppel ([https://sciprofiles.com/profile/author/UTJabVVKalRFNUFIMk9t2wELBYcDhtSG85VTJaUGvQanhWefFTWml2YnpOaERSZmXqMvVvNmXuT004S9rVw=](https://sciprofiles.com/profile/author/UTJabVVKalRFNUFIMk9t2wELBYcDhtSG85VTJaUGvQanhWefFTWml2YnpOaERSZmXqMvVvNmXuT004S9rVw=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Amir Sabet (https://sciprofiles.com/profile/3233318?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Pharmaceuticals* 2024, 17(1), 101; <https://doi.org/10.3390/ph17010101> (<https://doi.org/10.3390/ph17010101>) · 11 Jan 2024

Abstract Transarterial chemoembolization (TACE) is currently the standard of care in patients with unresectable hepatocellular carcinoma (HCC), and selective internal radionuclide therapy (SIRT) with ⁹⁰Y microspheres is mainly used as an alternative modality in patients considered poor candidates for TACE. Treatment with sorafenib [...] **Read more**.
(This article belongs to the Special Issue **Therapeutic Radionuclides in Nuclear Medicine** ([/journal/pharmaceuticals/special_issues/M8TAS21VQU](https://journal/pharmaceuticals/special_issues/M8TAS21VQU)))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00101/article_deploy/html/images/pharmaceuticals-17-00101-0001-550.jpg?1704963070) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00101/article_deploy/html/images/pharmaceuticals-17-00101-0002-550.jpg?1704963071) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00101/article_deploy/html/images/pharmaceuticals-17-00101-0003-550.jpg?1704963072) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00101/article_deploy/html/images/pharmaceuticals-17-00101-0004-550.jpg?1704963073)

Open Access Review 17 pages, 5955 KIB (1424-8247/17/1/100/pdf?version=1704962586)

From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation (1424-8247/17/1/100)

- by
- Sijqi Wang (https://sciprofiles.com/profile/3263052?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Fuchu He (https://sciprofiles.com/profile/430469?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Chunyan Tian (https://sciprofiles.com/profile/2037035?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
 - Aihua Sun (https://sciprofiles.com/profile/3290010?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Pharmaceuticals* 2024, 17(1), 100; <https://doi.org/10.3390/ph17010100> (<https://doi.org/10.3390/ph17010100>) · 11 Jan 2024

Viewed by 826

Abstract PROTAC is a rapidly developing engineering technology for targeted protein degradation using the ubiquitin–proteasome system, which has promising applications for inflammatory diseases, neurodegenerative diseases, and malignant tumors. This paper gives a brief overview of the development and design principles of PROTAC, with a [...] **Read more**.
(This article belongs to the Section **Pharmacology** ([/journal/pharmaceuticals/sections/pharm-pharmacology](https://journal/pharmaceuticals/sections/pharm-pharmacology)))

Show Figures

MDPI (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00100/article_deploy/html/images/pharmaceuticals-17-00100-ag-550.jpg?1704962737) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00100/article_deploy/html/images/pharmaceuticals-17-00100-g001-550.jpg?1704962722) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00100/article_deploy/html/images/pharmaceuticals-17-00100-g002-550.jpg?1704962723) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00100/article_deploy/html/images/pharmaceuticals-17-00100-g003-550.jpg?1704962724) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00100/article_deploy/html/images/pharmaceuticals-17-00100-g004-550.jpg?1704962724) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00100/article_deploy/html/images/pharmaceuticals-17-00100-g005-550.jpg?1704962725) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00100/article_deploy/html/images/pharmaceuticals-17-00100-g006-550.jpg?1704962726) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00100/article_deploy/html/images/pharmaceuticals-17-00100-g007-550.jpg?1704962727) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00100/article_deploy/html/images/pharmaceuticals-17-00100-g008-550.jpg?1704962728) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00100/article_deploy/html/images/pharmaceuticals-17-00100-g009-550.jpg?1704962730) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00100/article_deploy/html/images/pharmaceuticals-17-00100-g010-550.jpg?1704962731)

Open Access Article 26 pages, 7325 KB (1424-8247/17/1/96/pdf?version=1704961956)

Fabrication of Nanocrystals for Enhanced Distribution of a Fatty Acid Synthase Inhibitor (Orlistat) as a Promising Method to Relieve Solid Ehrlich Carcinoma-Induced Hepatic Damage in Mice (1424-8247/17/1/96)

- by Jawaher Abdullah Alamoudi (https://sciprofiles.com/profile/3322533?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Thanaa A. El-Masry (https://sciprofiles.com/profile/1975747?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Mohamed Nasr (https://sciprofiles.com/profile/author/SmxaxXsV05vQVpNK0hQU1UUFFWcES5mJpCzRlV9kTNVhZc3hTmFSrT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Ismail T. Ibrahim (https://sciprofiles.com/profile/author/bGwwZWNmYzhKNWRXcURKM2lYbFdrWGNwL1RRyJhORXJEQVhQSjVVVnYMD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Hanaa A. Ibrahim (https://sciprofiles.com/profile/3138737?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Hebatallah M. Saad (https://sciprofiles.com/profile/2032706?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Maysa M. F. El-Nagar (https://sciprofiles.com/profile/3136969?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Samar Zuhair Alshawa (https://sciprofiles.com/profile/1878524?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Amal Alrashidi (https://sciprofiles.com/profile/3233123?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Enas I. El Zahaby (https://sciprofiles.com/profile/author/MIlMkxZ2RyZnVUOXdl1aVzhMm5Ub3pXVVBGN3V4EhpZ3R1aHJlTlV3a20=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 96; https://doi.org/10.3390/ph17010096 (https://doi.org/10.3390/ph17010096) - 10 Jan 2024

Viewed by 527

Abstract Background: Orlistat (ORL) is an effective irreversible inhibitor of the lipase enzyme, and it possesses anticancer effects and limited aqueous solubility. This study was designed to improve the aqueous solubility, oral absorption, and tissue distribution of ORL via the formulation of nanocrystals (NCs). [...] Read more. (This article belongs to the Special Issue Recent Progress of Nanomedicine and Targeted Drug Delivery for Cancer Treatment 2.0 (Journal/pharmaceuticals/special_issues/894Y393QL6))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g001-550.jpg?1704962027) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g002-550.jpg?1704962032) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g003-550.jpg?1704962033) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g004-550.jpg?1704962035) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g004b-550.jpg?1704962038) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g005-550.jpg?1704962043) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g006-550.jpg?1704962045) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g007a-550.jpg?1704962047) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g007b-550.jpg?1704962049) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g008-550.jpg?1704962052) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g009-550.jpg?1704962053) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g010-550.jpg?1704962056) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g011-550.jpg?1704962058) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00096/article_deploy/html/images/pharmaceuticals-17-00096-g012-550.jpg?1704962061)

Open Access Article 11 pages, 786 KB (1424-8247/17/1/95/pdf?version=1704878292)

Logistic Regression Is Non-Inferior to the Response Surface Model in Patient Response Prediction of Video-Assisted Thoracoscopic Surgery (1424-8247/17/1/95)

- by Hui-Yu Huang (https://sciprofiles.com/profile/author/cE9VRVpPWW1NemVhNTkwQm9rNTBWMkkwRjhK1YNDNXlBaVYwI9oU1YxVT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Shih-Pin Lin (https://sciprofiles.com/profile/2084976?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Hsin-Yi Wang (https://sciprofiles.com/profile/author/bGUwa25WFN4NFZIMTJVUWwXbc0a0ndEFPk1qVGHnHM3OCILQXphZ0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Jing-Yang Liou (https://sciprofiles.com/profile/author/Vm5qN250TmQrODhSDBT0U0cGswcFK3bmIwTKR0dUNUUFpMcZUyWZOUT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Wen-Kuei Chang (https://sciprofiles.com/profile/2409058?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Chien-Kun Ting (https://sciprofiles.com/profile/4833317?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 95; https://doi.org/10.3390/ph17010095 (https://doi.org/10.3390/ph17010095) - 10 Jan 2024

Viewed by 467

Abstract Response surface models (RSMs) are a new trend in modern anesthesia. RSMs have demonstrated significant applicability in the field of anesthesia. However, the comparative analysis between RSMs and logistic regression (LR) in different surgeries remains relatively limited in the current literature. We hypothesized [...] Read more. (This article belongs to the Special Issue Population Pharmacokinetic and Pharmacodynamic and Clinical Strategies (Journal/pharmaceuticals/special_issues/Q6LBPG8ED))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00095/article_deploy/html/images/pharmaceuticals-17-00095-ag-550.jpg?1704878363) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00095/article_deploy/html/images/pharmaceuticals-17-00095-g001-550.jpg?1704878361) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00095/article_deploy/html/images/pharmaceuticals-17-00095-g002-550.jpg?1704878362)

Open Access Article 16 pages, 4513 KB (1424-8247/17/1/94/pdf?version=1704878230)

Improvement of the Thermal Stability and Aqueous Solubility of Three Matrine Salts Assembled by the Similar Structure Salt Formers (1424-8247/17/1/94)

- by Yeyang Wang (https://sciprofiles.com/profile/3193842?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Boxi Zhang (https://sciprofiles.com/profile/author/Wk1wM05xdW16TjlxZTdtCt4Mlk4eCtSVFMERsV05NVVYVVDY5REYvaz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Wenwen Wang (https://sciprofiles.com/profile/author/bVfjdnJmK2NkSWc0SmY3SEU0dmsvcVfKMERDUVpS2VlDU6JrTTVVUxCbz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Penghui Yuan (https://sciprofiles.com/profile/author/cQcyWXlY2NZMWZ1LylZEsY1LdnZ3Z20E4Z7ZNK1kxSHK3RE1cTkrdz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Kun Hu (https://sciprofiles.com/profile/author/a2grdU04cVlac3huclVDeGF2UXbyQT09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Li Zhang (https://sciprofiles.com/profile/2083684?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Dezhi Yang (https://sciprofiles.com/profile/1999319?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Yang Lu (https://sciprofiles.com/profile/1180112?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Guanhua Du (https://sciprofiles.com/profile/326954?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 94; https://doi.org/10.3390/ph17010094 (https://doi.org/10.3390/ph17010094) - 10 Jan 2024

Viewed by 492

Abstract Matrine (MAT), a natural Chinese herbal medicine, has a unique advantage in the treatment of various chronic diseases. However, its low melting point, low bioavailability, and high dosage restrict its subsequent development into new drugs. In this study, three kinds of MAT salts, [...] Read more. (This article belongs to the Section Pharmaceutical Technology (Journal/pharmaceuticals/sections/pharmaceutical_tech))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00094/article_deploy/html/images/pharmaceuticals-17-00094-ag-550.jpg?1704878329) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00094/article_deploy/html/images/pharmaceuticals-17-00094-g001-550.jpg?1704878315) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00094/article_deploy/html/images/pharmaceuticals-17-00094-g002-550.jpg?1704878317) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00094/article_deploy/html/images/pharmaceuticals-17-00094-g003-550.jpg?1704878319) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00094/article_deploy/html/images/pharmaceuticals-17-00094-g004-550.jpg?1704878321) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00094/article_deploy/html/images/pharmaceuticals-17-00094-g005-550.jpg?1704878322) (https://pub.mdpi-res.com/...)

Open Access Article 15 pages, 18328 KB (1424-8247/17/1/93/pdf?version=1704879279)

Mesenchymal Stem Cell-Derived Exosomes Ameliorate Doxorubicin-Induced Cardiotoxicity (1424-8247/17/1/93)

by Sawadh A. Ali (https://sciprofiles.com/profile/3324213?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Dinender K. Singla (https://sciprofiles.com/profile/1606507?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 93; https://doi.org/10.3390/ph17010093 (https://doi.org/10.3390/ph17010093) - 10 Jan 2024

Viewed by 589

Abstract Doxorubicin (DOX) is an incessantly used chemotherapeutic drug that can cause detrimental dose-dependent effects such as cardiotoxicity and congestive heart failure. Hence, there is a need to discover innovative therapeutic approaches to counteract DOX-induced cardiotoxicity (DIC). MSC-Exos have shown to reduce apoptosis and [...]

(This article belongs to the Special Issue Cancer Drugs Treatment and Toxicity 2023 (/journal/pharmaceuticals/special_issues/676TJN75KC))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00093/article_deploy/html/images/pharmaceuticals-17-00093-g001-550.jpg?1704879353) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00093/article_deploy/html/images/pharmaceuticals-17-00093-g002-550.jpg?1704879356) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00093/article_deploy/html/images/pharmaceuticals-17-00093-g003-550.jpg?1704879359) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00093/article_deploy/html/images/pharmaceuticals-17-00093-g004-550.jpg?1704879362) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00093/article_deploy/html/images/pharmaceuticals-17-00093-g005-550.jpg?1704879365) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00093/article_deploy/html/images/pharmaceuticals-17-00093-g006-550.jpg?1704879368) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00093/article_deploy/html/images/pharmaceuticals-17-00093-g007-550.jpg?1704879370) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00093/article_deploy/html/images/pharmaceuticals-17-00093-g008-550.jpg?1704879374)

Open Access Opinion 11 pages, 1338 KB (1424-8247/17/1/92/pdf?version=1704875245)

Chemical Adjustment of Fibrinolysis (1424-8247/17/1/92)

by Alexey M. Shibeko (https://sciprofiles.com/profile/2521704?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Ivan S. Ilin (https://sciprofiles.com/profile/author/Gi0vNzS1VzVbUdIdDZ1NEtMfJacrVWc9CWE1dGp8emQ1NGJoZV2VMTT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Nadezhda A. Podoplova (https://sciprofiles.com/profile/author/OwXfYTN4enRxeFFRRINcuJdPUFIKtW9S3IWR5IKN2VWfFLaTBXekRuc20=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Mikhail B. Sulimov (https://sciprofiles.com/profile/2011109?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Vladimir A. Pantelev (https://sciprofiles.com/profile/955577?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 92; https://doi.org/10.3390/ph17010092 (https://doi.org/10.3390/ph17010092) - 10 Jan 2024

Viewed by 504

Abstract Fibrinolysis is the process of the fibrin-platelet clot dissolution initiated after bleeding has been stopped. It is regulated by a cascade of proteolytic enzymes with plasmin at its core. In pathological cases, the balance of normal clot formation and dissolution is replaced by [...]

(This article belongs to the Section Biopharmaceuticals (/journal/pharmaceuticals/sections/biopharmaceuticals))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00092/article_deploy/html/images/pharmaceuticals-17-00092-g001-550.jpg?1704875319) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00092/article_deploy/html/images/pharmaceuticals-17-00092-g002-550.jpg?1704875320) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00092/article_deploy/html/images/pharmaceuticals-17-00092-g003-550.jpg?1704875321) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00092/article_deploy/html/images/pharmaceuticals-17-00092-g004-550.jpg?1704875322)

Open Access Article 22 pages, 2650 KB (1424-8247/17/1/91/pdf?version=1704871778)

The Immune-Stimulating and Anti-Diabetic Effects of Allium hookeri Leaves Grown in a Plant Factory with Artificial Lights in Immunosuppressed Obese C57BL/6 Mice (1424-8247/17/1/91)

by Jieun Jung (https://sciprofiles.com/profile/2309708?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Ji-Su Kim (https://sciprofiles.com/profile/author/alg2WkdcVNeINsvndSQk95WUjWUE5LaJWZjpdImN8FzF9JaQrZ0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Un-Yul Jeong (https://sciprofiles.com/profile/author/T2tTeuH6QTQweE1CWE5NWxVjUXZfTVFUzYj3RKN1AxYkNIYjZ2DZaMD0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Ui-Jin Bae (https://sciprofiles.com/profile/author/WUxEK3FPc1VJY2YmK1SZXILZVZnYk1aHlIz3VjZ3hIT3JWd1ZPwD1HUT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Mina Kim (https://sciprofiles.com/profile/479177?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Shin-Young Park (https://sciprofiles.com/profile/author/aG4wSVJFSnE2bzVkcNfodWswNTA1aU9XZnQrTJiakZqOVRBQks2V1J5ND0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

In-Guk Hwang (https://sciprofiles.com/profile/1533404?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Jeong-Wook Heo (https://sciprofiles.com/profile/author/d0d6bE5nWEIVMDV1ODNkWRDR2NHBgM0N6ZUJjUXf8EUTqemYjbm15QituTT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Chang-Ki Shim (https://sciprofiles.com/profile/2054076?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Jun-Sang Ham (https://sciprofiles.com/profile/940306?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Sung-Hyun Lee (https://sciprofiles.com/profile/805960?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 91; https://doi.org/10.3390/ph17010091 (https://doi.org/10.3390/ph17010091) - 09 Jan 2024

Viewed by 479

Abstract We investigated the immune-stimulating and anti-diabetic effects of Allium hookeri leaves grown in a plant factory with artificial lights. The immunomodulatory effects of A. hookeri leaves' ethanol extracts were evaluated with immune-related hematological factors in blood, the proliferation of splenocytes, NK cell activity, [...]

(This article belongs to the Section Pharmacology (/journal/pharmaceuticals/sections/pharm-pharmacology))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g001-550.jpg?1704871871) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g002-550.jpg?1704871872) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g003-550.jpg?1704871873) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g004-550.jpg?1704871874) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g005-550.jpg?1704871875) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g006-550.jpg?1704871876) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g007a-550.jpg?1704871877) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g007b-550.jpg?1704871878) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g008-550.jpg?1704871879) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g009-550.jpg?1704871880) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g010-550.jpg?1704871881) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00091/article_deploy/html/images/pharmaceuticals-17-00091-g011-550.jpg?1704871882)

Open Access Article 20 pages, 1232 KB (1424-8247/17/1/90/pdf?version=1704809527)

Drug-Induced Anaphylaxis: National Database Analysis (1424-8247/17/1/90)

by Olga Butranova (https://sciprofiles.com/profile/2144268?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Sergey Zyryanov (https://sciprofiles.com/profile/2201930?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Anastasia Gorbacheva (https://sciprofiles.com/profile/author/WkNrSnhYR05VdHleVJwzhHM29uJTNVaG1mYlduVnN3UGNvYjZBU2V3Zd0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Irina Asetskaya (https://sciprofiles.com/profile/author/VjZKM3dTMt9jaGd1NE9kUW1MUHVnSrmQRJpUyMpwFREROL1FznVhnTnNSUT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Vitaly Polivanov (https://sciprofiles.com/profile/3354813?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 90; https://doi.org/10.3390/ph17010090 (https://doi.org/10.3390/ph17010090) - 09 Jan 2024

Viewed by 516

Abstract (1) Background: National health system databases represent an important source of information about the epidemiology of adverse drug reactions including drug-induced allergy and anaphylaxis. Analysis of such databases may enhance the knowledge of healthcare professionals regarding the problem of drug-induced anaphylaxis. (2) Methods: [...]

(This article belongs to the Special Issue Therapeutic Drug Monitoring and Adverse Drug Reactions (/journal/pharmaceuticals/special_issues/Q4B8E1FM23))

Show Figures

https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00090/article_deploy/html/images/pharmaceuticals-17-00090-g001-550.jpg?1704809608) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00090/article_deploy/html/images/pharmaceuticals-17-00090-g002-550.jpg?1704809610)

Open Access Article 24 pages, 6495 KB (1424-8247/17/188/pdf?version=1704809278)

Biochanin A Inhibits the Growth and Biofilm of *Candida* Species (1424-8247/17/1/89)

by [Monika Janecko](https://sciprofiles.com/profile/3305705?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Elżbieta Kočanowicz](https://sciprofiles.com/profile/author/8U5OWdod2U0ZUEvUJc0N05V19j0Q2T09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 89; <https://doi.org/10.3390/ph17010089> - 09 Jan 2024

Viewed by 514

Abstract The aim of this study was to investigate the antifungal activity of biochanin A (BCA) against planktonic growth and biofilms of six *Candida* species, including *C. albicans*, *C. parapsilosis*, *C. glabrata*, *C. tropicalis*, *C. auris*, and *C. krusei* [...]. [Read more](#).
 (This article belongs to the Section [Natural Products](#) ([journal/pharmaceuticals/sections/natural_products](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089/article_deploy/html/images/pharmaceuticals-17-00089-g001-550.jpg?1704808302) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089/article_deploy/html/images/pharmaceuticals-17-00089-g002-550.jpg?1704808304) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089/article_deploy/html/images/pharmaceuticals-17-00089-g003-550.jpg?1704808306) ([https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089-g004-550.jpg?1704808309](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089/article_deploy/html/images/pharmaceuticals-17-00089-g004-550.jpg?1704808309)) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089/article_deploy/html/images/pharmaceuticals-17-00089-g005-550.jpg?1704808311) ([https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089-g006-550.jpg?1704808313](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089/article_deploy/html/images/pharmaceuticals-17-00089-g006-550.jpg?1704808313)) (<https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089-g007-550.jpg?1704808316>) (<https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089-g008-550.jpg?1704808319>) (<https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089-g009-550.jpg?1704808322>) (<https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089-g010-550.jpg?1704808323>) (<https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089-g011-550.jpg?1704808325>) (<https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089-g012-550.jpg?1704808329>) (<https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00089-g013-550.jpg?1704808332>)

Open Access Article 18 pages, 3466 KB (1424-8247/17/1/88/pdf?version=1704801352)

Towards a New Generation of Hormone Therapies: Design, Synthesis and Biological Evaluation of Novel 1,2,3-Triazoles as Estrogen-Positive Breast Cancer Therapeutics and Non-Steroidal Aromatase Inhibitors (1424-8247/17/1/88)

by [Huda R. M. Rashdan](https://sciprofiles.com/profile/582108?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Mohamad T. Abdelrahman](https://sciprofiles.com/profile/288894?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Anna Chiara De Luca](https://sciprofiles.com/profile/102115?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Maria Mangini](https://sciprofiles.com/profile/1267241?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 88; <https://doi.org/10.3390/ph17010088> - 09 Jan 2024

Viewed by 661

Abstract Aromatase inhibitors (AIs) show promising features as drugs to treat estrogen-responsive breast cancer as they block aromatase activity, the key enzyme in estrogen synthesis. The current AIs approved by the Food and Drug Administration for breast cancer treatment present severe adverse effects. For [...]. [Read more](#).
 (This article belongs to the Section [Medicinal Chemistry](#) ([journal/pharmaceuticals/sections/pharm_medicinal_chemistry](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00088/article_deploy/html/images/pharmaceuticals-17-00088-g001a-550.jpg?1704801453) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00088/article_deploy/html/images/pharmaceuticals-17-00088-g001b-550.jpg?1704801456) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00088/article_deploy/html/images/pharmaceuticals-17-00088-g002-550.jpg?1704801459) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00088/article_deploy/html/images/pharmaceuticals-17-00088-g003-550.jpg?1704801461) (<https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00088-g004-550.jpg?1704801462>) (<https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00088-g005-550.jpg?1704801463>) (<https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00088-g006-550.jpg?1704801464>) (<https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00088-sch001-550.jpg?1704801466>)

Open Access Article 13 pages, 4014 KB (1424-8247/17/1/87/pdf?version=1704799635)

An ADAM10 Exosite Inhibitor Is Efficacious in an In Vivo Collagen-Induced Arthritis Model (1424-8247/17/1/87)

by [Juan Diez](https://sciprofiles.com/profile/author/MDCxeFZJR1VVYXpibU1czk0zB1TUZyMmZBYnpESHYUjEdH0S9EY3AxWT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Michael E. Selsted](https://sciprofiles.com/profile/1280526?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Thomas D. Bannister](https://sciprofiles.com/profile/author/UJ2FVY21eHc1UnJQnNsU0IMTKxWkWHU1Ue5idENUQZ8wbDV8TEFTYz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Dmitriy Minond](https://sciprofiles.com/profile/1297743?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 87; <https://doi.org/10.3390/ph17010087> - 09 Jan 2024

Viewed by 522

Abstract Rheumatoid arthritis is a systemic autoimmune inflammatory disease that affects millions of people worldwide. There are multiple disease-modifying anti-rheumatic drugs available; however, many patients do not respond to any treatment. A disintegrin and metalloproteinase 10 has been suggested as a potential new target [...]. [Read more](#).
 (This article belongs to the Section [Pharmacology](#) ([journal/pharmaceuticals/sections/pharm-pharmacology](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00087/article_deploy/html/images/pharmaceuticals-17-00087-g001-550.jpg?1704799735) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00087/article_deploy/html/images/pharmaceuticals-17-00087-g002-550.jpg?1704799736) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00087/article_deploy/html/images/pharmaceuticals-17-00087-g003-550.jpg?1704799741) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00087/article_deploy/html/images/pharmaceuticals-17-00087-g004-550.jpg?1704799742) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00087/article_deploy/html/images/pharmaceuticals-17-00087-g005-550.jpg?1704799744) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00087/article_deploy/html/images/pharmaceuticals-17-00087-g006-550.jpg?1704799747)

Open Access Article 12 pages, 2060 KB (1424-8247/17/1/86/pdf?version=1704798598)

Total Synthesis and Anti-Inflammatory Evaluation of Osajin, Scandeneone and Analogues (1424-8247/17/1/86)

by [Rui Wang](https://sciprofiles.com/profile/author/bCs5bXBxDFg4dV1UnVQVmxoYwPHNys3dnpzV3dqa0E5cnFKbHEmFZZ20=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Ran Ma](https://sciprofiles.com/profile/author/ZFkyk3VlaG14U1hsS09FZUovZDFvbmJSeikYkNYSDFJUTB1dmptcEHWZz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Ke Feng](https://sciprofiles.com/profile/author/NmpSLzJOYwdiUJFOYXk4EFFaDV1a2hCbEhwa3Uwc3f5e4H0G5ISHVQVTO=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Hongchen Lu](https://sciprofiles.com/profile/author/R2ITSxFu1RVTMT4WXd5RTIOWXdpQnJSZkxvcik9kd2tZJrEbEdab29OST0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Wei Zhao](https://sciprofiles.com/profile/22225?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Hongzhen Jin](https://sciprofiles.com/profile/2472257?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 86; <https://doi.org/10.3390/ph17010086> - 09 Jan 2024

Viewed by 514

Abstract In this study, the total synthesis of osajin, scandeneone and their analogues have been accomplished. The key synthetic steps include aldol/intramolecular iodoetherification/elimination sequence reactions and a Suzuki coupling reaction to assemble the tricyclic core, chemoselective propargylation and Claisen rearrangement reactions to obtain natural [...]. [Read more](#).
 (This article belongs to the Special Issue [Design, Synthesis and Biological Evaluation with Potential Anti-inflammatory Activity](#) ([journal/pharmaceuticals/special_issues/E3ZL8ZIM5M](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00086/article_deploy/html/images/pharmaceuticals-17-00086-ag-550.jpg?1704798684) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00086/article_deploy/html/images/pharmaceuticals-17-00086-g001-550.jpg?1704798674) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00086/article_deploy/html/images/pharmaceuticals-17-00086-g002-550.jpg?1704798676) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00086/article_deploy/html/images/pharmaceuticals-17-00086-g003-550.jpg?1704798676) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00086/article_deploy/html/images/pharmaceuticals-17-00086-sch001-550.jpg?1704798677) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00086/article_deploy/html/images/pharmaceuticals-17-00086-sch002-550.jpg?1704798678)

Pharmaceuticals/pharmaceuticals-17-00086/article_deploy/html/images/pharmaceuticals-17-00086-sch003-550.jpg?17104798679) (https://pub.mdpi-res.com/...)

Open Access Review 11 pages, 1764 KB (1424-8247/17/1/85/pdf?version=1704799501)

Involvement of the Expression of G Protein-Coupled Receptors in Schizophrenia (1424-8247/17/1/85)

- by Raluca Kalinovic, Andrei Pascariu, Gabriela Viad, Diana Ntiusca, Andreea Silcudean, Ioan Ovidiu Sirbu, Catalin Marian, and Virgil Radu Enatescu

Pharmaceuticals 2024, 17(1), 85; https://doi.org/10.3390/ph17010085 - 09 Jan 2024

Viewed by 540

Abstract The expression of GPCRs has been associated with schizophrenia, and their expression may induce morphological changes in brain regions responsible for schizophrenia and disease-specific behavioral changes.

Read more

(This article belongs to the Special Issue Recent Advances in Drug Discovery and Evaluation for the Treatment of Affective Disorders and Schizophrenia)

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00085/article_deploy/html/images/pharmaceuticals-17-00085-g001-550.jpg?17104799564)

Open Access Review 24 pages, 1475 KB (1424-8247/17/1/84/pdf?version=1704792347)

Berries vs. Disease: Revolve of the Phytochemicals (1424-8247/17/1/84)

- by Felipe F. Lamenza, Puja Upadhaya, Peyton Roth, Suvekshya Shrestha, Sushmitha Jagadeesha, and Natalie Horn

Pharmaceuticals 2024, 17(1), 84; https://doi.org/10.3390/ph17010084 - 09 Jan 2024

Viewed by 639

Abstract Secondary metabolites and phytochemicals in plant-based diets are known to possess properties that inhibit the development of several diseases including a variety of cancers of the aerodigestive tract.

Read more

(This article belongs to the Special Issue Naturally-Occurring Dietary Compounds for Cancer Prevention and Therapy)

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00084/article_deploy/html/images/pharmaceuticals-17-00084-g001-550.jpg?17104792453)

Open Access Article 15 pages, 2211 KB (1424-8247/17/1/83/pdf?version=1704784087)

The Designed Pore-Forming Antimicrobial Peptide C14R Combines Excellent Activity against the Major Opportunistic Human Pathogen Pseudomonas aeruginosa with Low Cytotoxicity (1424-8247/17/1/83)

- by Vanessa Mildenberger, Daniel Alpinzar-Pedraza, Ernesto M. Martell-Huquet, Markus Krämer, Grigory Bolotnikov, Anselmo J. Otero-Gonzalez, Tarja Weil, Armando Rodriguez-Alfonso, Nico Preising, Ludger Ständker, Verena Vogel, Barbara Spellerberg, Ann-Kathrin Kissmann, and Frank Rosenau

Pharmaceuticals 2024, 17(1), 83; https://doi.org/10.3390/ph17010083 - 09 Jan 2024

Viewed by 621

Abstract The diminishing portfolio of mankind's available antibiotics urges science to develop novel potent drugs. Here, we present a peptide fitting the typical blueprint of amphiphilic and membrane-active antimicrobial peptides.

Read more

(This article belongs to the Section Biopharmaceuticals)

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00083/article_deploy/html/images/pharmaceuticals-17-00083-g001-550.jpg?17104784155)

Open Access Article 11 pages, 1067 KIB (1424-8247/17/1/82/pdf?version=1708178259)

Lansoprazole Ameliorates Isoniazid-Induced Liver Injury (1424-8247/17/1/82)

- by Eri Wakai, Takashi Shiromizu, Shota Otaki, Junko Koikiwa, Satoshi Tamaru, and Yuhei Nishimura

Pharmaceuticals 2024, 17(1), 82; https://doi.org/10.3390/ph17010082 - 08 Jan 2024

Viewed by 609

Abstract Isoniazid is a first-line drug in antitubercular therapy. Isoniazid is one of the most commonly used drugs that can cause liver injury or acute liver failure, leading to death or emergency liver transplantation.

Read more

(This article belongs to the Special Issue Zebrafish as a Powerful Tool for Drug Discovery 2023)

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00082/article_deploy/html/images/pharmaceuticals-17-00082-g001-550.jpg?17106224213)

Open Access Article 21 pages, 5588 KIB (1424-8247/17/1/81/pdf?version=1705374803)

124-Triazole-Tethered Indolinones as New Cancer-Fighting Small Molecules Targeting VEGFR-2: Synthesis, Biological Evaluations and Molecular Docking ((1424-8247/17/1/81))

by Ahmed E. Elsaawi (https://sciprofiles.com/profile/3269794?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
 Mai I. Shahin (https://sciprofiles.com/profile/3298016?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
 Hager A. Eldendary (https://sciprofiles.com/profile/author/UH16bzU1c1AvQUFSyWx5bDjUrRw5aY25021R1a3crNUnZOVQWWczdVNMXN1K2M0RHASV2XVWmpHT3dacnMrNg=?utm_source=mdpi.com&utm_medium=

Tarfah Al-Warhi (https://sciprofiles.com/profile/1102598?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
 Fatma E. Hassan (https://sciprofiles.com/profile/3168711?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
 Wagdy M. Eldelna (https://sciprofiles.com/profile/1102977?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 81; https://doi.org/10.3390/ph17010081 (https://doi.org/10.3390/ph17010081) - 08 Jan 2024

Viewed by 643

Abstract Targeting the VEGFR-2 signaling pathway is an invertebrate approach toward combating pancreatic and hepatocellular cancers. Based on Sunitinib, the FDA-approved VEGFR-2 inhibitor, novel indolin-2-one-triazole hybrids were designed and synthesized as anti-hepatocellular and anti-pancreatic cancer agents with VEGFR-2 inhibitory activity. All the targeted compounds [...] [Read more.](#)

(This article belongs to the Special Issue **The Role of Molecular Docking in the Design of Targeted Therapeutic Entities and Nanomaterials** (/journal/pharmaceuticals/special_issues/572083346P))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-ag-550.jpg?1705374954) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-g001-550.jpg?1705374940) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-g002-550.jpg?1705374942) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-g003-550.jpg?1705374943) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-g004-550.jpg?1705374944) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-g005-550.jpg?1705374944) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-g006-550.jpg?1705374946) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-g007-550.jpg?1705374947) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-g008-550.jpg?1705374948) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-sch001-550.jpg?1705374950) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-sch002-550.jpg?1705374952) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00081/article_deploy/html/images/pharmaceuticals-17-00081-sch003-550.jpg?1705374953)

Open Access Article 13 pages, 2906 KB (1424-8247/17/1/80/pdf?version=1704717586)

Identification of Antagonistic Action of Pyrrolizidine Alkaloids in Muscarinic Acetylcholine Receptor M1 by Computational Target Prediction Analysis ((1424-8247/17/1/80))

by Sara Abdalfattah (https://sciprofiles.com/profile/417997?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
 Caroline Kyozi (https://sciprofiles.com/profile/3283143?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
 Akhtar Anorbi (https://sciprofiles.com/profile/3348935?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
 Fjail A. Omer (https://sciprofiles.com/profile/author/GjBFekE22nqWZ1h1t3FuaDBUTrNvXpOTINVOX5VYp6bFvbmUcZzLOD0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Matteo Rosellini (https://sciprofiles.com/profile/author/RUgYt2FHbF4d4U0FyU1F6UWFL0G84TWd0UXRNepZFIMSdOK1R5Yk0zdz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Max Riedl (https://sciprofiles.com/profile/author/QXb2MGNTzFsSfYVZQ2YzZLNppcy05MTd6UFRobmMwWmFicFFPMDc0ND0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Christian Meesters (https://sciprofiles.com/profile/author/VDirZVM4MTawdzZ2SzNNK3RuUdKxYX2OUReAdbzY2QvK2Fnd2twWGzVST0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Thomas Efferth (https://sciprofiles.com/profile/9530?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 80; https://doi.org/10.3390/ph17010080 (https://doi.org/10.3390/ph17010080) - 08 Jan 2024

Viewed by 806

Abstract Pyrrolizidine alkaloids (PAs) are one of the largest distributed classes of toxins in nature. They have a wide range of toxicity, such as hepatotoxicity, pulmonary toxicity, neuronal toxicity, and carcinogenesis. Yet, biological targets responsible for these effects are not well addressed. Using methods [...] [Read more.](#)

(This article belongs to the Section **Pharmacology** (/journal/pharmaceuticals/sections/pharm-pharmacology))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00080/article_deploy/html/images/pharmaceuticals-17-00080-ag-550.jpg?1704717675) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00080/article_deploy/html/images/pharmaceuticals-17-00080-g001-550.jpg?1704717666) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00080/article_deploy/html/images/pharmaceuticals-17-00080-g002-550.jpg?1704717668) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00080/article_deploy/html/images/pharmaceuticals-17-00080-g003-550.jpg?1704717670) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00080/article_deploy/html/images/pharmaceuticals-17-00080-g004-550.jpg?1704717673) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00080/article_deploy/html/images/pharmaceuticals-17-00080-g005-550.jpg?1704717675)

Open Access Article 13 pages, 6863 KB (1424-8247/17/1/79/pdf?version=1704709149)

Cytocidal Effect of Irradiation on Gastric Cancer Cells Infected with a Recombinant Mammalian Orthoreovirus Expressing a Membrane-Targeted KillerRed ((1424-8247/17/1/79))

by Yoshinori Shirasaka (https://sciprofiles.com/profile/3350282?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
 Kentaro Yamada (https://sciprofiles.com/profile/1832736?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
 Tsuyoshi Etoh (https://sciprofiles.com/profile/3223393?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
 Kazuko Noguchi (https://sciprofiles.com/profile/author/cGF5bkdBSXR0TmVGC9nWHXl3FNC1FH1WgszRzBZTUNmNjJNGZGTknFWT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Takumi Hasegawa (https://sciprofiles.com/profile/author/SDhZUnJFSThVH04SnVWk1JRTU9E0ndOUJR1c10VHNHTjdT3RybVIMaz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Katsuhiko Ogawa (https://sciprofiles.com/profile/author/WXVUeivjOE55RWVUmlsWXVsaFJWVXkU01pLbF1VWk0eUJXcy9oSmk4TT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Takeshi Kobayashi (https://sciprofiles.com/profile/author/cDdBUVA2a2hCTDJTXZ4NmtEwNppZtqvYzkZyJJaVnDXAS5WF4cmNnOD0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Akira Nishizono (https://sciprofiles.com/profile/author/RjRnK1hWM05ND16bm93QUZzcU6L2Jdk9Pb3k2TkpL1TWNWjYUjDIO0T0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Masafumi Inomata (https://sciprofiles.com/profile/3100949?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 79; https://doi.org/10.3390/ph17010079 (https://doi.org/10.3390/ph17010079) - 08 Jan 2024

Viewed by 603

Abstract The outcomes of unresectable gastric cancer (GC) are unfavorable even with chemotherapy; therefore, a new treatment modality is required. The combination of an oncolytic virus and photodynamic therapy can be one of the promising modalities to overcome this. Mammalian orthoreovirus (MRV) is an [...] [Read more.](#)

(This article belongs to the Special Issue **Oncolytic Viruses: New Cancer Immunotherapy Drugs** (/journal/pharmaceuticals/special_issues/OGG8G101AY))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00079/article_deploy/html/images/pharmaceuticals-17-00079-g001-550.jpg?1704709215) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00079/article_deploy/html/images/pharmaceuticals-17-00079-g002-550.jpg?1704709219) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00079/article_deploy/html/images/pharmaceuticals-17-00079-g003-550.jpg?1704709221) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00079/article_deploy/html/images/pharmaceuticals-17-00079-g004-550.jpg?1704709223) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00079/article_deploy/html/images/pharmaceuticals-17-00079-g005-550.jpg?1704709224)

Open Access Article 14 pages, 1823 KB (1424-8247/17/1/78/pdf?version=1704703664)

Medication Dosage Impact on Mortality in Old-Age Individuals with Schizophrenia: A National Cohort Study ((1424-8247/17/1/78))

by Jia-Ru Li (https://sciprofiles.com/profile/author/RDNNWmJxMmM2Nu44VVJGQUpTWmpod3pLTHQdQX3RMnloS2VnY3NnR2Ytyaz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Ling-Ling Yeh (https://sciprofiles.com/profile/1111953?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Ji-Yu Lin (https://sciprofiles.com/profile/author/CHNHZEKZFFMIteFBBZHA4YmVvGFXMnBZEXR5G5KWNuJ0W9sFFaVT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Yi-Ju Pan (https://sciprofiles.com/profile/604194?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 78; https://doi.org/10.3390/ph17010078 (https://doi.org/10.3390/ph17010078) - 08 Jan 2024

Viewed by 494

Abstract As the prevalence of old-age individuals with schizophrenia (OAS) increases in a society undergoing demographic aging, the exploration of medication choices becomes increasingly crucial. Due to the current scarcity of literature on OAS, this study seeks to examine how the utilization and cumulative [...] [Read more.](#)

(This article belongs to the Special Issue **Recent Advances in Drug Discovery and Evaluation for the Treatment of Affective Disorders and Schizophrenia** (/journal/pharmaceuticals/special_issues/4E9F06KCOU))

Show Figures

MDPI

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00078/article_deploy/html/images/pharmaceuticals-17-00078-g001-550.jpg?1704703819) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00078/article_deploy/html/images/pharmaceuticals-17-00078-g002a-550.jpg?1704703821) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00078/article_deploy/html/images/pharmaceuticals-17-00078-g002b-550.jpg?1704703823) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00078/article_deploy/html/images/pharmaceuticals-17-00078-g003a-550.jpg?1704703825) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00078/article_deploy/html/images/pharmaceuticals-17-00078-g003b-550.jpg?1704703828) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00078/article_deploy/html/images/pharmaceuticals-17-00078-g004-550.jpg?1704703829)

Open Access Article

16 pages, 2754 KB (1424-8247/17/1/77/pdf?version=1704700619)

Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates (1424-8247/17/1/77)

by

● **Fatemeh Zabih** (https://sciprofiles.com/profile/author/RnBxVW9LOU44ZVVLKzEzK05XmpacFAzMG1PWE9mdjQ2L1pBTVJJRis4OD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- **Mariam Cherri** (https://sciprofiles.com/profile/1523143?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Xiao Guo** (https://sciprofiles.com/profile/2033704?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Fiorenza Rancan** (https://sciprofiles.com/profile/763304?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Fabian Schumacher** (https://sciprofiles.com/profile/416732?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Ehsan Mohammadifar** (https://sciprofiles.com/profile/3132364?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Burkhard Kleuser** (https://sciprofiles.com/profile/364642?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Wolfogang Bäumer** (https://sciprofiles.com/profile/2110162?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- **Michael Schirmer** (https://sciprofiles.com/profile/author/WExTVIFRQ1M4UXZLZXVvUmZR2XJMXJTOTJhd0ZBd3cz01EYWFN6WmNwQT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

● **Annika Vogt** (https://sciprofiles.com/profile/102781?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

● **Rainer Haag** (https://sciprofiles.com/profile/160112?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 77; https://doi.org/10.3390/ph17010077 (https://doi.org/10.3390/ph17010077) - 08 Jan 2024

Viewed by 677

Abstract Inflammatory skin diseases, such as psoriasis, atopic dermatitis, and alopecia areata, occur when the regulatory tolerance of the innate immune system is disrupted, resulting in the activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) inflammatory signaling pathway by interleukin 6 [..] **Read more.** (This article belongs to the Section **Pharmaceutical Technology** (*Journal/Pharmaceuticals/sections/pharmaceutical technology*))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00077/article_deploy/html/images/pharmaceuticals-17-00077-g001-550.jpg?1704700691) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00077/article_deploy/html/images/pharmaceuticals-17-00077-g002-550.jpg?1704700692) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00077/article_deploy/html/images/pharmaceuticals-17-00077-g003-550.jpg?1704700693) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00077/article_deploy/html/images/pharmaceuticals-17-00077-g004-550.jpg?1704700694) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00077/article_deploy/html/images/pharmaceuticals-17-00077-g005-550.jpg?1704700697) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00077/article_deploy/html/images/pharmaceuticals-17-00077-g006-550.jpg?1704700699)

Open Access Review

20 pages, 2930 KB (1424-8247/17/1/76/pdf?version=1704694186)

Alpha-Emitting Radionuclides: Current Status and Future Perspectives (1424-8247/17/1/76)

by ● **Matthias Miederer** (https://sciprofiles.com/profile/230001?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● **Martina Bienesová-Schäfer** (https://sciprofiles.com/profile/720157?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● **Constantin Mamat** (https://sciprofiles.com/profile/3671?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

● **David Kästner** (https://sciprofiles.com/profile/author/ZEgyU3Jf4TFqdE5uRz9pbXpEQJBRUzHpcGfob0VJVThkDHISQVZYyVVCOD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

● **Marc Pichler** (https://sciprofiles.com/profile/1357310?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

● **Enrico Mezler** (https://sciprofiles.com/profile/author/L3dXrRnRub6xZURiHU3ZFJHQUJTN0V6M1NLcTEvbi02V0VGo3TmFaS0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

● **Claudia Brogsitter** (https://sciprofiles.com/profile/author/R1p6Qkpi25WWTZHL1MwUXZJVIFRjNNSmVneGV2Ni9NX0RTNGUy9NST0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

● **Jörg Kotzerka** (https://sciprofiles.com/profile/1647390?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● **Klaus Kopka** (https://sciprofiles.com/profile/907163?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● **David A. Scheinberg** (https://sciprofiles.com/profile/81583?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

● **Michael R. McDevitt** (https://sciprofiles.com/profile/author/UW5YK3YwRHGbmZycDZTMEFwTnB6bXh2dFF2VWVZNTWw3FCTHRmc21GG0T0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 76; https://doi.org/10.3390/ph17010076 (https://doi.org/10.3390/ph17010076) - 08 Jan 2024

Viewed by 865

Abstract The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation combined is an important factor in understanding and implementing new therapies. Together with the continued approach of imaging [..] **Read more.** (This article belongs to the Special Issue **Therapeutic Radionuclides in Nuclear Medicine** (*Journal/Pharmaceuticals/special issues/M8TAS21VQU*))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00076/article_deploy/html/images/pharmaceuticals-17-00076-g001-550.jpg?1704694251) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00076/article_deploy/html/images/pharmaceuticals-17-00076-g002-550.jpg?1704694253) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00076/article_deploy/html/images/pharmaceuticals-17-00076-g003-550.jpg?1704694255) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00076/article_deploy/html/images/pharmaceuticals-17-00076-g004-550.jpg?1704694257) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00076/article_deploy/html/images/pharmaceuticals-17-00076-g005-550.jpg?1704694259) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00076/article_deploy/html/images/pharmaceuticals-17-00076-g006-550.jpg?1704694260) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00076/article_deploy/html/images/pharmaceuticals-17-00076-g007-550.jpg?1704694262) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00076/article_deploy/html/images/pharmaceuticals-17-00076-g008-550.jpg?1704694263)

Open Access Article

26 pages, 17665 KB (1424-8247/17/1/75/pdf?version=170473998)

A Novel Combined Dry Powder Inhaler Comprising Nanosized Ketoprofen-Embedded Mannitol-Coated Microparticles for Pulmonary Inflammations: Development, In Vitro-In Silico Characterization, and Cell Line Evaluation (1424-8247/17/1/75)

by ● **Heba Banat** (https://sciprofiles.com/profile/1407979?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● **Ildikó Csóka** (https://sciprofiles.com/profile/639403?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● **Dóra Paróczai** (https://sciprofiles.com/profile/939964?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● **Katalin Burian** (https://sciprofiles.com/profile/939975?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● **Árpád Farkas** (https://sciprofiles.com/profile/author/ay9VK1FzRkQ0Wm5YWEINRFRIKzKkVnRWWlloqXBkVBSUGxzMm1Y1T3AxRT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

and

● **Rita Ambrus** (https://sciprofiles.com/profile/161462?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 75; https://doi.org/10.3390/ph17010075 (https://doi.org/10.3390/ph17010075) - 07 Jan 2024

Viewed by 813

Abstract Pulmonary inflammations such as chronic obstructive pulmonary disease and cystic fibrosis are widespread and can be fatal, especially when they are characterized by abnormal mucus accumulation. Inhaled corticosteroids are commonly used for lung inflammations despite their considerable side effects. By utilizing particle engineering [..] **Read more.** (This article belongs to the Section **Pharmaceutical Technology** (*Journal/Pharmaceuticals/sections/pharmaceutical technology*))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-ag-550.jpg?1704774103) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-g001-550.jpg?1704774087) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-g002a-550.jpg?1704774090) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-g002b-550.jpg?1704774093) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-g003-550.jpg?1704774094) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-g004a-550.jpg?1704774096) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-g004b-550.jpg?1704774098) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-g005-550.jpg?1704774099) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-g006-550.jpg?1704774099) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-g007-550.jpg?1704774099) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-g008-550.jpg?1704774100) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00075/article_deploy/html/images/pharmaceuticals-17-00075-g009-550.jpg?1704774102)

Open Access Article

12 pages, 2370 KB (1424-8247/17/1/74/pdf?version=1704612136)

The AI-(AID-1-T) G-Quadruplex Has a Janus Effect on Primary and Recurrent Gliomas: Anti-Proliferation and Pro-Migration (1424-8247/17/1/74)

- Svetlana Pavlova (https://sciprofiles.com/profile/3259795?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- Ekaterina Savchenko (https://sciprofiles.com/profile/author/SIIVWJei9zG03b3h3YkhLEJmJUmDcYnJkMDIoNVOUlpMSVdLaFVt8z0p5Kq3Uy9wut-c3k1eb4&utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Anastasia Ryabova (https://sciprofiles.com/profile/1465355?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- Marina Ryzhova (https://sciprofiles.com/profile/author/cU9FTDK0VINGN21T0EJZQ0UxczlpZa09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Alexander Revishchin (https://sciprofiles.com/profile/author/a29JNFaMvZrMvVjVWIsSnE2WkVCMG55SiTBThZ0KzRsb21TE11Zz0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Igor Pronin (https://sciprofiles.com/profile/author/dJBMWHRaWk1nVDYycG03WT9xRjQdz09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Dmitry Usachev (https://sciprofiles.com/profile/author/NHNCROVzODNJRU4ycXJBODqzOVNXGszNEhQFN0T0VhQhUZ0z3Z1VZaz0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Alexey Kopylov (https://sciprofiles.com/profile/664818?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Galina Pavlova (https://sciprofiles.com/profile/969014?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Pharmaceuticals* 2024, 17(1), 74; <https://doi.org/10.3390/ph17010074> (<https://doi.org/10.3390/ph17010074>) - 07 Jan 2024

Viewed by 557

Abstract High-grade gliomas are considered an incurable disease. Despite all the various therapy options available, patient survival remains low, and the tumor usually returns. Tumor resistance to conventional therapy and stimulation of the migratory activity of surviving cells are the main factors that lead [...]. [Read more.](#)
(This article belongs to the Special Issue [Drug Therapy for Glioma](#) (*Journal of Pharmaceutics*/special_issues/H29563PD18).)

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00074/article_deploy/html/images/pharmaceutics-17-00074-g001-550.jpg?1704612203) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00074/article_deploy/html/images/pharmaceutics-17-00074-g002-550.jpg?1704612203) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00074/article_deploy/html/images/pharmaceutics-17-00074-g003-550.jpg?1704612204)

Open Access Article (1424-8247/17/1/73/pdf/version=1704680648) 17 pages, 5445 KB

Assessing Nasal Epithelial Dynamics: Impact of the Natural Nasal Cycle on Intranasal Spray Deposition (1424-8247/17/1/73)

- by ● Amr Seifeldinar (https://sciprofiles.com/profile/2722993?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- Xihuua Si (https://sciprofiles.com/profile/author/SC91KzRVTY85QWkUz2INROMnZozGNKZmXr0F5OVZMTBCM1UzM0iR70?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Jinxiang Xi (https://sciprofiles.com/profile/851165?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Pharmaceutics* 2024, 17(1), 73; <https://doi.org/10.3390/ph17010073> (<https://doi.org/10.3390/ph17010073>) - 06 Jan 2024

Viewed by 587

Abstract This study investigated the intricate dynamics of intranasal spray deposition within nasal models, considering variations in head orientation and stages of the nasal cycle. Employing controlled delivery conditions, we compared the deposition patterns of saline nasal sprays in models representing congestion (N1), normal [...]. [Read more.](#)
(This article belongs to the Special Issue [Advances in Pharmaceutical Sciences: In Honor of Dr. Jean Jacques Vanden Eynde \(JJ\)](#) (*Journal of Pharmaceutics*/special_issues/VN5JPSXZW9).)

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00073/article_deploy/html/images/pharmaceutics-17-00073-g001-550.jpg?1704680724) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00073/article_deploy/html/images/pharmaceutics-17-00073-g002-550.jpg?1704680726) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00073/article_deploy/html/images/pharmaceutics-17-00073-g003-550.jpg?1704680728) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00073/article_deploy/html/images/pharmaceutics-17-00073-g004-550.jpg?1704680731) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00073/article_deploy/html/images/pharmaceutics-17-00073-g005-550.jpg?1704680733) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00073/article_deploy/html/images/pharmaceutics-17-00073-g006-550.jpg?1704680735) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00073/article_deploy/html/images/pharmaceutics-17-00073-g007-550.jpg?1704680738) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00073/article_deploy/html/images/pharmaceutics-17-00073-g008-550.jpg?1704680740) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00073/article_deploy/html/images/pharmaceutics-17-00073-g009-550.jpg?1704680742) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00073/article_deploy/html/images/pharmaceutics-17-00073-g010-550.jpg?1704680743) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00073/article_deploy/html/images/pharmaceutics-17-00073-g011-550.jpg?1704680745)

Open Access Communication (1424-8247/17/1/72/pdf/version=1704519021) 13 pages, 3485 KB

A Preliminary Study on Hepatoprotective, Hypolipidemic and Aortic Morphometric Effects of Omega-3-Rich Fish Oil in Hypercholesterolemic Mice (1424-8247/17/1/72)

- by ● Ana Lina C. C. Sales (https://sciprofiles.com/profile/author/NjJWNnhXK201K1Bkc1dnbnFoMk10VVVvXu0dK5JbmlMU3JwKzZFl1oxYz0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Maísa G. S. Primo (https://sciprofiles.com/profile/author/aWh2RvBRUndDVGpaUDZNF2SEJVaG55UEZpUkGvk1jczdYIISWtvQTO?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Renato S. Mello Neto (https://sciprofiles.com/profile/2019648?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- Ana Victória S. Mendes (https://sciprofiles.com/profile/2020579?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- Mariley M. Furtado (https://sciprofiles.com/profile/author/S1VZVUJmdXc5d25UNjSdXpOZY9KvmRRCrTFnMXB3YnhLdExwVWZRHOVTO?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Joana Érica L. Rocha (https://sciprofiles.com/profile/author/RVExv2x3ay9MM0x10XhhvTCeXfQZG92YwpyZmszbVhuNFHeGtVakQ40D0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- José Otávio C. S. Almeida (https://sciprofiles.com/profile/author/L1F3NmpaxNXoEZHvL5d5Xh0alPbcHmcVE2K3dnempuzXIUaUwD125zbx0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- José Venicius S. Franca (https://sciprofiles.com/profile/1930888?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- Salmon R. Ancar (https://sciprofiles.com/profile/author/SUhTR3UvWEI5U2ZSSU0yV0xVWHFBTUjhS2luamYav0hMOXE0VDZ2dG15MD0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Ana Karolinne S. Brito (https://sciprofiles.com/profile/565766?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- Luana O. Lopes (https://sciprofiles.com/profile/2030094?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- Marcia S. Rizzo (https://sciprofiles.com/profile/1367719?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- Ana Karina M. F. Lústosa (https://sciprofiles.com/profile/author/d3AvOe40K3NkbTV6aHdSWDUzafTfTk5OTW0zcxjrdldJRHndHFVvGfmcz0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Paulo Humberto M. Nunes (https://sciprofiles.com/profile/author/bkh1dVBMdXhYZVp2Wmh5d2c3QVnqZDMvUnc0Unk1bWbQYm1Zd3Vzc3M4a0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Massimo Lucarini (https://sciprofiles.com/profile/277822?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- Alessandra Durazzo (https://sciprofiles.com/profile/115749?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- Daniel Dias Rufino Arcaño (https://sciprofiles.com/profile/59298?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Maria do Carmo C. Martins (https://sciprofiles.com/profile/554889?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceutics 2024, 17(1), 72; <https://doi.org/10.3390/ph17010072> (<https://doi.org/10.3390/ph17010072>) - 06 Jan 2024

Viewed by 604

Abstract This study aims to evaluate the hepatoprotective, hypolipidemic and aortic morphometric effects of fish oil rich in omega-3 in hypercholesterolemic BALB/c mice. This is an experimental model that included 16 male BALB/c mice (*Mus musculus*) divided into three groups (G1 (standard [...]). [Read more.](#)
(This article belongs to the Section [Medicinal Chemistry](#) (*Journal of Pharmaceutics*/sections/pharm_medicinal_chemistry)).

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00072/article_deploy/html/images/pharmaceutics-17-00072-g001-550.jpg?1704519094) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00072/article_deploy/html/images/pharmaceutics-17-00072-g002-550.jpg?1704519097) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00072/article_deploy/html/images/pharmaceutics-17-00072-g003-550.jpg?1704519098) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00072/article_deploy/html/images/pharmaceutics-17-00072-g004-550.jpg?1704519099) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00072/article_deploy/html/images/pharmaceutics-17-00072-g005-550.jpg?1704519102) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00072/article_deploy/html/images/pharmaceutics-17-00072-g006-550.jpg?1704519103) (https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-17-00072/article_deploy/html/images/pharmaceutics-17-00072-g007-550.jpg?1704519105)

Open Access Brief Report (1424-8247/17/1/71/pdf/version=1704350495) 9 pages, 791 KB

Using Nutraceuticals to Help Manage Traumatic Spinal Cord Injury (1424-8247/17/1/71)

- by ● Paul Stacey (https://sciprofiles.com/profile/author/ZmJYVEpZamdHmFw09BYW96UW03MVZOXpBVKR5SvBlaU540DvYqzJIVTO?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Arun Mensinkai (https://sciprofiles.com/profile/author/N3dTbXBNWIIYUVQNHrWszZzWU1ZQ0R6L0FJeUR03g1WtNIK3NOK0o4az0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Pankaj Bansal (https://sciprofiles.com/profile/3217021?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

Seved-Hossein Hosseini (https://sciprofiles.com/profile/author/VXhxZvRBVzc1NEFvUURqTIN6aUHXMjIHUUZuMXp4Vzd3MOJ5U9JVXpoRT0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
MDPI

Andrew Lavigne ([https://sciprofiles.com/profile/author/ay91d1FVY3zYmISQ59\)Wm92aEdTnFVERStDZ3RnJQtdBSIBwVmOxWT0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name](https://sciprofiles.com/profile/author/ay91d1FVY3zYmISQ59)Wm92aEdTnFVERStDZ3RnJQtdBSIBwVmOxWT0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name))
(toggle desktop layout cookie) Q

Basia Gwardjan (https://sciprofiles.com/profile/author/YW9YZmdrdEtXamgyMHFvZjNoQVCT59KT3JPMjJMMk5obVA4VfVZStqQT0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Sayna Leylchian (https://sciprofiles.com/profile/author/SIVQcUM5MhntTGJITHBpMDF4r2YrJdUdIn2JFT3U2MDdCbks3eTE1MD0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Zhihui (Joy) Deng (https://sciprofiles.com/profile/author/b213akDQaHR2aEw0NGxOVGFvR2WQT09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Vinjamuri Chari (https://sciprofiles.com/profile/author/S0Fmc3VNL0F3VFQdyFNTB0cDRtBkdRbWIBV1FVQXVcURZV5Wm9oVT0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Sandra Giles (https://sciprofiles.com/profile/author/WS9YV0dLajhLUNISNE9ydTZnencxUT09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Shanker Nesathurai (https://sciprofiles.com/profile/2520128?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 71; <https://doi.org/10.3390/ph17010071> (<https://doi.org/10.3390/ph17010071>) - 04 Jan 2024
Viewed by 672

Abstract Traumatic spinal cord injury (TSCI) is a significant public health challenge that has an adverse impact on functional independence, quality of life, and life expectancy. Management of people's chronic conditions is a key aspect of contemporary medical practice. Our study was an open [...] [Read more](#).
(This article belongs to the Special Issue [Natural Products for Potential Use of Neuroprotective and Neurorestorative Effects](#) ([/journal/pharmaceuticals/special_issues/QXJ352L30G](#)))

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00071/article_deploy/html/images/pharmaceuticals-17-00071-g001-550.jpg?1704350624) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00071/article_deploy/html/images/pharmaceuticals-17-00071-g002-550.jpg?1704350627)

Open Access Article 14 pages, 2458 KiB ([/1424-8247/17/1/70/pdf?version=1704339003](https://doi.org/10.3390/ph17010071/pdf2?version=1704339003))

Researching New Drug Combinations with Senolytic Activity Using Senescent Human Lung Fibroblasts MRC-5 Cell Line ([1424-8247/17/1/70](https://doi.org/10.3390/ph17010071))

by Maria Carolina Ximenes de Godoy (https://sciprofiles.com/profile/author/QWZETGxZK3pMQRRIINZVHFvYvYzV291OVJZWVY5b3hyQmxDRihSST0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Juliana Alves Macedo (https://sciprofiles.com/profile/2801412?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Alessandra Gambara (https://sciprofiles.com/profile/3183728?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 70; <https://doi.org/10.3390/ph17010070> (<https://doi.org/10.3390/ph17010070>) - 04 Jan 2024
Viewed by 710

Abstract Therapeutically targeting senescent cells seems to be an interesting perspective in treating chronic lung diseases, which are often associated with human aging. The combination of the drug dasatinib and the polyphenol quercetin is used in clinical trials as a senolytic, and the first [...] [Read more](#).
(This article belongs to the Special Issue [Targeting Apoptosis as a Strategy for Developing New Drugs](#) ([/journal/pharmaceuticals/special_issues/7R94Z8W879](#)))

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00070/article_deploy/html/images/pharmaceuticals-17-00070-g001-550.jpg?1704339079) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00070/article_deploy/html/images/pharmaceuticals-17-00070-g002-550.jpg?1704339083) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00070/article_deploy/html/images/pharmaceuticals-17-00070-g003-550.jpg?1704339087) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00070/article_deploy/html/images/pharmaceuticals-17-00070-g004-550.jpg?1704339088) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00070/article_deploy/html/images/pharmaceuticals-17-00070-g005-550.jpg?1704339090) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00070/article_deploy/html/images/pharmaceuticals-17-00070-g006-550.jpg?1704339091)

Open Access Article 11 pages, 561 KiB ([/1424-8247/17/1/69/pdf?version=1704276888](https://doi.org/10.3390/ph17010069/pdf2?version=1704276888))

Use of Exposure Data to Establish Causality in Drug-Adverse Event Relationships: An Example with Desvenlafaxine ([1424-8247/17/1/69](https://doi.org/10.3390/ph17010069))

by Andrea Rodríguez-Lopez (https://sciprofiles.com/profile/3275009?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Gina Mejía-Abril (https://sciprofiles.com/profile/1674796?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Pablo Zubizar (https://sciprofiles.com/profile/1215786?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Sofía Calleja (https://sciprofiles.com/profile/author/K2ZWVEIMZkFWYkZFTnUJghmdk8zRG1EZHxVVM0cVBHqJrSghobXZqJt0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Manuel Román (https://sciprofiles.com/profile/author/MzA1dTRNOFzR0k1TXM1OGpCWxFRdmUYz1qtVgd2ME9yTnRTLzFOeTQ5Zz0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Francisco Abad-Santos (https://sciprofiles.com/profile/1694501?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Dolores Ochoa (https://sciprofiles.com/profile/author/SExianVkvZ2NEFmJXZhemrY0VSVWYxc0yaDQxmd221htbVA5MzVhcz0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 69; <https://doi.org/10.3390/ph17010069> (<https://doi.org/10.3390/ph17010069>) - 03 Jan 2024
Viewed by 608

Abstract Causality algorithms help establish relationships between drug use and adverse event (AE) occurrence. High drug exposure leads to a higher likelihood of an AE being classified as an adverse drug reaction (ADR). However, there is a knowledge gap regarding what concentrations are predictive [...] [Read more](#).
(This article belongs to the Special Issue [Sex Differences in Pharmaceutical Practice](#) ([/journal/pharmaceuticals/special_issues/F63P58TAQE](#)))

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00069/article_deploy/html/images/pharmaceuticals-17-00069-g001-550.jpg?1704276980)

Open Access Article 19 pages, 2777 KiB ([/1424-8247/17/1/68/pdf?version=1704333524](https://doi.org/10.3390/ph17010068/pdf2?version=1704333524))

Antibacterial Action of Protein Fraction Isolated from *Rapana venosa* Hemolymph against *Escherichia coli* NBIMCC 8785 ([1424-8247/17/1/68](https://doi.org/10.3390/ph17010068))

by Mihalael Kirilova (https://sciprofiles.com/profile/1001945?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Yana Topalova (https://sciprofiles.com/profile/2071616?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Lyudmila Velkova (https://sciprofiles.com/profile/1156886?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Aleksandar Dolaski (https://sciprofiles.com/profile/1265627?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Dimitar Kaynarov (https://sciprofiles.com/profile/author/UWsrTnRasIlyWSshZXBOdbVDRlbnhuEsNmXanBFSGUvRENzBwCb0z0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Elmira Daskalova (https://sciprofiles.com/profile/author/WDDaYTdJLzI4WdhHVDhsRIdMcZINUT09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Nellie Zheleva (https://sciprofiles.com/profile/1192928?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 68; <https://doi.org/10.3390/ph17010068> (<https://doi.org/10.3390/ph17010068>) - 03 Jan 2024
Viewed by 719

Abstract Natural products and especially those from marine organisms are being intensively explored as an alternative to synthetic antibiotics. However, the exact mechanisms of their action are not yet well understood. The molecular masses of components in the hemolymph fraction with MW 50–100 kDa [...] [Read more](#).
(This article belongs to the Special Issue [Pharmaceutical Functions of Natural Compounds Derived from Molluscs and Arthropods](#) ([/journal/pharmaceuticals/special_issues/706V954144](#)))

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00068/article_deploy/html/images/pharmaceuticals-17-00068-g001-550.jpg?1704333595) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00068/article_deploy/html/images/pharmaceuticals-17-00068-g002-550.jpg?1704333596) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00068/article_deploy/html/images/pharmaceuticals-17-00068-g003-550.jpg?1704333597) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00068/article_deploy/html/images/pharmaceuticals-17-00068-g004-550.jpg?1704333599) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00068/article_deploy/html/images/pharmaceuticals-17-00068-g005-550.jpg?1704333601) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00068/article_deploy/html/images/pharmaceuticals-17-00068-g006-550.jpg?1704333604) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00068/article_deploy/html/images/pharmaceuticals-17-00068-g007-550.jpg?1704333608)

Open Access Article 22 pages, 6994 KiB ([/1424-8247/17/1/67/pdf?version=1704170277](https://doi.org/10.3390/ph17010067/pdf2?version=1704170277))

Examining the Antioxidant and Superoxide Radical Scavenging Activity of Anise, (*Pimpinella anisum* L. Seeds), Esculetin, and 4-Methyl-Esculetin Using X-ray Diffraction, Hydrodynamic Voltammetry and DFT Methods ([1424-8247/17/1/67](https://doi.org/10.3390/ph17010067))

by Miriam Rossi (https://sciprofiles.com/profile/435321?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Francesco Caruso (https://sciprofiles.com/profile/49287?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Natalie Thieke (https://sciprofiles.com/profile/author/ZEVR2ht1VBY0dXL0Z5bmlsa2fFM2hU1J4YnqvQnJaa0FBSnVSZU1KRT0?=utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Stuart Belli (https://sciprofiles.com/profile/565813?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Alana Kim (https://sciprofiles.com/profile/3304781?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Elisabetta Damiani (https://sciprofiles.com/profile/524356?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
Camilla Morresi (https://sciprofiles.com/profile/3075026?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Tiziana Bacchetti (https://sciprofiles.com/profile/1730966?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 67; <https://doi.org/10.3390/ph17010067> (<https://doi.org/10.3390/ph17010067>) - 31 Dec 2023
Viewed by 638

Abstract *Pimpinella anisum* L., or anise, is a plant that, besides its nutritional value, has been used in traditional medical practices and described in many cultures in the Mediterranean region. A possible reason for anise's therapeutic value is that it contains coumarins, which are [...] [Read more](#).
(This article belongs to the Special Issue [Natural Coumarins as Lead Compounds and Their Synthetic Analogues with Biological Activities](#) ([/journal/pharmaceuticals/special_issues/95T87NBSA0](#)))

[► Show Figures](#)

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g001-550.jpg?1704170343) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g002-550.jpg?1704170344) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g003-550.jpg?1704170345) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g004-550.jpg?1704170346) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g005-550.jpg?1704170347) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g007-550.jpg?1704170348) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g008-550.jpg?1704170350) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g009-550.jpg?1704170350) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g010-550.jpg?1704170351) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g011-550.jpg?1704170352) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g012-550.jpg?1704170353) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g013-550.jpg?1704170354) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g014-550.jpg?1704170355) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g015-550.jpg?1704170355) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g016-550.jpg?1704170356) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g017-550.jpg?1704170356) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g018-550.jpg?1704170357) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g019-550.jpg?1704170357) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g020-550.jpg?1704170358) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00067/article_deploy/html/images/pharmaceuticals-17-00067-g021-550.jpg?1704170359)

Open Access Article 23 pages, 8044 KIB (1424-8247/17/1/66/pdf?version=1703930258) ◀

Consumption of Policosanol (Raydel®) Improves Hepatic, Renal, and Reproductive Functions in Zebrafish: In Vivo Comparison Study among Cuban, Chinese, and American Policosanol (1424-8247/17/1/66)

- by [Kyung-Hyun Cho](#) (https://sciprofiles.com/profile/623875?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Ji-Eun Kim](#) (https://sciprofiles.com/profile/author/alFrc18TDZ5VnY4LzRnR3pZ0hU9YQSiEQEnKQ822WZ7Q1U5dTFEMD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Hyo-Seon Nam](#) (https://sciprofiles.com/profile/author/R215TzE0UFnXbUk4Z0Vbtk3SEVZ7kbBN3FjdZK2R3UWxR10hMQUxND0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- [Seung-Hee Baek](#) (https://sciprofiles.com/profile/2766059?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Ashutosh Bahuguna](#) (https://sciprofiles.com/profile/2967217?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 66; <https://doi.org/10.3390/ph17010066> (<https://doi.org/10.3390/ph17010066>) - 30 Dec 2023

Viewed by 687

Abstract The current study compared three policosanols from Cuba (sugarcane, Raydel®), policosanol (1), China (rice bran, Shaanxi, policosanol (2), and the USA (sugarcane, Lesstano®, policosanol (3)) in the treatment of dyslipidemia and protection of the liver, ovary, and testis in [...] [Read more](#).
(This article belongs to the Special Issue [Bioactive Substances, Oxidative Stress, and Inflammation](#) ([/journal/pharmaceuticals/special_issues/90C166403U](#)))

[► Show Figures](#)

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g001-550.jpg?1703930324) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g002-550.jpg?1703930326) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g003-550.jpg?1703930328) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g004-550.jpg?1703930330) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g005-550.jpg?1703930332) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g006-550.jpg?1703930335) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g007-550.jpg?1703930338) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g008-550.jpg?1703930341) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g009a-550.jpg?1703930343) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g009b-550.jpg?1703930344) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g010-550.jpg?1703930348) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00066/article_deploy/html/images/pharmaceuticals-17-00066-g011-550.jpg?1703930351)

Open Access Review 19 pages, 556 KB (1424-8247/17/1/65/pdf?version=1703932566)

A Narrative Review: Analysis of Supplemental Parenteral Nutrition in Adults at the End of Life (1424-8247/17/1/65)

- by [Francisco Rivas Garcia](#) (https://sciprofiles.com/profile/2935749?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Rafael Jesús Giménez Martínez](#) (https://sciprofiles.com/profile/1449064?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Felipe José Huertas Camarasa](#) (https://sciprofiles.com/profile/author/TUNhRUmMIFxZEFITG9QUEQ4djTUT09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Joan Carles March Cerdá](#) (https://sciprofiles.com/profile/author/djHVDFIKzEWm5wR1JmREZpY2zVwXpOGFVtJkrMWq1Q2iYZ0xnczEzV0ZLTjY4U3p0ZzZtGdFcVWJbDdHq9==?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- [Fuensanta Lloris Messegue](#) (https://sciprofiles.com/profile/author/ZFNGbGVoeDB6UkVuMnYMTBqVfVibkHEMDB4YStiaHvB3cExOWjVnQ3NZMFBSM1dFeDZiKJhUu9TR1EUQ==?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [María Margarita López-Vieta Gallardo](#) (https://sciprofiles.com/profile/60809?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 65; <https://doi.org/10.3390/ph17010065> (<https://doi.org/10.3390/ph17010065>) - 30 Dec 2023

Viewed by 915

Abstract "End of life" is a stage defined by the existence of an irreversible prognosis that ends with a person's death. One of the aspects of interest regarding end of life focuses on parenteral nutrition, which is usually administered in order to avoid malnutrition [...] [Read more](#).
(This article belongs to the Special Issue [Pharmaceutical Preparations, Challenges in Formulations and Compatibility Studies](#) ([/journal/pharmaceuticals/special_issues/S478N1767P](#)))

[► Show Figures](#)

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00065/article_deploy/html/images/pharmaceuticals-17-00065-g001-550.jpg?1703923669)

Open Access Article 16 pages, 1331 KIB (1424-8247/17/1/64/pdf?version=1704268514) ◀

Eugenol-Rich Essential Oil from *Pimenta dioica*: In Vitro and In Vivo Potentialities against *Leishmania amazonensis* (1424-8247/17/1/64)

- by [Lianet Monzote](#) (https://sciprofiles.com/profile/429964?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Laura Machin](#) (https://sciprofiles.com/profile/2441844?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Adiel González](#) (https://sciprofiles.com/profile/author/c3hySWVwOWJHMmJL1N6SHh4dZtmaGpBSGSIV3VcJUnzRE4rQUS5DnU4OD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Ramón Scull](#) (https://sciprofiles.com/profile/author/NW9BN0pEaVoxQW1nZUw2Z3hvUGRgRk9oc243GSr1UHMVXBMc2R4eDVEV0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Yamilet I. Gutiérrez](#) (https://sciprofiles.com/profile/author/N2MRTIIXw1IVVBtU9OYzZmVGRhcmJ4d2T5nliVXdjXILU3ZFaFY4dz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- [Prabodh Satyal](#) (https://sciprofiles.com/profile/674807?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Lars Gilte](#) (https://sciprofiles.com/profile/128450?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [William N. Setzer](#) (https://sciprofiles.com/profile/90636?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 64; <https://doi.org/10.3390/ph17010064> (<https://doi.org/10.3390/ph17010064>) - 29 Dec 2023

Viewed by 639

Abstract *Pimenta dioica* L. is one of the most recognized species with diverse biological activities. In this study, in vitro activity and in vivo efficacy of essential oil from *P. dioica* (EO-Pd) was evaluated. The main compound was also included in the animal studies and [...] [Read more](#).
(This article belongs to the Special Issue [Drug Discovery of Antiprotozoal Agents](#) ([/journal/pharmaceuticals/special_issues/LSS2D3H6Y1](#)))

[► Show Figures](#)

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00064/article_deploy/html/images/pharmaceuticals-17-00064-g001-550.jpg?1704268584) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00064/article_deploy/html/images/pharmaceuticals-17-00064-g002-550.jpg?1704268585) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00064/article_deploy/html/images/pharmaceuticals-17-00064-g003-550.jpg?1704268586)

pubmed.ncbi.nlm.nih.gov/pharmaceuticals/pharmaceuticals-17-00064/article_deploy/html/images/pharmaceuticals-17-00064-g003-550.jpg?1704268587

Open Access Article 15 pages, 1762 KIB (1424-8247/17/1/63/pdf?version=1704167406)

Paclitaxel and Therapeutic Drug Monitoring with Microsampling in Clinical Practice (1424-8247/17/1/63)

- Mirjana Radovanovic (https://sciprofiles.com/profile/2743421?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Peter Galetis (https://sciprofiles.com/profile/2792880?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Alex Flynn (https://sciprofiles.com/profile/author/anozOExMbEVkdE13RzRmWER3Q0djdKx3c3lQRXFLUpVcmxZY0NzElF2QTO=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Jennifer H. Martin (https://sciprofiles.com/profile/2478378?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Jennifer J. Schneider (https://sciprofiles.com/profile/200631?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 63; https://doi.org/10.3390/ph17010063 (https://doi.org/10.3390/ph17010063) - 29 Dec 2023

Viewed by 597

Abstract Paclitaxel is an anticancer agent efficacious in various tumors. There is large interindividual variability in drug plasma concentrations resulting in a wide variability in observed toxicity in patients. Studies have shown the time the concentration of paclitaxel exceeds 0.05 µM is a predictive [...] [Read more](#).

(This article belongs to the Special Issue **Applications of Liquid Chromatography Coupled with Mass Spectrometry (LC-MS/MS) in Drug Analysis** (*/journal/pharmaceuticals/special_issues/61L1B27981*))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00063/article_deploy/html/images/pharmaceuticals-17-00063-g001-550.jpg?1704167505) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00063/article_deploy/html/images/pharmaceuticals-17-00063-g002-550.jpg?1704167508) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00063/article_deploy/html/images/pharmaceuticals-17-00063-g003-550.jpg?1704167509) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00063/article_deploy/html/images/pharmaceuticals-17-00063-g004-550.jpg?1704167511)

Open Access Article 23 pages, 11040 KIB (1424-8247/17/1/62/pdf?version=1704038466)

Assessment of Some Unsymmetrical Porphyrins as Promising Molecules for Photodynamic Therapy of Cutaneous Disorders (1424-8247/17/1/62)

- Andrea Mihaela Burloiu (https://sciprofiles.com/profile/1868622?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Gina Manda (https://sciprofiles.com/profile/97420?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Dumitru Lupuliasa (https://sciprofiles.com/profile/1952748?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Radu Petre Socoteanu (https://sciprofiles.com/profile/121602?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Dragos Paul Mihai (https://sciprofiles.com/profile/327862?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Ionela Victoria Neage (https://sciprofiles.com/profile/author/TElqTUNiCRBNlJYkNwOHFQUHb0YwScDjHwKNNU1BhVklHeVrYZe1MD0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Laurentiu-Iliuta Anghelache (https://sciprofiles.com/profile/3332687?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Mihaela Surcel (https://sciprofiles.com/profile/author/MUdDcXpZbGpmY3NdENIRFbheRLTVZ3YzZoJ2qeFFsbXArAeE5NXB3cz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Mihai Anastasescu (https://sciprofiles.com/profile/439795?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Laura Olariu (https://sciprofiles.com/profile/author/d3VU00xVmlDRit2cnR6UXJCZmxZaHnObHYPZDVFNkSySERVMU5POEFFMD0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Carasela Elena Gird (https://sciprofiles.com/profile/1059565?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Stefania Felicia Barbuceanu (https://sciprofiles.com/profile/2049162?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Luis Filipe Vieira Ferreira (https://sciprofiles.com/profile/262450?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Rica Bosceanu (https://sciprofiles.com/profile/8796?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 62; https://doi.org/10.3390/ph17010062 (https://doi.org/10.3390/ph17010062) - 29 Dec 2023

Viewed by 599

Abstract In order to select for further development novel photosensitizers for photodynamic therapy in cutaneous disorders, three unsymmetrical porphyrins, namely 5-(4-hydroxy-3-methoxyphenyl)-10,15,20-tris-(4-acetoxy-3-methoxyphenyl) porphyrin (P2.2), 5-(2-hydroxy-5-methoxyphenyl)-10,15,20-tris-(4-carboxymethylphenyl) porphyrin (P3.2), and 5-(2,4-dihydroxyphenyl)-10,15,20-tris-(4-acetoxy-3-methoxyphenyl) porphyrin (P4.2), along with their fully symmetrical counterparts 5,10,15,20-tetrakis-(4-acetoxy-3-methoxyphenyl) porphyrin (P2.1) and 5,10,15,20-tetrakis-(4-carboxymethylphenyl) porphyrin (P3.1) were [...] [Read more](#).

(This article belongs to the Special Issue **The 20th Anniversary of Pharmaceuticals—How Artificial Intelligence Is Reshaping Pharmaceuticals Technology** (*/journal/pharmaceuticals/special_issues/BJ8P51W7HR*))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g001-550.jpg?1704038558) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g002-550.jpg?1704038559) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g003-550.jpg?1704038560) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g004-550.jpg?1704038561) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g005-550.jpg?1704038564) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g006-550.jpg?1704038566) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g007-550.jpg?1704038571) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g008-550.jpg?1704038572) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g009-550.jpg?1704038575) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g010-550.jpg?1704038576) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g011-550.jpg?1704038577) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00062/article_deploy/html/images/pharmaceuticals-17-00062-g012-550.jpg?1704038579)

Open Access Article 15 pages, 1263 KIB (1424-8247/17/1/61/pdf?version=1704167237)

Antipsychotics and Mortality in Adult and Geriatric Patients with Schizophrenia (1424-8247/17/1/61)

- Ling-Ling Yeh (https://sciprofiles.com/profile/1111953?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Wei-Chen Lee (https://sciprofiles.com/profile/author/bC9UYS(TW)UwaE13aUhWNRyODhHbHVSS1E1eDVuM3YMU0p1NlFCNjI2az0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Kuei-Hong Kuo (https://sciprofiles.com/profile/1728974?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Yi-Ju Pan (https://sciprofiles.com/profile/604194?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 61; https://doi.org/10.3390/ph17010061 (https://doi.org/10.3390/ph17010061) - 29 Dec 2023

Viewed by 542

Abstract Patients with schizophrenia have a high mortality risk, and the role of antipsychotic medications remains inconclusive. In an aging society, older patients with schizophrenia warrant increased attention. This study investigated the association of antipsychotic medication dosages with mortality in patients with schizophrenia by [...] [Read more](#).

(This article belongs to the Special Issue **Drug Analysis and Therapeutic Drug Monitoring** (*/journal/pharmaceuticals/special_issues/1D3UA8YN65*))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00061/article_deploy/html/images/pharmaceuticals-17-00061-g001-550.jpg?1704167306) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00061/article_deploy/html/images/pharmaceuticals-17-00061-g002-550.jpg?1704167309) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00061/article_deploy/html/images/pharmaceuticals-17-00061-g003-550.jpg?1704167316)

Open Access Article 12 pages, 2240 KIB (1424-8247/17/1/60/pdf?version=1703845507)

In Silico Screening of Multi-Domain Targeted Inhibitors for PTK6: A Strategy Integrating Drug Repurposing and Consensus Docking (1424-8247/17/1/60)

- Yujing Zhou (https://sciprofiles.com/profile/author/bV11K203aWN1RVRNaXd1eQvMHIDZGRndU5Qm9PwDKwksK01xd0yZz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Ming Wah Wong (https://sciprofiles.com/profile/117655?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 60; https://doi.org/10.3390/ph17010060 (https://doi.org/10.3390/ph17010060) - 29 Dec 2023

Viewed by 544

Abstract Protein tyrosine kinase 6 (PTK6), also known as breast tumor kinase (BRK), serves as a non-receptor intracellular tyrosine kinase within the Src kinases family. Structurally resembling other Src kinases, PTK6 possesses an Src homology 3 (SH3) domain, an Src homology 2 (SH2) domain, [...] [Read more](#).

(This article belongs to the Special Issue **Computer-Aided Drug Design and Drug Discovery** (*/journal/pharmaceuticals/special_issues/CDY0D8W0CQ*))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00060/article_deploy/html/images/pharmaceuticals-17-00060-g001-550.jpg?1703845584) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00060/article_deploy/html/images/pharmaceuticals-17-00060-g002-550.jpg?1703845584) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00060/article_deploy/html/images/pharmaceuticals-17-00060-g003-550.jpg?1703845585) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00060/article_deploy/html/images/pharmaceuticals-17-00060-g004-550.jpg?1703845586) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00060/article_deploy/html/images/pharmaceuticals-17-00060-g005-550.jpg?1703845587) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00060/article_deploy/html/images/pharmaceuticals-17-00060-g006-550.jpg?1703845589)

Open Access Editorial 5 pages, 167 KIB (1424-8247/17/1/59/pdf?version=1703834177)

Special Issue "Drug Treatments for Inflammatory Bowel Diseases" (1424-8247/17/1/59)

MDPI logo
Anderson Luiz-Ferreira (https://sciprofiles.com/profile/281667?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Carmine Stoffi (https://sciprofiles.com/profile/279287?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 59; https://doi.org/10.3390/ph17010059 (https://doi.org/10.3390/ph17010059) - 29 Dec 2023

Abstract Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic idiopathic, relapsing and remitting inflammatory diseases that affect the gastrointestinal tract, causing significant morbidity and loss of quality of life in affected individuals [...] Full article (1424-8247/17/1/59) (This article belongs to the Special Issue Drug Treatments for Inflammatory Bowel Diseases (/journal/pharmaceuticals/special_issues/drug_colitis))

Open Access Article 17 pages, 6093 KIB (1424-8247/17/1/59/pdf?version=1703832900) CC BY

The Discovery of Novel Agents against Staphylococcus aureus by Targeting Sortase A: A Combination of Virtual Screening and Experimental Validation (1424-8247/17/1/58)

by Kang Liu (https://sciprofiles.com/profile/3022889?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Jianqbo Tong (https://sciprofiles.com/profile/3233598?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Xu Liu (https://sciprofiles.com/profile/author/T0kxNGNCRWdOc2VWMGNpckdkUG4vYU9rjChTGdMIZUd3crQ1hHNk9jbz0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Dan Liang (https://sciprofiles.com/profile/author/LzFcfWQOz2iVEcwWUNxZ3JPQ21YcTVBWRhczJdXcZcWU0TXY0TRIND0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Fangzhe Ren (https://sciprofiles.com/profile/1521234?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Nan Jiang (https://sciprofiles.com/profile/author/hjNpK1VYM0cyZFhP0RnRDFIVfJ0TkFQdXFBU5nU1ZqW5C8WVLZG5nND0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Zhenyu Hao (https://sciprofiles.com/profile/3232533?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Shixia Li (https://sciprofiles.com/profile/3234289?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Qiang Wang (https://sciprofiles.com/profile/2368639?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 58; https://doi.org/10.3390/ph17010058 (https://doi.org/10.3390/ph17010058) - 29 Dec 2023

Abstract Staphylococcus aureus (S. aureus), commonly known as "superbugs", is a highly pathogenic bacterium that poses a serious threat to human health. There is an urgent need to replace traditional antibiotics with novel drugs to combat S. aureus. Sortase A (SrtA) is [...] Read more. (This article belongs to the Section Biopharmaceuticals (/journal/pharmaceuticals/sections/biopharmaceuticals))

Show Figures (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00058/article_deploy/html/images/pharmaceuticals-17-00058-ag-550.jpg?1703833016) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00058/article_deploy/html/images/pharmaceuticals-17-00058-g001-550.jpg?1703833007) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00058/article_deploy/html/images/pharmaceuticals-17-00058-g002-550.jpg?1703833008) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00058/article_deploy/html/images/pharmaceuticals-17-00058-g003-550.jpg?1703833009) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00058/article_deploy/html/images/pharmaceuticals-17-00058-g004-550.jpg?1703833010) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00058/article_deploy/html/images/pharmaceuticals-17-00058-g005-550.jpg?1703833011) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00058/article_deploy/html/images/pharmaceuticals-17-00058-g006-550.jpg?1703833013) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00058/article_deploy/html/images/pharmaceuticals-17-00058-g007-550.jpg?1703833014)

Open Access Correction 1 pages, 504 KIB (1424-8247/17/1/57/pdf?version=1703816530)

Correction: Volkova et al. Cyclodextrin's Effect on Permeability and Partition of Nortriptyline Hydrochloride. Pharmaceuticals 2023, 16, 1022 (1424-8247/17/1/57)

by Tatyana Volkova (https://sciprofiles.com/profile/2455523?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Olga Simonova (https://sciprofiles.com/profile/author/RHNZN1F6DRSN1dwcMlQK2x0c2o0UT09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and German Perlovich (https://sciprofiles.com/profile/1598173?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 57; https://doi.org/10.3390/ph17010057 (https://doi.org/10.3390/ph17010057) - 29 Dec 2023

Abstract In the original publication [...] Full article (1424-8247/17/1/57) (This article belongs to the Special Issue Cyclodextrin-Based Drug Delivery System and Its Pharmaceutical and Biomedical Application (/journal/pharmaceuticals/special_issues/SB95818D2R))

Show Figures (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00057/article_deploy/html/images/pharmaceuticals-17-00057-g002-550.jpg?1703816597)

Open Access Article 17 pages, 4377 KIB (1424-8247/17/1/56/pdf?version=170377306) CC BY

The Tandem of Liquid Chromatography and Network Pharmacology for the Chemical Profiling of Pule'an Tablets and the Prediction of Mechanism of Action in Treating Prostatitis (1424-8247/17/1/56)

by Hui Zhuge (https://sciprofiles.com/profile/3288466?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Zhiwei Ge (https://sciprofiles.com/profile/3289722?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Jiao Jiao Wang (https://sciprofiles.com/profile/author/NDh3bmkRkhsTEVLTWimaTkWUEVYjlmJVUOW9WRURdHFJVjyNjEhOD0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Jianbiao Yao (https://sciprofiles.com/profile/author/WThFd1IXeS9QcFgNFp2N3pBQ2NVS09UYyPZjJtS1Eyc2xqSWiyZTREQTh0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Jiayu He (https://sciprofiles.com/profile/author/SmpjYrWZVNJSVRNTDd1UVhcnpvTEpxR0lZm1pOdZV3SUFxKy9OK3haND0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Yi Wang (https://sciprofiles.com/profile/199262?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Yingchao Wang (https://sciprofiles.com/profile/2264217?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Yu Tang (https://sciprofiles.com/profile/2340160?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 56; https://doi.org/10.3390/ph17010056 (https://doi.org/10.3390/ph17010056) - 28 Dec 2023

Abstract Prostatitis, a prevalent urinary tract disorder in males, has a complex etiology that leads to severe clinical discomfort. Pule'an Tablets, a classic single-component formulation primarily based on rapeseed pollen, have been clinically proven to have a beneficial therapeutic effect on both prostatitis and [...] Read more. (This article belongs to the Special Issue Recent Advances in the Discovery and Development of Drugs for Civilization Diseases (/journal/pharmaceuticals/special_issues/DHU303RD21))

Show Figures (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00056/article_deploy/html/images/pharmaceuticals-17-00056-ag-550.jpg?170377409) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00056/article_deploy/html/images/pharmaceuticals-17-00056-g001-550.jpg?170377399) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00056/article_deploy/html/images/pharmaceuticals-17-00056-g002-550.jpg?170377401) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00056/article_deploy/html/images/pharmaceuticals-17-00056-g003-550.jpg?170377402) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00056/article_deploy/html/images/pharmaceuticals-17-00056-g004-550.jpg?170377403) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00056/article_deploy/html/images/pharmaceuticals-17-00056-g005-550.jpg?170377404) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00056/article_deploy/html/images/pharmaceuticals-17-00056-g006-550.jpg?170377406) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00056/article_deploy/html/images/pharmaceuticals-17-00056-g007-550.jpg?170377407) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00056/article_deploy/html/images/pharmaceuticals-17-00056-g008-550.jpg?170377407) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00056/article_deploy/html/images/pharmaceuticals-17-00056-g009-550.jpg?170377408)

Open Access Article 12 pages, 2262 KIB (1424-8247/17/1/55/pdf?version=1703838027)

Comparative Studies on the Photoreactivity, Efficacy, and Safety of Depigmenting Agents (1424-8247/17/1/55)

by Sandra Mota (https://sciprofiles.com/profile/author/L3RITIExcFR2SIlxNDJRSTNd0tSWFVnL0o3RU5Tto2cGdvTtNxMlAwdz0?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Gonçalo P. Rosa (https://sciprofiles.com/profile/719137?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Maria Carmo Barreto (https://sciprofiles.com/profile/286881?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Jorge Garrido (https://sciprofiles.com/profile/725241?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Emilia Sousa (https://sciprofiles.com/profile/148085?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Maria T. Cruz (https://sciprofiles.com/profile/658545?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Isabel F. Almeida (https://sciprofiles.com/profile/881342?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Clara Quintas (https://sciprofiles.com/profile/1169246?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 55; https://doi.org/10.3390/ph17010055 (https://doi.org/10.3390/ph17010055) - 28 Dec 2023

Abstract Depigmenting products are increasingly used to counteract skin hyperpigmentation and related psychosocial issues. This study aimed to compare different depigmenting agents—4-butylresorcinol; bakuchiol; tranexamic acid; ascorbyl glucoside; alpha-arbutin; and ascorbic acid—for photoreactivity, tyrosinase inhibition, and safety. Photoreactivity was assessed using the Reactive Oxygen Species [...] Read more. (This article belongs to the Section Pharmacology (/journal/pharmaceuticals/sections/pharm-pharmacology))

Show Figures
MDPI
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00055/article_deploy/html/images/pharmaceuticals-17-00055-g001-550.jpg?1703838097) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00055/article_deploy/html/images/pharmaceuticals-17-00055-g002-550.jpg?1703838098) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00055/article_deploy/html/images/pharmaceuticals-17-00055-g003-550.jpg?1703838099) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00055/article_deploy/html/images/pharmaceuticals-17-00055-g004-550.jpg?1703838100)

Open Access Review 42 pages, 2077 KIB (1424-8247/17/1/54/pdf?version=1703761584)

Triterpenes Drug Delivery Systems, a Modern Approach for Arthritis Targeted Therapy (1424-8247/17/1/54)

by [Célia Faustino](https://sciprofiles.com/profile/715488?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/715488?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Nélia Duarte](https://sciprofiles.com/profile/739227?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/739227?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Lidia Pinheiro](https://sciprofiles.com/profile/903786?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/903786?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 54; <https://doi.org/10.3390/ph17010054> (<https://doi.org/10.3390/ph17010054>) - 28 Dec 2023
Viewed by 712

Abstract Arthritis is a major cause of disability. Currently available anti-arthritis drugs, such as disease-modifying anti-rheumatic drugs (DMARDs), have serious side-effects associated with long-term use. Triterpenoids are natural products with known anti-inflammatory properties, and many have revealed efficiency against arthritis both in vitro and [...]
[Read more](#).
(This article belongs to the Section [Pharmaceutical Technology](#) ([journal/pharmaceuticals/sections/pharmaceutical_technology](#)))

Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00054/article_deploy/html/images/pharmaceuticals-17-00054-g0-550.jpg?1703841179) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00054/article_deploy/html/images/pharmaceuticals-17-00054-g001-550.jpg?1703761658) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00054/article_deploy/html/images/pharmaceuticals-17-00054-g002-550.jpg?1703761660) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00054/article_deploy/html/images/pharmaceuticals-17-00054-g003-550.jpg?1703761661) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00054/article_deploy/html/images/pharmaceuticals-17-00054-g004-550.jpg?1703761665)

Open Access Article 16 pages, 2611 KIB (1424-8247/17/1/53/pdf?version=1703756588)

The Use of Population Pharmacokinetics to Extrapolate Food Effects from Human Adults and Beagle Dogs to the Pediatric Population Illustrated with Paracetamol as a Test Case (1424-8247/17/1/53)

by [Elke Gastreys](https://sciprofiles.com/profile/1088906?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1088906?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Louis Sandhu](https://sciprofiles.com/profile/author/Qx2BuZ1LWRWYK1JWVbX1Z5amuJHSmZEcG96akhIWRFB1ZpaWJEVIVwND0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/Qx2BuZ1LWRWYK1JWVbX1Z5amuJHSmZEcG96akhIWRFB1ZpaWJEVIVwND0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Marina Stelova](https://sciprofiles.com/profile/author/VXdnQW5tQml2TnBjQ3VlZzONWh6ZVRySHJuaWJESFzSUNuWIEMzVKN0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/VXdnQW5tQml2TnBjQ3VlZzONWh6ZVRySHJuaWJESFzSUNuWIEMzVKN0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Maria Vertzoni](https://sciprofiles.com/profile/2003458?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/2003458?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[An Vermeulen](https://sciprofiles.com/profile/author/K1dFWFNQbqyL01JT1FGGkc2QV5K016WFNYcEJDOXk2TTEzQldTeEZZcz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/K1dFWFNQbqyL01JT1FGGkc2QV5K016WFNYcEJDOXk2TTEzQldTeEZZcz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 53; <https://doi.org/10.3390/ph17010053> (<https://doi.org/10.3390/ph17010053>) - 28 Dec 2023
Viewed by 586

Abstract To date, food–drug interactions in the pediatric population remain understudied. The current food effect studies are mostly performed in adults and do not mimic the real-life situation in the pediatric population. Since the potential benefits of food effect studies performed in pediatrics should [...]
[Read more](#).
(This article belongs to the Special Issue [Pharmacology of Pediatric Medicines](#) ([journal/pharmaceuticals/special_issues/Pediatric_Medicines](#)))

Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00053/article_deploy/html/images/pharmaceuticals-17-00053-g001-550.jpg?1703756680) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00053/article_deploy/html/images/pharmaceuticals-17-00053-g002-550.jpg?1703756682) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00053/article_deploy/html/images/pharmaceuticals-17-00053-g003-550.jpg?1703756685) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00053/article_deploy/html/images/pharmaceuticals-17-00053-g004-550.jpg?1703756686) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00053/article_deploy/html/images/pharmaceuticals-17-00053-g005-550.jpg?1703756687) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00053/article_deploy/html/images/pharmaceuticals-17-00053-g006-550.jpg?1703756688)

Open Access Article 15 pages, 1839 KIB (1424-8247/17/1/52/pdf?version=1703746880)

The Effective Synthesis of New Benzoquinoline Derivatives as Small Molecules with Anticancer Activity (1424-8247/17/1/52)

by [Gheorghita Zbancioc](https://sciprofiles.com/profile/478244?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/478244?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Ionel I. Mangalagu](https://sciprofiles.com/profile/10160?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/10160?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Costel Moldoveanu](https://sciprofiles.com/profile/1414533?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1414533?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 52; <https://doi.org/10.3390/ph17010052> (<https://doi.org/10.3390/ph17010052>) - 28 Dec 2023
Viewed by 564

Abstract In this study, some novel benzo[c]quinoline derivatives were synthesized, their structural characteristics were described, and their in vitro anticancer efficacy was investigated. The synthesis involves an initial quaternization of the nitrogen atom from benzo[c]quinoline and then a [3+2] dipolar [...]
[Read more](#).
(This article belongs to the Special Issue [Medicinal Chemistry of Indole and Quinoline Derivatives: Trends, and Future Directions as Therapeutic Drugs](#) ([journal/pharmaceuticals/special_issues/CU6105Y27.1](#)))

Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00052/article_deploy/html/images/pharmaceuticals-17-00052-g001-550.jpg?1703746982) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00052/article_deploy/html/images/pharmaceuticals-17-00052-g002-550.jpg?1703746983) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00052/article_deploy/html/images/pharmaceuticals-17-00052-sch001-550.jpg?1703746985) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00052/article_deploy/html/images/pharmaceuticals-17-00052-sch002-550.jpg?1703746987) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00052/article_deploy/html/images/pharmaceuticals-17-00052-sch003-550.jpg?1703746990) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00052/article_deploy/html/images/pharmaceuticals-17-00052-sch004-550.jpg?1703746993)

Open Access Article 15 pages, 3357 KIB (1424-8247/17/1/51/pdf?version=1703744282)

Surgical Primary Tumor Resection Reduces Accumulation of CD11b⁺ Myeloid Cells in the Lungs Augmenting the Efficacy of an Intranasal Cancer Vaccination against Secondary Lung Metastasis (1424-8247/17/1/51)

by [Michael Donkor](https://sciprofiles.com/profile/2300839?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/2300839?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Jamie Y. Choe](https://sciprofiles.com/profile/2734782?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/2734782?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Danielle Marie Reid](https://sciprofiles.com/profile/2745871?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/2745871?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Hope K. Fiaidjoe](https://sciprofiles.com/profile/333286?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/333286?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Byron Quinn](https://sciprofiles.com/profile/author/K3d5S1mTUROTHFoSVA2SnZ1WmyUUV1SC9QSHYUkvwzVNEdHVV0tVt0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/K3d5S1mTUROTHFoSVA2SnZ1WmyUUV1SC9QSHYUkvwzVNEdHVV0tVt0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Amalendu Ranjan](https://sciprofiles.com/profile/1217964?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1217964?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Mark Pulse](https://sciprofiles.com/profile/author/NWR3MGYzS1rjeG56VXVPd3JC22pDMORIRXRDOVVYNAbXbpmVd4U2E5UT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/NWR3MGYzS1rjeG56VXVPd3JC22pDMORIRXRDOVVYNAbXbpmVd4U2E5UT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Pankaj Chaudhary](https://sciprofiles.com/profile/1344249?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1344249?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Riyaz Basha](https://sciprofiles.com/profile/98246?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/98246?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Harlan P. Jones](https://sciprofiles.com/profile/185212?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/185212?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 51; <https://doi.org/10.3390/ph17010051> (<https://doi.org/10.3390/ph17010051>) - 28 Dec 2023
Viewed by 930

Abstract A hallmark of effective cancer treatment is the prevention of tumor recurrence and metastasis to distal organs, which are responsible for most cancer deaths. However, primary tumor resection is expected to be curative as most solid tumors have been shown both experimentally and [...]
[Read more](#).
(This article belongs to the Section [Pharmaceutical Technology](#) ([journal/pharmaceuticals/sections/pharmaceutical_technology](#)))

Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00051/article_deploy/html/images/pharmaceuticals-17-00051-g001-550.jpg?1703745362) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00051/article_deploy/html/images/pharmaceuticals-17-00051-g002a-550.jpg?1703745366) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00051/article_deploy/html/images/pharmaceuticals-17-00051-g002b-550.jpg?1703745369) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00051/article_deploy/html/images/pharmaceuticals-17-00051-g003-550.jpg?1703745372) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00051/article_deploy/html/images/pharmaceuticals-17-00051-g004-550.jpg?1703745376) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00051/article_deploy/html/images/pharmaceuticals-17-00051-g005-550.jpg?1703745378) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00051/article_deploy/html/images/pharmaceuticals-17-00051-g006-550.jpg?1703745380)

Open Access Article 16 pages, 2632 KIB (1424-8247/17/1/50/pdf?version=1703744745)

A Ru(II)-Strained Complex with 2,9-Diphenyl-1,10-phenanthroline Ligand Induces Selective Photoactivatable Chemotherapeutic Activity on Human Alveolar Carcinoma Cells via Apoptosis (1424-8247/17/1/50)

by [Najwa Mansour](https://sciprofiles.com/profile/2866985?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/2866985?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Stephanie Mehanna](https://sciprofiles.com/profile/2244961?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/2244961?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

[Kikki Bodman-Smith](https://sciprofiles.com/profile/author/VmhsQXh4NUhKb2xWSm3enFtcz4OSHRXRGcQvbkVwdz4UbmVSNhZz0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/VmhsQXh4NUhKb2xWSm3enFtcz4OSHRXRGcQvbkVwdz4UbmVSNhZz0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) **MDPI**

[Constantine F. Daher](https://sciprofiles.com/profile/3253248?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3253248?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Rony S. Khayzar](https://sciprofiles.com/profile/2227986?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/2227986?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) **Pharmaceuticals** 2024, 17(1), 50; <https://doi.org/10.3390/ph17010050> (https://doi.org/10.3390/ph17010050) - 28 Dec 2023
Viewed by 672

Abstract [Ru(bipy)₂(dpphen)]Cl₂ (where bipy = 2,2'-bipyridine and dpphen = 2,9-diphenyl-1,10-phenanthroline) (complex 1) is a sterically strained compound that exhibits promising in vitro phototoxicity on an array of cell lines. Since lung adenocarcinoma cancer remains the most common lung cancer and [...] [Read more.](#)
(This article belongs to the Special Issue [The 20th Anniversary of *Pharmaceuticals*—Metal-Based Drugs for Cancer Treatment, Antibacterial and Antiviral Applications](#) ([/journal/pharmaceuticals/special_issues/70A4B37AYW](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00050/article_deploy/html/images/pharmaceuticals-17-00050-g001-550.jpg?1703744964) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00050/article_deploy/html/images/pharmaceuticals-17-00050-g002-550.jpg?1703744965) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00050/article_deploy/html/images/pharmaceuticals-17-00050-g003-550.jpg?1703744966) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00050/article_deploy/html/images/pharmaceuticals-17-00050-g004-550.jpg?1703744969) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00050/article_deploy/html/images/pharmaceuticals-17-00050-g005-550.jpg?1703744973) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00050/article_deploy/html/images/pharmaceuticals-17-00050-g006-550.jpg?1703744975) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00050/article_deploy/html/images/pharmaceuticals-17-00050-g007-550.jpg?1703744975) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00050/article_deploy/html/images/pharmaceuticals-17-00050-g008-550.jpg?1703744977) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00050/article_deploy/html/images/pharmaceuticals-17-00050-g009-550.jpg?1703744979)

Open Access Editorial 4 pages, 161 KiB (1424-8247/17/1/49/pdf?version=1703736517)

Special Issue: "Molecular Imaging in Oncology: Radiopharmaceuticals for PET and SPECT 2022" (1424-8247/17/1/49)

by [Junbo Zhang](https://sciprofiles.com/profile/150552?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/150552?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) **Pharmaceuticals** 2024, 17(1), 49; <https://doi.org/10.3390/ph17010049> (https://doi.org/10.3390/ph17010049) - 28 Dec 2023
Viewed by 571

Abstract Molecular imaging is partly defined as in vivo imaging of biological or biochemical processes using various markers [...]. [Full article](#) (1424-8247/17/1/49)
(This article belongs to the Special Issue [Molecular Imaging in Oncology, Radiopharmaceuticals for PET and SPECT 2022](#) ([/journal/pharmaceuticals/special_issues/Imaging_Oncology_Radiopharmaceuticals](#)))

Open Access Article 14 pages, 3502 KiB (1424-8247/17/1/48/pdf?version=1703727121)

Radioisynthesis Standardization and Preclinical Assessment of the [⁶⁸Ga]Ga-DOTA-Ubiquinidin_{29,41}: A Translational Study Targeting Differential Diagnosis of Infectious Processes (1424-8247/17/1/48)

by [Ana Cláudia Camargo Miranda](https://sciprofiles.com/profile/1525822?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1525822?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Leonardo Lima Fuscaldi](https://sciprofiles.com/profile/612777?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/612777?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Jorge Mejia](https://sciprofiles.com/profile/1510480?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1510480?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Fábio Fernando Alves da Silva](https://sciprofiles.com/profile/1460465?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1460465?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Walter Miguel Turato](https://sciprofiles.com/profile/953440?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/953440?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Fernanda Ferreira Mendonça](https://sciprofiles.com/profile/author/UWdJSjNRdmXVMjB0cnFHWZoMjMmSTN2SEwRWlncUFZEMlUjXnQVNVVjZjBhUmd6Ym5wZjA3c28yMmJBTQ==?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/UWdJSjNRdmXVMjB0cnFHWZoMjMmSTN2SEwRWlncUFZEMlUjXnQVNVVjZjBhUmd6Ym5wZjA3c28yMmJBTQ==?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Solange Amorim Nogueira](https://sciprofiles.com/profile/3287364?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3287364?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Akemi Osawa](https://sciprofiles.com/profile/author/TW9eSjFtenRvL3FFBkxYjgrWUhsQVlySUSHZGn2d3kZQ1pAR2wvV1QvJTM=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/TW9eSjFtenRvL3FFBkxYjgrWUhsQVlySUSHZGn2d3kZQ1pAR2wvV1QvJTM=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Lilian Yuri Itaya Yamaga](https://sciprofiles.com/profile/author/dGxQaGzZ1pCQhktJNENXFwNGJOTGFRkD5aURQZJhnUmJRMWnkNzJoRTO=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/dGxQaGzZ1pCQhktJNENXFwNGJOTGFRkD5aURQZJhnUmJRMWnkNzJoRTO=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Luciana Malavolta](https://sciprofiles.com/profile/577731?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/577731?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Marcel Fiolos de Barboza](https://sciprofiles.com/profile/1460433?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1460433?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 48; <https://doi.org/10.3390/ph17010048> (https://doi.org/10.3390/ph17010048) - 28 Dec 2023
Viewed by 745

Abstract Human bacterial infections significantly contribute to the increase in healthcare-related burdens. This scenario drives the study of novel techniques for the early and precise diagnosis of infectious processes. Some alternatives include Nuclear Medicine- and Molecular Imaging-based strategies. However, radiopharmaceuticals that are available for [...] [Read more.](#)
(This article belongs to the Special Issue [Gallium 68 Radiochemistry and Labelling Strategies](#) ([/journal/pharmaceuticals/special_issues/A9D6KF3N9G](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00048/article_deploy/html/images/pharmaceuticals-17-00048-g001-550.jpg?1703727201) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00048/article_deploy/html/images/pharmaceuticals-17-00048-g002-550.jpg?1703727202) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00048/article_deploy/html/images/pharmaceuticals-17-00048-g003-550.jpg?1703727203) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00048/article_deploy/html/images/pharmaceuticals-17-00048-g004-550.jpg?1703727204) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00048/article_deploy/html/images/pharmaceuticals-17-00048-g005-550.jpg?1703727204) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00048/article_deploy/html/images/pharmaceuticals-17-00048-g006-550.jpg?1703727205) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00048/article_deploy/html/images/pharmaceuticals-17-00048-g007-550.jpg?1703727206) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00048/article_deploy/html/images/pharmaceuticals-17-00048-g008-550.jpg?1703727207) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00048/article_deploy/html/images/pharmaceuticals-17-00048-g009-550.jpg?1703727208)

Open Access Article 14 pages, 3923 KiB (1424-8247/17/1/47/pdf?version=1703729493)

Protective Effect of Monoterpene Isoespinantol in a Rat Model of Prediabetes Induced by Fructose (1424-8247/17/1/47)

by [Luciana Di Sarli Gutiérrez](https://sciprofiles.com/profile/2911317?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/2911317?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [María Cecilia Castro](https://sciprofiles.com/profile/author/bWp6ZnVZTZMjcjTWkhBcINCncvNmFIN3FIRjVSWFRcWExrd2JidjZXTTO=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/bWp6ZnVZTZMjcjTWkhBcINCncvNmFIN3FIRjVSWFRcWExrd2JidjZXTTO=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Sherley Farromeque Vásquez](https://sciprofiles.com/profile/3174634?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3174634?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Hernán González Villagaría](https://sciprofiles.com/profile/author/OwIwRkZ6UVlvTkVgVEhKtTHMMEShancwNEHSmJFTFaQp4dW1G28yVTO=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/OwIwRkZ6UVlvTkVgVEhKtTHMMEShancwNEHSmJFTFaQp4dW1G28yVTO=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Luisa González Arbeláez](https://sciprofiles.com/profile/author/Qm82MmR6OThGcmtgMKRlJ3JTzrldGVMeUFWRCtmdGVjZU5aWGxXODFCSTO=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/Qm82MmR6OThGcmtgMKRlJ3JTzrldGVMeUFWRCtmdGVjZU5aWGxXODFCSTO=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Benjamin Rojano](https://sciprofiles.com/profile/2438206?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/2438206?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Guillermo Schinella](https://sciprofiles.com/profile/1336434?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1336434?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Barbara Maiztegul](https://sciprofiles.com/profile/author/ZINWV1U3U0J4YUjRUXRqAmY3MEViu9J0ZucDRcn4VUChCaXpGM1A4bz0=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/ZINWV1U3U0J4YUjRUXRqAmY3MEViu9J0ZucDRcn4VUChCaXpGM1A4bz0=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

[Flavio Francini](https://sciprofiles.com/profile/1916661?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1916661?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 47; <https://doi.org/10.3390/ph17010047> (https://doi.org/10.3390/ph17010047) - 28 Dec 2023
Viewed by 712

Abstract A high-fructose diet (HFD) induces murine alterations like those recorded in human prediabetes. Protective effects of isoespinantol (monoterpene isolated from Oxandra cf. xylopioides) on changes induced by HFD were evaluated. Animals were maintained for 21 days with a standard diet (C), 10% fructose [...] [Read more.](#)
(This article belongs to the Special Issue [Drug Candidates for the Treatment of Metabolic Syndrome](#) ([/journal/pharmaceuticals/special_issues/39XL716389](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00047/article_deploy/html/images/pharmaceuticals-17-00047-g001-550.jpg?1703729559) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00047/article_deploy/html/images/pharmaceuticals-17-00047-g002-550.jpg?1703729561) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00047/article_deploy/html/images/pharmaceuticals-17-00047-g003-550.jpg?1703729562) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00047/article_deploy/html/images/pharmaceuticals-17-00047-g004-550.jpg?1703729563) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00047/article_deploy/html/images/pharmaceuticals-17-00047-g005-550.jpg?1703729564) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00047/article_deploy/html/images/pharmaceuticals-17-00047-g006-550.jpg?1703729565) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00047/article_deploy/html/images/pharmaceuticals-17-00047-g007-550.jpg?1703729567) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00047/article_deploy/html/images/pharmaceuticals-17-00047-g008-550.jpg?1703729568) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00047/article_deploy/html/images/pharmaceuticals-17-00047-g009-550.jpg?1703729568)

Open Access Article 19 pages, 5486 KiB (1424-8247/17/1/46/pdf?version=1703683700)

(coumarin-3-yl)cinnamide Promotes Immunomodulatory, Neuroprotective, and Lung Function-Preserving Effects during Severe Malaria (1424-8247/17/1/46)

by [Paulo Gaio](https://sciprofiles.com/profile/3296058?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3296058?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

[Allysson Cramer](https://sciprofiles.com/profile/3299740?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3299740?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

[Natália Fernanda de Melo Oliveira](https://sciprofiles.com/profile/author/a3AxeFNTQm9z3V3V3dWVEEa25OYkRJa3pIMX16dFIETDkxMlHhYmXJUT0=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/a3AxeFNTQm9z3V3V3dWVEEa25OYkRJa3pIMX16dFIETDkxMlHhYmXJUT0=2?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Samuel Porto (https://sciprofiles.com/profile/author/L0jYSFhKT3p1ckkzL1dSQ29sRKR5b0h3QmdTbIRmZVBBSE42TKlVSWHKTTO=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) **MDPI**
- Lucas Kramer (https://sciprofiles.com/profile/author/bXBia0Ruaj3UIFZbDdIL0sZeXvHmml2WnJNVHJMVmVnR0UzbtNISVRCMD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Rayane Aparecida Nonato Rabelo (https://sciprofiles.com/profile/author/ak5obXUYrXJ2bWc3aVVKVGSZ5W0UWhGbnJAK8oVfJVRJREaOvZVNVQaz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Rafaela das Dores Pereira (https://sciprofiles.com/profile/3180339?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Laura Lis de Oliveira Santos (https://sciprofiles.com/profile/author/cZgwZxN3QZ2BK3VBWjdLUFWTFUKfISUpwa3MvK1NmSmFK1c2MXGzSIZ1QT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- César Luis Nascimento Barbosa (https://sciprofiles.com/profile/author/QXFWYWRudldnTj6SnZTRjNscnFARUic0JneU9ha3gyvVIRy9IQOxyZ0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Fabricao Marcus Silva Oliveira (https://sciprofiles.com/profile/author/Q1dLV0lMThJUmVJnFo4RDdOd2DZXFzdnTuaFq4dkY4eIYznFkQ20xND0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Mauro Martins Teixeira (https://sciprofiles.com/profile/1919420?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Remo Castro Russo (https://sciprofiles.com/profile/1610458?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Maria João Matos (https://sciprofiles.com/profile/1107223?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Fabiana Simão Machado (https://sciprofiles.com/profile/3156567?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 46; https://doi.org/10.3390/ph17010046 (https://doi.org/10.3390/ph17010046) - 27 Dec 2023
Viewed by 700

Abstract *Plasmodium berghoi* ANKA (PbA) infection in mice resembles several aspects of severe malaria in humans, such as cerebral malaria and acute respiratory distress syndrome. Herein, the effects of *N*-(coumarin-3-yl)cinnamamide (M220) against severe experimental malaria have been investigated. Treatment with M220 proved to [..] [Read more](#).

(This article belongs to the Special Issue **The 20th Anniversary of Pharmaceuticals—New Insights in Medicinal Chemistry of Nitrogen-Containing Compounds** (*Journal of pharmaceuticals/special_issues/C99K2RPOFE*))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00046/article_deploy/html/images/pharmaceuticals-17-00046-g001-550.jpg?1703683852) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00046/article_deploy/html/images/pharmaceuticals-17-00046-g002-550.jpg?1703683855) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00046/article_deploy/html/images/pharmaceuticals-17-00046-g003-550.jpg?1703683857) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00046/article_deploy/html/images/pharmaceuticals-17-00046-g004-550.jpg?1703683861) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00046/article_deploy/html/images/pharmaceuticals-17-00046-g005-550.jpg?1703683865) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00046/article_deploy/html/images/pharmaceuticals-17-00046-g006-550.jpg?1703683868)

Open Access Article 12 pages, 4466 KB (1424-8247/17/1/45/pdf?version=1703672936)

First In Vivo Application of Foam-Based Intrathoracic Chemotherapy (FBIC) in a Swine Model (1424-8247/17/1/45)

by Carolina Khosrawipour (https://sciprofiles.com/profile/author/V2JUckRLWnJxM05ML3JIR3FTc9obmZiN05ORXFUa2JJR2k2VEp2UVlyTT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Jakub Nicpoń (https://sciprofiles.com/profile/author/ZmdzKzFibI6ZUJJaEvsQU5SIF2SmxWk5JY3wY09RRkZmKvVwMEitbz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Zdzisław Kielbowicz (https://sciprofiles.com/profile/author/Nk1uYVtUHI0YXh6OWYdIFwMnpDb29ad1RUZFFVOWrcnFGdm4RVBCaz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Przemysław Prządka (https://sciprofiles.com/profile/1594467?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Bartomej Liszka (https://sciprofiles.com/profile/1465168?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Kacper Zieliński (https://sciprofiles.com/profile/author/a0ZVTNLtYlXSnkramZ4dXV5ZEX1dmIFRmISSTIQOx0zNkV3FaS3hPd0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Veria Khosrawipour (https://sciprofiles.com/profile/1998087?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Shiri Li (https://sciprofiles.com/profile/MIR6eHN5QUHLdHwMVRmZGFNEdLWkpqVDICh2RZa0RIUVZPSDkwNDNJT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Hien Lau (https://sciprofiles.com/profile/author/NmNkbXNWeWIMYkPjYzkyNjZwXc1eTnXek4M3g1VE9tcdGw5ReDihVt0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Joanna Kulas (https://sciprofiles.com/profile/author/SmtVYXjPEIDR00vQV1WmJkGNNNEgyQXQ2cFJ0QXE1NzhiT3hhdm1Saz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Agata Diakun (https://sciprofiles.com/profile/author/R3VQZFVMEzRkplQWNZTTI2ZU9oQmtMbnMS25WmncNuZk5TOW5JMD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Wojciech Kielan (https://sciprofiles.com/profile/author/c0dwiditLN1B1MIEVTUwazluTz92VW0yU3dFWFLZIEUyWmtieD4aUEwOD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Agata Mikolajczk-Martinez (https://sciprofiles.com/profile/2431917?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Mariusz Chabowski (https://sciprofiles.com/profile/author/aWp3amxvM9GUXpUL2JYVINd1JjbmIYkNKSZ42NxsAWZMTHNsUirYz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 45; https://doi.org/10.3390/ph17010045 (https://doi.org/10.3390/ph17010045) - 27 Dec 2023
Viewed by 606

Abstract Background: For decades, both intraperitoneal and pleural chemotherapy (IPC) have been delivered as a liquid solution. Recent studies suggest that foam carriers outperform liquid carriers for locoregional chemotherapy. For the first time, this study aims to evaluate the feasibility, safety, and characteristics of [..] [Read more](#).

(This article belongs to the Special Issue **Advancements and Challenges of Intrapleural and Peritoneal Drug Delivery** (*Journal of pharmaceuticals/special_issues/JD1K0S2VUUV*))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00045/article_deploy/html/images/pharmaceuticals-17-00045-g001-550.jpg?1703673010) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00045/article_deploy/html/images/pharmaceuticals-17-00045-g002-550.jpg?1703673011) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00045/article_deploy/html/images/pharmaceuticals-17-00045-g003-550.jpg?1703673012) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00045/article_deploy/html/images/pharmaceuticals-17-00045-g004-550.jpg?1703673015) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00045/article_deploy/html/images/pharmaceuticals-17-00045-g005-550.jpg?1703673018)

Open Access Article 14 pages, 5448 KB (1424-8247/17/1/44/pdf?version=1703669213)

Gallium-68-Labeled KISS1-54 Peptide for Mapping KISS1 Receptor via PET: Initial Evaluation in Human Tumor Cell Lines and in Tumor-Bearing Mice (1424-8247/17/1/44)

- Ina Israel (https://sciprofiles.com/profile/3228922?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Gabriele Riehl (https://sciprofiles.com/profile/author/S1dnY1B1cA3QnZ1VtHfMzZM1VGZz09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Elke Butt (https://sciprofiles.com/profile/900710?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Andreas K. Buck (https://sciprofiles.com/profile/author/dVZ0TWM3c3FRSUFJZzJuRIM1eHhnZ09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

and Samuel Samnick (https://sciprofiles.com/profile/2253262?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 44; https://doi.org/10.3390/ph17010044 (https://doi.org/10.3390/ph17010044) - 27 Dec 2023
Viewed by 574

Abstract Kisspeptins (KPs, KISS1) and their receptor (KISS1R) play a pivotal role as metastasis suppressor for many cancers. Low or lost KP expression is associated with higher tumor grade, increased metastatic potential, and poor prognosis. Therefore, KP expression has prognostic relevance and correlates with [..] [Read more](#).

(This article belongs to the Special Issue **PET and SPECT Molecular Imaging in Drug Development** (*Journal of pharmaceuticals/special_issues/965212NBNL*))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00044/article_deploy/html/images/pharmaceuticals-17-00044-g001a-550.jpg?1703669285) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00044/article_deploy/html/images/pharmaceuticals-17-00044-g001b-550.jpg?1703669287) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00044/article_deploy/html/images/pharmaceuticals-17-00044-g002-550.jpg?1703669289) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00044/article_deploy/html/images/pharmaceuticals-17-00044-g003-550.jpg?1703669291) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00044/article_deploy/html/images/pharmaceuticals-17-00044-g004-550.jpg?1703669293) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00044/article_deploy/html/images/pharmaceuticals-17-00044-g005-550.jpg?1703669297)

Open Access Article 17 pages, 7951 KB (1424-8247/17/1/43/pdf?version=1703845214)

Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway (1424-8247/17/1/43)

- Fenglin Luo (https://sciprofiles.com/profile/author/OHZzVE5Fvko5NEZwK2Q0Z3Uzdjg3bSt1eTdrKx4b0g3RY4YalMlyYhSQTO=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Yimeng Tang (https://sciprofiles.com/profile/author/NjRjHJuTVZTUo4YXpRgPlY9DVE4JktreHdHVThjdHNRy5mY05HV0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Lin Zheng (https://sciprofiles.com/profile/author/aXJSB2pkWHDsN0c4L0NEYUyYam1TY3MwTKF0TS9cGZGNVQzOVUSNDBKRT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Ying Yang (https://sciprofiles.com/profile/author/YHqVnhyVDNdn1dERHA4U9yMIVJb2VrZDjwcEplNzldMDirQnNldmRKdz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)



- Haoyue Gao (https://sciprofiles.com/profile/author/VEZoblUyZVRycWjITPIPTTBNGN6d3Vwb0ixNVlweKwvHBSU9eXJUVT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Shiyi Tian (https://sciprofiles.com/profile/author/ajcrN1liRG1BRXRCN2krckIOhFNUZDBBcW92WkzdkhYyk1RVW9EYjXTT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Hongyu Chen (https://sciprofiles.com/profile/author/RIZZWVA0nNgREhYzNWQ2VCNVWRGMZKXZV1V1pWZlQXNGRETTNOZ0ZNdz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Chenxi Tang (https://sciprofiles.com/profile/author/L3QwRFRpeHuzZih4hQvGtXtGrEeE4YUJVlceEFr53vmeXlxLzFGeEV2ST0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Shanshan Tang (https://sciprofiles.com/profile/author/bTc5NVJUQHWRjNsUJpTDVQSNrVNZFEokIcRhsdIXdIHJJeTVdCk5az0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Qiong Man (https://sciprofiles.com/profile/32197587utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Yiyue Wu (https://sciprofiles.com/profile/32197597utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 43; <https://doi.org/10.3390/ph17010043> (<https://doi.org/10.3390/ph17010043>) - 27 Dec 2023

Viewed by 570

Abstract Colorectal cancer (CRC) is one of the most common malignancies. Isoliquiritigenin (ISL), a flavonoid phytoestrogen, has shown anti-tumour activities against various cancers. However, its anti-CRC mechanism has not been clarified. In this study, the potential molecular mechanism of ISL against CRC was investigated [..] [Read more](#).
(This article belongs to the Special Issue *Bioactive Compounds from Plants and Foods with Pharmaceutical Interest 2023* ([/journal/pharmaceuticals/special_issues/K6906051X](https://journal/pharmaceuticals/special_issues/K6906051X)))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00043/article_deploy/html/images/pharmaceuticals-17-00043-g001-550.jpg?1703845304) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00043/article_deploy/html/images/pharmaceuticals-17-00043-g002-550.jpg?1703845307) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00043/article_deploy/html/images/pharmaceuticals-17-00043-g003-550.jpg?1703845310) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00043/article_deploy/html/images/pharmaceuticals-17-00043-g004-550.jpg?1703845315) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00043/article_deploy/html/images/pharmaceuticals-17-00043-g005-550.jpg?1703845315) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00043/article_deploy/html/images/pharmaceuticals-17-00043-g006-550.jpg?1703845319) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00043/article_deploy/html/images/pharmaceuticals-17-00043-g007-550.jpg?1703845322)

Open Access Article

16 pages, 2156 KB ([\(1424-8247/17/1/42/pdf?version=1703668584\)](#))

Potency and Powder X-ray Diffraction (PXRD) Evaluation of Levothyroxine Sodium Tablets under Ambient, Accelerated, and Stressed Conditions ([\(1424-8247/17/1/42\)](#))

by ● Mercy A. Okezie (https://sciprofiles.com/profile/27111657utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Stephen R. Byrn (https://sciprofiles.com/profile/117337utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Josiah Probst (https://sciprofiles.com/profile/author/ZXpEdnV1ND4wNDh1cUVob1JNc1c0QlkYzF2pFeTRUJmSVJUODRjaz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

● Madison Lucas (https://sciprofiles.com/profile/author/dIRnZKJo3VNCe01Z1NpKvYNY1ZaZ2G5TQZ42JId1p6T3BuRZUQZOZF0z0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

● Kari L. Clase (https://sciprofiles.com/profile/author/b0GyRk9cv2g1ekSVMjKm21nMXp1U3FYldeHGJia0dMRVEvM0xa1d0Yz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 42; <https://doi.org/10.3390/ph17010042> (<https://doi.org/10.3390/ph17010042>) - 27 Dec 2023

Viewed by 653

Abstract Levthyroxine tablets, although highly prescribed in the United States, have been one of the most frequently recalled products. Because of the importance of the medication, several efforts have been put in place by the United States Food and Drug Administration (US FDA) to [..] [Read more](#).
(This article belongs to the Special Issue *Polymorphs, Salts, Cocrystals and Cationic Lipid Nanoparticle Complexes in Drug Delivery* ([/journal/pharmaceuticals/special_issues/5UZZ2H897B](https://journal/pharmaceuticals/special_issues/5UZZ2H897B)))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00042/article_deploy/html/images/pharmaceuticals-17-00042-g001-550.jpg?1703668654) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00042/article_deploy/html/images/pharmaceuticals-17-00042-g002-550.jpg?1703668654) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00042/article_deploy/html/images/pharmaceuticals-17-00042-g003-550.jpg?1703668656) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00042/article_deploy/html/images/pharmaceuticals-17-00042-g004-550.jpg?1703668658) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00042/article_deploy/html/images/pharmaceuticals-17-00042-sch001-550.jpg?1703668660)

Open Access Review

17 pages, 4955 KB ([\(1424-8247/17/1/41/pdf?version=1703744555\)](#))

Molecular Marvels: Small Molecules Paving the Way for Enhanced Gene Therapy ([\(1424-8247/17/1/41\)](#))

by ● Sebastian Hesselbeck (https://sciprofiles.com/profile/33041087utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

● Xinliang Cheng (https://sciprofiles.com/profile/2993807utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 41; <https://doi.org/10.3390/ph17010041> (<https://doi.org/10.3390/ph17010041>) - 27 Dec 2023

Viewed by 739

Abstract In the rapidly evolving landscape of genetic engineering, the advent of CRISPR-Cas technologies has catalyzed a paradigm shift, empowering scientists to manipulate the genetic code with unprecedented accuracy and efficiency. Despite the remarkable capabilities inherent to CRISPR-Cas systems, recent advancements have witnessed the [..] [Read more](#).
(This article belongs to the Special Issue *The 20th Anniversary of Biopharmaceuticals—Emerging Trends in Biopharmaceuticals* ([/journal/pharmaceuticals/special_issues/Y15QW0H30](https://journal/pharmaceuticals/special_issues/Y15QW0H30)))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g001-550.jpg?1703744669) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g002-550.jpg?1703744671) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g003-550.jpg?1703744672) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g004-550.jpg?1703744673) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g005-550.jpg?1703744675) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g006-550.jpg?1703744677) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g007-550.jpg?1703744678) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g008-550.jpg?1703744679) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g009-550.jpg?1703744681) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g010a-550.jpg?1703744682) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g010b-550.jpg?1703744683) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g011-550.jpg?1703744685) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g012-550.jpg?1703744686) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g013-550.jpg?1703744687) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g014-550.jpg?1703744687) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g015-550.jpg?1703744688) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00041/article_deploy/html/images/pharmaceuticals-17-00041-g016-550.jpg?1703744689)

Open Access Article

16 pages, 5419 KIB ([\(1424-8247/17/1/40/pdf?version=1703659398\)](#))

***Juniperus oxycedrus* L. ssp. Essential Oil Microneedles: A Promising Antimicrobial and Wound Healing Activity** ([\(1424-8247/17/1/40\)](#))

by ● Basem Battah (https://sciprofiles.com/profile/8452397utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Lama Shhibe (https://sciprofiles.com/profile/author/VU1zHd5b1RJR2tcWINDhoazdV5y8rdEZDRDFxcC85aENQmRfEPjSbz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

● Osama Ahmad (https://sciprofiles.com/profile/author/ZTtBjUhtMT1R2i5Z3JkMu15UnZNU0g4MytlcW5sSDA5RWjP0FFSWillcaz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

● Chadi Soukkarieh (https://sciprofiles.com/profile/33157387utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Souad Mahmoud Al Okla (https://sciprofiles.com/profile/32399737utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Teresa Chianese (https://sciprofiles.com/profile/33797437utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Luigi Rosati (https://sciprofiles.com/profile/16276927utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Lalitkumar K. Vora (https://sciprofiles.com/profile/15488147utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Li Zhao (https://sciprofiles.com/profile/author/RnhzNFU4R3VzRUl6UjphUENUU1dHT0tzTE9FM9RWDZVHRzOXpQ2kzczo2=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

● Alessandra Marrazzo (https://sciprofiles.com/profile/31648827utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Marco Ferrari (https://sciprofiles.com/profile/29091657utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Linlin Li (https://sciprofiles.com/profile/author/bU5wNFazaFNGdHZQqArU3pCSUSV0N0WG1FZ1M1dmZaGdZUFDUJfEzZ0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

● Ryan F. Donnelly (https://sciprofiles.com/profile/1303477utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Stefania Zanetti (https://sciprofiles.com/profile/1055147utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

● Vittorio Mazzerolo (https://sciprofiles.com/profile/18429137utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

● Matthew Gavino Donadu (https://sciprofiles.com/profile/4261547utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 40; <https://doi.org/10.3390/ph17010040> (<https://doi.org/10.3390/ph17010040>) - 27 Dec 2023

Abstract. The use of essential oil (EO) in treating infected wounds is still challenging. A lot of effort has been made to make such an application more convenient. Recently, microneedles (MNDs) have been considered as a smart dermal delivery system to overcome the poor [...] [Read more.](#)
(This article belongs to the Special Issue [Bioactive Compounds from Plants and Foods with Pharmaceutical Interest 2023](#) ([/journal/pharmaceuticals/special_issues/K69060516X](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00040/article_deploy/html/images/pharmaceuticals-17-00040-g001-550.jpg?1703659527) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00040/article_deploy/html/images/pharmaceuticals-17-00040-g002-550.jpg?1703659529) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00040/article_deploy/html/images/pharmaceuticals-17-00040-g003-550.jpg?1703659532) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00040/article_deploy/html/images/pharmaceuticals-17-00040-g004-550.jpg?1703659537) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00040/article_deploy/html/images/pharmaceuticals-17-00040-g005-550.jpg?1703659538) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00040/article_deploy/html/images/pharmaceuticals-17-00040-g006-550.jpg?1703659542) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00040/article_deploy/html/images/pharmaceuticals-17-00040-g007-550.jpg?1703659543) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00040/article_deploy/html/images/pharmaceuticals-17-00040-g008-550.jpg?1703659547) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00040/article_deploy/html/images/pharmaceuticals-17-00040-g009-550.jpg?1703659549)

Open Access Editorial 3 pages, 168 KB ([/1424-8247/17/1/39/pdf?version=1703657117](#))

Pharmacological Advances for Treatment in Hypertension ([/1424-8247/17/1/39](#))

by [Arquimedes Gasparotto Junior](#) (https://sciprofiles.com/profile/8152867utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals **2024**, *17*(1), 39; <https://doi.org/10.3390/ph17010039> (<https://doi.org/10.3390/ph17010039>) - 27 Dec 2023

Viewed by 511
Abstract. Hypertension plays a significant role in the development of cardiovascular disease and renal diseases, which can heighten the likelihood of experiencing related conditions like myocardial infarction, stroke, and heart failure [...] [Full article](#) ([/1424-8247/17/1/39](#))
(This article belongs to the Special Issue [Pharmacological Advances for Treatment in Hypertension](#) ([/journal/pharmaceuticals/special_issues/pharm_Hypertension](#)))

Open Access Review 25 pages, 3434 KB ([/1424-8247/17/1/38/pdf?version=1703604241](#))

Active Compounds of *Panax ginseng* in the Improvement of Alzheimer's Disease and Application of Spatial Metabolomics ([/1424-8247/17/1/38](#))

by [Meng Zhang](#) (https://sciprofiles.com/profile/30021967utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Huazhou Niu](#) (https://sciprofiles.com/profile/3284850?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Qingqing Li](#) (https://sciprofiles.com/profile/3202858?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Lili Xiao](#) (https://sciprofiles.com/profile/author/dWnWpPUGxocEJpDFobYpYbEpmMFN2bFV3Y0vKRPQm1LaUJnJKSt0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Hui Li](#) (https://sciprofiles.com/profile/3258768?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
[Wei Wu](#) (https://sciprofiles.com/profile/2909329?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 38; <https://doi.org/10.3390/ph17010038> (<https://doi.org/10.3390/ph17010038>) - 26 Dec 2023

Viewed by 985
Abstract. *Panax ginseng* C.A. Meyer (*P. ginseng*) is one of the more common traditional Chinese medicines (TCMs). It contains numerous chemical components and exhibits a range of pharmacological effects. An enormous burden is placed on people's health and life by Alzheimer's disease [...] [Read more.](#)
(This article belongs to the Special Issue [Novel Applications of Metabolomics in Drug Discovery](#) ([/journal/pharmaceuticals/special_issues/J3V1NRYTB](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00038/article_deploy/html/images/pharmaceuticals-17-00038-g001-550.jpg?1703604340) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00038/article_deploy/html/images/pharmaceuticals-17-00038-g002-550.jpg?1703604342) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00038/article_deploy/html/images/pharmaceuticals-17-00038-g003-550.jpg?1703604344) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00038/article_deploy/html/images/pharmaceuticals-17-00038-g004-550.jpg?1703604346) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00038/article_deploy/html/images/pharmaceuticals-17-00038-g005-550.jpg?1703604347) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00038/article_deploy/html/images/pharmaceuticals-17-00038-g006-550.jpg?1703604349) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00038/article_deploy/html/images/pharmaceuticals-17-00038-g007-550.jpg?1703604350)

Open Access Article 19 pages, 2915 KB ([/1424-8247/17/1/37/pdf?version=1703581591](#))

An In Silico Investigation of the Molecular Interactions between Volatile Anesthetics and Actin ([/1424-8247/17/1/37](#))

by [Barbara Truglia](#) (https://sciprofiles.com/profile/3276711?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
[Nicola Carbone](#) (https://sciprofiles.com/profile/author/Z1F1S2RWY1BwCS9HtmLcXFiKz44HhFRZU2eIdRUQVaz2kUXUQFIST0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Ibrahim Ghadre](#) (https://sciprofiles.com/profile/author/Wj0WHNEdBRVIF6aGVNR2pZTWpVjJdGcyJTRUCDY1ajJkQk3L2pTt0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Sara Valero](#) (https://sciprofiles.com/profile/author/Y1g0WihJL0tYeRvSVY1RnptUJrnczV3NDi5bTQOUHtBGS9aZkhKfZNRt0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Marinella Zito](#) (https://sciprofiles.com/profile/author/ak1MzVWZiZUZ6Mjhhc1EyMDQrL0ZRCjRafFuMnZzai83eWVEZ/Ficz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Eric Adriano Zizzi](#) (https://sciprofiles.com/profile/1166721?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

[Marco Agostino Deriu](#) (https://sciprofiles.com/profile/918908?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

[J. A. Tuszyński](#) (https://sciprofiles.com/profile/1157?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 37; <https://doi.org/10.3390/ph17010037> (<https://doi.org/10.3390/ph17010037>) - 26 Dec 2023

Viewed by 578
Abstract. Volatile anesthetics (VAs) are medicinal chemistry compounds commonly used to enable surgical procedures for patients who undergo painful treatments and can be partially or fully sedated, remaining in an unconscious state during the operation. The specific molecular mechanism of anesthesia is still an [...] [Read more.](#)
(This article belongs to the Section [Pharmacology](#) ([/journal/pharmaceuticals/sections/pharm-pharmacology](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00037/article_deploy/html/images/pharmaceuticals-17-00037-g001-550.jpg?1703581680) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00037/article_deploy/html/images/pharmaceuticals-17-00037-g002a-550.jpg?1703581682) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00037/article_deploy/html/images/pharmaceuticals-17-00037-g002b-550.jpg?1703581683) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00037/article_deploy/html/images/pharmaceuticals-17-00037-g003-550.jpg?1703581686) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00037/article_deploy/html/images/pharmaceuticals-17-00037-g004a-550.jpg?1703581687) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00037/article_deploy/html/images/pharmaceuticals-17-00037-g004b-550.jpg?1703581688)

Open Access Editorial 2 pages, 160 KB ([/1424-8247/17/1/36/pdf?version=1703563992](#))

Advancements and Perspectives in Polysaccharide-Based Nanoparticles for Theranostic Nanomedicine ([/1424-8247/17/1/36](#))

by [Jingdi Chen](#) (https://sciprofiles.com/profile/1831333?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 36; <https://doi.org/10.3390/ph17010036> (<https://doi.org/10.3390/ph17010036>) - 26 Dec 2023

Viewed by 512
Abstract. It is with great enthusiasm [...] [Full article](#) ([/1424-8247/17/1/36](#))
(This article belongs to the Special Issue [Polysaccharide-Based Nanoparticles for Theranostic Nanomedicine](#) ([/journal/pharmaceuticals/special_issues/Polysaccharide_Nanomedicine](#)))

Open Access Article 14 pages, 5370 KIB ([/1424-8247/17/1/35/pdf?version=1704700775](#))

Synthesis and Antiviral Activity of Novel β -D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses ([/1424-8247/17/1/35](#))

by [Elizaveta S. Darnotuk](#) (https://sciprofiles.com/profile/author/QzU3ZVhFZGhKOWhWS0xSEh5aXZSMDm1pyRTZOb2UwVGRMSUJqUjU0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Andrei E. Siniavin](#) (https://sciprofiles.com/profile/994208?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

[Natalya S. Shastina](#) (https://sciprofiles.com/profile/author/T09yNzVWaEdWdW4WXNzTBwRzVhdWNGK0FYR3M3dXWwCYRM2FQUNZT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

[Sergey I. Luyksaar](#) (https://sciprofiles.com/profile/39461?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

[Anna M. Inshakova](#) (https://sciprofiles.com/profile/author/aGy21vG21MNzM3a2JWnlkUNBNdt0bWRINhCMWJKOE5mNkrVUWaz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Natalia E. Bondareva](#) (https://sciprofiles.com/profile/author/cy8MFpnMmYyaUIUQmNcmhVRDZ3Um1ZaGSWV1Y0QUdhGdNFXhMvNzYT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Sergey A. Zolotov](#) (https://sciprofiles.com/profile/author/TC9PUVNEsnF0TjNRbGpUanBGVE81NTRFNINRSxObUj3cONGakYjUDJVT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

[Nadezhda L. Lubenec](#) (https://sciprofiles.com/profile/author/QytmVXBUMkVLSWgrOfZtJhRSrKQYVRLz3M3bEj2RyYmXhVUs5ektNtT0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Anna B. Sheremet (https://sciprofiles.com/profile/author/aWVISO5oEtycEh1QJbxd0JWtUk5RbHh4YIU0NDhGWUlvAnB2VXk0Zz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) **MDPI**¹⁰
Denis Y. Logunov (https://sciprofiles.com/profile/21705427utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Nailya A. Ziganopova (https://sciprofiles.com/profile/24095097utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Vladimir A. Gushchin (https://sciprofiles.com/profile/23002747utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Alexander L. Gintsburg (https://sciprofiles.com/profile/author/dFd5Mz1MVHhPjWxJW0zJWRBOSuZ09zODJ3VU02M2SuR0e1eVv3dWST0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals **2024**, *17*(1), 35; <https://doi.org/10.3390/ph17010035> (<https://doi.org/10.3390/ph17010035>) - 26 Dec 2023
 Viewed by 816

Abstract The spread of COVID-19 infection continues due to the emergence of multiple transmissible and immune-evasive variants of the SARS-CoV-2 virus. Although various vaccines have been developed and several drugs have been approved for the treatment of COVID-19, the development of new drugs to [...] [Read more](#). (This article belongs to the Special Issue [Small Molecules Targeting Viral Polymerases](#) ([/journal/pharmaceuticals/special_issues/molecule_viral_polymerases](#)))

Show Figures
 (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00035/article_deploy/html/images/pharmaceuticals-17-00035-g001-550.jpg?1704700852) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00035/article_deploy/html/images/pharmaceuticals-17-00035-g002-550.jpg?1704700854) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00035/article_deploy/html/images/pharmaceuticals-17-00035-sch001-550.jpg?1704700856) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00035/article_deploy/html/images/pharmaceuticals-17-00035-sch002-550.jpg?1704700858)

Open Access **Review** 17 pages, 679 KB ([\(1424-8247/17/1/34/pdf?version=1703638803\)](#))

Photodynamic Action of Curcumin and Methylene Blue against Bacteria and SARS-CoV-2—A Review ([/1424-8247/17/1/34](#))

by **Siu Kan Law** (https://sciprofiles.com/profile/33652497utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 and **Albert Wing Nang Leung** (https://sciprofiles.com/profile/author/cWISNm9ZbHRzdnNkWNvR3JxduvQia4aItSdK1mQWx0TnhaNVN2b01WRTo=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Chuanshan Xu (https://sciprofiles.com/profile/7627567utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals **2024**, *17*(1), 34; <https://doi.org/10.3390/ph17010034> (<https://doi.org/10.3390/ph17010034>) - 25 Dec 2023
 Viewed by 759

Abstract Coronavirus disease 19 (COVID-19) has occurred for more than four years, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 is a strain of coronavirus, which presents high rates of morbidity around the world. Up to the present date, there are [...] [Read more](#). (This article belongs to the Special Issue [Photodynamic Therapy 2023](#) ([/journal/pharmaceuticals/special_issues/99439V4D1H](#)))

Show Figures
 (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00034/article_deploy/html/images/pharmaceuticals-17-00034-ag-550.jpg?1703840921) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00034/article_deploy/html/images/pharmaceuticals-17-00034-g001-550.jpg?1703840916) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00034/article_deploy/html/images/pharmaceuticals-17-00034-g002-550.jpg?1703840916)

Open Access **Article** 25 pages, 4607 KIB ([\(1424-8247/17/1/33/pdf?version=1703504027\)](#))

HIV-1 Transcription Inhibition Using Small RNA-Binding Molecules ([/1424-8247/17/1/33](#))

by **Pooja Khatkar** (https://sciprofiles.com/profile/16230977utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Gifty Mensah (https://sciprofiles.com/profile/author/a2x5MmxZczjXR1ZYSG6rStdOZmlY9wV3pNlII1FGZGRDd4Y1N3B1W0T0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Shangbo Ning (https://sciprofiles.com/profile/author/amJhcXY0a07jSGFUYXQ3m12eE1Vtnj;SENDAHJLJY9tekVSOGHUz1p3OD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Maria Cowen (https://sciprofiles.com/profile/author/ZUx2dVZUWC9EN28vWWJLbnR2czlGQT09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Yuriy Kim (https://sciprofiles.com/profile/1413623?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Anastasia Williams (https://sciprofiles.com/profile/author/IT2VSN0xySDZMh3ZVcNkNMN3BuQmsrQT09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Fardokht A. Abulwerdi (https://sciprofiles.com/profile/author/UC8xQkzqMURqM5e4cDBDQJoc9UUVm5MaTlvU3yUYkV2NUjPcmZ2THJGbz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Yunjie Zhao (https://sciprofiles.com/profile/1566846?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Chen Zeng (https://sciprofiles.com/profile/author/TG16rnh5TVJQWJzcDVYSDRGOURUW8XbV6KqWTDVc2lvaKHoT1NhUSIRMD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Stuart F. J. Le Grice (https://sciprofiles.com/profile/873147utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Fatab Kashanchi (https://sciprofiles.com/profile/294057utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals **2024**, *17*(1), 33; <https://doi.org/10.3390/ph17010033> (<https://doi.org/10.3390/ph17010033>) - 25 Dec 2023
 Viewed by 817

Abstract The HIV-1 transactivator protein Tat interacts with the transactivation response element (TAR) at the three-nucleotide UCU bulge to facilitate the recruitment of transcription elongation factor-b (P-TEFb) and induce the transcription of the integrated proviral genome. Therefore, the Tat-TAR interaction, unique to the virus, [...] [Read more](#). (This article belongs to the Special Issue [HIV and Viral Hepatitis: Prevention, Treatment and Coinfection](#) ([/journal/pharmaceuticals/special_issues/P8STP8KXC3](#)))

Show Figures
 (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00033/article_deploy/html/images/pharmaceuticals-17-00033-g001-550.jpg?1703504107) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00033/article_deploy/html/images/pharmaceuticals-17-00033-g002-550.jpg?1703504109) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00033/article_deploy/html/images/pharmaceuticals-17-00033-g003-550.jpg?1703504111) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00033/article_deploy/html/images/pharmaceuticals-17-00033-g004-550.jpg?1703504113) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00033/article_deploy/html/images/pharmaceuticals-17-00033-g005-550.jpg?1703504116) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00033/article_deploy/html/images/pharmaceuticals-17-00033-g006-550.jpg?1703504119) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00033/article_deploy/html/images/pharmaceuticals-17-00033-g007a-550.jpg?1703504123) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00033/article_deploy/html/images/pharmaceuticals-17-00033-g007b-550.jpg?1703504124) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00033/article_deploy/html/images/pharmaceuticals-17-00033-g008-550.jpg?1703504128) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00033/article_deploy/html/images/pharmaceuticals-17-00033-g009-550.jpg?1703504130)

Open Access **Article** 19 pages, 7282 KIB ([\(1424-8247/17/1/32/pdf?version=1703498127\)](#))

Synthesis and Biological Evaluation of Chalcones/Flavanones: En Route to Proapoptotic Agents with Antiestrogenic Potency ([/1424-8247/17/1/32](#))

by **Stepan K. Krymova** (https://sciprofiles.com/profile/2133710?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Diana I. Salnikova (https://sciprofiles.com/profile/1080642?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Lyubov G. Dzhenkova (https://sciprofiles.com/profile/author/REhH2nJYtRvYfwTJJBk03WDJKz1R3r0jpbVzVhCdzJzExPkyg4Z0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Fedor B. Bogdanov (https://sciprofiles.com/profile/2464466?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Alexander A. Korlyukov (https://sciprofiles.com/profile/author/tek4N2JScjGWEp5cDdicndMa2U1Rku5Skf1RnYyTZRDZRXVJBUzHpoZz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Alexander M. Scherbakov (https://sciprofiles.com/profile/381871?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
Andrey E. Shekhotikhin (https://sciprofiles.com/profile/1550420?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals **2024**, *17*(1), 32; <https://doi.org/10.3390/ph17010032> (<https://doi.org/10.3390/ph17010032>) - 25 Dec 2023
 Viewed by 616

Abstract Breast and other estrogen receptor α-positive cancers tend to develop resistance to existing drugs. Chalcone derivatives possess anticancer activity based on their ability to form covalent bonds with targets acting as Michael acceptors. This study aimed to evaluate the anticancer properties of a [...] [Read more](#). (This article belongs to the Special Issue [Recent Developments of Chalcones and Their Derivatives in Medicinal Chemistry](#) ([/journal/pharmaceuticals/special_issues/4482WUCKOP](#)))

Show Figures
 (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00032/article_deploy/html/images/pharmaceuticals-17-00032-ag-550.jpg?1703498231) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00032/article_deploy/html/images/pharmaceuticals-17-00032-g001-550.jpg?1703498224) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00032/article_deploy/html/images/pharmaceuticals-17-00032-g002-550.jpg?1703498225) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00032/article_deploy/html/images/pharmaceuticals-17-00032-g004-550.jpg?1703498226) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00032/article_deploy/html/images/pharmaceuticals-17-00032-g005-550.jpg?1703498227) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00032/article_deploy/html/images/pharmaceuticals-17-00032-sch001-550.jpg?1703498228) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00032/article_deploy/html/images/pharmaceuticals-17-00032-sch002-550.jpg?1703498229) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00032/article_deploy/html/images/pharmaceuticals-17-00032-sch003-550.jpg?1703498230) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00032/article_deploy/html/images/pharmaceuticals-17-00032-sch004-550.jpg?1703498230)

Open Access **Review** 15 pages, 7125 KIB ([\(1424-8247/17/1/31/pdf?version=1703493479\)](#))

Illuminating Dersimelagon: A Novel Agent in the Treatment of Erythropoietic Protoporphyria and X-Linked Protoporphyria ([/1424-8247/17/1/31](#))

by **Katelyn E. Madigan** (https://sciprofiles.com/profile/3178043?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).

- Sean R. Rudnick (https://sciprofiles.com/profile/author/cFE1d29PQm5eZVA4OVA5bDBOQJRNY1EVWUKU9Y4bVpNeINZUTZjQytpWT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) **MDPI**
- Matthew A. Agnew (https://sciprofiles.com/profile/author/OXRGAthUM0UjUqXUm81U2RlWGVQbVdNUxvbjZHVUJ2dTVhN2RR5Vdpcz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (toggle desktop layout cookie) Q
- Nurma Uroji (https://sciprofiles.com/profile/author/dkYvZz3WEV5dW9COWJLRWhtSK9Vk80aDiaV0sxQ20RnYwNzdHWfTdx0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Herbert L. Bonkovsky (https://sciprofiles.com/profile/1361814?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) *Pharmaceuticals* 2024, 17(1), 31; https://doi.org/10.3390/ph17010031 (https://doi.org/10.3390/ph17010031) - 25 Dec 2023
Viewed by 465

Abstract Erythropoietic protoporphyria (EPP) is a genetic disorder stemming from reduced ferrochelatase expression, the final enzyme in the pathway of heme biosynthesis. A closely related condition, X-linked protoporphyria (XLP), bears similar clinical features although it arises from the heightened activity of δ -aminolevulinic acid synthase [a]. [Read more.](#)

Show Figures

- (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00031/article_deploy/html/images/pharmaceuticals-17-00031-g001-550.jpg?1703493544) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00031/article_deploy/html/images/pharmaceuticals-17-00031-g002-550.jpg?1703493548) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00031/article_deploy/html/images/pharmaceuticals-17-00031-g003-550.jpg?1703493550) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00031/article_deploy/html/images/pharmaceuticals-17-00031-g004-550.jpg?1703493551) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00031/article_deploy/html/images/pharmaceuticals-17-00031-g005-550.jpg?1703493553) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00031/article_deploy/html/images/pharmaceuticals-17-00031-g006-550.jpg?1703493555) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00031/article_deploy/html/images/pharmaceuticals-17-00031-g007-550.jpg?1703493556)

Open Access Article 29 pages, 3591 KiB (1424-8247/17/1/30/pdf?version=1703590493)

New 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinazoline and 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinoline Derivatives: Synthesis and Biological Evaluation as Novel Anticancer Agents by Targeting G-Quadruplex (1424-8247/17/1/30)

- Jean Guillon (https://sciprofiles.com/profile/355905?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Marc Le Borgne (https://sciprofiles.com/profile/46056?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Vittoria Milano (https://sciprofiles.com/profile/author/Wm9Gc2RfMh4UllaMIbhbTRUMkRzMzNDU3FHhKppjJxWFJ6SkztMERUUT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Aurore Guédin-Beaurepaire (https://sciprofiles.com/profile/author/OHNhN1JoZHRbYehsN3FFL29jY2QvR2tmZmtwYTRrYTFpQn6dDY5amQ2MIE1dzJ2YtJtGwxc3FObkN2OWJFWQ==7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Stéphane Moreau (https://sciprofiles.com/profile/3325173?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Noël Pinaud (https://sciprofiles.com/profile/1534191?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Luisa Ravira (https://sciprofiles.com/profile/1840029?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Solène Songmoutou (https://sciprofiles.com/profile/author/NnRwWGHqNY9eSmdnRhbFA1M3pJZEfHMuZZRZIRzJX2pKdn4dTdKWGMzRUSZK3kaG1k1Dc3IKkIMbQ==7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Sandra Albenque-Rubio (https://sciprofiles.com/profile/author/aHBtKzNuZ21SK0Y5d0h2ekZFCfhueWYstJqDzWz3waQZV0pDY3VPD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Mathieu Marchivie (https://sciprofiles.com/profile/696993?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Haouraa Kalout (https://sciprofiles.com/profile/3299763?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Charley Walker (https://sciprofiles.com/profile/author/RmM5UJHWNmXTSDbVZkdaMmx2MGFRmH0cUdnd2RGEzT0U0bER1cXBKcGJwRfDZ21FTEwUcW5pRCszYkdJT2w1Rg==7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Louise Chevallier (https://sciprofiles.com/profile/author/WDITM3U2NXhiaTNvEi2MHZPbmMN29PUz1WDRuaDl2QcyNkpsQmw2RT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Corinne Buré (https://sciprofiles.com/profile/author/K2trL1I2eVhWZ2hhHFTOTYxT3FPzNIQXDpX0JqJbjg0V21d2RDZz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Eric Laryg (https://sciprofiles.com/profile/2547379?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Valérie Gabelica (https://sciprofiles.com/profile/author/RIKFTW0wbFzWm9HaGNVN2hocEJpJgMSEhNFZqRjFYRk1UGJdlJMOD0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Jean-Louis Mergny (https://sciprofiles.com/profile/357626?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Virginie Baylot (https://sciprofiles.com/profile/author/a0FbM4RnU2RVZJUGxDTFNetKQvT1dDMiU5UJURw0SGJWVlUUGN0M0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Jacky Ferrer (https://sciprofiles.com/profile/author/KzRGTzNh3ZRVU0gzM2hlcVhNSzZPR2FEQU4vOHMyU2VXTJNjanHbW5ZRT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Yamina Idrissi (https://sciprofiles.com/profile/author/V0M2N2RcEhHbFnaXF0SFZQVcrRmJvJBrOFRIXhTM0RuzluSvtKST0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Show full author list

Pharmaceuticals 2024, 17(1), 30; https://doi.org/10.3390/ph17010030 (https://doi.org/10.3390/ph17010030) - 25 Dec 2023

Viewed by 659

Abstract The syntheses of novel 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinazolines 12 and 2,4-bis[(substituted-aminomethyl)phenyl]phenylquinolines 13 are reported here in six steps starting from various halogeno-quinazoline-2,4-(1*H*,3*H*)-diones or substituted anilines. The antiproliferative activities of the products were determined in vitro against a panel of breast (MCF-7 and [a]). [Read more.](#)
(This article belongs to the Special Issue **G-quadruplex Ligands: Recent Advances** (*Journal of Pharmaceutical Sciences and Biotechnology* (Journal of Pharmaceutical Sciences and Biotechnology) [issues/R12BW44AX9](#)))

Show Figures

- (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-ag-550.jpg?1703590594) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-g001-550.jpg?1703590579) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-g002-550.jpg?1703590580) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-g003-550.jpg?1703590582) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-g004-550.jpg?1703590583) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-g005-550.jpg?1703590584) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-g006-550.jpg?1703590586) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-g007-550.jpg?1703590587) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-sch001a-550.jpg?1703590590) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-sch001b-550.jpg?1703590592) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-sch002-550.jpg?1703590592) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00030/article_deploy/html/images/pharmaceuticals-17-00030-sch003-550.jpg?1703590594)

Open Access Review 21 pages, 2750 KiB (1424-8247/17/1/29/pdf?version=1703491185)

Novel Opioids in the Setting of Acute Postoperative Pain: A Narrative Review (1424-8247/17/1/29)

- Ashley Wang (https://sciprofiles.com/profile/3226922?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Jasper Murphy (https://sciprofiles.com/profile/3226926?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Lana Shteynman (https://sciprofiles.com/profile/3226923?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Neil Daksla (https://sciprofiles.com/profile/3261525?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
 - Abhishek Gupta (https://sciprofiles.com/profile/3226925?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
 - Sergio Bergese (https://sciprofiles.com/profile/2740021?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Pharmaceuticals* 2024, 17(1), 29; https://doi.org/10.3390/ph17010029 (https://doi.org/10.3390/ph17010029) - 25 Dec 2023
Viewed by 673

Abstract Although traditional opioids such as morphine and oxycodone are commonly used in the management of acute postoperative pain, novel opioids may play a role as alternatives that provide potent pain relief while minimizing adverse effects. In this review, we discuss the mechanisms of [a]. [Read more.](#)
(This article belongs to the Special Issue **New Endogenous Opioid Peptides and Peptidomimetics with Potential Biological Importance** (*Journal of Pharmaceutical Sciences and Biotechnology* (*Journal of Pharmaceutical Sciences and Biotechnology*) [special issues/TTM3M9K3GU](#)))

Show Figures

- (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00029/article_deploy/html/images/pharmaceuticals-17-00029-g001-550.jpg?1703491268) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00029/article_deploy/html/images/pharmaceuticals-17-00029-g002-550.jpg?1703491268) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00029/article_deploy/html/images/pharmaceuticals-17-00029-g003-550.jpg?1703491269) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00029/article_deploy/html/images/pharmaceuticals-17-00029-g004-550.jpg?1703491269) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00029/article_deploy/html/images/pharmaceuticals-17-00029-g005-550.jpg?1703491270) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00029/article_deploy/html/images/pharmaceuticals-17-00029-g006-550.jpg?1703491270)

Open Access Article 12 pages, 594 KiB (1424-8247/17/1/28/pdf?version=1703408853)

Efficacy of Perampanel in Refractory and Super-Refractory Status Epilepticus with Suspected Inflammatory Etiology: A Case Series (1424-8247/17/1/28)

- Annacarmen Nilo (https://sciprofiles.com/profile/2593925?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Alberto Vogrig (https://sciprofiles.com/profile/2556471?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Marco Belluzzo (https://sciprofiles.com/profile/author/SBHU0MxOVIcDkRiREZNeJskE2UTRFUTJ2bTFTMU5yQkhCaWNKZWhNeXZsv1ZsUUR5NzFpNgdWV0pENVcxZQ==?utm_source=mdpi.com&utm_medium=webs

MDPI

Christian Lettieri (https://sciprofiles.com/profile/author/VjczcEEveXZhbVfMtnhLTxNPUV5Y0i4aXZVQ3N0V1E5YwZmUGNpWERUZmFLa2RBR0FmOnluUnc2TFEISkdSNQ==?utm_source=mdpi.com&utm_medium=we

Lorenzo Verriello (https://sciprofiles.com/profile/2434180?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Mariarosaria Valente (https://sciprofiles.com/profile/1403269?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Giada Pauletto (https://sciprofiles.com/profile/2227951?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 28; https://doi.org/10.3390/ph17010028 (https://doi.org/10.3390/ph17010028) - 24 Dec 2023

Viewed by 556

Abstract (1) Background: Increasing evidence supports the anti-inflammatory and neuroprotective role of peramppanel (PER), mediated by decreased expression of pro-inflammatory cytokines and by interference with apoptosis processes. Therefore, the use of PER to treat status epilepticus (SE) with suspected inflammatory etiology is appealing and [...] **Read more**.

(This article belongs to the Special Issue **Targeted Therapies for Epilepsy** (/journal/pharmaceuticals/special_issues/6V28RDW9HA))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00028/article_deploy/html/images/pharmaceuticals-17-00028-ag-550.jpg?1703507149) (https://

pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00028/article_deploy/html/images/pharmaceuticals-17-00028-g001-550.jpg?1703507103)

Open Access Article

11 pages, 2411 KB (1424-8247/17/1/27/pdf?version=1703406147)

A Pharmacodynamic Study of Aminoglycosides against Pathogenic *E. coli* through Monte Carlo Simulation (1424-8247/17/1/27)

by Eun-Bee Lee (https://sciprofiles.com/profile/1461133?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and

Kyubae Lee (https://sciprofiles.com/profile/3278393?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 27; https://doi.org/10.3390/ph17010027 (https://doi.org/10.3390/ph17010027) - 24 Dec 2023

Viewed by 659

Abstract This research focuses on combating the increasing problem of antimicrobial resistance, especially in *Escherichia coli* (*E. coli*), by assessing the efficacy of aminoglycosides. The study specifically addresses the challenge of developing new therapeutic approaches by integrating experimental data with mathematical modeling [...] **Read more**.

(This article belongs to the Topic **Pharmacokinetic and Pharmacodynamic Modelling in Drug Discovery and Development** (topics/O083251917))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00027/article_deploy/html/images/pharmaceuticals-17-00027-g001-550.jpg?1703406279) (https://

pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00027/article_deploy/html/images/pharmaceuticals-17-00027-g002-550.jpg?1703406280) (https://pub.mdpi-

res.com/pharmaceuticals/pharmaceuticals-17-00027/article_deploy/html/images/pharmaceuticals-17-00027-g003-550.jpg?1703406282) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00027/article_deploy/html/images/pharmaceuticals-17-00027-g004-550.jpg?1703406283) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00027/article_deploy/html/images/pharmaceuticals-17-00027-g005-550.jpg?1703406284) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00027/article_deploy/html/images/pharmaceuticals-17-00027-g006-550.jpg?1703406286)

Open Access Article

14 pages, 3903 KB (1424-8247/17/1/26/pdf?version=1703323220)

Nuclear Cross-Section of Proton-Induced Reactions on Enriched ⁴⁸Ti Targets for the Production of Theranostic ⁴⁷Sc Radionuclide, ⁴⁶Sc, ⁴⁴Sc, ⁴⁴Sc, ⁴⁴Sc, and ⁴⁸V (1424-8247/17/1/26)

by Liliana Mou (https://sciprofiles.com/profile/1581451?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Lucia De Dominicis (https://sciprofiles.com/profile/3241724?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Sara Cisterino (https://sciprofiles.com/profile/577376?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Hanna Skliarova (https://sciprofiles.com/profile/author/cUFDbjJ4aW9IMnR1QzhzYkU3eEhb1J3SGISbhnNZDK2K2R5y8wU1JVQTO=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Matteo Campostrini (https://sciprofiles.com/profile/3318650?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Valentino Rigato (https://sciprofiles.com/profile/author/ZFInU0jVEVRvzRhQK5PVH1U1RwSVk0TVrT3hWUPtGUU215UE9OND0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Laura De Nardo (https://sciprofiles.com/profile/2105547?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Laura Meléndez-Alafort (https://sciprofiles.com/profile/1190956?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Juan Esposito (https://sciprofiles.com/profile/585488?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Férid Haddad (https://sciprofiles.com/profile/author/bG5LQ1VIVUNDRE8rS2V3eVNPFCvQmQZWFImeEt3WHZ4225NUVIEVWFrBz0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

and

Gaia Pupillo (https://sciprofiles.com/profile/1581465?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 26; https://doi.org/10.3390/ph17010026 (https://doi.org/10.3390/ph17010026) - 23 Dec 2023

Viewed by 557

Abstract The cross-sections of the ⁴⁸Ti(p,x)⁴⁷Sc, ⁴⁶Sc, ⁴⁴Sc, ⁴⁴Sc, ⁴⁴Sc, and ⁴⁸V nuclear reactions were measured from 18 to 70 MeV, with particular attention to ⁴⁷Sc production. Enriched ⁴⁸Ti powder was deposited on an [...] **Read more**.

(This article belongs to the Special Issue **New Trends in Applications and Production of Metal Radionuclides for Nuclear Medicine** (/journal/pharmaceuticals/special_issues/M0H0807H2Y))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g001-550.jpg?1703323297) (https://

pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g002-550.jpg?1703323299) (https://pub.mdpi-

res.com/pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g003-550.jpg?1703323299) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g004-550.jpg?1703323299) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g005-550.jpg?1703323300) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g006-550.jpg?1703323301) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g007-550.jpg?1703323302) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g008-550.jpg?1703323304) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g009-550.jpg?1703323306) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g010-550.jpg?1703323306) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g011-550.jpg?1703323307) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00026/article_deploy/html/images/pharmaceuticals-17-00026-g012-550.jpg?1703323308)

Open Access Review

9 pages, 1764 KB (1424-8247/17/1/25/pdf?version=1703317639)

Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma (1424-8247/17/1/25)

by Kerstin Michalski (https://sciprofiles.com/profile/3230278?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Wiebke Schlotterburg (https://sciprofiles.com/profile/3345248?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Philipp E. Hartrampf (https://sciprofiles.com/profile/1015643?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Aleksander Kosmala (https://sciprofiles.com/profile/1021619?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Andreas K. Buck (https://sciprofiles.com/profile/author/dVZ0TWM3c3FRSUFjZzJuRIM1eHhNz09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Stefanie Hahner (https://sciprofiles.com/profile/author/ITExNbW5YV2Jhb21xTXUySnk1Nms4Zz09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

and

Andreas Schirbel (https://sciprofiles.com/profile/573644?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 25; https://doi.org/10.3390/ph17010025 (https://doi.org/10.3390/ph17010025) - 23 Dec 2023

Viewed by 536

Abstract Adrenocortical carcinoma (ACC) represents a rare tumor entity with limited treatment options and usually rapid tumor progression in case of metastatic disease. As further treatment options are needed and ACC metastases are sensitive to external beam radiation, novel theranostic approaches could complement established [...] **Read more**.

(This article belongs to the Special Issue **Therapeutic Radionuclides in Nuclear Medicine** (/journal/pharmaceuticals/special_issues/M8TAS21VQU))

► **Show Figures**

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00025/article_deploy/html/images/pharmaceuticals-17-00025-g001-550.jpg?1703317707) (https://

pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00025/article_deploy/html/images/pharmaceuticals-17-00025-g002-550.jpg?1703317710) (https://pub.mdpi-

res.com/pharmaceuticals/pharmaceuticals-17-00025/article_deploy/html/images/pharmaceuticals-17-00025-g003-550.jpg?1703317713) (https://pub.mdpi-res.com/

pharmaceuticals/pharmaceuticals-17-00025/article_deploy/html/images/pharmaceuticals-17-00025-g004-550.jpg?1703317715)

Open Access Article

13 pages, 2960 KB (1424-8247/17/1/24/pdf?version=1703499821)

Anthocyanin Oligomers Induce Apoptosis and Autophagy by Inhibiting the mTOR Signaling Pathway in Human Breast Cancer Cells (1424-8247/17/1/24)

by Min-Gu Lee (https://sciprofiles.com/profile/2922427?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),

Hyun-Jin Hong (https://sciprofiles.com/profile/author/WDXzJi4eWiiMedYdWppRzRoU1c3MmpUihYUW53b3NIOwdoTjvdMvCdCND0=?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

and

Kyung-Soo Nam (https://sciprofiles.com/profile/1421507?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 24; https://doi.org/10.3390/ph17010024 (https://doi.org/10.3390/ph17010024) - 22 Dec 2023

Viewed by 570

Abstract Anthocyanin oligomers (AOs) are phytochemicals synthesized by fermenting anthocyanins extracted from grape skins and are more biologically active than monomeric anthocyanins. In this study, we evaluate the effects of an AO on triple-negative MDA-MB-231 and HER2-overexpressing SK-BR-3 breast cancer cells. The cell viability [...] [Read more](#).

(This article belongs to the Special Issue [Natural Products for the Treatment of Breast Cancer](#) ([/journal/pharmaceuticals/special_issues/natural_products_for_the_treatment_of_breast_cancer](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00024/article_deploy/html/images/pharmaceuticals-17-00024-g001-550.jpg?1703499900) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00024/article_deploy/html/images/pharmaceuticals-17-00024-g002-550.jpg?1703499901) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00024/article_deploy/html/images/pharmaceuticals-17-00024-g003-550.jpg?1703499904) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00024/article_deploy/html/images/pharmaceuticals-17-00024-g004-550.jpg?1703499907) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00024/article_deploy/html/images/pharmaceuticals-17-00024-g005-550.jpg?1703499909) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00024/article_deploy/html/images/pharmaceuticals-17-00024-g006-550.jpg?1703499911) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00024/article_deploy/html/images/pharmaceuticals-17-00024-g007-550.jpg?1703499912)

Open Access Article 34 pages, 24442 KiB ([/1424-8247/17/1/23/pdf?version=1703581491](#))

Cytocompatibility, Antimicrobial and Antioxidant Activity of a Mucoadhesive Biopolymeric Hydrogel Embedding Selenium Nanoparticles Phytosynthesized by Sea Buckthorn Leaf Extract ([/1424-8247/17/1/23](#))

- by [Naomi Tritean](#) (https://sciprofiles.com/profile/3025214?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
- [Luminița Dimitriu](#) (https://sciprofiles.com/profile/2494331?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
- [Stefan-Ovidiu Dima](#) (https://sciprofiles.com/profile/2080755?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
- [Rusăndica Stoica](#) (https://sciprofiles.com/profile/2737613?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
- [Bogdan Trică](#) (https://sciprofiles.com/profile/765056?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
- [Marius Ghiurea](#) (https://sciprofiles.com/profile/300211?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
- [Ionuț Moraru](#) (https://sciprofiles.com/profile/528269?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
- [Anisoara Cîmpean](#) (https://sciprofiles.com/profile/196464?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
- [Florin Oancea](#) (https://sciprofiles.com/profile/218443?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- [Diana Constantinescu-Arușandei](#) (https://sciprofiles.com/profile/109155?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 23; <https://doi.org/10.3390/ph17010023> (<https://doi.org/10.3390/ph17010023>) - 22 Dec 2023

Viewed by 606

Abstract Phytosynthesized selenium nanoparticles (SeNPs) are less toxic than the inorganic salts of selenium and show high antioxidant and antibacterial activity. Chitosan prevents microbial biofilm formation and can also determine microbial biofilm dispersal. Never-dried bacterial nanocellulose (NDBC) is an efficient carrier of bioactive compounds [...] [Read more](#).

(This article belongs to the Special Issue [Hydrogels for Pharmaceutical and Biomedical Applications 2024](#) ([/journal/pharmaceuticals/special_issues/4DT23T6TLI](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00023/article_deploy/html/images/pharmaceuticals-17-00023-ag-550.jpg?1703682885) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00023/article_deploy/html/images/pharmaceuticals-17-00023-g001-550.jpg?1703581569) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00023/article_deploy/html/images/pharmaceuticals-17-00023-g002-550.jpg?1703581572) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00023/article_deploy/html/images/pharmaceuticals-17-00023-g003-550.jpg?1703581573) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00023/article_deploy/html/images/pharmaceuticals-17-00023-g004-550.jpg?1703581576) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00023/article_deploy/html/images/pharmaceuticals-17-00023-g005-550.jpg?1703581581) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00023/article_deploy/html/images/pharmaceuticals-17-00023-g006-550.jpg?1703581584) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00023/article_deploy/html/images/pharmaceuticals-17-00023-g007-550.jpg?1703581587) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00023/article_deploy/html/images/pharmaceuticals-17-00023-g008-550.jpg?1703581591) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00023/article_deploy/html/images/pharmaceuticals-17-00023-g009-550.jpg?1703581596) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00023/article_deploy/html/images/pharmaceuticals-17-00023-g010-550.jpg?1703581600)

Open Access Review 22 pages, 1609 KiB ([/1424-8247/17/1/22/pdf?version=1704187732](#))

Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis ([/1424-8247/17/1/22](#))

- by [Sarfraz K. Niazi](#) (https://sciprofiles.com/profile/1813238?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- [Zamara Marian](#) (https://sciprofiles.com/profile/3323573?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 22; <https://doi.org/10.3390/ph17010022> (<https://doi.org/10.3390/ph17010022>) - 22 Dec 2023

[Cited by 1](#) ([/1424-8247/17/1/22/metrics](#)) | Viewed by 1537

Abstract In the dynamic landscape of drug discovery, Computer-Aided Drug Design (CADD) emerges as a transformative force, bridging the realms of biology and technology. This paper overviews CADDs historical evolution, categorization into structure-based and ligand-based approaches, and its crucial role in rationalizing and expediting [...] [Read more](#).

(This article belongs to the Special Issue [Computer-Aided Drug Design and Drug Discovery](#) ([/journal/pharmaceuticals/special_issues/CDY0D8W0CQ](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00022/article_deploy/html/images/pharmaceuticals-17-00022-ag-550.jpg?1704187817) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00022/article_deploy/html/images/pharmaceuticals-17-00022-g001-550.jpg?1704187799) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00022/article_deploy/html/images/pharmaceuticals-17-00022-g002-550.jpg?1704187800) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00022/article_deploy/html/images/pharmaceuticals-17-00022-g003-550.jpg?1704187800)

Open Access Article 13 pages, 1449 KiB ([/1424-8247/17/1/21/pdf?version=1703238618](#))

Therapeutic Drug Monitoring and Pharmacogenetic Testing as Guides to Psychotropic Drug Dose Adjustment: An Observational Study ([/1424-8247/17/1/21](#))

- by [Elodie Cuvelier](#) (https://sciprofiles.com/profile/1906934?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name),
- [Houda Khazri](#) (https://sciprofiles.com/profile/author/MHNCcGM4R/VkTFpCaWQ0NU5FMIitRnhQ1OZYMKhVVDiYtcxVWVQa0hUaz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- [Cléo Lecluse](#) (https://sciprofiles.com/profile/author/WkR6ekJEbHo2Vlc3V3FncEFIMTFpbJkYUzSmkE4MURMUGJmbm56aFJZT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Benjamin Hennart](#) (https://sciprofiles.com/profile/author/NkkzdHhHaWfUzJoUXdtakVLRHZ3TVJxRGYzU2NcCd4VGxhZXJ0bkZxWT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Ali Amad](#) (https://sciprofiles.com/profile/author/EHhHal95d2g1Q81TW5mU3IH0Y5iWnFWYw1ua9jBFb3BLV2IsK0tMd2s1TT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Jean Roche](#) (https://sciprofiles.com/profile/author/TDVQMHRIQUJMDfWcWRaRmVhaWtJNVJGdXgZ2Dk3ckREMxQdWbU1vaTRFcz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Michel Tod](#) (https://sciprofiles.com/profile/author/aGpyMHZTIFXISFFURdEXtmRQSFYSStETWhmQpRnBLVIZJdFQ2OCi3VT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Guillaume Vaiva](#) (https://sciprofiles.com/profile/author/S3BpdFjdXIM2JvNGZvVHBrChdDVXIGVmgR3RDU28dykUweDESrGH0Yz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Olivier Cottencin](#) (https://sciprofiles.com/profile/author/T1BSNW1UJQ1VTBfCk84UTRjVWp1RHdSRnlHaVRycnFYaTR3UDImaXdlMcZ0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Pascal Odou](#) (https://sciprofiles.com/profile/author/RUw0dmdUJDN4TnZsY3Q3MkRUUVjWfRQNVY1t1R3Ywa1NZaW50sZMrST0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Delphine Allorge](#) (https://sciprofiles.com/profile/author/OV1aWN1K1dVMzcvL2ZsdmhRamtORg12N14dAZ0d3BSMGRGUGpES05TT0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Bertrand Décaudin](#) (https://sciprofiles.com/profile/1532695?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- [Nicolas Simon](#) (https://sciprofiles.com/profile/1440014?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 21; <https://doi.org/10.3390/ph17010021> (<https://doi.org/10.3390/ph17010021>) - 22 Dec 2023

Viewed by 593

Abstract To avoid the failures in therapy with psychotropic drugs, treatments can be personalized by applying the results of therapeutic drug monitoring and pharmacogenetic testing. The objective of the present single-center observational study was to describe the changes in psychotropic drug management prompted by [...] [Read more](#).

(This article belongs to the Special Issue [Drug Analysis and Therapeutic Drug Monitoring](#) ([/journal/pharmaceuticals/special_issues/I1D3UA8YN65](#)))

Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00021/article_deploy/html/images/pharmaceuticals-17-00021-g001-550.jpg?1703238791) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00021/article_deploy/html/images/pharmaceuticals-17-00021-g002-550.jpg?1703238793) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00021/article_deploy/html/images/pharmaceuticals-17-00021-g003-550.jpg?1703238795)

Open Access Article 17 pages, 2700 KiB ([/1424-8247/17/1/20/pdf?version=1703237315](#))

Antiarthritic and Anti-Inflammatory Properties of *Cannabis sativa* Essential Oil in an Animal Model ([/1424-8247/17/1/20](#))

- by [Hamid Kabyd](#) (https://sciprofiles.com/profile/2973624?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Hajar Azraida](#) (https://sciprofiles.com/profile/3323601?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Fatimazahra Agouram](#) (https://sciprofiles.com/profile/author/VldZQ2gzK2RocWY2NGh3amZIT3AvS2zcUENic0NH0EJEUtkzaEITyk5Yz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Sara Oufouir (https://sciprofiles.com/profile/author/bDd0ZHny2ZmTGF3amJYNWZjL0iSVEdOcXNRK3o3QXJrTGI0QhUa28xaz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Jawad Laadraoui (https://sciprofiles.com/profile/author/V1YvRzZWWdRUzPHLzUwDnFXbWZMblkyMJFwG4ZiRVRk5MVZEVTJGQT0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Abdelmounaim Baslam (https://sciprofiles.com/profile/2628454?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Abdefatah Aitaba (https://sciprofiles.com/profile/2919446?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Meryem El Ouazzani (https://sciprofiles.com/profile/author/a20xbU90YmdKqRRUVd3aUFRWtInVGNnT0FvYzW0VDVmtQ1dnbVhrl3ZYTt0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Loubna Elvazouli (https://sciprofiles.com/profile/author/STR5NTN2TDQcMHA0NnVhQIRLkMcZmp6OE5saFN1bVJOWE5OUGNaeXJOTt0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Rachida Aboufatima (https://sciprofiles.com/profile/author/TIRPd1JdURaU1pWTDIncVdTUTIUZhbOmMxFTVQNWZ4K0NtEYvRnFTax0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Stefania Garzoli (https://sciprofiles.com/profile/116660?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Abderrahman Chait (https://sciprofiles.com/profile/author/ahpbXlweHUVdDhCK0JZINKNmZrUT09?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 20; <https://doi.org/10.3390/ph17010020> (<https://doi.org/10.3390/ph17010020>) - 22 Dec 2023

Viewed by 636

Abstract Arthritis and inflammatory conditions require effective therapies, but conventional drugs have side effects. This study explored *Cannabis sativa* L. essential oil (CSEO) as a safer alternative. A chemical characterization of EO conducted via GC/MS showed the presence of sesquiterpene hydrocarbons (67.63%), oxygenated sesquiterpenes [...]

Read more.
(This article belongs to the Special Issue [Chromatographic and Mass Spectrometry Techniques to Detect Secondary Metabolites from Natural Products of Pharmaceutical Interest](#) ([journal/pharmaceuticals/special_issues/A397B5XU5G](#)))

Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00020/article_deploy/html/images/pharmaceuticals-17-00020-g001-550.jpg?1703237388) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00020/article_deploy/html/images/pharmaceuticals-17-00020-g002-550.jpg?1703237391) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00020/article_deploy/html/images/pharmaceuticals-17-00020-g003-550.jpg?1703237392) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00020/article_deploy/html/images/pharmaceuticals-17-00020-g004-550.jpg?1703237394) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00020/article_deploy/html/images/pharmaceuticals-17-00020-g005-550.jpg?1703237395) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00020/article_deploy/html/images/pharmaceuticals-17-00020-g006-550.jpg?1703237397)

Open Access Article 18 pages, 2070 KIB ([/1424-8247/17/1/19/pdf?version=1703227299](#))

700-80-Based Self-Assembled Mixed Micelles Boost Valsartan Transdermal Delivery ([/1424-8247/17/1/19](#))

- Alaa Eldeen B. Yassin (https://sciprofiles.com/profile/725348?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Salam Massadeh (https://sciprofiles.com/profile/161780?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Abdullah A. Alshwaimi (https://sciprofiles.com/profile/author/ZVzcFJQZ0FR0zszFFQ0dQmTIQ2YtGN2cXkUvUV2UWcxdBCE9NTT0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- Raslan H. Kittaneh (https://sciprofiles.com/profile/3226588?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Mustafa E. Omer (https://sciprofiles.com/profile/1054297?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Dilshad Ahmad (https://sciprofiles.com/profile/author/aJ0WIEvcENDQ0dXKBUVVYUZ00DhKz0FvXV20zbnBdWZTVIqcz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Al Hassan Aodah (https://sciprofiles.com/profile/1655276?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Faiyaz Shakeel (https://sciprofiles.com/profile/811216?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Majed Halwani (https://sciprofiles.com/profile/848775?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Saleh A. Alanazi (https://sciprofiles.com/profile/author/Nl3GkIsbTREmMdnUG1PWjdaeXJOMFUTDIX0xaaEJTRkSZEhYRnraz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Prawez Alam (https://sciprofiles.com/profile/1126724?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 19; <https://doi.org/10.3390/ph17010019> (<https://doi.org/10.3390/ph17010019>) - 22 Dec 2023

Viewed by 701

Abstract Valsartan (Val) is an important antihypertensive medication with poor absorption and low oral bioavailability. These constraints are due to its poor solubility and dissolution rate. The purpose of this study was to optimize a mixed micelle system for the transdermal delivery of Val [...]

Read more.
(This article belongs to the Special Issue [Self-Assembled Nanoparticles: An Emerging Delivery Platform for Drugs](#) ([journal/pharmaceuticals/special_issues/U198Y8X3JE](#)))

Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00019/article_deploy/html/images/pharmaceuticals-17-00019-g001-550.jpg?1703227372) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00019/article_deploy/html/images/pharmaceuticals-17-00019-g002-550.jpg?1703227375) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00019/article_deploy/html/images/pharmaceuticals-17-00019-g003-550.jpg?1703227377) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00019/article_deploy/html/images/pharmaceuticals-17-00019-g004-550.jpg?1703227378) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00019/article_deploy/html/images/pharmaceuticals-17-00019-g005-550.jpg?1703227379) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00019/article_deploy/html/images/pharmaceuticals-17-00019-g006-550.jpg?1703227380)

Open Access Article 20 pages, 5618 KIB ([/1424-8247/17/1/18/pdf?version=1703252704](#))

Computational Molecular Docking and Simulation-Based Assessment of Anti-Inflammatory Properties of *Nyctanthes arbor-tristis* Linn Phytochemicals ([/1424-8247/17/1/18](#))

- Varish Ahmad (https://sciprofiles.com/profile/996726?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Mohammad Imran Khan (https://sciprofiles.com/profile/3245411?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Qazi Mohammad Sajid Jamal (https://sciprofiles.com/profile/1125108?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Faisal A. Alzahrani (https://sciprofiles.com/profile/538205?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Raed Albiheyri (https://sciprofiles.com/profile/1824464?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 18; <https://doi.org/10.3390/ph17010018> (<https://doi.org/10.3390/ph17010018>) - 22 Dec 2023

Viewed by 678

Abstract The leaves, flowers, seeds, and bark of the *Nyctanthes arbor-tristis* Linn plant have been pharmacologically evaluated to signify the medicinal importance traditionally described for various ailments. We evaluated the anti-inflammatory potentials of 26 natural compounds using AutoDock 4.2 and Molecular Dynamics (MD) simulation [...]

Read more.
(This article belongs to the Special Issue [Recent Advances in Plant Derived Anti-inflammatory Compounds](#) ([journal/pharmaceuticals/special_issues/84746VRYHA](#)))

Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00018/article_deploy/html/images/pharmaceuticals-17-00018-g001-550.jpg?1703252769) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00018/article_deploy/html/images/pharmaceuticals-17-00018-g002-550.jpg?1703252772) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00018/article_deploy/html/images/pharmaceuticals-17-00018-g003-550.jpg?1703252774) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00018/article_deploy/html/images/pharmaceuticals-17-00018-g004-550.jpg?1703252777) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00018/article_deploy/html/images/pharmaceuticals-17-00018-g005-550.jpg?1703252780) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00018/article_deploy/html/images/pharmaceuticals-17-00018-g006-550.jpg?1703252782)

Open Access Article 16 pages, 1998 KIB ([/1424-8247/17/1/17/pdf?version=1703154460](#))

Nanoemulsion Improves the Anti-Inflammatory Effect of Intraperitoneal and Oral Administration of Carvacryl Acetate ([/1424-8247/17/1/17](#))

- Rafael Limongi de Souza (https://sciprofiles.com/profile/1654285?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Luiza Carolina França Oprezka (https://sciprofiles.com/profile/225183?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Mayara Castro de Moraes (https://sciprofiles.com/profile/1209542?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Camilla de Oliveira Melo (https://sciprofiles.com/profile/author/RnJyChHrVhKMIbBN0JFcW1xR2VrcjV4RINna2tXZTY1K1FOcUNHdUROcz0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Bruna Emanuely Guedes de Oliveira (https://sciprofiles.com/profile/author/U0FDd05KaHbUmV2RjVkak0NDVCeW0zDdSQk4UWNMc2RldXpXQW0yQT0=2utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Damião Pergentino de Sousa (https://sciprofiles.com/profile/4131?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- Cristiane Flora Villarreal (https://sciprofiles.com/profile/219908?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- Eluio Eleamen Oliveira (https://sciprofiles.com/profile/1634140?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 17; <https://doi.org/10.3390/ph17010017> (<https://doi.org/10.3390/ph17010017>) - 21 Dec 2023

Viewed by 557

Abstract Carvacryl acetate (CA) is a monoterpene obtained from carvacrol, which exhibits anti-inflammatory activity. However, its low solubility in aqueous media limits its application and bioavailability. Herein, we aimed to develop a carvacryl acetate nanoemulsion (CANE) and assess its anti-inflammatory potential in preclinical trials. [...]

Read more.
(This article belongs to the Section [Pharmaceutical Technology](#) ([journal/pharmaceuticals/sections/pharmaceutical_technology](#)))

Show Figures
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00017/article_deploy/html/images/pharmaceuticals-17-00017-g001-550.jpg?1703154530) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00017/article_deploy/html/images/pharmaceuticals-17-00017-g002-550.jpg?1703154533) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00017/article_deploy/html/images/pharmaceuticals-17-00017-g003-550.jpg?1703154535) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00017/article_deploy/html/images/pharmaceuticals-17-00017-g004-550.jpg?1703154538) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00017/article_deploy/html/images/pharmaceuticals-17-00017-g005-550.jpg?1703154541) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00017/article_deploy/html/images/pharmaceuticals-17-00017-g006-550.jpg?1703154544)

Pharmaceuticals/pharmaceuticals-17-00017/article_deploy/html/images/pharmaceuticals-17-00017-g006-550.jpg?1703154540 (toggle desktop layout cookie) Q ≡

Open Access Review 16 pages, 354 KIB (1424-8247/17/1/16/pdf?version=1703152813)

Ketamine, an Old-New Drug: Uses and Abuses (1424-8247/17/1/16)

- by Katarina Savić Vučković, Ana Jotić, Branislava Medić, Dragana Srebro, Aleksandar Vučković

- Žanko Žujović, • Ana Opanković, • Sonja Vučković

Abstract Ketamine as an old-new drug has a variety of clinical implications. In the last 30 years, ketamine has become popular for acute use in humans. Ketamine in standard doses is principally utilized for the induction and maintenance of surgical procedures. Besides its use [...] Read more.

Open Access Article 20 pages, 5634 KIB (1424-8247/17/1/15/pdf?version=1703147806)

A New Approach for Preparing Stable High-Concentration Peptide Nanoparticle Formulations (1424-8247/17/1/15)

- by Chloe Hu, Nanzhi Zang, Yu Tong Tam, Desmond Dizon, Kaylee Lee, Jodie Beth, Elizabeth Torres, Yusi Cui, Chun-Wan Yen, Dennis H. Leung

Abstract The subcutaneous administration of therapeutic peptides would provide significant benefits to patients. However, subcutaneous injections are limited in dosing volume, potentially resulting in high peptide concentrations that can incur significant challenges with solubility limitations, high viscosity, and stability liabilities. Herein, we report on [...]

(This article belongs to the Special Issue Strategies for Improving Peptide Stability and Delivery (Journal/pharmaceuticals/special_issues/56CA1ST7N2))



Open Access Systematic Review 13 pages, 1177 KIB (1424-8247/17/1/14/pdf?version=1703159515)

Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated with Targeted Therapies: A Systematic Review and Meta-Analysis (1424-8247/17/1/14)

- by Marta Krzysztofik, Paweł Brzeński, Przemysław Cuber, Artur Kacprzyk

- Aleksandra Kulbat, • Karolina Richter, • Tomasz Wojewoda, • Wojciech M. Wysocki

Abstract Targeted therapies represent major advancements in the treatment of chronic skin conditions such as psoriasis. While previous studies have shown an increased risk of melanoma and non-melanoma skin cancer (NMSC) in patients receiving TNF-α inhibitors, the risks associated with newer biologics (IL-12/23 inhibitors, [...]) Read more.



Open Access Article 11 pages, 2043 KIB (1424-8247/17/1/13/pdf?version=1703145546)

Exploring Enzymatic Hydrolysis of Urine Samples for Investigation of Drugs Associated with Drug-Facilitated Sexual Assault (1424-8247/17/1/13)

- by Kathrine Skov, Sys Stybe Johansen, Kristian Linnet, Brian Schou Rasmussen, Marie Katrine Klose Nielsen

Abstract Analyzing urine is common in drug-facilitated sexual assault cases if the analysis of blood is not optimal. The efficient enzymatic pretreatment of urine is important for clearing glucuronides and improving the detection of the parent drug. The aim was to investigate the efficiency [...] Read more.

Show Figures
 MDPI (0)
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00013/article_deploy/html/images/pharmaceuticals-17-00013-g001-550.jpg?1703145614 (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00013/article_deploy/html/images/pharmaceuticals-17-00013-g002-550.jpg?1703145615) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00013/article_deploy/html/images/pharmaceuticals-17-00013-g003-550.jpg?1703145616) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00013/article_deploy/html/images/pharmaceuticals-17-00013-g004-550.jpg?1703145617) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00013/article_deploy/html/images/pharmaceuticals-17-00013-g005-550.jpg?1703145619)

Open Access Review 14 pages, 1752 KIB (1424-8247/17/1/12/pdf?version=1703145258)

Repurposing Therapeutic Drugs Complexed to Vanadium in Cancer (1424-8247/17/1/12)
 by Ana Luisa De Sousa-Coelho (https://sciprofiles.com/profile/7496317?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Gil Fraqueza (https://sciprofiles.com/profile/11796897?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Manuel Aureliano (https://sciprofiles.com/profile/209022?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 12; <https://doi.org/10.3390/ph17010012> (registering DOI) - 21 Dec 2023
 Viewed by 659

Abstract Repurposing drugs by uncovering new indications for approved drugs accelerates the process of establishing new treatments and reduces the high costs of drug discovery and development. Metal complexes with clinically approved drugs allow further opportunities in cancer therapy—many vanadium compounds have previously shown [...] **Read more.**
 (This article belongs to the Special Issue **Recent Advances and Future Approaches in Preventive and Therapeutic Effects of Vanadium Complexes (Journal/Pharmaceuticals/special_issues/BBD95DFNM)**)

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00012/article_deploy/html/images/pharmaceuticals-17-00012-g001-550.jpg?1703145337 (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00012/article_deploy/html/images/pharmaceuticals-17-00012-g002-550.jpg?1703145338) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00012/article_deploy/html/images/pharmaceuticals-17-00012-g003-550.jpg?1703145339) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00012/article_deploy/html/images/pharmaceuticals-17-00012-g004-550.jpg?1703145340) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00012/article_deploy/html/images/pharmaceuticals-17-00012-g005-550.jpg?1703145341)

Open Access Systematic Review 25 pages, 2015 KIB (1424-8247/17/1/11/pdf?version=1703138093)

Anti-Inflammatory Activity of Pequi Oil (Caryocar brasiliense): A Systematic Review (1424-8247/17/1/11)
 by Vitória R. P. Silva (https://sciprofiles.com/profile/3222030?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Andréia C. Pinheiro (https://sciprofiles.com/profile/2467458?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Alícia S. Ombredane (https://sciprofiles.com/profile/author/ellrhzJDOTNpbVZNSXlmbzRN2V13aGdCVFM523dPNEf1d3jISzZFcHvZRT0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Natália Ornelas Martins (https://sciprofiles.com/profile/3267724?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Glécia V. S. Luz (https://sciprofiles.com/profile/2799586?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Marcela L. B. Carneiro (https://sciprofiles.com/profile/1238298?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Graziella A. Joaquina (https://sciprofiles.com/profile/2489338?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 11; <https://doi.org/10.3390/ph17010011> (registering DOI) - 21 Dec 2023
 Viewed by 860

Abstract Disorders in the inflammatory process underlie the pathogenesis of numerous diseases. The utilization of natural products as anti-inflammatory agents is a well-established approach in both traditional medicine and scientific research, with studies consistently demonstrating their efficacy in managing inflammatory conditions. Pequi oil, derived [...] **Read more.**
 (This article belongs to the Section **Natural Products (Journal/Pharmaceuticals/sections/natural_products)**)

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00011/article_deploy/html/images/pharmaceuticals-17-00011-g001-550.jpg?1703138170 (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00011/article_deploy/html/images/pharmaceuticals-17-00011-g002-550.jpg?1703138173) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00011/article_deploy/html/images/pharmaceuticals-17-00011-g003-550.jpg?1703138175) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00011/article_deploy/html/images/pharmaceuticals-17-00011-g004-550.jpg?1703138177)

Open Access Article 12 pages, 2227 KIB (1424-8247/17/1/10/pdf?version=1703231625)

Trace Metal Impurities Effects on the Formation of [⁶⁴Cu]Cu-diacyetyl-bis(N⁴-methylthiosemicarbazone) ([⁶⁴Cu]Cu-ATSM) (1424-8247/17/1/10)
 by Mitsuhiro Shinada (https://sciprofiles.com/profile/1871395?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Hisashi Suzuki (https://sciprofiles.com/profile/author/N0pNVWdGUJUNTHMvaG9EOEJrdllPMkrMHVRS65vzR3WwXat1ZCN1FYz0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Masayuki Hanyu (https://sciprofiles.com/profile/author/WXdKvNmeEx6T3FwNXNWSDBIQBMZ1BPR253RIZhU0qjMnRITTNuOCiKUT0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Chika Igarashi (https://sciprofiles.com/profile/author/enRkOTZPL0Ioc2VIMDU3azVUcnJctjBjaGixWWpKRTILSGU2bCtQIAwdz0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Hiroki Matsumoto (https://sciprofiles.com/profile/author/UWRVjYjkb1pmRXpKV3NQZnErjYU32RoQ3B8YU81R2sxVlIxeFdmSDBRZz0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Masashi Takahashi (https://sciprofiles.com/profile/3299569?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Fukiko Hihara (https://sciprofiles.com/profile/author/K2JzEazUydzNIAHnRipXVHRzT82MjBCQjIWMzFASGR4VWxNUJFodzBUdz0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Tomoko Tachibana (https://sciprofiles.com/profile/3136970?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Chizuru Sogawa (https://sciprofiles.com/profile/author/eXFVcmZmK15T3jRkFYOTdqeW1XSNpUNH8aSGE1dnjBjVN2amI4YXZHz0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Ming-Rong Zhang (https://sciprofiles.com/profile/2475975?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Tatsuya Higashi (https://sciprofiles.com/profile/991981?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Hidemitsu Sato (https://sciprofiles.com/profile/author/WTR0STVHRm92a0RWVjF6bzRdVhla1JIZ0wYXaZUpBNW5YdUVRVRCNT0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Hiroaki Kurihara (https://sciprofiles.com/profile/author/b3dxbd6WWQvUm1P9jNDZWoOaXoN1EIXajE5ai8x1puNdH3ek1DbkhST0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Yukie Yoshii (https://sciprofiles.com/profile/1651668?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and Yoshihiro Doi (https://sciprofiles.com/profile/author/Q1JtbTqWUUMwem1sR0cxhY5Y21KSGVTNjV2bEzPjUuIDRkDWEVYz2VmOD0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
Pharmaceuticals 2024, 17(1), 10; <https://doi.org/10.3390/ph17010010> (registering DOI) - 21 Dec 2023
 Viewed by 496

Abstract [⁶⁴Cu]Cu-diacyetyl-bis(N⁴-methylthiosemicarbazone) ([⁶⁴Cu]Cu-ATSM) is a radioactive hypoxia-targeting therapeutic agent being investigated in clinical trials for malignant brain tumors. For the quality management of [⁶⁴Cu]Cu-ATSM, understanding trace metal impurities' effects on the chelate formation of [⁶⁴...] **Read more.**
 (This article belongs to the Special Issue **Copper Radiopharmaceuticals for Theranostic Applications (Journal/Pharmaceuticals/special_issues/QDCI781UMX)**)

Show Figures
https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00010/article_deploy/html/images/pharmaceuticals-17-00010-g001-550.jpg?1703231702 (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00010/article_deploy/html/images/pharmaceuticals-17-00010-g002-550.jpg?1703231704) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00010/article_deploy/html/images/pharmaceuticals-17-00010-g003-550.jpg?1703231706) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00010/article_deploy/html/images/pharmaceuticals-17-00010-g004-550.jpg?1703231707) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00010/article_deploy/html/images/pharmaceuticals-17-00010-g005-550.jpg?1703231708) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00010/article_deploy/html/images/pharmaceuticals-17-00010-g006-550.jpg?1703231708)

Open Access Article 19 pages, 4736 KIB (1424-8247/17/1/9/pdf?version=1703128990)

CP-673451, a Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces Apoptosis in *Opisthorchis viverrini*-Associated Cholangiocarcinoma via Nrf2 Suppression and Enhanced ROS (1424-8247/17/1/9)
 by Jinchutha Duangdara (https://sciprofiles.com/profile/author/cE14QWY0UowalNmC2NY0ThSiWjOwiiXhXl1VveENXmIYqSVUJcmfFOWhahi93VBoSItHcXJSYVVB0QwZg=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Boonyakorn Boonsri (https://sciprofiles.com/profile/author/K2ZpN0kDaQxWnd4azJkQnFLcGwrci8vR2k2dmhK1FKRHk1WppUmRQU0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Apinya Savintia (https://sciprofiles.com/profile/author/YnR0RvBXazZIZW9DeG8yZy9BbzZuGd0nQRKzJ5TmJsQjUwMUVURWttcz0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Kittiya Supradit (https://sciprofiles.com/profile/author/dE1BTXEYcGQMkFQVXFOMGIwWbThSVQ1dRkVFEseGRNeGJVT1BGVklwYz0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Pakpoom Thintharua (https://sciprofiles.com/profile/3315238?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Supeecha Kumkate (https://sciprofiles.com/profile/author/U013UVgyQ3NNMFRMHJTRtGdmdWTE5hQ25PL1JocnRZnHhZjcmhicz0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), Chinna-wuri Suriyongplengsaeng (https://sciprofiles.com/profile/author/Mm0zN2RpeWU4MGJQ1FT09ZcFrPjH0TdzBzERCWmPEtJ4SDFWDRiOD0=7?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- [Noppadol Larbcharensub](https://sciprofiles.com/profile/author/STMxTmZQbnpwFzAl2d3Z2RwD3lXcIM5em9JQkOekVVTU1oR3dOSkY3bz0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/STMxTmZQbnpwFzAl2d3Z2RwD3lXcIM5em9JQkOekVVTU1oR3dOSkY3bz0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Somkit Mingphruehdi](https://sciprofiles.com/profile/author/R0lJCdVCTzSuSHJcUthMG0M3dSUmDbfJRY1RkT1R4WDFYazkyNDNoLUT0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/R0lJCdVCTzSuSHJcUthMG0M3dSUmDbfJRY1RkT1R4WDFYazkyNDNoLUT0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Narongsak Rungsakulkij](https://sciprofiles.com/profile/author/eFNpRDBqcm5EWHdubzVnbfPzoY2VW80R0VxRnhUandGeGlvU3ZxeUzUyZ0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/eFNpRDBqcm5EWHdubzVnbfPzoY2VW80R0VxRnhUandGeGlvU3ZxeUzUyZ0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Paramin Muangkaew](https://sciprofiles.com/profile/author/OFHnQ1piWndIUHbzVW5XZR0SVFJWWVSGJmZUmU0xUEduZEOxcGVFYz0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/OFHnQ1piWndIUHbzVW5XZR0SVFJWWVSGJmZUmU0xUEduZEOxcGVFYz0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Pongsatorn Tangtawee](https://sciprofiles.com/profile/author/SnFzcl3dXF4ek5zWwsvNIU5alc5NHUJdDxmUdScOZZ1jWJUWxzIMD0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/SnFzcl3dXF4ek5zWwsvNIU5alc5NHUJdDxmUdScOZZ1jWJUWxzIMD0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Watoe Vassanasiri](https://sciprofiles.com/profile/author/M1E3Z0rR2EzU1kwMHYrSzBMSckMM0JxdC3hbHFISzRDQSczFbYQ0FLVT0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/M1E3Z0rR2EzU1kwMHYrSzBMSckMM0JxdC3hbHFISzRDQSczFbYQ0FLVT0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Wikran Suragul](https://sciprofiles.com/profile/author/SG05Y0V2NTVQNkQ0ej5NWfBN0s4NDJXT1JTFVZTFZPSnHQIRYeFlpYz0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/SG05Y0V2NTVQNkQ0ej5NWfBN0s4NDJXT1JTFVZTFZPSnHQIRYeFlpYz0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- [Tavan Janvilisri](https://sciprofiles.com/profile/1161364?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1161364?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [Rutaiwan Tohtong](https://sciprofiles.com/profile/1387557?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1387557?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)
- [David O. Bates](https://sciprofiles.com/profile/820997?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/820997?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- [Kanoakan Wongprasert](https://sciprofiles.com/profile/821268?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/821268?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 9; <https://doi.org/10.3390/ph17010009> (https://doi.org/10.3390/ph17010009) - 20 Dec 2023
Viewed by 686

Abstract Platelet-derived growth factors (PDGFs) and PDGF receptors (PDGFRs) play essential roles in promoting cholangiocarcinoma (CCA) cell survival by mediating paracrine crosstalk between tumor and cancer-associated fibroblasts (CAFs), indicating the potential of PDGFR as a target for CCA treatment. Clinical trials evaluating PDGFR inhibitors [...] [Read more](#).

(This article belongs to the Special Issue [Cancer Drugs Treatment and Toxicity 2023](#) ([Journal/pharmaceuticals/special_issues/676TJN75KC](#))

► Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00009/article_deploy/html/images/pharmaceuticals-17-00009-ag-550.jpg?1703129108) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00009/article_deploy/html/images/pharmaceuticals-17-00009-g001-550.jpg?1703129095) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00009/article_deploy/html/images/pharmaceuticals-17-00009-g002-550.jpg?1703129098) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00009/article_deploy/html/images/pharmaceuticals-17-00009-g003-550.jpg?1703129099) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00009/article_deploy/html/images/pharmaceuticals-17-00009-g004-550.jpg?1703129101) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00009/article_deploy/html/images/pharmaceuticals-17-00009-g005-550.jpg?1703129104) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00009/article_deploy/html/images/pharmaceuticals-17-00009-g006-550.jpg?1703129107) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00009/article_deploy/html/images/pharmaceuticals-17-00009-g007-550.jpg?1703129108)

Open Access Article

13 pages, 2617 KIB (1424-8247/17/1/8/pdf?version=1703085310)

Identification of a New Integration Site and Study on Site-Specific Integration in CHO-K1 Cells (1424-8247/17/1/8)

- [Hong Liu](https://sciprofiles.com/profile/3279000?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3279000?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- [Wei Zhang](https://sciprofiles.com/profile/author/RmYwQUdoN3RtYRGNE2dkFNQXaxTTQJSEJdnFNiGa2IWcERXMDJzZ0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/RmYwQUdoN3RtYRGNE2dkFNQXaxTTQJSEJdnFNiGa2IWcERXMDJzZ0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- [Liping Xie](https://sciprofiles.com/profile/3286864?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3286864?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- [Youjia Hu](https://sciprofiles.com/profile/3176282?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3176282?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 8; <https://doi.org/10.3390/ph17010008> (https://doi.org/10.3390/ph17010008) - 20 Dec 2023
Viewed by 499

Abstract Site-specific integration is an important approach used to address the problem of unstable cell lines in industry. In this study, we observed a reduction in the gene copy number and antibody production in a CHOK1 cell line BA03 capable of high antibody expression. [...] [Read more](#).

(This article belongs to the Section [Biopharmaceuticals](#) ([Journal/pharmaceuticals/sections/biopharmaceuticals](#))

► Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00008/article_deploy/html/images/pharmaceuticals-17-00008-g001-550.jpg?1703085405) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00008/article_deploy/html/images/pharmaceuticals-17-00008-g002-550.jpg?1703085407) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00008/article_deploy/html/images/pharmaceuticals-17-00008-g003-550.jpg?1703085408) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00008/article_deploy/html/images/pharmaceuticals-17-00008-g004-550.jpg?1703085410) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00008/article_deploy/html/images/pharmaceuticals-17-00008-g005-550.jpg?1703085411) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00008/article_deploy/html/images/pharmaceuticals-17-00008-g006-550.jpg?1703085414) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00008/article_deploy/html/images/pharmaceuticals-17-00008-g007-550.jpg?1703085417)

Open Access Review

32 pages, 845 KIB (1424-8247/17/1/7/pdf?version=1703664528)

A Mechanistic Review on How Berberine Use Combats Diabetes and Related Complications: Molecular, Cellular, and Metabolic Effects (1424-8247/17/1/7)

- [Vahid Reza Askari](https://sciprofiles.com/profile/4486987?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/4486987?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- [Kimia Khosravi](https://sciprofiles.com/profile/3301952?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3301952?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- [Vafa Baradaran Rahimi](https://sciprofiles.com/profile/author/NTZZTG14QUJcXpZdS93MTd4YS8zXVxYXdlbDlUW9wcHhuc2U1UjZmMD0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/author/NTZZTG14QUJcXpZdS93MTd4YS8zXVxYXdlbDlUW9wcHhuc2U1UjZmMD0e?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- [Stefania Garzoli](https://sciprofiles.com/profile/1166607?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1166607?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 7; <https://doi.org/10.3390/ph17010007> (https://doi.org/10.3390/ph17010007) - 20 Dec 2023
Viewed by 680

Abstract Berberine (BBR) is an isoquinoline alkaloid that can be extracted from herbs such as Coptis, Phellodendron, and Berberis. BBR has been widely used as a folk medicine to treat various disorders. It is a multi-target drug with multiple mechanisms. Studies have shown that [...] [Read more](#).

(This article belongs to the Section [Medicinal Chemistry](#) ([Journal/pharmaceuticals/sections/pharmaceuticals_medical_chemistry](#))

► Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00007/article_deploy/html/images/pharmaceuticals-17-00007-g001-550.jpg?1703664643)

Open Access Article

13 pages, 5061 KIB (1424-8247/17/1/6/pdf?version=1703069796)

Sinomenium acutum Modulates Platelet Aggregation and Thrombus Formation by Regulating the Glycoprotein VI-Mediated Signaling in Mice (1424-8247/17/1/6)

- [Yeon-Ji Kim](https://sciprofiles.com/profile/3133814?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3133814?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- [Tae In Kim](https://sciprofiles.com/profile/815440?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/815440?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- [Ami Lee](https://sciprofiles.com/profile/2563520?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/2563520?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- [Kyungho Kim](https://sciprofiles.com/profile/1705697?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1705697?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- [Youn-Hwan Hwang](https://sciprofiles.com/profile/234941?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/234941?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 6; <https://doi.org/10.3390/ph17010006> (https://doi.org/10.3390/ph17010006) - 20 Dec 2023
Viewed by 478

Abstract *Sinomenium acutum* (SA) has long been used as a traditional medicine in China, Japan, and Korea to treat a wide range of diseases. It has been traditionally used to ameliorate inflammation and improve blood circulation. However, its role in platelet activation has not [...] [Read more](#).

(This article belongs to the Section [Natural Products](#) ([Journal/pharmaceuticals/sections/natural_products](#))

► Show Figures

(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00006/article_deploy/html/images/pharmaceuticals-17-00006-g001-550.jpg?1703069871) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00006/article_deploy/html/images/pharmaceuticals-17-00006-g002-550.jpg?1703069872) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00006/article_deploy/html/images/pharmaceuticals-17-00006-g003-550.jpg?1703069874) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00006/article_deploy/html/images/pharmaceuticals-17-00006-g004-550.jpg?1703069876) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00006/article_deploy/html/images/pharmaceuticals-17-00006-g005-550.jpg?1703069877)

Open Access Article

30 pages, 10378 KIB (1424-8247/17/1/5/pdf?version=1703066212)

Dual Role of Vitamin C-Encapsulated Liposomal Berberine in Effective Colon Anticancer Immunotherapy (1424-8247/17/1/5)

- [Martyna Mianowska](https://sciprofiles.com/profile/3111550?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/3111550?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- [Magdalena Zaremba-Czogała](https://sciprofiles.com/profile/1299638?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1299638?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- [Adrianna Zygmont](https://sciprofiles.com/profile/1784333?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1784333?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- [Mohamed Mahmud](https://sciprofiles.com/profile/883339?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/883339?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name).
- [Regine Süß](https://sciprofiles.com/profile/1658756?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/1658756?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and
- [Jerzy Gubernator](https://sciprofiles.com/profile/847239?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) (https://sciprofiles.com/profile/847239?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals 2024, 17(1), 5; <https://doi.org/10.3390/ph17010005> (https://doi.org/10.3390/ph17010005) - 20 Dec 2023
Viewed by 760

Abstract The aim of the study was to achieve effective colon anticancer immunotherapy using the alkaloid berberine. In the presented paper we attempt to develop a formulation of berberine loaded into liposomal carriers using the vitamin C gradient method, characterized by efficient drug encapsulation, [...] [Read more](#).

(This article belongs to the Special Issue [Combining Immunotherapy and Targeted Therapies in Cancer Treatment](#) ([Journal/pharmaceuticals/special_issues/9Y9M5DO1H4](#))

[Show Figures](#)

https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-ag-550.jpg?1703066318 (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g001-550.jpg?1703066284) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g002-550.jpg?1703066285) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g003-550.jpg?1703066286) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g004-550.jpg?1703066287) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g005-550.jpg?1703066288) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g006-550.jpg?1703066289) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g007-550.jpg?1703066292) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g008-550.jpg?1703066293) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g009-550.jpg?1703066294) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g010-550.jpg?1703066295) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g011-550.jpg?1703066297) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g012-550.jpg?1703066298) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g013-550.jpg?1703066300) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g014-550.jpg?1703066302) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g015-550.jpg?1703066303) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g016-550.jpg?1703066305) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g017-550.jpg?1703066307) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g018-550.jpg?1703066309) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g019-550.jpg?1703066310) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g020-550.jpg?1703066311) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g021-550.jpg?1703066314) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g022-550.jpg?1703066315) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g023-550.jpg?1703066317) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00005/article_deploy/html/images/pharmaceuticals-17-00005-g024-550.jpg?1703066318)

Open Access Review 18 pages, 945 KiB [\(1424-8247/17/1/4/pdf?version=1703061423\)](#)

Emerging Pharmaceutical Therapies to Address the Inadequacy of a Gluten-Free Diet for Celiac Disease (1424-8247/17/1/4)

- by [Martina Crepaldi](#) (https://sciprofiles.com/profile/3222935?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Michela Palo](#) (https://sciprofiles.com/profile/3275854?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Daria Maniero](#) (https://sciprofiles.com/profile/author/RVicyITStTa3NcMXREQXhQmtDLzd3THJEdz2NocXNVeXduTRFCVHb4cz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- [Luisa Bertin](#) (https://sciprofiles.com/profile/3379712?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Eduardo Vincenzo Savarino](#) (https://sciprofiles.com/profile/1024547?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Robert P. Anderson](#) (https://sciprofiles.com/profile/3240312?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Fabiana Zingone](#) (https://sciprofiles.com/profile/900555?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 4; <https://doi.org/10.3390/ph17010004> (<https://doi.org/10.3390/ph17010004>) - 20 Dec 2023
Viewed by 671

Abstract Celiac disease (CeD) is a chronic autoimmune disorder triggered by the ingestion of gluten, affecting around 1% of the global population. It is a multifactorial disease involving both genetics and environmental factors. Nowadays, the only available treatment for CeD is a life-long gluten-free [...]. [Read more.](#)
(This article belongs to the Special Issue [Drug Candidates for the Treatment of Immune Disease 2023](#) ([/journal/pharmaceuticals/special_issues/YL49G89Y51](#)))

[Show Figures](#)
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00004/article_deploy/html/images/pharmaceuticals-17-00004-g001-550.jpg?1703061536) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00004/article_deploy/html/images/pharmaceuticals-17-00004-g002-550.jpg?1703061538)

Open Access Article 19 pages, 1225 KiB [\(1424-8247/17/1/3/pdf?version=1703225534\)](#)

Effects of COVID-19 on the Liver and Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta and Non-Delta Variants: An Analysis in a Single Centre (1424-8247/17/1/3)

- by [Monica Muntean](#) (https://sciprofiles.com/profile/1768156?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Violeta Briciu](#) (https://sciprofiles.com/profile/1878391?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Mihaela Lupse](#) (https://sciprofiles.com/profile/2372736?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Doina Colcar](#) (https://sciprofiles.com/profile/2757640?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Raul Vlad Macciasan](#) (https://sciprofiles.com/profile/3179204?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Agnes Csizsar](#) (https://sciprofiles.com/profile/3179404?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Alexandra Manole](#) (https://sciprofiles.com/profile/3178569?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Amanda Radulescu](#) (https://sciprofiles.com/profile/2419341?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 3; <https://doi.org/10.3390/ph17010003> (<https://doi.org/10.3390/ph17010003>) - 19 Dec 2023
Viewed by 634

Abstract The aim of this study was to ascertain patient characteristics, outcomes, and liver injuries in patients infected with different SARS-CoV-2 variants. Data from consecutive adult patients with severe/critical COVID-19 admitted to our hospital during the peak month of the Delta wave were compared [...]. [Read more.](#)
(This article belongs to the Special Issue [Infectious Disease Epidemiology and Pharmaceutical Development](#) ([/journal/pharmaceuticals/special_issues/W3K3C37QO](#)))

[Show Figures](#)
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00003/article_deploy/html/images/pharmaceuticals-17-00003-g001-550.jpg?1703225635) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00003/article_deploy/html/images/pharmaceuticals-17-00003-g002-550.jpg?1703225638)

Open Access Article 16 pages, 1686 KiB [\(1424-8247/17/1/2/pdf?version=1702986778\)](#)

Postoperative Nausea and Vomiting Following Endoscopic Sinus Surgery under the Guidance of Adequacy of Anesthesia or Pupillometry with Intravenous Propofol Remifentanyl (1424-8247/17/1/2)

- by [Michal J. Stasiowski](#) (https://sciprofiles.com/profile/author/ZVZDempEbnRZGRrcTJfA0FUGnBYTTAVJENSRXpG9TWkT43dFdwNW1Bbz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

- [Nikola Zmarzly](#) (https://sciprofiles.com/profile/871278?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Benjamin Oskar Grabarek](#) (https://sciprofiles.com/profile/884956?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Jakub Gašiorek](#) (https://sciprofiles.com/profile/1073234?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 2; <https://doi.org/10.3390/ph17010002> (<https://doi.org/10.3390/ph17010002>) - 19 Dec 2023
Viewed by 558

Abstract Postoperative nausea and vomiting (PONV) constitutes an adverse event after endoscopic sinus surgery (ESS) under general anesthesia (GA) with intravenous opioids, such as remifentanyl (RMF). Monitoring the nociception/antinociception balance using the surgical pleth index (SPI) or pupillary dilatation reflex (PRD) helps guide intravenous [...]. [Read more.](#)
(This article belongs to the Section [Pharmacology](#) ([/journal/pharmaceuticals/sections/pharm-pharmacology](#)))

[Show Figures](#)
(https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00002/article_deploy/html/images/pharmaceuticals-17-00002-ag-550.jpg?1702986892) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00002/article_deploy/html/images/pharmaceuticals-17-00002-g001-550.jpg?1702986885) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00002/article_deploy/html/images/pharmaceuticals-17-00002-g0A1-550.jpg?1702986887) (https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-17-00002/article_deploy/html/images/pharmaceuticals-17-00002-g0A2-550.jpg?1702986890)

Open Access Article 12 pages, 633 KiB [\(1424-8247/17/1/1/pdf?version=1702971389\)](#)

Inhalation of *Pelargonium graveolens* Essential Oil Alleviates Pain and Related Anxiety and Stress in Patients with Lumbar Spinal Stenosis and Moderate to Severe Pain (1424-8247/17/1/1)




- by [Eunhye Seo](#) (https://sciprofiles.com/profile/1846886?utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name), [Yeonah Cho](#) (https://sciprofiles.com/profile/author/MUdOZGjHRkorU2cxNGRVWEZjMDR9SnBRdz2OaGp1NE9OaKz0uIdQVC9WZz0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name) and [Jeong-Min Lee](#) (https://sciprofiles.com/profile/author/Q3FjCw9ESmYwFJNWNjbDNBA6JtK4t4Tm5DSWMM3UmIaEdVcUxZclcxST0=7utm_source=mdpi.com&utm_medium=website&utm_campaign=avatar_name)

Pharmaceuticals **2024**, *17*(1), 1; <https://doi.org/10.3390/ph17010001> (<https://doi.org/10.3390/ph17010001>) - 19 Dec 2023
Viewed by 599

Abstract Pain in lumbar spinal stenosis (LSS) patients is closely associated with psychological factors, including anxiety, stress, and depression, and is a critical determinant of

Review

Moringa oleifera: A Review of the Pharmacology, Chemical Constituents, and Application for Dental Health

Meiny Faudah Amin ^{1,*}, Taufiq Ariwibowo ¹, Salsabila Aqila Putri ² and Dikdik Kurnia ²

¹ Department Conservative Dentistry, Faculty of Dentistry, Universitas Trisakti, Jakarta Barat 11440, Indonesia; taufiq@trisakti.ac.id

² Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Sumedang 45363, Indonesia; salsabila21021@mail.unpad.ac.id (S.A.P.); dikdik.kurnia@unpad.ac.id (D.K.)

* Correspondence: meiny.faudah@trisakti.ac.id

Abstract: *Moringa oleifera* L., commonly known as Kelor in Indonesia and miracle tree in English, has a rich history of utilization for medicinal, nutritional, and water treatment purposes dating back to ancient times. The plant is renowned for its abundance of vitamins, minerals, and various chemical constituents, making it a valuable resource. Among its notable pharmacological properties are its effectiveness as an anti-diabetic, anti-diarrheal, anti-helminthic, anti-leishmanial, anti-fungal, anti-bacterial, anti-allergic, anti-cancer, anti-inflammatory, and anti-oxidant agent. In this comprehensive review, we delve into the extensive pharmacological applications and phytochemical constituents of *M. oleifera* and its application in dental health.

Keywords: *Moringa oleifera*; pharmacological use; phytochemical constituent



Citation: Amin, M.F.; Ariwibowo, T.; Putri, S.A.; Kurnia, D. *Moringa oleifera*: A Review of the Pharmacology, Chemical Constituents, and Application for Dental Health. *Pharmaceuticals* **2024**, *17*, 142. <https://doi.org/10.3390/ph17010142>

Academic Editor: Domenico Iacopetta

Received: 14 November 2023

Revised: 13 January 2024

Accepted: 16 January 2024

Published: 22 January 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Moringa oleifera L. comes from the Moringaceae family and is commonly known as Kelor in Indonesia, Sahajan in India, and Horseradish tree or Drumstick tree in English. It is also described as a miracle tree due to its nutritional value, diverse functions, and medicinal properties. *M. oleifera* can grow up to 12 m in tropical and subtropical environments. Although it is native to South Asia, the cultivation itself has already spread to the Middle East, Africa, Asia, and other areas. Traditionally, *M. oleifera* has been used in medicine, skincare, breastmilk production, and even food. Almost all parts of *M. oleifera* can be useful. Nowadays, *M. oleifera* is also used for water purification, animal feed, as a bio-stimulant, bio-pesticide, and biomass as biodiesel production in industrial and agricultural processes [1–6]. Table 1 describes the traditional usage of *M. oleifera*.

Table 1. Traditional usage of *M. oleifera*.

Part of Plant	Usage	References
Seed	Skincare, haircare, fertilizer, cure for eye disease, fever, snake bite, headache, bladder, ulcer, gastritis, gout, stimulant, antispasmodic, stomachache, anemia, joint pain, hypertension, water purification.	[2–4]
Leaf	Wound healing, snake bites, stimulation, breast milk production, diarrhea, animal feed, constipation, bronchitis, glandular swelling, rheumatism, influenza, food, malaria, arthritis.	[2–6]
Root	Anticoagulation, wound healing, laxative, diuretic, toothache, cold, sores, asthma, bronchitis, epilepsy, urinary discharge, laxative, antiparalytic, cardiac tonic.	[3–5]
Pod (Fruit)	Diabetic, antipyretic, asthma, spleen, skin tumor, joint pain.	[4,5]
Flower	Stimulant, tonic, cholagogue, cold, inflammation, muscle disease, tumor, cholera.	[4,5]
Bark (Stem)	Heart compilation, fever, eye disease, digestive disorder, animal feed, headache, hypoglycemia, toothache.	[4–6]

As a food and stimulant, *M. oleifera* is known to have an abundance of nutritional value and is comparatively easy to cultivate because of its rapid growth and good adaptability to climate change. Thus, in poor countries, *M. oleifera* is used as a source of proteins, calories, minerals, and vitamins. It has been reported that dry leaves of *M. oleifera* contain more calories, protein, carbohydrate, fiber, vitamin B, calcium, magnesium, phosphorus, potassium, copper, and iron than fresh leaves. Meanwhile, fresh leaves contain more vitamin C and E. Between the leaf, seed, and pod of *M. oleifera*, proteins, vitamin E, and magnesium have been found to be more abundant in the seed [7–9].

Due to many its traditional usages, research has been conducted to prove its ability as medicine. It is reported to have pharmacological properties such as anti-diabetic, anti-diarrheal, anti-helmintic, anti-leishmanial, anti-fungi, anti-bacterial, anti-allergic, anti-cancer, anti-inflammatory, and anti-oxidant. Hastuty and Nitia reported the efficiency of *M. oleifera* leaf extract to raise hemoglobin levels in young girls. They showed a value of 10.83 g/dL before treatment, while after treatment with *M. oleifera*, the hemoglobin levels increased to 12.72 g/dL [10]. Yuliastuti and Kurnia also reported the effect of *M. oleifera* on hemoglobin levels in anemic pregnant women. The result showed a significant difference, where before treatment, the respondents showed hemoglobin levels about 10.2 g/dL, and after treatment these increased to 10.8 g/dL ($p = 0.003 < 0.05$) [11].

Dental health has been a concern for researchers to this day. The various infections that can occur in the teeth cause a decline in health. Dental infections occur due to the growth of various kinds of microbes in the dental and oral area. Among these are odontogenic infections and periradicular periodontitis that occur in the root canal system caused by anaerobic bacteria such as *Porphyromonas gingivalis*, *Enterococcus faecalis*, and *Candida albicans* [12–14]. *E. faecalis* is reported to infect root canals up to 30–80% [15]. In addition, based on polymerase chain reaction (PCR) analysis, the bacteria *Tannerella forsythia*, *Treponema denticola*, *Dialister pneumosintes*, and *Prevotella tanneriae* were also reported to infect root canals with high prevalence [16]. These infections occur due to biofilm formation by microbes on the tooth area [17]. The use of antibiotics is a very useful treatment due to their effectiveness, low cost, and compatibility. However, resistance to antibiotic agents by microbes has been identified. Gram-negative bacteria have been reported to be resistant to beta-lactam antibiotics due to an enzyme that can open the ring in the beta-lactam structure, thus inactivating the action of the drug [18].

Therefore, natural product drug discovery research is of particular interest to researchers as a natural antibacterial agent. The main parameters in determining antibacterial activity are the inhibition zone value, minimum inhibition concentration (MIC) as a reference for the minimum concentration that can inhibit bacterial growth, and minimum bactericidal concentration (MBC) as a reference for the minimum concentration needed to kill a microorganism [19]. Based on the bioactivity and phytochemicals contained in *M. oleifera*, this plant has become one of the natural sources for dental disease treatment. *M. oleifera* seed extract was reported to provide MIC and antibiofilm values against *P. gingivalis* of 12.5 mg/mL and 6.25 mg/mL, respectively [20]. *M. oleifera* nanosuspension can inhibit *Aggregatibacter actinomycetemcomitans*, *P. gingivalis*, *Prevotella intermedia*, *Fusobacterium nucleatum* with an MIC and MBC of 25% and 12.5%, respectively [21]. Based on this description, this review will explain the bioactivity contained in *M. oleifera* and describe the role of the plant for dental health and the chemical components contained therein.

2. Phytochemical Constituent

The pharmacological effects of *M. oleifera* are influenced by its phytochemical components. Previous studies have reported that there are several groups of compounds that are unique to each part of *M. oleifera*. The flowers are known to contain flavonoids, alkaloids, sucrose, and amino acids such as kaempferitrin, isoquercitrin, and rhamnetin. Furthermore, the stem contains alkaloid compounds such as moringinine and moringin, octacosanoic acid, β -sitosterol, and 4-hydroxymellein. The seed contains high contents of 4-(α -l-rhamnosyloxy) phenylacetone nitrile, benzylglucosinolate, 4-(α -l-rhamnosyloxy) benzylisothiocyanate, *O*-ethyl-4-

(α -l-rhamnosyloxy) benzyl, and 4-(α -l-rhamnopyranosyloxy)-benzylglucosinolate carbamate, while the fruit contains cytokines. In addition, the whole pods were specific for *O*-[2'-hydroxy-3'-(2''-heptenyloxy)]-propyl undecanoate, methyl-*p*-hydroxybenzoate, thiocarbamates, isothiocyanate, nitrile, and *O*-ethyl-4-[(α -l-rhamnosyloxy)-benzyl] carbamate [22]. The seeds of *M. oleifera* contain total flavonoids 144.07 mg/kg, total polyphenols 145.16 mg/100 g, and proanthocyanidines 140.49 mg/kg. In addition, the oil of *M. oleifera* contains 18.24 mg rutin equivalent/g (total flavonoids), 37.94 mg ascorbic acid equivalent/g (total antioxidant capacity), and 40.17 mg GA equivalent/g (total phenols). Based on this description, the following are some of the structures of phytochemical components contained in *M. oleifera* [23].

2.1. Phenolic

Niazirin (1) was obtained through an ethanol and butanol extraction of the seeds and leaves of *M. oleifera*. It was reported to inhibit α -glucosidase inhibitor with an IC_{50} value of 382.2 μ M. [24–28]. Caffeoylquinic acid (2), 4-*O*-caffeoylquinic acid (3), 4-*O*-(3'-*O*- α -D-glucopyranosyl)-caffeoylquinic acid (4), 4-*O*-(4'-*O*- α -D-glucopyranosyl)-caffeoylquinic acid (5), 4-*O*- β -D-glucopyranoside benzoic acid (6), 5-*O*-caffeoylquinic acid (7), benzaldehyde 4-*O*- α -L-rhamnopyranoside (8), chlorogenic acid (9), methyl caffeoylquinic acid (10), methyl 4-caffeoylquinic acid (11), and 3,4-dihydroxybenzoic acid (12) could be obtained through an ethyl acetate and butanol extraction of *M. oleifera* leaves. The structures of the compounds are shown in Figure 1 [24–28].




Figure 1. Phenolic compounds in ethanol and butanol extracts of seeds and leaves of *M. oleifera*.

Other phenolic compounds that could be isolated from various parts of *M. oleifera* were caffeic acid (13), gallic acid (14), *p*-coumaric (15), and vanillin (16). Cryptochlorogenic acid (17) also could be obtained from *M. oleifera*, and it was also reported to have anticancer activity against MCF-7 with an IC_{50} value of 20.8 M. The structures are shown in Figure 2 [28–30].




Figure 2. Phenolic compounds of other parts of *M. oleifera*.

2.2. Glucosinolate

Glucosinolate compounds, as shown in Figure 3, could be isolated from the ethanol extracts of seeds of *M. oleifera*. These include the following compounds: 4-(3'-O-acetyl- α -L-rhamnosyloxy) benzyl isothiocyanate (18), 4-(α -L-rhamnopyranosyloxy)-benzylglucosinolate (19), 4-(α -L-rhamnosyl) benzyl ethyl ester (20), moringaside C (21), moringaside D (22), moringaside E (23), moringaside F (24), moringaside G (25), moringin (26), niazimicin (27), and glucomoringin (28). Furthermore, compound 23 exhibited α -glucosidase inhibitory activity with an IC_{50} value of 382.8 μ M, meanwhile compound 26 had a reported an anti-adipogenic effect and an anticancer activity against HeLa cells with an IC_{50} value of 9.2 μ g/mL. Meanwhile, compound 28 exhibited anti-allergic properties with IC_{50} values towards β -hexosaminidase and histamine releases of 10.43 and 27.22 μ M, respectively. It is also reported to have antiviral properties against H1N1 with an IC_{50} value of 0.98 μ g/mL [13,15,26,30–37].




Figure 3. Glucosinolate compounds of seed ethanol extract of *M. oleifera*.

Other glucosinolates found in *M. oleifera* were 4-(4'-O-acetyl- α -L-rhamnosyloxy) benzyl isothiocyanate (29), benzyl glucosinolate (30), 4-[(2'-O-acetyl- α -L-rhamnosyloxy) benzyl] isothiocyanate (31), 4-[(3'-O-acetyl- α -L-rhamnosyloxy) benzyl] isothiocyanate (32), niazinin (33), and niazinin B (34). Furthermore, compound 31 and 32 exhibited NO inhibitory activity with IC_{50} values of 1.67 and 2.66 μ M, respectively, meanwhile compound 33 exhibited antileishmanial properties with an IC_{50} value of 5.25 mM. The structures are shown in Figure 4 [24,38–41].




Figure 4. Glucosinolate compounds of other parts of *M. oleifera*.

2.3. Flavonoid

The leaves, barks, and seeds of *M. oleifera* contained various flavonoid compounds, as shown in Figure 5. The flavonoids reported were astragalins (35), isoquercitrin (36), kaempferol (37), kaempferol 3-*O*-glucoside (38), kaempferol acetyl glycoside (39), kaempferol-3-*O*-(6''-malonyl-glucoside) (40), quercetin (41), quercetin 3-*O*- β -D-glucopyranoside (42), quercetin-3-acetyl-glucoside (43), quercetin-3-*O*-(6''-malonyl-glucoside) (44), quercetin-3-*O*- β -D-(6''-*O*-3-hydroxy-3-methylglutaryl)-glucoside (45), rutin (46), vitexin (47), and 3,5,6-trihydroxy-2-(2,3,4,5,6-pentahydroxyphenyl)-4*H*chromen-4-one (48). Those compounds could be obtained through extraction with methanol, ethanol, butanol, and ethyl acetate. Compounds 35, 36, and 46 were reported to inhibit CYP3A4 and CYP2D6, with IC_{50} values of 69.5 and 90 μ M for compound 35, whereas compounds 36 and 46 were reported to be CYP3A4 inhibitors with IC_{50} values of 65.5 and 60 μ M, respectively.

Compounds 37, 41, and 48 were reported to have anti-allergic properties by inhibiting β -hexosaminidase and histamine release, with IC_{50} values of 29.39 and 46.94 μ M, respectively, for compound 37. Compound 41 exhibited IC_{50} values of 19.07 and 7.77 μ M, respectively. Compound 48 showed IC_{50} values of 17.70 and 44.87 μ M, respectively. Furthermore, compound 46 also inhibited α -glucosidase and pancreatic lipase with IC_{50} values of 40 and 35 μ g/mL, respectively. Compound 47 also exhibited antiviral properties against virus H1N1 with an IC_{50} value of 3.42 μ g/mL [13,24–27,33,39,42–46].

Apigenin (49), kaempferol-3-*O*-[methyl-(*S*)-3-hydroxy-3-methylglutaroyl(1 \rightarrow 6)]- β -D-glucopyranoside (50), and multiflorin-B (51) also could be obtained from *M. oleifera* ethanol extracts [42,47,48].




Figure 5. Cont.




Figure 5. Flavonoid compounds of leaves, barks, and seeds of *M. oleifera*.

2.4. Fatty Acid

Figure 6 shows the structure of fatty acid compounds from the ethanol, methanol, and ethyl acetate extracts of leaves, seeds, and flowers of *M. oleifera*. The compounds are glycerol-1-(9-octadecanoate) (52), heneicosanoic acid (53), monoacetyl glycerol (54), monacosan-15-one (55), octacosanol (56), oleic acid (57), 3,4-methyleneazelaic acid (58), and triolein acid (59). Compound 57 exhibited anti-allergic properties by inhibiting β -hexosaminidase and histamine release, with IC_{50} values of 53.76 and 56.05 μ M, respectively [40,42,49–53].




Figure 6. Cont.




Figure 6. Fatty acid compounds of leaves, seeds, and flowers of ethanol, methanol, and ethyl acetate extracts of *M. oleifera*.

2.5. Ester

Ethyl geranyl acetate (**60**), ethyl-(*E*)-undec-6-enoate (**61**), methyl heptanoate (**62**), methyl-4-(α -L-rhamnopyranosyloxy) benzyl carbamate (**63**), *O*-ethyl-4-(α -L-rhamnosyloxy)benzyl carbamate (**64**), and 2-formyl-5-methyl-1*H*-pyrrol-1-ylbutanoic acid (**65**) were ester groups isolated from leaves, flowers, and seeds of ethanol, methanol, and *n*-hexane *M. oleifera* extracts. The structures are shown in Figure 7. Compound **61** exhibited anti-allergic properties by inhibiting β -hexosaminidase and histamine release with IC₅₀ values of 82.68 and 82.07 μ M, respectively [42,49,50,53–55].




Figure 7. Ester compounds of leaves, flowers, and seeds of ethanol, methanol, and *n*-hexane extracts of *M. oleifera*.

2.6. Alkaloid

The roots, seeds, and leaves of *M. oleifera* contain alkaloids, as shown in Figure 8. Some of them could be obtained from butanol extraction. The alkaloids contained in *M. oleifera* include the following: marumoside A (**66**), marumoside B (**67**), aurantiamide acetate (**68**), hostine D (**69**), methyl 4-(α -L-rhamnopyranosyloxy) benzylcarbamate (**70**), pyrrolemorine A (**71**), pyrrolemorine B (**72**), pyrrolemorine C (**73**), pyrrolemorine D (**74**), pyrrolemorine E (**75**), pyrrolemorine F (**76**), pyrrolemorine G (**77**), pyrrolemarumine (**78**), tangutorid E (**79**), and tangutorid F (**80**). Compounds **71** and **75** demonstrated notable neuroprotective effects. At a concentration of 0.1 μ M, they effectively mitigated PC12 cell damage caused by oxygen glucose deprivation and concurrently reduced the expression of NF- κ B [42,47,56,57].




Figure 8. Alkaloid compounds of roots, seeds, and leaves of *M. oleifera*.

2.7. Sterol

All parts of *M. oleifera* contain sterol compounds, as shown in Figure 9. The compounds could be isolated from methanol, ethanol, ethyl acetate, and acetone extracts. The following are sterols isolated from various parts of *M. oleifera*: β -sitosterone (81), stigmasterol (82), β -sitosterol-3-O-glucoside (83), β -sitosteryl oleate (84), and 24-methylene-9,19-cyclolanostan-3-ol (85). Compounds 82 and 83 exhibited anti-allergic properties by inhibiting β -hexosaminidase and histamine release with IC_{50} values of 75.92 and 38.27 μ M, respectively, for compound 82; meanwhile, compound 83 only inhibited β -hexosaminidase release with an IC_{50} value of 24.93 μ M. Moreover, compound 82 exhibited anti-inflammatory characteristics by inhibiting caspase 1 and NF- κ B. It also exhibited anti-adipogenic properties by reducing the S and G2/M phases, inhibiting ROS, and enhancing glucose uptake [13,31,37,58–61].




Figure 9. Sterol compounds of *M. oleifera*.

2.8. Terpene

(*S*) Linalyl- β -D-glucoside (86), (*S*) linalyl- β -primeveroside (87), lupeol (88), tuberonic acid (89), γ -diosphenol (90), and 2,2,4,4-tetramethyl-6-(1-oxobutyl)-1,3,5-cyclohexanetrione (91) were terpenes isolated from *M. oleifera*. Compound 88 exhibited anti-adipogenic properties by reducing the S and G2/M phases, inhibiting ROS, and enhancing glucose uptake. The structure of the compounds is shown in Figure 10 [52,54,62].




Figure 10. Terpene compounds of *M. oleifera*.

2.9. Other Compounds

The leaf extract of *M. oleifera* contained 4-hydroxyphenylacetonitrile (92), lutein (93), adenosine (94), uridine (95), 3-pyridinecarboxamide (96), 5-hydroxymethyl-2-furaldehyde

(97), 5-hydroxymethyl-2-furancarboxylic acid (98), bis-isothiocyanatomethyl benzene (99), and pyropheophorbide-a (100). Compound 92 exhibited activity to induce the secretion of insulin. Other compounds isolated from *M. oleifera* were L-tryptophan (101), benzyl β -D-glucopyranoside (102), benzyl- β -primeveroside (103), (+)-pinosresinol-4-O- β -D-glucopyranoside (104), isolariciresinol-3a-O- β -D-glucopyranoside (105), lariciresinol-9-O- β -D-glucopyranoside (106), fluoropyrazine (107), (10-hydroxy-1,3-dimethylchrysen-3-yl)-5-hydroxypentan-1-one (108), hexademethylated 3 β ,11 β -dihydroxyfriedelane (109), 6,7-dipropanone-5-hydroxyphenyl-3-methylphenanthrene-1-carboxylic acid (110), (2R)-2-phenylmethoxybutane-1,4-diol (111), (2S)-2-phenylmethoxybutane-1,4-diol (112), 2-hexenyl- β -D-glucopyranoside (113), omoringone (114), 1,3-dibenzyl urea (115), 1-hydroxy-3-phenylpropan-2-yl benzoate (116), 1-octadecene (117), 2,3,4-trihydroxybenzaldehyde (118), 3,4-dihydroxy benzonitrile (119), 3,7,11,15-tetramethyl-2-hexadecen-1-ol (120), 3-hydroxy- β -ionone (121), N-benzyl S-ethyl thioformate (122), benzyl benzylcarbamate (123), methyl-4-hydroxybenzoate (124), and pyrrolezanthine (125). The structures of these compounds are shown in Figure 11.




Figure 11. Cont.




Figure 11. The structures of compounds of leaf extract of *M. oleifera*.

Compound **104** displayed a potent inhibition of CYP3A4, with an IC₅₀ value of 41.5 µg/mL, while compound **105** exhibited CYP3A4 inhibition with an IC₅₀ value of 100 µg/mL. Compound **107** also demonstrated CYP3A4 inhibitory activity, with an IC₅₀ value of 72.5 µg/mL. In addition to their enzyme inhibitory effects, compounds **109** and **110** showcased strong antioxidant properties, as indicated by DPPH IC₅₀ values of 0.475 and 0.671 mg/mL, respectively. Furthermore, compound **122** exhibited significant antibacterial activity, with MIC values of 32 µg/mL against pathogens such as *S. dysenteriae*, *S. boydii*, and *S. aureus* [13,25,30,37,41,43,51,58,63–69].

3. Pharmacological Properties

3.1. Anti-Hemorrhage

Anti-hemorrhage properties in medicine are used to prevent excessive bleeding due to injury or surgery. Excessive bleeding could lead to death. Adeyemi et al. investigated the anti-hemorrhage properties of *M. oleifera* extracts. The experiment was studied by utilizing the venom of *Echis ocellatus*. The result reported that the ethanol extract of *M. oleifera* showed the highest effectiveness in neutralizing hemorrhage, with a dose of 800 mg/kg for 2 mL of 0.22 mg/kg venom. They also investigated the incubation factor and demonstrated its enhanced potency when pre-incubated with venom from *E. ocellatus* [43].

3.2. Anti-Allergic

Allergy is a condition where the immune system in the body mistakenly identifies substances as harmful and triggers reactions that affect various parts of the body. The development of anti-allergy medicine has been evolving to improve treatment and understand allergy mechanisms. Rani et al. evaluated the effectiveness of the anti-allergic properties of the leaves, pods, and seeds of *M. oleifera*. The extracts were macerated with ethanol at 80% and yielded nine compounds from the isolation. The study showed that the extracts of *M. oleifera* could inhibit the early and late phases of allergic reactions. In particular, the leaf extracts could better suppress the release of β-hexosaminidase (IC₅₀ 7.17 µg/mL), IL-4 (IC₅₀ 2.32 µg/mL), and TNF-α (IC₅₀ 1.2 µg/mL) compared to ketotifen fumarate as a positive control. *M. oleifera* seed extract could inhibit histamine release better compared to other extracts and the positive control, with an IC₅₀ value of 5.97 µg/mL. Further study showed that compared to other isolated compounds, glucomoringin (**28**) had a better inhibition against beta-hexosaminidase in the early phase and TNF-α release in the late phase (IC₅₀ 10.43 µg/mL); meanwhile, quercetin (**41**) had a better inhibition against histamine release (IC₅₀ 7.77 µg/mL). In the last allergic phase, β-sitosterol-3-O-glucoside (**83**) showed a better inhibition against IL-4 release compared to other isolated compounds, with an IC₅₀ value of 7.33 µg/mL [50].

3.3. Antimicrobial

Antimicrobial properties of compounds always gain interest due to their crucial role in preventing infectious diseases. In an era where microorganisms keep evolving and show resistance to antimicrobial agents, the development of natural antimicrobial agents has become urgent. Various parts of *M. oleifera* extracts with antibacterial activity were studied against *E. coli* and *S. aureus* using the agar well diffusion method. The study showed that the 80% methanol extract of leaves, pulp, and seed had the best inhibition against *E. coli*. The 70 and 80% methanol extract of flowers showed the same value against *S. aureus*, and the aqueous pulp extract showed a better result against *S. aureus* compared to other extracts [70]. Abadallah and Ali studied the comparison of aqueous and ethanol extracts of *M. oleifera* against several bacteria. The MIC value and zone inhibition of the ethanol extract showed better results compared to the aqueous extract. *Shigella* spp. was the most susceptible to both extracts [71]. The extracts of *M. oleifera* showed potential for antibacterial and anti-fungal properties, as shown in Table 2.

Table 2. Antimicrobial activity of *M. oleifera* against (A) Gram negative bacteria, (B) Gram positive bacteria, and (C) fungi.

<i>M. oleifera</i>	Microorganism	Inhibition Zone (mm)	MIC (mg/mL)	MBC (mg/mL)	References
(A) Gram Negative Bacteria					
Stem methanol extract	<i>Vibrio cholerae</i>	-	2.50	-	[72]
	<i>Vibrio mimicus</i>	-	1.25	-	
Leaves ethanol extract	<i>V. cholerae</i>	-	0.08	-	[72]
	<i>V. mimicus</i>	-	5	-	
Pods ethanol extract	<i>V. cholerae</i>	-	0.31	-	[72]
	<i>V. mimicus</i>	-	2.5	-	
Flower chloroform extract	<i>V. cholerae</i>	-	0.63	-	[72]
	<i>V. mimicus</i>	-	1.25	-	
Ethanol extract	<i>Proteus mirabilis</i>	-	3.75 µg/mL	-	[55]
	<i>Fusarium sp.</i>	12	-	-	
Methanol extract	<i>Burkholderia cepacia</i>	19	-	-	[55]
	<i>Yersinia enterocolitica</i>	19	-	-	
	<i>Proteus vulgaris</i>	15	-	-	
	<i>Escherichia coli</i>	15	-	-	
Aqueous extract	<i>Yersinia enterocolitica</i>	15	-	-	[55]
	<i>Serratia rubidaea</i>	15	-	-	
	<i>Salmonella pollum</i>	15	-	-	
	<i>Pullarum sp.</i>	5	-	-	
Root powder extract	<i>P. mirabilis</i>	-	3.75 µg/mL	-	[73]
	<i>E. coli</i>	-	87%	-	
Nanoparticles loaded to extract	<i>Aspergillus niger</i>	55	-	-	[74]
Ethanol extract	<i>Aeromonas caviae</i>	23.8	-	-	[75]
	<i>Vibrio parahaemolyticus</i>	21.9	-	-	
Aqueous extract	<i>Aeromonas caviae</i>	22.3	-	-	[75]
	<i>V. parahaemolyticus</i>	20.7	-	-	
Methanol pod extract	<i>P. aeruginosa</i>	22	-	-	[76]
Acetone extract	<i>E. coli</i>	-	5	5	[77]
	<i>Enterobacter cloacae</i>	-	5	5	
	<i>P. vulgaris</i>	-	5	5	
Leaf ethanol extract	<i>E. coli</i>	18.3	-	-	[78]
Leaf methanol extract	<i>E. coli</i>	19	-	-	[78]
Leaf aqueous extract	<i>E. coli</i>	14	-	-	[78]
Aqueous extract	<i>E. coli</i>	18.25	25	-	[79]
Ethanol extract		27.75	390 µg/mL	-	
Aqueous extract	<i>Klebsiella pneumoniae</i>	21.75	50	-	[79]
Ethanol extract		28.5	780 µg/mL	-	
Aqueous extract		20.65	50	-	[79]
Ethanol extract	<i>Citrobacter sp.</i>	19.5	390 µg/mL	-	
Aqueous extract		14.75	25	-	[79]
Ethanol extract	<i>P. vulgaris</i>	24.75	780 µg/mL	-	
Aqueous extract		17.5	25	-	[79]
Ethanol extract	<i>P. aeruginosa</i>	22.25	780 µg/mL	-	
Aqueous extract		20	-	-	[79]
Methanol extract	<i>Staphylococcus aureus</i>	24	-	-	
Aqueous extract		18	-	-	[80]
Methanol extract	<i>E. coli</i>	16	-	-	
Methanol extract	<i>Klebsiella spp.</i>	25	-	-	[81]
Ethanol extract	<i>Enterococcus faecalis</i>	27.5	10% (w/v)	-	[82]
Ethanol extract	<i>Salmonella typhi</i>	8	8	8.5	[83]
Chloroform extract	<i>Shigella dysenteriae</i>	-	1500 µg/mL	2000 µg/mL	[31]
Ethanol seed extract	<i>E. coli</i>	16	100	-	[25]
	<i>Shigella flexneri</i>	15	100	-	
(B) Gram Positive Bacteria					
Methanol extract	<i>Aspergillus flavus</i>	12	-	-	[55]
Nanoparticles loaded to extract	<i>A. flavus</i>	55	-	-	[74]
	<i>S. aureus</i>	23.3	-	-	[75]
Ethanol extract	<i>Enterococcus aureus</i>	19.4	-	-	
Aqueous extract	<i>S. aureus</i>	25.4	-	-	[75]
	<i>E. aureus</i>	17.8	-	-	
Acetone extract	<i>S. aureus</i>	-	5	5	[77]
	<i>Micrococcus kristinae</i>	-	0.5	1	
Leaf ethanol extract	<i>Bacillus subtilis</i>	19	-	-	[78]
	<i>S. aureus</i>	21.3	-	-	
Leaf methanol extract	<i>B. subtilis</i>	22	-	-	[78]
	<i>S. aureus</i>	23.6	-	-	
Leaf aqueous extract	<i>B. subtilis</i>	12	-	-	[78]
	<i>S. aureus</i>	18	-	-	
Aqueous extract	<i>Corynebacterium</i>	22.5	25	-	[79]
Ethanol extract	<i>pseudotuberculosis</i>	25.65	390 µg/mL	-	
Aqueous extract		25.5	25	-	[79]
Ethanol extract	<i>Corynebacterium ulcerans</i>	30.5	390 µg/mL	-	

Table 2. Cont.

<i>M. oleifera</i>	Microorganism	Inhibition Zone (mm)	MIC (mg/mL)	MBC (mg/mL)	References
Aqueous extract	<i>S. aureus</i>	14.75	50	-	[79]
Ethanol extract		26.75	390 µg/mL	-	
Aqueous extract	<i>B. subtilis</i>	23	-	-	[80]
Methanol extract		23	-	-	
Ethanol extract	<i>Staphylococcus epidermidis</i>	12	-	-	[80]
Ethanol extract	<i>S. aureus</i>	19.5	10% (w/v)	-	[82]
(C) Fungi					
Aqueous extract	<i>Candida albicans</i>	5	-	-	[55]
Ethanol extract	<i>C. albicans</i>	-	718.33 µg/mL	-	[74]
Nanoparticles loaded to extract	<i>C.albicans</i>	75	-	-	[74]
Methanol pod extract	<i>Colletotrichum</i> sp.	14	-	-	[76]
Ethanol extract	<i>C.albicans</i>	1.87 cm	-	-	[63]
Aqueous extract		1.87 cm	-	-	
Ethyl acetate extract	<i>Microsporium gypseum</i>	9.67	1.56	-	[26]
Methanol extract	<i>Rhizopus stolonifer</i>	8.67	6.25	-	[26]
	<i>R. stolonifer</i>	9.66	1.56	-	

Note: - (not tested).

The antiviral activities of *M. oleifera* extracts against several viruses are shown in Table 3.

Table 3. Antiviral activity of *M. oleifera* against several viruses.

<i>M. oleifera</i>	Viral	IC ₅₀ (µg/mL)	CC ₅₀ (µg/mL)	EC ₅₀ (µg/mL)	References
Leaf extract	SARS-CoV-2 "NRC-03-nhCoV"	52.79	111.54	-	[27]
Crude ethanol extract	SARS-CoV-2	12.29	7277	-	[28]
Seed extract	IAVs	-	-	1.27	[29]
Seed extract	H1N1	0.26	-	-	[84]
Aqueous extract	HSV-1	43.2%	-	-	[30]
	HSV-2	21.4%	-	-	
Leaf ethanol extract	H9	-	100	-	[33]
Methanol extract	HSV-1F	-	724.5	74.8	[34]
	VU-09	-	-	79.6	
Aqueous leaf extract	AqMOL	-	697.8	721.8	[35]
	ACV	-	>30	0.48	

Note: - (not tested).

3.4. Anthelmintic

Parasitic worm infections can infect various parts of the body, which could lead to health issues for the host. This could lead to the economic loss of livestock. To prevent these losses, the development of anthelmintic medicine has gained interest due to parasitic worm that affect not only affect livestock but also human health. Utilizing earthworms 3–5 cm in length and 0.1–0.2 cm in width, Nilani et al. evaluated the anthelmintic properties of the seed oil *M. oleifera*. The seed oil was divided into two concentrations, 25 and 50 mg/mL, they exhibit anthelmintic properties, with paralysis times of 21 and 16 min respectively while the death time 30 and 24 min, respectively. The study also reported that oleic acid (57) at a concentration of 25 mg/mL contained in seed oil showed a paralysis time 23 min and a death time 33 min [36].

3.5. Antihypertensive

Hypertension is a cardiovascular disease that causes sustained blood pressure levels. It could lead to health complications, including heart disease, kidney, and stroke. Randriamboajonvy et al. utilizing spontaneous hypertensive rats (SHR) as experiment model to demonstrate the effect of *M. oleifera* seed oil. The result showed a significant reduction in nocturnal heart rate without a change in diurnal heart rate after ten days of treatment. The use of seed oil in SHR increased the capacity of the left ventricle during diastole, which was substantially lower in SHR rats as in comparison with WKY (con-

trol) rats. Ejection fraction, a measure of systolic ventricular function, was substantially reduced in both SHR groups (control and seed oil-treated) in comparison with to WKY rats. This suggests that seed oil treatment did not have a positive effect on systolic ventricular function in SHR. The increased isovolumic relaxation time, indicative of diastolic function impairment in SHR, was completely reversed by seed oil treatment. *M. oleifera* seed oil treatment also led to a reduction in cardiomyocyte size in SHR seed oil-treated hearts compared to those in SHR control hearts. Furthermore, the study explored the potential involvement of peroxisome proliferator-activated receptor (PPAR) signaling pathways in seed oil's protective effect against cardiac fibrosis in SHR. The expression of PPAR α and PPAR δ in cardiac tissue was assessed, revealing increased staining in the left ventricle of SHR seed oil-treated rats compared to SHR controls. These findings collectively suggest a beneficial impact of *M. oleifera* seed oil on cardiac structure and function in SHR, accompanied by an upregulation of PPAR- α and δ signaling pathways [37].

Acuram et al. studied the antihypertensive properties of methanol and ethyl acetate extracts related to inhibition of angiotensin converting enzyme (ACE), furthermore, blood pressure was also investigated. The hypertension was induced in mice with N ^{ω} -nitro-L-arginine methyl ester (L-name). The result demonstrated that compared to methanol extract, ethyl acetate showed more significant inhibition of ACE and lowering blood pressure on the last day [85].

3.6. Antileishmanial

Infection from the genus Leishmanial affecting health issues in tropical and subtropical regions such as Asia, Africa, America, and Mediterranean. This infection is transmitted from sandflies to humans. Kaur et al. studied the anti-leishmanial properties of *M. oleifera* extract against promastigotes of *Leishmania donovani*. The roots were extracted with 70% ethanol and the leaves were extracted with methanol. The roots ethanolic extract and the leaves' methanolic extract exhibited moderate inhibitory activity, with IC₅₀ values of 83.0 and 47.5 μ g/mL, respectively. Upon fractionation, the methanolic extract of leaves showed enhanced antileishmanial activity, particularly in its ethyl acetate fraction, which displayed increased potency with an IC₅₀ value of 27.5 mg/mL. Niazin was isolated from ethyl acetate fraction gave antileishmanial properties with IC₅₀ value of 5.25 mM [41].

3.7. Wound Healing

Tofiq et al. macerated the leaves of *M. oleifera* with 70% ethanol. The experiment was conducted in 7 groups and observed wound healing properties. The result demonstrated that ointment with 10% concentration of extract formulation showed a better effect, representing less scarring, brighter skin, and more regenerated hair follicles compared to gentamicin ointment. Ramadhany et al. made *M. oleifera* leaves extract by soxhlet with ethanol. The extract was made into 4 and 15% gel and investigated their wound healing properties on gingival wounds. The study analyzes the neutrophils, fibroblasts, angiogenesis, and epithelial thickness for seven days. It resulted in 15% *M. oleifera* gel extract having a better effect in reducing neutrophils, increasing the number fibroblasts and angiogenesis. However, 4% *M. oleifera* gel extract was better at increasing epithelial thickness [86].

3.8. Antioxidant

Antioxidant properties are used to decrease oxidative stress, which could lead to damaging tissues. Antioxidants function as electron donors to free radicals and neutralize them. Thus, made antioxidant properties become one of most researched topics. Antioxidant activities of *M. oleifera* by several bio-assay methods are shown in Table 4.

Table 4. Antioxidant activity of *M. oleifera* by several bio-assay methods.

<i>M. oleifera</i>	Bio-Assay	IC ₅₀	EC ₅₀ (mg/mL)	References
Roots extract	Xanthine oxidase	16 µL	-	[44]
Leaf extract		30 µL	-	
Stem bark extract		38 µL	-	
Roots extract	2-deoxyguanosine	40 µL	-	[44]
Leaf extract		58 µL	-	
Stem bark extract		72 µL	-	
<i>n</i> -Butanol extract	DPPH	92.62%	0.07	[45]
Ethyl acetate extract		90.27%	0.08	
Petroleum ether extract		-	0.35	
Aqueous extract	ABTS	-	0.44	[45]
<i>n</i> -Butanol extract		99.46%	0.01	
Ethyl acetate extract		97.49%	0.04	
Crude extract	ABTS	77.82%	-	[45]
Petroleum ether extract		-	0.18	
Aqueous extract		-	0.29	
<i>n</i> -Butanol extract	Hydroxy radical-scavenging	94.46%	-	[45]
Ethyl acetate extract		80.68%	-	
Leaf extract	DPPH	1.87 mg/mL	-	[46]
Leaf extract	FRAP	0.99 mM Fe ²⁺ /g	-	[46]
Root extract	ABTS	1.24 mg/mL	-	[46]
Ethyl acetate extract	DPPH	526.7 µMol	-	[87]
Acetone extract		435.7 µMol	-	
Ethanol extract	DPPH	0.44 mg/mL	-	[88]
Ethanol extract	Hydroxy peroxide free radical scavenging	0.54 mg/mL	-	[88]
Ethanol extract		FRAP	0.25 mg/mL	
Ethyl acetate extract	DPPH	71.9 µg/mL	-	[89]
Ethyl acetate extract	ABTS	54.79 µg/mL	-	[89]

Note: - (not tested).

3.9. Anti-diarrheal

Misra et al. evaluated the anti-diarrheal potential of *M. oleifera*. Leaves of *M. oleifera* were extracted with petroleum ether and then subjected to ethanol for seven days. The animal models were divided into six groups, as control and as doses of extract, and castor oil was used to induce diarrhea. The study showed that the ethanol extract successfully acted as an anti-diarrheal within 52 min, with an extract dose 150 mg/kg, and showed total stools of 0.130 mg [90].

3.10. Hepatoprotective

Pari and Kumar conducted an evaluation of the hepatoprotective properties of an ethanol extract obtained from *Moringa oleifera* leaves in rats with liver damage caused by anti-tubercular medications such as isoniazid (INH), rifampicin (RMP), and pyrazinamide (PZA). This extract had considerable protective effects when administered orally, as indicated by its impact on numerous parameters. This included the serum levels of glutamic pyruvic transaminase (alanine aminotransferase), glutamic oxaloacetic transaminase (aspartate aminotransferase), bilirubin, and alkaline phosphatase, as well as the levels of lipids and lipid peroxidation in the liver [91].

Khalid et al. assessed the potential protective effects of *M. oleifera* leaf powder and a 70% ethanol extract of *M. oleifera* leaves in alleviating liver and kidney dysfunction induced by polycystic ovary syndrome (PCOS) in female albino mice. PCOS was induced by administering intramuscular injections of testosterone enanthate at a dose of 1.0 mg/100 g body weight for a duration of thirty-five days. The study conducted assessments of renal function (RFT), liver function (LFT), and the oxidative stress biomarker malondialdehyde (MDA) in the serum at intervals of 0, 7, and 14 days. The mice that received treatments of *M. oleifera* exhibited significant reductions in the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin, urea, and creatinine compared to the PCOS-induced controls. Conversely,

there was a notable increase in the levels of total protein, albumin, globulin, and the albumin/globulin (A/G) ratio. Furthermore, oxidative stress levels exhibited significant reductions in response to treatments, exposure duration, and their combined effect. The findings of this study suggest that both *Moringa oleifera* leaf powder and extract have the potential to reduce oxidative stress and improve renal and hepatic activity in female albino mice with PCOS-induced dysfunction [58].

3.11. Anti-Inflammatory

Inflammation is a recognized physiological reaction that serves to safeguard the body against infections and promote the healing of tissue injuries. However, persistent or chronic inflammation can potentially support the growth of various disorders and diseases associated with inflammation. Sulaiman et al. assessed the anti-inflammatory potential of an *M. oleifera* aqueous extract. The assay was conducted by carrageenan-induced paw edema. The extract was made at different doses and showed inhibitory effects in a dose-dependent manner. At dose 100 mg/kg, after five hours, the inhibition showed a value of 50%. The suggested anti-inflammatory mechanism was the extract which contained flavonoids with an inhibitory action against NF-k [64].

Fard et al. studied the anti-inflammatory potential of an *M. oleifera* extract on macrophages stimulated with lipopolysaccharide (LPS) in RAW264.7 macrophages. The anti-inflammatory properties of ethanol extracts derived from *M. oleifera*'s bioactive leaves were assessed by examining their ability to inhibit nitric oxide (NO) production using the Griess reaction and to modulate the expression of pro-inflammatory mediators in macrophages. The ethanol leaf extract exhibited a significant inhibition of various inflammatory markers, including NO production, as well as prostaglandin E₂, TNF- α , IL-6, and IL-1 β secretion. Concurrently, the bioactive extract dose-dependently stimulated the production of IL-10. Furthermore, the ethanol extract effectively suppressed the protein expression of inflammatory markers such as inducible NO synthase, cyclooxygenase-2, and NF-kB p65, also in a dose-dependent manner [65].

Previously, Xu et al. investigated the antioxidant properties of *M. oleifera*, and also investigated its anti-inflammatory properties. The study was conducted by determining the NO production of RAW264.7 macrophages. The study revealed that the leaf extract gave a lower NO production, at 100 μ g/mL, while the seed extract presented higher NO production. It concluded that the leaf extract had better anti-inflammatory properties compared to the seed extract [46].

An ethyl acetate fraction of *M. oleifera* was assessed to have anti-inflammatory potential against LPS-induced macrophages. The study showed that macrophages which were treated with the ethyl acetate fraction exhibited a reduction in the production of pro-inflammatory mediators. This reduction was observed between the mRNA and protein levels. The study findings indicated that the fraction downregulated the mRNA expression of various inflammatory markers, including IL-1, IL-6, TNF- α , PTGS2, NF-kB P50, and RelA. Furthermore, the fraction effectively inhibited the expression of inflammatory mediators such as IL-6, TNF- α , and cyclooxygenase-2. Notably, the fraction effects included the inhibition of I κ B- α phosphorylation and the ability to decrease the expression of nuclear factor NF-kB p65, thereby impeding its nuclear translocation [52].

3.12. Anti-Diabetic

One of the traditional usages of *M. oleifera* was as a diabetic medicine. Gupta et al., and Al-Malki and El Rabey studied the proper effects of *M. oleifera* as an anti-diabetic medicine. Pod and seed powders of *M. oleifera* were used in various doses. The animal model used was a streptozotocin-induced diabetic male rat. The parameters used were the determination of IL-6, immunoglobulin A, immunoglobulin G, fasting blood sugar, glycosylated hemoglobin, albumin, potassium, sodium, creatinine, and uric acid. Both studies showed that *M. oleifera* extracts could restore the abnormalities to a slightly normal

level; however, a higher dose was suspected to be more effective. The water consumption of all subject groups also returned to normal after treatment [59,60].

Previously, Hamed et al. examined the antioxidant properties of *M. oleifera* leaf extracts. Furthermore, they also investigated the anti-diabetic activity of purified flavonoids from crude extracts by determining their α -glucosidase inhibitory effects. The results showed that purified flavonoids inhibited α -glucosidase by 54.41% at 100 $\mu\text{g/mL}$ and 99.01% at 800 $\mu\text{g/mL}$ in an uncompetitive manner [48]. Chen et al. reported that the ethanol leaf extracts of *M. oleifera* could be used as anti-diabetic medicine. They investigated the activity by determining the α -glucosidase value. The study showed an IC_{50} value of 123 $\mu\text{g/mL}$ [61].

3.13. Anticancer

Jung evaluated the anticancer properties of *M. oleifera* leaf extracts against A549 human lung cancer cells. The evaluation was conducted by MTT assay, and the changes and apoptotic effects were observed. The observation revealed that *M. oleifera* extract treatment resulted in a dose-dependent downregulation of caspase-3 and an upregulation of cleaved caspase-3, indicating an induction of apoptosis. There was a significant dose-dependent downregulation of Akt, p-IkB, NF-kB, p-Erk, β -catenin, and cyclin D1, all of which play roles in cell survival and proliferation. Treatment with soluble *M. oleifera* extracts for 48 h resulted in a significantly reduced release of reactive oxygen species (ROS) in comparison to the untreated control group. This implies a decrease in oxidative stress. In summary, the study concluded that MOL treatment induced apoptosis, inhibited the growth of tumor cells, and reduced the levels of internal reactive oxygen species (ROS) in human lung cancer cells. These outcomes emphasize the potential of *M. oleifera* leaf extracts as a promising candidate for further research and development in the context of lung cancer therapy [66]. The anticancer activities of *M. oleifera* against several cancer cell types are shown in Table 5.

Table 5. Anticancer activity of *M. oleifera* against several cancer cell types.

<i>M. oleifera</i>	Bio-Assay	IC_{50} ($\mu\text{g/mL}$)	Other Values	References
Seed essential oil	HeLa	442.8	23.9%	[67,68]
	HepG2	751.9	34.93%	
	MCF-7	226.1	40.48%	
	CACO-2	1000	50.28%	
	L929	1000	42.99%	
Aqueous extract	HeLa	70	70 $\mu\text{g/mL}$	[67,68]
Aqueous extract	A375	-	36.40%	[69]
Aqueous extract	Bcl-2	-	0.68 to 0.53-fold	[69]
Aqueous extract	Bax	-	2.62-fold increase at the m-RNA level;	[69]
			1.85-fold increase at the protein level	
Aqueous extract	MOE activation of Caspase-3/7	-	Increase 1.75-fold	[69]
Aqueous extract	MOE activation of Caspase-9	-	Increase 1.42-fold	[69]
Aqueous extract	MCF-7	100	-	[92]
	HTC116	125	-	
	AsPC-1	240	-	
Leaf extract	Urethane-induced lung cancer in rats	-	Induced in glutathione 3.8 mg/g, superoxide dismutase 900.6 U/g, and malondialdehyde 172 nmol/g	[93]
Leaf extract	Urethane-induced lung cancer in rats	-	Increase 50% EGFR-mRNA, 10.8% improvements of mucin level and the presence of PCNA-positive cells in lung	[93]
CO ₂ root extract	MCF-7	-	Spanning 100 to 500 $\mu\text{g/mL}$	[94]
<i>n</i> -Hexane extract		180.6	-	[95]
Chloroform extract		190.2	-	
Ethyl acetate extract	Hep-2	40.2	-	
Methanol extract		170.1	-	
Crude extract	HCT116	9.5 (24 h)	-	
Crude extract	CYP3A4	5.04 (48 h)	-	[96]
Crude extract		52.50	-	[54]

Table 5. Cont.

<i>M. oleifera</i>	Bio-Assay	IC ₅₀ (µg/mL)	Other Values	References
Chloroform extract	MCF-7	6.25		
Dichloromethane extract	MCF-7	5	1.87-fold increase in p53 expression, 1.47-fold increase in Bax expression, 1.05-fold increase in cytochrome C levels, 2.21-fold increase in caspase 8 expression	[97]
Ethyl acetate extract	MDA-MB-231	233.5	Increase 44.2% of late apoptotic cells; increased level of cleaved caspase 3 protein, Bax mRNA, and p53 mRNA; decreased anti-apoptotic Bcl-2 protein	[98]

Note: - (not tested).

Based on the data attained by Do et al., as shown in Table 3, this study demonstrated that *M. oleifera* extract induced apoptosis in A375 cells, as evidenced by chromatin condensation and the externalization of phosphatidylserine (PS), which are characteristic features of apoptotic cell death. The apoptosis process was initiated by the activation of caspase-9 and caspase-3/7, the cleavage of PARP, and the translocation of apoptosis-inducing factor into the nucleus. These findings provide insights into the apoptotic mechanisms triggered by *M. oleifera* extract in A375 cells [69]. Meanwhile, Pappas et al. assessed the gene expression of *M. oleifera* aqueous wild and cultivated leaf extracts against human pancreas cancer cells AsPC-1, MCF-7, and HCT-116 colon cancer cells. The aqueous extract exerted its effects by down-regulating p53 expression in all tested cell lines and by down-regulating c-myc in AsPC-1 cells. Additionally, specific marker genes associated with each cell line, such as BRCA-1 in MCF-7, mta-1 in AsPC-1, and Ki-67 in HTC116 cells, were down-regulated. Furthermore, the survivin (BIRC5) gene, an inhibitor of apoptosis, was down-regulated in all three cell lines, suggesting a shared target mechanism of Moringa constituents across these cell lines [92].

Kumar et al. discovered that an extract of *M. oleifera* leaves demonstrated effective inhibition of Dalton lymphoma (DL) cell proliferation. This inhibition was characterized by alterations in mitochondrial membrane potential ($\Delta\Psi_m$) and noticeable changes in overall cell morphology. Notably, DL cells treated with the extract experienced cell cycle arrest at the G2/M phase and a significant upregulation in the expression of p53 and p21. Furthermore, the treatment resulted in increased levels of pro-apoptotic markers, including Bax, Cytochrome-c (Cyt-c), and caspase-3, while reducing the expression levels of the anti-apoptotic Bcl-2 protein. These changes strongly suggest the induction of apoptosis in DL cells. Mechanistically, the anticancer efficacy of *M. oleifera* extract was attributed to the inactivation of the MEK/ERK-mediated pathway in DL cells. Additionally, it is noteworthy that the inhibition of DL growth by MOML was accompanied by apoptosis induction and improvements in hematological parameters in DL-induced mice [99].

4. Utilization of *M. oleifera* in Dental Health

Research on several bacteria that are pathogenic to dental health has been carried out, such as *Streptococcus mutans*, *Enterococcus faecalis*, *Staphylococcus aureus*, and others. Table 6 shows some data on the antibacterial activity of *M. oleifera* against oral pathogenic bacteria.

Jwa evaluated the aqueous and ethanol extracts of *M. oleifera* against *S. mutans*, which were found in the cariogenic biofilm of dental caries. Both extracts reduced the bacteria's growth at concentrations of 25 and 6.25 µg/mL, respectively. At the same concentration, heated ethanol extract exhibited inhibitory activity better than non-heated extracts. This study showed that the ethanol extract was more effective than the aqueous extract against *S. mutans* [109]. Soraya et al. investigated the anti-bacterial properties of *M. oleifera* gel in inhibiting the growth of *S. mutans*, which were involved in the pathogenesis of dental caries. After 48 h, it was observed that the 12.5% concentration exhibited the highest effectiveness in reducing *S. mutans* growth. Within 24 h, the 6.25 and 3.125% concentrations displayed remarkable capabilities in suppressing *S. mutans* growth. Notably, the 6.25%

concentration showed superior efficacy in reducing the formation of *S. mutans* biofilms. The application of *M. oleifera* gel extract created conditions in which *S. mutans*, a commensal bacterium, struggled to form a biofilm, with inhibition levels surpassing 70%. This was evidenced by the absence of substantial biofilm development. It is worth mentioning that at all tested concentrations, *M. oleifera* exhibited a toxic effect on *S. mutans* cells. The ethanol extract gel of *M. oleifera* demonstrated the ability to curtail both the growth and biofilm formation of *S. mutans* on tooth surfaces while concurrently exerting toxicity on *S. mutans* cells, potentially due to the presence of anti-bacterial compounds [110]. The anti-bacterial properties of herbal toothpaste, formulated with *M. oleifera* root essential oil, were assessed against bacteria commonly associated with tooth plaque, namely *S. mutans* and *S. aureus*. The Muller Hinton agar well diffusion method was used for this evaluation. The findings of this study demonstrated that *S. mutans* exhibited susceptibility to the herbal toothpaste, as indicated by a significant inhibition zone measuring 31 mm [111].

Table 6. Antibacterial activity of *M. oleifera* to some oral pathogenic bacteria.

<i>M. oleifera</i>	Microorganism	Inhibition Zone (mm)	MIC ($\mu\text{g/mL}$)	MBC	References
Ethanol extract	<i>P. aeruginosa</i>	21.21	458	-	[100]
Ethanol extract	<i>S. aureus</i>	20.55	>1	-	[101]
Aqueous extract	<i>S. aureus</i>	12	58.75 mg/mL	-	[100]
Methanol extract	<i>E. faecalis</i>	44.83	-	-	[102]
Leaves ethanolic extract	<i>S. aureus</i>	19.25	-	-	[103]
Roots ethanolic extract	<i>S. aureus</i>	9.25	-	-	[103]
Seed ethanolic extract	<i>S. aureus</i>	10.50	-	-	[103]
Seed ethanolic extract	<i>S. mutans</i>	3.25	-	-	[103]
Bark ethyl acetate extract	<i>S. mutans</i>	4.75	-	-	[103]
Root bark methanolic extract	<i>S. aureus</i>	16.33	-	-	[104]
Leaf extract	<i>S. aureus</i>	19	12.5 mg/mL	-	[105]
Diethyl ether, <i>n</i> -Hexane, and Ethyl acetate extract	<i>S. mutans</i> biofilm	0.20/(OD 520 nm)	-	-	[106]
Diethyl ether extract	<i>S. aureus</i>	-	15.6	-	[107]
Diethyl ether extract	<i>E. faecalis</i>	-	15.6	-	[107]
Diethyl ether extract	<i>S. aureus</i>	-	15.6	-	[107]
Leaf extract	<i>E. faecalis</i>	11.89 (at 100 $\mu\text{g/mL}$)	-	-	[108]
Leaf extract	<i>E. faecalis</i>	35.5 (at 24 h) 48.83 (at 48 h)	75	-	[102]

Note: - (not tested).

Alharbi et al. examined the antimicrobial efficacy of *M. oleifera* leaf extract, octenidine dihydrochloride (OCT), sodium hypochlorite (NaOCl), and their combinations as an intracanal irrigant against *E. faecalis*. Decoronation and root canal preparation were performed on single-rooted mandibular premolars. After autoclaving, each root specimen was inoculated with *E. faecalis* and incubated at 37 °C for 48 h. Subsequently, based on the irrigation solution used, the specimens were split into six groups: 2.5% NaOCl (Group 1), 0.1% OCT (Group 2), *M. oleifera* leaf extract (Group 3), a combination of *M. oleifera* extract and 1.25% NaOCl (Group 4), a combination of *M. oleifera* extract and OCT (Group 5), and normal saline (Group 6). Both *M. oleifera* extract and 0.1% OCT demonstrated antibacterial effects against *E. faecalis* comparable to 2.5% NaOCl and could be considered as potential root canal irrigants. Furthermore, combination groups exhibited superior anti-microbial activity compared to individual irrigants [112].

Rochyani investigated the inhibitory potential of *M. oleifera* leaf extract on the biofilm formation of *E. faecalis* bacteria. The experiment was divided into several groups, including a negative control group (CMC solvent 0.1%), a positive control group (ChKM), and four test groups extracts of 20, 40, 60, and 80%, respectively. The results indicate that the *M. oleifera* leaf extract demonstrates a significant inhibitory effect on the biofilm formation of *E. faecalis* bacteria. Notably, the inhibitory effect observed in the 80% extract was found to be substantially greater than that achieved by the positive control group using ChKM [113].

Shanmugapriya et al. investigated the antimicrobial effects of *M. oleifera* extracts on pooled plaque collected from orthodontic patients. To achieve this, *M. oleifera* extracts were prepared through maceration. Subgingival plaque samples were collected, and the microorganisms present were cultured under anaerobic conditions. The microorganisms were subsequently subjected to treatment with the extracts, and their MIC and MBC were determined. Additionally, the cytotoxic effects of the extracts were assessed using a brine shrimp assay. The results of the study revealed that the 5% aqueous extract of *M. oleifera* exhibited a dose-dependent antimicrobial activity against oral anaerobic organisms. Notably, this anti-microbial effect became more pronounced with longer exposure times of the treated samples. Furthermore, in the cytotoxicity assay, the aqueous extract showed superior performance in lower concentrations in comparison to the ethanol extract. This was evident from the higher number of live nauplii observed in the aqueous extract group, indicating its lower cytotoxicity [114].

Sopandani et al. evaluated the antibacterial efficacy of *M. oleifera* extract at various concentrations (25, 50, 75, and 100%) when used as an irrigation solution against *E. faecalis* within the root canal ex vivo. Quantitative polymerase chain reaction (qPCR) was employed to assess the population of *E. faecalis* within the root canal following treatment with *M. oleifera* extract. The results indicated that *M. oleifera* extract solutions at concentrations of 75 and 100% exhibited comparable effectiveness to a 5.25% sodium hypochlorite (NaOCl) solution as a positive control [114].

Rieuwpassa et al. assessed the effectiveness of *M. oleifera* leaf extract in modulating the anti-inflammatory cytokine IL-1 of the bacteria *Porphyromonas gingivalis*, a key contributor to chronic periodontitis. The study revealed a significant variation in IL-1 levels across different observation days. Administration of the extract led to a reduction in pro-inflammatory cytokine IL-1 levels, as evident from the observations on days D0, D1, D3, D5, and D7 in the experimental Wistar rats induced with *Porphyromonas gingivalis* bacteria [115].

Kumar et al. evaluated the antibacterial effectiveness of a 5% *M. oleifera* mouthwash enhanced with silver nanoparticles against oral aerobic microorganisms. The mouthwash was prepared by utilizing a 5% *M. oleifera* aqueous extract for the synthesis of silver nanoparticles. The characterization of the mouthwash was performed through scanning electron microscopy analysis and energy dispersive X-ray analysis. To assess its anti-bacterial properties, the mouthwash was tested against *S. mutans*, *S. aureus*, *E. faecalis*, and *C. albicans* using the agar well diffusion assay. The results indicated that the 5% *Moringa oleifera*-silver nanoparticle mouthwash exhibited a pronounced effect on *S. aureus* and a comparable impact on *S. mutans* [114].

5. Conclusions

M. oleifera has a variety of pharmacological effects, such as anti-hemorrhage, anti-allergic, antimicrobial, anthelmintic, antihypertensive, antileukemia, antioxidant, anti-diabetic, hepatoprotection, anti-inflammatory, and anticancer effects. This plant is effective against dental infections. Antimicrobial research against microbes that cause dental infections has been carried out on the leaves of *M. oleifera* both in aqueous and ethanol extracts. This plant is reported to be active in vitro to inhibit several oral bacteria such as *E. faecalis*, *S. mutans*, *P. gingivalis*, *S. aureus*, and *C. albicans*, and has been tested ex vivo. The chemical components contained in *M. oleifera* are phenolics, glucosinolates, flavonoids, fatty acids, esters, alkaloids, sterols, terpenes, and several other compounds. Based on the pharmacological effects and chemical components contained in *M. oleifera*, this plant has

the potential to be further developed to produce an antibacterial agent product, especially for dental health. The search for bioactive compounds in *M. oleifera* that have a major role as antibacterials in oral pathogens can be carried out through isolation. Furthermore, both extracts and isolated compounds from *M. oleifera* can be further traced for their activity through in vitro, in vivo, and clinical trials.

Author Contributions: Conceptualization, M.F.A.; methodology, M.F.A.; software, S.A.P.; validation, T.A. and S.A.P.; formal analysis, M.F.A. and T.A.; investigation, T.A.; resources, M.F.A. and S.A.P.; data curation, S.A.P. and D.K.; writing—original draft preparation, M.F.A. and T.A.; writing—review and editing, M.F.A., D.K. and S.A.P.; visualization, S.A.P. and M.F.A.; supervision, M.F.A. and D.K.; project administration, S.A.P. and T.A.; funding acquisition, M.F.A. and T.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The author is grateful to Trisakti University for all research facilities.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Granella, S.J.; Bechlin, T.R.; Christ, D.; Coelho, S.R.M.; de Oliveira Paz, C.H. An approach to recent applications of *Moringa oleifera* in the agricultural and biofuel industries. *S. Afr. J. Bot.* **2021**, *137*, 110–116. [[CrossRef](#)]
2. Leone, A.; Spada, A.; Battezzati, A.; Schiraldi, A.; Aristil, J.; Bertoli, S. Cultivation, genetic, ethnopharmacology, phytochemistry and pharmacology of *Moringa oleifera* leaves: An overview. *Int. J. Mol. Sci.* **2015**, *16*, 12791–12835. [[CrossRef](#)]
3. Matic, I.; Guidi, A.; Kenzo, M.; Mattei, M.; Galgani, A. Investigation of medicinal plants traditionally used as dietary supplements: A review on *Moringa oleifera*. *J. Public Health Afr.* **2018**, *9*, 191–199. [[CrossRef](#)]
4. Mishra, G.; Singh, P.; Verma, R.; Kumar, S.; Srivastav, S.; Jha, K.; Khosa, R. Traditional uses, phytochemistry and pharmacological properties of *Moringa oleifera* plant: An overview. *Der Pharm. Lett.* **2011**, *3*, 141–164.
5. Padayachee, B.; Baijnath, H. An updated comprehensive review of the medicinal, phytochemical and pharmacological properties of *Moringa oleifera*. *S. Afr. J. Bot.* **2020**, *129*, 304–316. [[CrossRef](#)]
6. Valdivié-Navarro, M.; Martínez-Aguilar, Y.; Mesa-Fleitas, O.; Botello-León, A.; Hurtado, C.B.; Velázquez-Martí, B. Review of *Moringa oleifera* as forage meal (leaves plus stems) intended for the feeding of non-ruminant animals. *Anim. Feed. Sci. Technol.* **2020**, *260*, 114338. [[CrossRef](#)]
7. Brillhante, R.S.N.; Sales, J.A.; Pereira, V.S.; Castelo, D.d.S.C.M.; de Aguiar Cordeiro, R.; de Souza Sampaio, C.M.; Paiva, M.d.A.N.; Dos Santos, J.B.F.; Sidrim, J.J.C.; Rocha, M.F.G. Research advances on the multiple uses of *Moringa oleifera*: A sustainable alternative for socially neglected population. *Asian Pac. J. Trop. Med.* **2017**, *10*, 621–630. [[CrossRef](#)] [[PubMed](#)]
8. Gopalakrishnan, L.; Doriya, K.; Kumar, D.S. *Moringa oleifera*: A review on nutritive importance and its medicinal application. *Food Sci. Hum. Wellness* **2016**, *5*, 49–56. [[CrossRef](#)]
9. Trigo, C.; Castello, M.L.; Ortola, M.D.; Garcia-Mares, F.J.; Desamparados Soriano, M. *Moringa oleifera*: An unknown crop in developed countries with great potential for industry and adapted to climate change. *Foods* **2020**, *10*, 31. [[CrossRef](#)]
10. Hastuty, Y.D. Ekstrak daun kelor dan efeknya pada kadar hemoglobin remaja putri. *J. Kesehat. Poltekkes Plb.* **2022**, *17*, 121–127. [[CrossRef](#)]
11. Yuliasuti, S.; Kurnia, H. Pengaruh pemberian serbuk halus daun kelor (*Moringa oleifera*) terhadap kadar hb ibu hamil trimester iii dengan anemia di wilayah kerja puskesmas mangunreja kab. Tasikmalaya the influence of *Moringa oleifera* fine powder. *Media Inf.* **2021**, *17*, 122–127. [[CrossRef](#)]
12. Ferraz, C.C.R.; Henry, M.A.; Hargreaves, K.M.; Diogenes, A. Lipopolysaccharide from *Porphyromonas gingivalis* sensitizes capsaicin-sensitive nociceptors. *J. Endod.* **2011**, *37*, 45–48. [[CrossRef](#)] [[PubMed](#)]
13. Gao, Y.; Jiang, X.; Lin, D.; Chen, Y.; Tong, Z. The starvation resistance and biofilm formation of *Enterococcus faecalis* in coexistence with *Candida albicans*, *Streptococcus gordonii*, *Actinomyces viscosus*, or *Lactobacillus acidophilus*. *J. Endod.* **2016**, *42*, 1233–1238. [[CrossRef](#)] [[PubMed](#)]
14. Miranda, T.T.; Vianna, C.R.; Rodrigues, L.; Rosa, C.A.; Corrêa Jr, A. Differential proteinase patterns among *Candida albicans* strains isolated from root canal and lingual dorsum: Possible roles in periapical disease. *J. Endod.* **2015**, *41*, 841–845. [[CrossRef](#)]
15. Salem, A.S.; Tompkins, G.R.; Cathro, P.R. Alkaline tolerance and biofilm formation of Root Canal isolates of *Enterococcus faecalis*: An in Vitro Study. *J. Endod.* **2022**, *48*, 542–547. [[CrossRef](#)] [[PubMed](#)]

16. Gomes, B.P.; Montagner, F.; Jacinto, R.C.; Zaia, A.A.; Ferraz, C.C.R.; Souza-Filho, F.J. Polymerase chain reaction of *Porphyromonas gingivalis*, *Treponema denticola*, and *Tannerella forsythia* in primary endodontic infections. *J. Endod.* **2007**, *33*, 1049–1052. [[CrossRef](#)]
17. Senges, C.; Wrbas, K.-T.; Altenburger, M.; Follo, M.; Spitzmüller, B.; Wittmer, A.; Hellwig, E.; Al-Ahmad, A. Bacterial and *Candida albicans* adhesion on different root canal filling materials and sealers. *J. Endod.* **2011**, *37*, 1247–1252. [[CrossRef](#)]
18. Montagner, F.; Jacinto, R.C.; Signoretti, F.G.C.; de Mattos, V.S.; Grecca, F.S.; de Almeida Gomes, B.P.F. Beta-lactamic resistance profiles in *Porphyromonas*, *Prevotella*, and *Parvimonas* species isolated from acute endodontic infections. *J. Endod.* **2014**, *40*, 339–344. [[CrossRef](#)] [[PubMed](#)]
19. Putri, S.A.; Nur Shadrina, A.A.; Julaeha, E.; Kurnia, D. Potential Nevadensin from *Ocimum basilicum* as Antibacterial Agent against *Streptococcus mutans*: In Vitro and In Silico Studies. *Comb. Chem. High Throughput Screen.* **2023**, *26*, 1746–1754. [[CrossRef](#)]
20. Madhloom, F. Antimicrobial Effect of *Moringa oleifera* L. and Red Pomegranate against Clinically Isolated *Porphyromonas gingivalis*: In vitro Study. *Arch. Razi Inst.* **2022**, *77*, 1405. [[CrossRef](#)]
21. Nugraha, A.P.; Triwardhani, A.; Sitalaksmi, R.M.; Ramadhani, N.F.; Luthfi, M.; Ulfa, N.M. Phytochemical, antioxidant, and antibacterial activity of *Moringa oleifera* nanosuspension against peri-implantitis bacteria: An in vitro study. *J. Oral Biol. Craniofacial Res.* **2023**, *13*, 720–726. [[CrossRef](#)] [[PubMed](#)]
22. Bhattacharya, A.; Tiwari, P.; Sahu, P.K.; Kumar, S. A review of the phytochemical and pharmacological characteristics of *Moringa oleifera*. *J. Pharm. Bioallied Sci.* **2018**, *10*, 181.
23. Özcan, M. *Moringa* spp: Composition and bioactive properties. *S. Afr. J. Bot.* **2020**, *129*, 25–31. [[CrossRef](#)]
24. Cheenpracha, S.; Park, E.-J.; Yoshida, W.Y.; Barit, C.; Wall, M.; Pezzuto, J.M.; Chang, L.C. Potential anti-inflammatory phenolic glycosides from the medicinal plant *Moringa oleifera* fruits. *Bioorg. Med. Chem.* **2010**, *18*, 6598–6602. [[CrossRef](#)]
25. Lar, P.; Ojile, E.; Dashe, E.; Oluoma, J. Antibacterial activity on *Moringa oleifera* seed extracts on some gram negative bacterial isolates. *Afr. J. Nat. Sci.* **2011**, *14*, 57–62.
26. Zaffer, M.; Ganie, S.A.; Gulia, S.S.; Yadav, S.S.; Singh, R.; Ganguly, S. Antifungal efficacy of *Moringa oleifera* Lam. *AJPCT* **2015**, *3*, 28–33.
27. El-Meidany, W.M.; Abdel-Gawad, F.K.; Mahmoud, S.H.; Ali, M.A. In vitro antiviral effect of cinnamon oil, *Moringa oleifera* extract, Manuka honey, and *Nigella sativa* oil against SARS-CoV-2 compared to remdesivir. *Bull. Natl. Res. Cent.* **2023**, *47*, 156. [[CrossRef](#)]
28. Allam, O.G.; Kutkat, O.; Gaballah, M.; El-Halawany, A.M.; Mostafa, A.; Shouman, S.; Ali, M.A.; El Farouk, O. Virucidal effect of *Moringa oleifera* against SARS-CoV-2 and Influenza A/H1N1. *Afr. J. Biol. Sci.* **2023**, *19*, 69–78. [[CrossRef](#)]
29. Xiong, Y.; Rajoka, M.S.R.; Mehwish, H.M.; Zhang, M.; Liang, N.; Li, C.; He, Z. Virucidal activity of *Moringa* A from *Moringa oleifera* seeds against Influenza A Viruses by regulating TFEB. *Int. Immunopharmacol.* **2021**, *95*, 107561. [[CrossRef](#)] [[PubMed](#)]
30. Nasr-Eldin, M.A.; Abdelhamid, A.; Baraka, D. Antibiofilm and antiviral potential of leaf extracts from *Moringa oleifera* and rosemary (*Rosmarinus officinalis* Lam.). *Egypt. J. Microbiol.* **2017**, *52*, 129–139. [[CrossRef](#)]
31. Mahbub, K.R.; Hoq, M.M.; Ahmed, M.M.; Sarker, A. In vitro antibacterial activity of *Crescentia cujete* and *Moringa oleifera*. *Bangladesh Res. Publ. J.* **2011**, *5*, 337–343.
32. Effendi, D.N.; Yuliawati, K.M.; Patricia, V.M. Uji Aktivitas Antibakteri Ekstrak Daun Kelor (*Moringa oleifera* L.) Terhadap Bakteri *Staphylococcus epidermidis*. *Proc. Bdg. Conf. Ser. Pharm.* **2023**, *3*, 528–533.
33. Ashraf, M.; Alam, S.S.; Fatima, M.; Altaf, I.; Khan, F.; Afzal, A. Comparative anti-influenza potential of *Moringa oleifera* leaves and amantadine invitro. *Pak. Postgrad. Med. J.* **2017**, *28*, 127–131. [[CrossRef](#)]
34. Goswami, D.; Mukherjee, P.K.; Kar, A.; Ojha, D.; Roy, S.; Chattopadhyay, D. *Screening of Ethnomedicinal Plants of Diverse Culture for Antiviral Potentials*; NISCAIR-CSIR: New Delhi, India, 2016.
35. Kurokawa, M.; Wadhwani, A.; Kai, H.; Hidaka, M.; Yoshida, H.; Sugita, C.; Watanabe, W.; Matsuno, K.; Hagiwara, A. Activation of cellular immunity in herpes simplex virus type 1-infected mice by the oral administration of aqueous extract of *Moringa oleifera* Lam. leaves. *Phytother. Res.* **2016**, *30*, 797–804. [[CrossRef](#)]
36. Nilani, P.; Pinaka, M.K.; Duraisamy, B.; Dhamodaran, P.; Jeyaprakash, M. Anthelmintic activity of *Moringa oleifera* seed oil-validation of traditional use. *J. Adv. Sci. Res.* **2012**, *3*, 65–66.
37. Randriamboavonjy, J.I.; Loirand, G.; Vaillant, N.; Lauzier, B.; Derbré, S.; Michalet, S.; Pacaud, P.; Tesse, A. Cardiac protective effects of *Moringa oleifera* seeds in spontaneous hypertensive rats. *Am. J. Hypertens.* **2016**, *29*, 873–881. [[CrossRef](#)]
38. Bennett, R.N.; Mellon, F.A.; Foidl, N.; Pratt, J.H.; Dupont, M.S.; Perkins, L.; Kroon, P.A. Profiling glucosinolates and phenolics in vegetative and reproductive tissues of the multi-purpose trees *Moringa oleifera* L. (horseradish tree) and *Moringa stenopetala* L. *J. Agric. Food Chem.* **2003**, *51*, 3546–3553. [[CrossRef](#)]
39. Huang, L.; Yuan, C.; Wang, Y. Bioactivity-guided identification of anti-adipogenic isothiocyanates in the moringa (*Moringa oleifera*) seed and investigation of the structure-activity relationship. *Molecules* **2020**, *25*, 2504. [[CrossRef](#)]
40. Ragasa, C.Y.; Ng, V.A.S.; Shen, C.-C. Chemical constituents of *Moringa oleifera* Lam. seeds. *Int. J. Pharmacogn. Phytochem. Res.* **2016**, *8*, 495–498.
41. Kaur, A.; Kaur, P.K.; Singh, S.; Singh, I.P. Antileishmanial compounds from *Moringa oleifera* Lam. *Z. Für Naturforschung C* **2014**, *69*, 110–116. [[CrossRef](#)]
42. Jiang, M.-Y.; Lu, H.; Pu, X.-Y.; Li, Y.-H.; Tian, K.; Xiong, Y.; Wang, W.; Huang, X.-Z. Laxative Metabolites from the Leaves of *Moringa oleifera*. *J. Agric. Food Chem.* **2020**, *68*, 7850–7860. [[CrossRef](#)] [[PubMed](#)]
43. Adeyemi, S.; Larayetan, R.; Onoja, A.; Ajayi, A.; Yahaya, A.; Ogunmola, O.O.; Adeyi, A.; Chijioke, O. Anti-hemorrhagic activity of ethanol extract of *Moringa oleifera* leaf on envenomed albino rats. *Sci. Afr.* **2021**, *12*, e00742. [[CrossRef](#)]

44. Atawodi, S.E.; Atawodi, J.C.; Idakwo, G.A.; Pfundstein, B.; Haubner, R.; Wurtele, G.; Bartsch, H.; Owen, R.W. Evaluation of the polyphenol content and antioxidant properties of methanol extracts of the leaves, stem, and root barks of *Moringa oleifera* Lam. *J. Med. Food* **2010**, *13*, 710–716. [[CrossRef](#)] [[PubMed](#)]
45. Zhao, B.; Deng, J.; Li, H.; He, Y.; Lan, T.; Wu, D.; Gong, H.; Zhang, Y.; Chen, Z. Optimization of phenolic compound extraction from Chinese *Moringa oleifera* leaves and antioxidant activities. *J. Food Qual.* **2019**, *2019*, 5346279. [[CrossRef](#)]
46. Xu, Y.-B.; Chen, G.-L.; Guo, M.-Q. Antioxidant and anti-inflammatory activities of the crude extracts of *Moringa oleifera* from Kenya and their correlations with flavonoids. *Antioxidants* **2019**, *8*, 296. [[CrossRef](#)]
47. Sahakitpichan, P.; Mahidol, C.; Disadee, W.; Ruchirawat, S.; Kanchanapoom, T. Unusual glycosides of pyrrole alkaloid and 4'-hydroxyphenylethanamide from leaves of *Moringa oleifera*. *Phytochemistry* **2011**, *72*, 791–795. [[CrossRef](#)] [[PubMed](#)]
48. Karthivashan, G.; Tangestani Fard, M.; Arulselvan, P.; Abas, F.; Fakurazi, S. Identification of bioactive candidate compounds responsible for oxidative challenge from hydro-ethanolic extract of *Moringa oleifera* leaves. *J. Food Sci.* **2013**, *78*, C1368–C1375. [[CrossRef](#)]
49. Guevara, A.P.; Vargas, C.; Sakurai, H.; Fujiwara, Y.; Hashimoto, K.; Maoka, T.; Kozuka, M.; Ito, Y.; Tokuda, H.; Nishino, H. An antitumor promoter from *Moringa oleifera* Lam. *Mutat. Res./Genet. Toxicol. Environ. Mutagen.* **1999**, *440*, 181–188. [[CrossRef](#)] [[PubMed](#)]
50. Abd Rani, N.Z.; Kumolosasi, E.; Jasamai, M.; Jamal, J.A.; Lam, K.W.; Husain, K. In vitro anti-allergic activity of *Moringa oleifera* Lam. extracts and their isolated compounds. *BMC Complement. Altern. Med.* **2019**, *19*, 361. [[CrossRef](#)]
51. Igbo, U.E.; Igoli, J.O.; Onyiriuka, S.O.; Ogukwe, C.E.; Ayuk, A.A.; Gray, A.I. Isolation and characterization of Pyropheophorbide-a from *Moringa oleifera* Lam. *Trop. J. Nat. Prod. Res.* **2019**, *3*, 314–318. [[CrossRef](#)]
52. Luetragoon, T.; Pankla Sranujit, R.; Noysang, C.; Thongsri, Y.; Potup, P.; Suphrom, N.; Nuengchamngong, N.; Usuwanthim, K. Bioactive compounds in *Moringa oleifera* Lam. leaves inhibit the pro-inflammatory mediators in lipopolysaccharide-induced human monocyte-derived macrophages. *Molecules* **2020**, *25*, 191. [[CrossRef](#)]
53. Punia, J.; Singh, R. Antioxidant potential and nutritional content of stem, bark and pod of Drumstick tree (*Moringa oleifera* Lam.) from semi-arid region of Haryana. *J. Indian Chem. Soc.* **2017**, *94*, 103–110.
54. Fantoukh, O.I.; Albadry, M.A.; Parveen, A.; Hawwal, M.F.; Majrashi, T.; Ali, Z.; Khan, S.I.; Chittiboyina, A.G.; Khan, I.A. Isolation, synthesis, and drug interaction potential of secondary metabolites derived from the leaves of miracle tree (*Moringa oleifera*) against CYP3A4 and CYP2D6 isozymes. *Phytomedicine* **2019**, *60*, 153010. [[CrossRef](#)]
55. Oluduro, O.; Aderiyi, B.; Connolly, J.; Akintayo, E.; Famurewa, O. Characterization and antimicrobial activity of 4-([beta]-d-glucopyranosyl-1 [arrow right] 4-[alpha]-l-rhamnopyranosyloxy)-benzyl thiocarboxamide; a novel bioactive compound from *Moringa oleifera* seed extract. *Folia Microbiol.* **2010**, *55*, 422. [[CrossRef](#)]
56. Li, F.-H.; Wang, H.-Q.; Su, X.-M.; Li, C.-K.; Li, B.-M.; Chen, R.-Y.; Kang, J. Constituents isolated from n-butanol extract of leaves of *Moringa oleifera*. *Zhongguo Zhong Yao Za Zhi/Zhongguo Zhongyao Zazhi/China J. Chin. Mater. Medica* **2018**, *43*, 114–118.
57. Sashidhara, K.V.; Singh, S.P.; Kant, R.; Maulik, P.R.; Sarkar, J.; Kanojiya, S.; Kumar, K.R. Cytotoxic cycloartane triterpene and rare isomeric bisclerodane diterpenes from the leaves of *Polyalthia longifolia* var. *pendula*. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 5767–5771. [[CrossRef](#)]
58. Khalid, S.; Arshad, M.; Raza, K.; Mahmood, S.; Siddique, F.; Aziz, N.; Khan, S.; Khalid, W.; AL-Farga, A.; Aqlan, F. Assessment of hepatoprotective, nephroprotective efficacy, and antioxidative potential of *Moringa oleifera* leaf powder and ethanolic extract against PCOS-induced female albino mice (*Mus Musculus*). *Food Sci. Nutr.* **2023**, *11*, 7206–7217. [[CrossRef](#)]
59. Al-Malki, A.L.; El Rabey, H.A. The antidiabetic effect of low doses of *Moringa oleifera* Lam. seeds on streptozotocin induced diabetes and diabetic nephropathy in male rats. *BioMed Res. Int.* **2015**, *2015*, 381040. [[CrossRef](#)]
60. Gupta, R.; Mathur, M.; Bajaj, V.K.; Katariya, P.; Yadav, S.; Kamal, R.; Gupta, R.S. Evaluation of antidiabetic and antioxidant activity of *Moringa oleifera* in experimental diabetes. *J. Diabetes* **2012**, *4*, 164–171. [[CrossRef](#)]
61. Chen, G.-L.; Xu, Y.-B.; Wu, J.-L.; Li, N.; Guo, M.-Q. Hypoglycemic and hypolipidemic effects of *Moringa oleifera* leaves and their functional chemical constituents. *Food Chem.* **2020**, *333*, 127478. [[CrossRef](#)]
62. Vasanth, K.; Minakshi, G.C.; Velu, K.; Priya, T.; Kumar, R.M.; Kaliappan, I.; Dubey, G.P. Anti-adipogenic β -sitosterol and lupeol from *Moringa oleifera* suppress adipocyte differentiation through regulation of cell cycle progression. *J. Food Biochem.* **2022**, *46*, e14170. [[CrossRef](#)] [[PubMed](#)]
63. Abbas, H.H.; Atiyah, M.M. Anti-fungal activities of aqueous and alcoholic leaf extracts of *Moringa oleifera* Lam. on *Candida albicans* isolated from diabetic foot infections. In *Proceedings of the AIP Conference Proceedings*; AIP Publishing: New York, NY, USA, 2023.
64. Sulaiman, M.R.; Zakaria, Z.; Bujarimin, A.; Somchit, M.; Israf, D.; Moin, S. Evaluation of *Moringa oleifera* aqueous extract for antinociceptive and anti-inflammatory activities in animal models. *Pharm. Biol.* **2008**, *46*, 838–845. [[CrossRef](#)]
65. Ariyani, F.; Amin, I.; Fardiaz, D. Ekstrak Air Daun Sirih (Piper betle Linn) sebagai Antioksidan Alami pada Pengolahan Ikan Patin (*Pangasius hypophthalmus*) Asin Kering. *J. Pascapanen Dan Bioteknologi Kelaut. Dan Perikanan.* **2015**, *10*, 45–59. [[CrossRef](#)]
66. Jung, I.L. Soluble extract from *Moringa oleifera* leaves with a new anticancer activity. *PLoS ONE* **2014**, *9*, e95492. [[CrossRef](#)] [[PubMed](#)]
67. Elsayed, E.A.; Sharaf-Eldin, M.A.; Wadaan, M. In vitro evaluation of cytotoxic activities of essential oil from *Moringa oleifera* seeds on HeLa, HepG2, MCF-7, CACO-2 and L929 cell lines. *Asian Pac. J. Cancer Prev* **2015**, *16*, 4671–4675. [[CrossRef](#)]
68. Nair, S.; Varalakshmi, K. Anticancer, cytotoxic potential of *Moringa oleifera* extracts on HeLa cell line. *J. Nat. Pharm.* **2011**, *2*, 138–142.

69. Do, B.H.; Nguyen, T.P.T.; Ho, N.Q.C.; Le, T.L.; Hoang, N.S.; Doan, C.C. Mitochondria-mediated Caspase-dependent and Caspase-independent apoptosis induced by aqueous extract from *Moringa oleifera* leaves in human melanoma cells. *Mol. Biol. Rep.* **2020**, *47*, 3675–3689. [[CrossRef](#)] [[PubMed](#)]
70. Dodiya, B.; Amin, B.; Kamlaben, S.; Patel, P. Antibacterial activity and phytochemical screening of different parts of *Moringa oleifera* against selected gram positive and gram negative bacteria. *J. Pharm. Chem. Biol. Sci.* **2015**, *3*, 421–425.
71. Abadallah, M.; Ali, M. Antibacterial activity of *Moringa oleifera* leaf extracts against bacteria isolated from patients attending general Sani Abacha specialist hospital damaturu. *J. Allied Pharm. Sci.* **2019**, *1*, 61–66.
72. Brillhante, R.S.N.; Sales, J.A.; de Souza Sampaio, C.M.; Barbosa, F.G.; Paiva, M.d.A.N.; de Melo Guedes, G.M.; de Alencar, L.P.; de Ponte, Y.B.; Bandeira, T.d.J.P.G.; Moreira, J.L.B. *Vibrio* spp. from *Macrobrachium amazonicum* prawn farming are inhibited by *Moringa oleifera* extracts. *Asian Pac. J. Trop. Med.* **2015**, *8*, 919–922. [[CrossRef](#)]
73. Morgan, C.; Opio, C.; Migabo, S. Chemical composition of *Moringa (Moringa oleifera)* root powder solution and effects of *Moringa* root powder on *E. coli* growth in contaminated water. *S. Afr. J. Bot.* **2020**, *129*, 243–248. [[CrossRef](#)]
74. Zahran, E.M.; Mohamad, S.A.; Yahia, R.; Badawi, A.M.; Sayed, A.M.; Abdelmohsen, U.R. Anti-otomycotic potential of nanoparticles of *Moringa oleifera* leaf extract: An integrated in vitro, in silico and phase 0 clinical study. *Food Funct.* **2022**, *13*, 11083–11096. [[CrossRef](#)] [[PubMed](#)]
75. Peixoto, J.R.O.; Silva, G.C.; Costa, R.A.; Vieira, G.H.F.; Fonteles Filho, A.A.; dos Fernandes Vieira, R.H.S. In vitro antibacterial effect of aqueous and ethanolic *Moringa* leaf extracts. *Asian Pac. J. Trop. Med.* **2011**, *4*, 201–204. [[CrossRef](#)] [[PubMed](#)]
76. Sayeed, M.A.; Hossain, M.S.; Chowdhury, M.E.H.; Haque, M. In vitro antimicrobial activity of methanolic extract of *Moringa oleifera* lam. fruits. *J. Pharmacogn. Phytochem.* **2012**, *1*, 94–98.
77. Moyo, B.; Masika, P.J.; Muchenje, V. Antimicrobial activities of *Moringa oleifera* Lam leaf extracts. *Afr. J. Biotechnol.* **2012**, *11*, 2797–2802. [[CrossRef](#)]
78. Kumar, V.; Pandey, N.; Mohan, N.; Singh, R.P. Antibacterial & antioxidant activity of different extract of *Moringa oleifera* Leaves—an in vitro study. *Int. J. Pharm. Sci. Rev. Res.* **2012**, *12*, 89–94.
79. Fouad, E.A.; Elnaga, A.S.A.; Kandil, M.M. Antibacterial efficacy of *Moringa oleifera* leaf extract against pyogenic bacteria isolated from a dromedary camel (*Camelus dromedarius*) abscess. *Vet. World* **2019**, *12*, 802. [[CrossRef](#)]
80. Syeda, A.M.; Riazunnisa, K. Data on GC-MS analysis, in vitro anti-oxidant and anti-microbial activity of the *Catharanthus roseus* and *Moringa oleifera* leaf extracts. *Data Brief* **2020**, *29*, 105258. [[CrossRef](#)] [[PubMed](#)]
81. Aboud, A.S.; Jazar, Z.H.; Mansoor, R.F.; Zboon, H.A. Effect of ethanol and aqueous extract of *Moringa oleifera* on bacteria isolated from wound infection. *Int. J. Sci. Res. Arch.* **2023**, *9*, 941–949. [[CrossRef](#)]
82. Cahyani, D.E.; Rusdi, B.; Mulqie, L. Antibacterial activity and klt-bioautography analysys of ethanol extract of kelor leaves (*Moringa oleifera* L.) against *Staphylococcus aureus* dan *Escherichia coli* Bacteria. *Proc. Bdg. Conf.Ser. Pharm.* **2023**, *3*, 168–176.
83. Doughari, J.; Pukuma, M.; De, N. Antibacterial effects of *Balanites aegyptiaca* L. Drel. and *Moringa oleifera* Lam. on *Salmonella typhi*. *Afr. J. Biotechnol.* **2007**, *6*, 2212–2215. [[CrossRef](#)]
84. Xiong, Y.; Riaz Rajoka, M.S.; Zhang, M.; He, Z. Isolation and identification of two new compounds from the seeds of *Moringa oleifera* and their antiviral and anti-inflammatory activities. *Nat. Prod. Res.* **2022**, *36*, 974–983. [[CrossRef](#)]
85. Lovely, K.A.; Hernandez, C.L.C. Anti-hypertensive effect of *Moringa oleifera* Lam. *Cogent Biol.* **2019**, *5*, 1596526.
86. Ramadhany, E.P.; Ambarawati, I.G.A.D.; Musyaffa, M.R. Effect of 4% and 15% moringa leaf extract gel on gingival wound healing in rats. *Maj. Kedokt. Gigi Indones.* **2022**, *8*, 192–199. [[CrossRef](#)]
87. Oldoni, T.L.C.; Merlin, N.; Bicas, T.C.; Prasnowski, A.; Carpes, S.T.; Ascari, J.; de Alencar, S.M.; Massarioli, A.P.; Bagatini, M.D.; Morales, R. Antihyperglycemic activity of crude extract and isolation of phenolic compounds with antioxidant activity from *Moringa oleifera* Lam. leaves grown in Southern Brazil. *Food Res. Int.* **2021**, *141*, 110082. [[CrossRef](#)]
88. Segwatibe, M.K.; Cosa, S.; Bassey, K. Antioxidant and Antimicrobial Evaluations of *Moringa oleifera* Lam Leaves Extract and Isolated Compounds. *Molecules* **2023**, *28*, 899. [[CrossRef](#)]
89. Hamed, Y.S.; Abdin, M.; Rayan, A.M.; Akhtar, H.M.S.; Zeng, X. Synergistic inhibition of isolated flavonoids from *Moringa oleifera* leaf on α -glucosidase activity. *Lwt* **2021**, *141*, 111081. [[CrossRef](#)]
90. Misra, A.; Srivastava, S.; Srivastava, M. Evaluation of anti diarrheal potential of *Moringa oleifera* (Lam.) leaves. *J. Pharmacogn. Phytochem.* **2014**, *2*, 43–46.
91. Pari, L.; Kumar, N.A. Hepatoprotective activity of *Moringa oleifera* on antitubercular drug-induced liver damage in rats. *J. Med. Food* **2002**, *5*, 171–177. [[CrossRef](#)]
92. Pappas, I.S.; Siomou, S.; Bozinou, E.; Lalas, S.I. *Moringa oleifera* leaves crude aqueous extract down-regulates of BRCA1, mta-1 and oncogenes c-myc and p53 in AsPC-1, MCF-7 and HTC-116 cells. *Food Biosci.* **2021**, *43*, 101221. [[CrossRef](#)]
93. Ibrahim, M.A.; Mohamed, S.R.; Dkhil, M.A.; Thagfan, F.A.; Abdel-Gaber, R.; Soliman, D. The effect of *Moringa oleifera* leaf extracts against urethane-induced lung cancer in rat model. *Environ. Sci. Pollut. Res.* **2023**, *30*, 37280–37294. [[CrossRef](#)] [[PubMed](#)]
94. Panchaware, P.S.; Shekokar, S.S.; Pachpor, A.G. Study of cytotoxic effects of CO₂ extract of shigru (*Moringa oleifera* lam.) Root, in MCF-7 cell line of breast cancer. *World J. Biol. Pharm. Health Sci.* **2023**, *15*, 128–137. [[CrossRef](#)]
95. Krishnamurthy, P.T.; Vardarajalu, A.; Wadhvani, A.; Patel, V. Identification and characterization of a potent anticancer fraction from the leaf extracts of *Moringa oleifera* L. *Indian J. Exp. Biol.* **2015**, *53*, 98–103.

96. Tragulpakseerojn, J.; Yamaguchi, N.; Pamonsinlapatham, P.; Wetwitayaklung, P.; Yoneyama, T.; Ishikawa, N.; Ishibashi, M.; Apirakaramwong, A. Anti-proliferative effect of *Moringa oleifera* Lam (Moringaceae) leaf extract on human colon cancer HCT116 cell line. *Trop. J. Pharm. Res.* **2017**, *16*, 371–378. [[CrossRef](#)]
97. Mohd Fisall, U.F.; Ismail, N.Z.; Adebayo, I.A.; Arsad, H. Dichloromethane fraction of *Moringa oleifera* leaf methanolic extract selectively inhibits breast cancer cells (MCF7) by induction of apoptosis via upregulation of Bax, p53 and caspase 8 expressions. *Mol. Biol. Rep.* **2021**, *48*, 4465–4475. [[CrossRef](#)] [[PubMed](#)]
98. Wisitpongpun, P.; Suphrom, N.; Potup, P.; Nuengchamnon, N.; Calder, P.C.; Usuwanthim, K. In vitro bioassay-guided identification of anticancer properties from *Moringa oleifera* Lam. leaf against the MDA-MB-231 cell line. *Pharmaceuticals* **2020**, *13*, 464. [[CrossRef](#)]
99. Kumar, S.; Verma, P.K.; Shukla, A.; Singh, R.K.; Patel, A.K.; Yadav, L.; Kumar, S.; Kumar, N.; Acharya, A. *Moringa oleifera* L. leaf extract induces cell cycle arrest and mitochondrial apoptosis in Dalton's Lymphoma: An in vitro and in vivo study. *J. Ethnopharmacol.* **2023**, *302*, 115849. [[CrossRef](#)] [[PubMed](#)]
100. Rahman, M.M.; Sheikh, M.M.I.; Sharmin, S.A.; Islam, M.S.; Rahman, M.A.; Rahman, M.M.; Alam, M. Antibacterial activity of leaf juice and extracts of *Moringa oleifera* Lam. against some human pathogenic bacteria. *CMU J. Nat. Sci.* **2009**, *8*, 219.
101. Angestia, W.; Ningrum, V.; Lee, T.L.; Lee, S.-C.; Bakar, A. Antibacterial activities of moringa olifera freeze dried extract on staphylococcus aureus. *J. Dentomaxillofacial Sci.* **2020**, *5*, 154–157. [[CrossRef](#)]
102. Arévalo-Híjar, L.; Aguilar-Luis, M.A.; Caballero-García, S.; Gonzáles-Soto, N.; Valle-Mendoza, D. Antibacterial and cytotoxic effects of *Moringa oleifera* (Moringa) and *Azadirachta indica* (Neem) methanolic extracts against strains of *Enterococcus faecalis*. *Int. J. Dent.* **2018**, *2018*, 1071676. [[CrossRef](#)]
103. Elgamily, H.; Moussa, A.; Elboraey, A.; Hoda, E.-S.; Al-Moghazy, M.; Abdalla, A. Microbiological assessment of *Moringa oleifera* extracts and its incorporation in novel dental remedies against some oral pathogens. *Open Access Maced. J. Med. Sci.* **2016**, *4*, 585. [[CrossRef](#)]
104. Zaffer, M.; Ahmad, S.; Sharma, R.; Mahajan, S.; Gupta, A.; Agnihotri, R.K. Antibacterial activity of bark extracts of *Moringa oleifera* Lam. against some selected bacteria. *Pak. J. Pharm. Sci.* **2014**, *27*, 1857–1862. [[PubMed](#)]
105. Amanze, E.K.; Nwankpa, U.D.; Udekwu, C.E.; Ogbonna, H.N.; Nwokafor, C.V.; Udensi, C.G. Antibacterial activity of *Moringa oleifera* root bark extract against some pathogenic organisms. *Asian J. Immunol.* **2020**, *4*, 21–27.
106. Ichsan, M.; Soraya, C.; Mubarak, Z.; Nur, S.; Gani, B.A. The Potency of *Moringa oleifera* on the Biofilm Formation, Adhesion, and Growth of *Streptococcus Mutants* Based on Incubation Times. *J. Int. Dent. Med. Res.* **2023**, *16*, 943–949.
107. Marrufo, T.; Encarnação, S.; Silva, O.M.D.; Duarte, A.; Neto, F.F.; Barbosa, F.M.; Agostinho, A.B. Chemical characterization and determination of antioxidant and antimicrobial activities of the leaves of *Moringa oleifera*. *Int. Netw. Environ. Manag. Confl.* **2013**, *2*, 1–15.
108. Gulzar, R.A.; Ajitha, H.S. Comparative evaluation of antimicrobial efficacy of *Moringa oleifera* extract and calcium hydroxide against *E. faecalis*. *Int. J. Dent. Oral. Sci.* **2021**, *8*, 2605–2609. [[CrossRef](#)]
109. Jwa, S.-K. Efficacy of *Moringa oleifera* leaf extracts against cariogenic biofilm. *Prev. Nutr. Food Sci.* **2019**, *24*, 308. [[CrossRef](#)] [[PubMed](#)]
110. Soraya, C.; Syafriza, D.; Gani, B.A. Antibacterial effect of *Moringa oleifera* gel to prevent the growth, biofilm formation, and cytotoxicity of *Streptococcus mutans*. *J. Int. Dent. Med. Res.* **2022**, *15*, 1053–1061.
111. Amalunweze, A.; Ezumezu, C. Production of herbal toothpaste using *Moringa* root essential oil extract. *Int. J. Adv. Biochem. Res.* **2022**, *6*, 49–51.
112. Alharbi, A.M.; Alharbi, T.M.; Alqahtani, M.S.; Elfasakhany, F.M.; Afifi, I.K.; Rajeh, M.T.; Fattouh, M.; Kenawi, L.M.M. A Comparative Evaluation of Antibacterial Efficacy of *Moringa oleifera* Leaf Extract, Octenidine Dihydrochloride, and Sodium Hypochlorite as Intracanal Irrigants against *Enterococcus faecalis*: An In Vitro Study. *Int. J. Dent.* **2023**, *2023*, 7690497. [[CrossRef](#)]
113. Rochyani, L. The inhibition of leaf extract *Moringaoleifera* on the formation biofilm bacteria *Enterococcus faecalis*. *DENTA* **2020**, *14*, 44–50. [[CrossRef](#)]
114. Kumar, G.K.; Ramamurthy, S.; Ulaganathan, A.; Varghese, S.; Praveen, A.A.; Saranya, V. *Moringa oleifera* Mouthwash Reinforced with Silver Nanoparticles—Preparation, Characterization and its Efficacy Against Oral Aerobic Microorganisms—In Vitro Study. *Biomed. Pharmacol. J.* **2022**, *15*, 2051–2059. [[CrossRef](#)]
115. Rieuwpassa, I.E.; Ramadany, S.; Achmad, H.; Sitanaya, R.; Lesmana, H.; Djais, A.I.; Sesioria, A.; Inayah, N.H.; Mutmainnah, N. The Effectiveness of *Moringa* Leaf Extract (*Moringa oleifera*) Against *Porphyromonas gingivalis* Bacteria in Periodontitis Cases Through IL-1 Cytokine Analysis. *J. Int. Dent. Med. Res.* **2022**, *15*, 611–617.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Moringa oleifera: A Review of the Pharmacology, Chemical Constituents, and Application for Dental Health

by Meiny Faudah Amin FKG

Submission date: 04-Oct-2024 10:41AM (UTC+0700)

Submission ID: 2425690972

File name: pharmaceuticals-17-00142.pdf (2.66M)

Word count: 13836

Character count: 86153



Review

Moringa oleifera: A Review of the Pharmacology, Chemical Constituents, and Application for Dental Health

Meiny Faudah Amin ^{1,*}, Taufiq Ariwibowo ¹, Salsabila Aqila Putri ² and Dikdik Kurnia ²¹ Department Conservative Dentistry, Faculty of Dentistry, Universitas Trisakti, Jakarta Barat 11440, Indonesia; taufiq@trisakti.ac.id² Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Sumedang 45363, Indonesia; salsabila21021@mail.unpad.ac.id (S.A.P.); dikdik.kurnia@unpad.ac.id (D.K.)

* Correspondence: meiny.faudah@trisakti.ac.id

Abstract: *Moringa oleifera* L., commonly known as Kelor in Indonesia and miracle tree in English, has a rich history of utilization for medicinal, nutritional, and water treatment purposes dating back to ancient times. The plant is renowned for its abundance of vitamins, minerals, and various chemical constituents, making it a valuable resource. Among its notable pharmacological properties are its effectiveness as an anti-diabetic, anti-diarrheal, anti-helminthic, anti-leishmanial, anti-fungal, anti-bacterial, anti-allergic, anti-cancer, anti-inflammatory, and anti-oxidant agent. In this comprehensive review, we delve into the extensive pharmacological applications and phytochemical constituents of *M. oleifera* and its application in dental health.

Keywords: *Moringa oleifera*; pharmacological use; phytochemical constituent



Citation: Amin, M.F.; Ariwibowo, T.; Putri, S.A.; Kurnia, D. *Moringa oleifera*: A Review of the Pharmacology, Chemical Constituents, and Application for Dental Health. *Pharmaceuticals* **2024**, *17*, 142. <https://doi.org/10.3390/ph17010142>

Academic Editor: Domenico Iacopetta

Received: 14 November 2023

Revised: 13 January 2024

Accepted: 16 January 2024

Published: 22 January 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Moringa oleifera L. comes from the Moringaceae family and is commonly known as Kelor in Indonesia, Sahajan in India, and Horseradish tree or Drumstick tree in English. It is also described as a miracle tree due to its nutritional value, diverse functions, and medicinal properties. *M. oleifera* can grow up to 12 m in tropical and subtropical environments. Although it is native to South Asia, the cultivation itself has already spread to the Middle East, Africa, Asia, and other areas. Traditionally, *M. oleifera* has been used in medicine, skincare, breastmilk production, and even food. Almost all parts of *M. oleifera* can be useful. Nowadays, *M. oleifera* is also used for water purification, animal feed, as a bio-stimulant, bio-pesticide, and biomass as biodiesel production in industrial and agricultural processes [1–6]. Table 1 describes the traditional usage of *M. oleifera*.

Table 1. Traditional usage of *M. oleifera*.

Part of Plant	Usage	References
Seed	Skincare, haircare, fertilizer, cure for eye disease, fever, snake bite, headache, bladder, ulcer, gastritis, gout, stimulant, antispasmodic, stomachache, anemia, joint pain, hypertension, water purification.	[2–4]
Leaf	Wound healing, snake bites, stimulation, breast milk production, diarrhea, animal feed, constipation, bronchitis, glandular swelling, rheumatism, influenza, food, malaria, arthritis.	[2–6]
Root	Anticoagulation, wound healing, laxative, diuretic, toothache, cold, sores, asthma, bronchitis, epilepsy, urinary discharge, laxative, antiparalytic, cardiac tonic.	[3–5]
Pod (Fruit)	Diabetic, antipyretic, asthma, spleen, skin tumor, joint pain.	[4,5]
Flower	Stimulant, tonic, cholagogue, cold, inflammation, muscle disease, tumor, cholera.	[4,5]
Bark (Stem)	Heart compilation, fever, eye disease, digestive disorder, animal feed, headache, hypoglycemia, toothache.	[4–6]

As a food and stimulant, *M. oleifera* is known to have an abundance of nutritional value and is comparatively easy to cultivate because of its rapid growth and good adaptability to climate change. Thus, in poor countries, *M. oleifera* is used as a source of proteins, calories, minerals, and vitamins. It has been reported that dry leaves of *M. oleifera* contain more calories, protein, carbohydrate, fiber, vitamin B, calcium, magnesium, phosphorus, potassium, copper, and iron than fresh leaves. Meanwhile, fresh leaves contain more vitamin C and E. Between the leaf, seed, and pod of *M. oleifera*, proteins, vitamin E, and magnesium have been found to be more abundant in the seed [7–9].

Due to many its traditional usages, research has been conducted to prove its ability as medicine. It is reported to have pharmacological properties such as anti-diabetic, anti-diarrheal, anti-helminthic, anti-leishmanial, anti-fungi, anti-bacterial, anti-allergic, anti-cancer, anti-inflammatory, and anti-oxidant. Hastuty and Nitia reported the efficiency of *M. oleifera* leaf extract to raise hemoglobin levels in young girls. They showed a value of 10.83 g/dL before treatment, while after treatment with *M. oleifera*, the hemoglobin levels increased to 12.72 g/dL [10]. Yuliasuti and Kurnia also reported the effect of *M. oleifera* on hemoglobin levels in anemic pregnant women. The result showed a significant difference, where before treatment, the respondents showed hemoglobin levels about 10.2 g/dL, and after treatment these increased to 10.8 g/dL ($p = 0.003 < 0.05$) [11].

Dental health has been a concern for researchers to this day. The various infections that can occur in the teeth cause a decline in health. Dental infections occur due to the growth of various kinds of microbes in the dental and oral area. Among these are odontogenic infections and periradicular periodontitis that occur in the root canal system caused by anaerobic bacteria such as *Porphyromonas gingivalis*, *Enterococcus faecalis*, and *Candida albicans* [12–14]. *E. faecalis* is reported to infect root canals up to 30–80% [15]. In addition, based on polymerase chain reaction (PCR) analysis, the bacteria *Tannerella forsythia*, *Treponema denticola*, *Dialister pneumosintes*, and *Prevotella tanneriae* were also reported to infect root canals with high prevalence [16]. These infections occur due to biofilm formation by microbes on the tooth area [17]. The use of antibiotics is a very useful treatment due to their effectiveness, low cost, and compatibility. However, resistance to antibiotic agents by microbes has been identified. Gram-negative bacteria have been reported to be resistant to beta-lactam antibiotics due to an enzyme that can open the ring in the beta-lactam structure, thus inactivating the action of the drug [18].

Therefore, natural product drug discovery research is of particular interest to researchers as a natural antibacterial agent. The main parameters in determining antibacterial activity are the inhibition zone value, minimum inhibition concentration (MIC) as a reference for the minimum concentration that can inhibit bacterial growth, and minimum bactericidal concentration (MBC) as a reference for the minimum concentration needed to kill a microorganism [19]. Based on the bioactivity and phytochemicals contained in *M. oleifera*, this plant has become one of the natural sources for dental disease treatment. *M. oleifera* seed extract was reported to provide MIC and antibiofilm values against *P. gingivalis* of 12.5 mg/mL and 6.25 mg/mL, respectively [20]. *M. oleifera* nanosuspension can inhibit *Aggregatibacter actinomycetemcomitans*, *P. gingivalis*, *Prevotella intermedia*, *Fusobacterium nucleatum* with an MIC and MBC of 25% and 12.5%, respectively [21]. Based on this description, this review will explain the bioactivity contained in *M. oleifera* and describe the role of the plant for dental health and the chemical components contained therein.

2. Phytochemical Constituent

The pharmacological effects of *M. oleifera* are influenced by its phytochemical components. Previous studies have reported that there are several groups of compounds that are unique to each part of *M. oleifera*. The flowers are known to contain flavonoids, alkaloids, sucrose, and amino acids such as kaempferitrin, isoquercitrin, and rhamnetin. Furthermore, the stem contains alkaloid compounds such as moringinine and moringin, octacosanoic acid, β -sitosterol, and 4-hydroxymellein. The seed contains high contents of 4-(α -l-rhamnosyloxy) phenylacetone nitrile, benzylglucosinolate, 4-(α -l-rhamnosyloxy) benzylisothiocyanate, O-ethyl-4-

(α -l-rhamnosyloxy) benzyl, and 4-(α -l-rhamnopyranosyloxy)-benzylglucosinolate carbamate, while the fruit contains cytokines. In addition, the whole pods were specific for *O*-[2'-hydroxy-3'-(2''-heptenyloxy)]-propyl undecanoate, methyl-*p*-hydroxybenzoate, thiocarbamates, isothiocyanate, nitrile, and *O*-ethyl-4-[(α -l-rhamnosyloxy)-benzyl] carbamate [22]. The seeds of *M. oleifera* contain total flavonoids 144.07 mg/kg, total polyphenols 145.16 mg/100 g, and proanthocyanidines 140.49 mg/kg. In addition, the oil of *M. oleifera* contains 18.24 mg rutin equivalent/g (total flavonoids), 37.94 mg ascorbic acid equivalent/g (total antioxidant capacity), and 40.17 mg GA equivalent/g (total phenols). Based on this description, the following are some of the structures of phytochemical components contained in *M. oleifera* [23].

2.1. Phenolic

Niazirin (1) was obtained through an ethanol and butanol extraction of the seeds and leaves of *M. oleifera*. It was reported to inhibit α -glucosidase inhibitor with an IC_{50} value of 382.2 μ M. [24–28]. Caffeoylquinic acid (2), 4-*O*-caffeoylquinic acid (3), 4-*O*-(3'-*O*- α -D-glucopyranosyl)-caffeoylquinic acid (4), 4-*O*-(4'-*O*- α -D-glucopyranosyl)-caffeoylquinic acid (5), 4-*O*- β -D-glucopyranoside benzoic acid (6), 5-*O*-caffeoylquinic acid (7), benzaldehyde 4-*O*- α -L-rhamnopyranoside (8), chlorogenic acid (9), methyl caffeoylquininate (10), methyl 4-caffeoylquininate (11), and 3,4-dihydroxybenzoic acid (12) could be obtained through an ethyl acetate and butanol extraction of *M. oleifera* leaves. The structures of the compounds are shown in Figure 1 [24–28].




Figure 1. Phenolic compounds in ethanol and butanol extracts of seeds and leaves of *M. oleifera*.

Other phenolic compounds that could be isolated from various parts of *M. oleifera* were caffeic acid (13), gallic acid (14), *p*-coumaric (15), and vanillin (16). Cryptochlorogenic acid (17) also could be obtained from *M. oleifera*, and it was also reported to have anticancer activity against MCF-7 with an IC_{50} value of 20.8 M. The structures are shown in Figure 2 [28–30].




Figure 2. Phenolic compounds of other parts of *M. oleifera*.

2.2. Glucosinolate

Glucosinolate compounds, as shown in Figure 3, could be isolated from the ethanol extracts of seeds of *M. oleifera*. These include the following compounds: 4-(3'-O-acetyl- α -L-rhamnosyloxy) benzyl isothiocyanate (18), 4-(α -L-rhamnopyranosyloxy)-benzylglucosinolate (19), 4-(α -L-rhamnosyl) benzyl ethyl ester (20), moringaside C (21), moringaside E (22), moringaside F (23), moringaside G (24), moringin (25), niazimicin (26), and glucomoringin (27). Furthermore, compound 23 exhibited α -glucosidase inhibitory activity with an IC_{50} value of 382.8 μ M, meanwhile compound 26 had a reported an anti-adipogenic effect and an anticancer activity against HeLa cells with an IC_{50} value of 9.2 μ g/mL. Meanwhile, compound 28 exhibited anti-allergic properties with IC_{50} values towards β -hexosaminidase and histamine releases of 10.43 and 27.22 μ M, respectively. It is also reported to have antiviral properties against H1N1 with an IC_{50} value of 0.98 μ g/mL [13,15,26,30–37].




Figure 3. Glucosinolate compounds of seed ethanol extract of *M. oleifera*.

Other glucosinolates found in *M. oleifera* were 4-(4'-O-acetyl- α -L-rhamnosyloxy) benzyl isothiocyanate (29), benzyl glucosinolate (30), 4-[(2'-O-acetyl- α -L-rhamnosyloxy) benzyl] isothiocyanate (31), 4-[(3'-O-acetyl- α -L-rhamnosyloxy) benzyl] isothiocyanate (32), niazinin (33), and niazinin B (34). Furthermore, compound 31 and 32 exhibited NO inhibitory activity with IC₅₀ values of 1.67 and 2.66 μ M, respectively, meanwhile compound 33 exhibited antileishmanial properties with an IC₅₀ value of 5.25 mM. The structures are shown in Figure 4 [24,38–41].





Figure 4. Glucosinolate compounds of other parts of *M. oleifera*.

2.3. Flavonoid

The leaves, barks, and seeds of *M. oleifera* contained various flavonoid compounds, as shown in Figure 5. The flavonoids reported were astragalin (35), isoquercitrin (36), kaempferol (37), kaempferol 3-O-glucoside (38), kaempferol acetyl glycoside (39), kaempferol-3-O-(6''-malonyl-glucoside) (40), quercetin (41), quercetin 3-O- β -D-glucopyranoside (42), quercetin-3-acetyl-glucoside (43), quercetin-3-O-(6''-malonyl-glucoside) (44), quercetin-3-O- β -D-(6''-O-3-hydroxy-3-methylglutaryl)-glucoside (45), rutin (46), vitexin (47), and 3,5,6-trihydroxy-2-(2,3,4,5,6-pentahydroxyphenyl)-4Hchromen-4-one (48). Those compounds could be obtained through extraction with methanol, ethanol, butanol, and ethyl acetate. Compounds 35, 36, and 46 were reported to inhibit CYP3A4 and CYP2D6, with IC₅₀ values of 69.5 and 90 μ M for compound 35, whereas compounds 36 and 46 were reported to be CYP3A4 inhibitors with IC₅₀ values of 65.5 and 60 μ M, respectively.

Compounds 37, 41, and 48 were reported to have anti-allergic properties by inhibiting β -hexosaminidase and histamine release, with IC₅₀ values of 29.39 and 46.94 μ M, respectively, for compound 37. Compound 41 exhibited IC₅₀ values of 19.07 and 7.77 μ M, respectively. Compound 48 showed IC₅₀ values of 17.70 and 44.87 μ M, respectively. Furthermore, compound 46 also inhibited α -glucosidase and pancreatic lipase with IC₅₀ values of 40 and 35 μ g/mL, respectively. Compound 47 also exhibited antiviral properties against virus H1N1 with an IC₅₀ value of 3.42 μ g/mL [13,24–27,33,39,42–46].

Apigenin (49), kaempferol-3-O-[methyl-(S)-3-hydroxy-3-methylglutaryl(1 \rightarrow 6)]- β -D-glucopyranoside (50), and multiflorin-B (51) also could be obtained from *M. oleifera* ethanol extracts [42,47,48].



20
Figure 5. Cont.




Figure 5. Flavonoid compounds of leaves, barks, and seeds of *M. oleifera*.

2.4. Fatty Acid

Figure 6 shows the structure of fatty acid compounds from the ethanol, methanol, and ethyl acetate extracts of leaves, seeds, and flowers of *M. oleifera*. The compounds are glycerol-1-(9-octadecanoate) (52), heneicosanoic acid (53), monoacetyl glycerol (54), monacosan-15-one (55), octacosanol (56), oleic acid (57), 3,4-methyleneazelaic acid (58), and triolein acid (59). Compound 57 exhibited anti-allergic properties by inhibiting β -hexosaminidase and histamine release, with IC_{50} values of 53.76 and 56.05 μ M, respectively [40,42,49–53].




Figure 6. Cont.




Figure 6. Fatty acid compounds of leaves, seeds, and flowers of ethanol, methanol, and ethyl acetate extracts of *M. oleifera*.

2.5. Ester

Ethyl geranyl acetate (60), ethyl-*E*-undec-6-enoate (61), methyl heptanoate (62), methyl-4-(α -L-rhamnopyranosyloxy) benzyl carbamate (63), *O*-ethyl-4-(α -L-rhamnosyloxy)benzyl carbamate (64), and 2-formyl-5-methyl-1*H*-pyrrol-1-ylbutanoic acid (65) were ester groups isolated from leaves, flowers, and seeds of ethanol, methanol, and *n*-hexane *M. oleifera* extracts. The structures are shown in Figure 7. Compound 61 exhibited anti-allergic properties by inhibiting β -hexosaminidase and histamine release with IC_{50} values of 82.68 and 82.07 μ M, respectively [42,49,50,53–55].




Figure 7. Ester compounds of leaves, flowers, and seeds of ethanol, methanol, and *n*-hexane extracts of *M. oleifera*.

2.6. Alkaloid

The roots, seeds, and leaves of *M. oleifera* contain alkaloids, as shown in Figure 8. Some of them could be obtained from butanol extraction. The alkaloids contained in *M. oleifera* include the following: marumoside A (66), marumoside B (67), aurantiamide acetate (68), hostine D (69), methyl 4-(α -L-rhamnopyranosyloxy) benzylcarbamate (70), pyrrolemorine A (71), pyrrolemorine B (72), pyrrolemorine C (73), pyrrolemorine D (74), pyrrolemorine E (75), pyrrolemorine F (76), pyrrolemorine G (77), pyrrolemarumine (78), tangutorid E (79), and tangutorid F (80). Compounds 71 and 75 demonstrated notable neuroprotective effects. At a concentration of 0.1 μ M, they effectively mitigated PC12 cell damage caused by oxygen glucose deprivation and concurrently reduced the expression of NF- κ B [42,47,56,57].




Figure 8. Alkaloid compounds of roots, seeds, and leaves of *M. oleifera*.

2.7. Sterol

All parts of *M. oleifera* contain sterol compounds, as shown in Figure 9. The compounds could be isolated from methanol, ethanol, ethyl acetate, and acetone extracts. The following are sterols isolated from various parts of *M. oleifera*: β -sitosterone (81), stigmasterol (82), β -sitosterol-3-O-glucoside (83), β -sitosteryl oleate (84), and 24-methylene-9,19-cyclolanostan-3-ol (85). Compounds 82 and 83 exhibited anti-allergic properties by inhibiting β -hexosaminidase and histamine release with IC_{50} values of 75.92 and 38.27 μ M, respectively, for compound 82; meanwhile, compound 83 only inhibited β -hexosaminidase release with an IC_{50} value of 24.93 μ M. Moreover, compound 82 exhibited anti-inflammatory characteristics by inhibiting caspase 1 and NF- κ B. It also exhibited anti-adipogenic properties by reducing the S and G2/M phases, inhibiting ROS, and enhancing glucose uptake [13,31,37,58–61].




Figure 9. Sterol compounds of *M. oleifera*.

2.8. Terpene

(S) Linalyl- β -D-glucoside (86), (S) linalyl- β -primeveroside (87), lupeol (88), tuberonic acid (89), γ -diosphenol (90), and 2,2,4,4-tetramethyl-6-(1-oxobutyl)-1,3,5-cyclohexanetrione (91) were terpenes isolated from *M. oleifera*. Compound 88 exhibited anti-adipogenic properties by reducing the S and G2/M phases, inhibiting ROS, and enhancing glucose uptake. The structure of the compounds is shown in Figure 10 [52,54,62].




Figure 10. Terpene compounds of *M. oleifera*.

2.9. Other Compounds

The leaf extract of *M. oleifera* contained 4-hydroxyphenylacetonitrile (92), lutein (93), adenosine (94), uridine (95), 3-pyridinecarboxamide (96), 5-hydroxymethyl-2-furaldehyde

(97), 5-hydroxymethyl-2-furancarboxylic acid (98), bis-isothiocyanatomethyl benzene (99), and pyropheophorbide-a (100). Compound 92 exhibited activity to induce the secretion of insulin. Other compounds isolated from *M. oleifera* were L-tryptophan (101), benzyl β -D-glucopyranoside (102), benzyl- β -primeveroside (103), (+)-pinoresinol-4-O- β -D-glucopyranoside (104), isolariciresinol-3a-O- β -D-glucopyranoside (105), lariciresinol-9-O- β -D-glucopyranoside (106), fluoropyrazine (107), (10-hydroxy-1,3-dimethylchrysen-3-yl)-5-hydroxypentan-1-one (108), hexademethylated 3 β ,11 β -dihydroxyfriedelane (109), 6,7-dipropanone-5-hydroxyphenyl-3-methylphenanthrene-1-carboxylic acid (110), (2R)-2-phenylmethoxybutane-1,4-diol (111), (2S)-2-phenylmethoxybutane-1,4-diol (112), 2-hexenyl- β -D-glucopyranoside (113), omoringone (114), 1,3-dibenzyl urea (115), 1-hydroxy-3-phenylpropan-2-yl benzoate (116), 1-octadecene (117), 2,3,4-trihydroxybenzaldehyde (118), 3,4-dihydroxy benzonitrile (119), 3,7,11,15-tetramethyl-2-hexadecen-1-ol (120), 3-hydroxy- β -ionone (121), N-benzyl S-ethyl thioformate (122), benzyl benzylcarbamate (123), methyl-4-hydroxybenzoate (124), and pyrrolezanthine (125). The structures of these compounds are shown in Figure 11.




Figure 11. Cont.




Figure 11. The structures of compounds of leaf extract of *M. oleifera*.

Compound **104** displayed a potent inhibition of CYP3A4, with an IC₅₀ value of 41.5 µg/mL, while compound **105** exhibited CYP3A4 inhibition with an IC₅₀ value of 100 µg/mL. Compound **107** also demonstrated CYP3A4 inhibitory activity, with an IC₅₀ value of 72.5 µg/mL. In addition to their enzyme inhibitory effects, compounds **109** and **110** showcased strong antioxidant properties, as indicated by DPPH IC₅₀ values of 0.475 and 0.671 mg/mL, respectively. Furthermore, compound **122** exhibited significant antibacterial activity, with MIC values of 32 µg/mL against pathogens such as *S. dysenteriae*, *S. boydii*, and *S. aureus* [13,25,30,37,41,43,51,58,63–69].

3. Pharmacological Properties

3.1. Anti-Hemorrhage

Anti-hemorrhage properties in medicine are used to prevent excessive bleeding due to injury or surgery. Excessive bleeding could lead to death. Adeyemi et al. investigated the anti-hemorrhage properties of *M. oleifera* extracts. The experiment was studied by utilizing the venom of *Echis ocellatus*. The result reported that the ethanol extract of *M. oleifera* showed the highest effectiveness in neutralizing hemorrhage, with a dose of 800 mg/kg for 2 mL of 0.22 mg/kg venom. They also investigated the incubation factor and demonstrated its enhanced potency when pre-incubated with venom from *E. ocellatus* [43].

3.2. Anti-Allergic

Allergy is a condition where the immune system in the body mistakenly identifies substances as harmful and triggers reactions that affect various parts of the body. The development of anti-allergy medicine has been evolving to improve treatment and understand allergy mechanisms. Rani et al. evaluated the effectiveness of the anti-allergic properties of the leaves, pods, and seeds of *M. oleifera*. The extracts were macerated with ethanol at 80% and yielded nine compounds from the isolation. The study showed that the extracts of *M. oleifera* could inhibit the early and late phases of allergic reactions. In particular, the leaf extracts could better suppress the release of β-hexosaminidase (IC₅₀ 7.17 µg/mL), IL-4 (IC₅₀ 2.32 µg/mL), and TNF-α (IC₅₀ 1.2 µg/mL) compared to ketotifen fumarate as a positive control. *M. oleifera* seed extract could inhibit histamine release better compared to other extracts and the positive control, with an IC₅₀ value of 5.97 µg/mL. Further study showed that compared to other isolated compounds, glucomoringin (**28**) had a better inhibition against beta-hexosaminidase in the early phase and TNF-α release in the late phase (IC₅₀ 10.43 µg/mL); meanwhile, quercetin (**41**) had a better inhibition against histamine release (IC₅₀ 7.77 µg/mL). In the last allergic phase, β-sitosterol-3-O-glucoside (**83**) showed a better inhibition against IL-4 release compared to other isolated compounds, with an IC₅₀ value of 7.33 µg/mL [50].

3.3. Antimicrobial

Antimicrobial properties of compounds always gain interest due to their crucial role in preventing infectious diseases. In an era where microorganisms keep evolving and show resistance to antimicrobial agents, the development of natural antimicrobial agents has become urgent. Various parts of *M. oleifera* extracts with antibacterial activity were studied against *E. coli* and *S. aureus* using the agar well diffusion method. The study showed that the 80% methanol extract of leaves, pulp, and seed had the best inhibition against *E. coli*. The 70 and 80% methanol extract of flowers showed the same value against *S. aureus*, and the aqueous pulp extract showed a better result against *S. aureus* compared to other extracts [70]. Abadallah and Ali studied the comparison of aqueous and ethanol extracts of *M. oleifera* against several bacteria. The MIC value and zone inhibition of the ethanol extract showed better results compared to the aqueous extract. *Shigella* spp. was the most susceptible to both extracts [71]. The extracts of *M. oleifera* showed potential for antibacterial and anti-fungal properties, as shown in Table 2.

Table 2. Antimicrobial activity of *M. oleifera* against (A) Gram negative bacteria, (B) Gram positive bacteria, and (C) fungi.

<i>M. oleifera</i>	Microorganism	Inhibition Zone (mm)	MIC (mg/mL)	MBC (mg/mL)	References
(A) Gram Negative Bacteria					
Stem methanol extract	<i>Vibrio cholerae</i>	-	2.50	-	[72]
	<i>Vibrio mimicus</i>	-	1.25	-	
Leaves ethanol extract	<i>V. cholerae</i>	-	0.08	-	[72]
	<i>V. mimicus</i>	-	5	-	
Pods ethanol extract	<i>V. cholerae</i>	-	0.31	-	[72]
	<i>V. mimicus</i>	-	2.5	-	
Flower chloroform extract	<i>V. cholerae</i>	-	0.63	-	[72]
	<i>V. mimicus</i>	-	1.25	-	
Ethanol extract	<i>Proteus mirabilis</i>	-	3.75 µg/mL	-	[55]
	<i>Fusarium</i> sp.	12	-	-	
Methanol extract	<i>Burkholderia cepacia</i>	19	-	-	[55]
	<i>Yersinia enterocolitica</i>	19	-	-	
	<i>Proteus vulgaris</i>	15	-	-	
	<i>Escherichia coli</i>	15	-	-	
	<i>Yersinia enterocolitica</i>	15	-	-	
Aqueous extract	<i>Serratia rubidua</i>	15	-	-	[55]
	<i>Salmonella pollum</i>	15	-	-	
	<i>Pullarum</i> sp.	5	-	-	
Root powder extract	<i>P. mirabilis</i>	-	3.75 µg/mL	-	[73]
	<i>E. coli</i>	-	87%	-	
Nanoparticles loaded to extract	<i>Aspergillus niger</i>	55	-	-	[74]
Ethanol extract	<i>Aeromonas caviae</i>	23.8	-	-	[75]
	<i>Vibrio parahaemolyticus</i>	21.9	-	-	
Aqueous extract	<i>Aeromonas caviae</i>	22.3	-	-	[75]
	<i>V. parahaemolyticus</i>	20.7	-	-	
Methanol pod extract	<i>P. aeruginosa</i>	22	-	-	[76]
Acetone extract	<i>E. coli</i>	-	5	5	[77]
	<i>Enterobacter cloacae</i>	-	5	5	
	<i>P. vulgaris</i>	-	5	5	
Leaf ethanol extract	<i>E. coli</i>	18.3	-	-	[78]
Leaf methanol extract	<i>E. coli</i>	19	-	-	[78]
Leaf aqueous extract	<i>E. coli</i>	14	-	-	[78]
Aqueous extract	<i>E. coli</i>	18.25	25	-	[79]
Ethanol extract	<i>E. coli</i>	27.75	390 µg/mL	-	
Aqueous extract	<i>Klebsiella pneumoniae</i>	21.75	50	-	[79]
Ethanol extract	<i>Klebsiella pneumoniae</i>	28.5	780 µg/mL	-	
Aqueous extract	<i>Citrobacter</i> sp.	20.65	50	-	[79]
Ethanol extract	<i>Citrobacter</i> sp.	19.5	390 µg/mL	-	
Aqueous extract	<i>P. vulgaris</i>	14.75	25	-	[79]
Ethanol extract	<i>P. vulgaris</i>	24.75	780 µg/mL	-	
Aqueous extract	<i>P. aeruginosa</i>	17.5	25	-	[79]
Ethanol extract	<i>P. aeruginosa</i>	22.25	780 µg/mL	-	
Aqueous extract	<i>Staphylococcus aureus</i>	20	-	-	[79]
Methanol extract	<i>Staphylococcus aureus</i>	24	-	-	
Aqueous extract	<i>E. coli</i>	18	-	-	[80]
Methanol extract	<i>E. coli</i>	16	-	-	
Methanol extract	<i>Klebsiella</i> spp.	25	-	-	[81]
Ethanol extract	<i>Enterococcus faecalis</i>	27.5	10% (w/v)	-	[82]
Ethanol extract	<i>Salmonella typhi</i>	8	8	8.5	[83]
Chloroform extract	<i>Shigella dysenteriae</i>	-	1500 µg/mL	2000 µg/mL	[31]
Ethanol seed extract	<i>E. coli</i>	16	100	-	[25]
	<i>Shigella flexneri</i>	15	100	-	
(B) Gram Positive Bacteria					
Methanol extract	<i>Aspergillus flavus</i>	12	-	-	[55]
Nanoparticles loaded to extract	<i>A. flavus</i>	55	-	-	[74]
	<i>S. aureus</i>	23.3	-	-	[75]
Ethanol extract	<i>Enterococcus aureus</i>	19.4	-	-	
Aqueous extract	<i>S. aureus</i>	25.4	-	-	[75]
	<i>E. aureus</i>	17.8	-	-	
Acetone extract	<i>S. aureus</i>	-	5	5	[77]
	<i>Micrococcus kristinae</i>	-	0.5	1	
Leaf ethanol extract	<i>Bacillus subtilis</i>	19	-	-	[78]
	<i>S. aureus</i>	21.3	-	-	
Leaf methanol extract	<i>B. subtilis</i>	22	-	-	[78]
	<i>S. aureus</i>	23.6	-	-	
Leaf aqueous extract	<i>B. subtilis</i>	12	-	-	[78]
	<i>S. aureus</i>	18	-	-	
Aqueous extract	<i>Corynebacterium pseudotuberculosis</i>	22.5	25	-	[79]
Ethanol extract	<i>Corynebacterium pseudotuberculosis</i>	25.65	390 µg/mL	-	
Aqueous extract	<i>Corynebacterium ulcerans</i>	25.5	25	-	[79]
Ethanol extract	<i>Corynebacterium ulcerans</i>	30.5	390 µg/mL	-	

Table 2. Cont.

<i>M. oleifera</i>	Microorganism	Inhibition Zone (mm)	MIC (mg/mL)	MBC (mg/mL)	References
Aqueous extract	<i>S. aureus</i>	14.75	50	-	[79]
Ethanol extract		26.75	390 µg/mL	-	
Aqueous extract	<i>B. subtilis</i>	23	-	-	[80]
Methanol extract		23	-	-	
Ethanol extract	<i>Staphylococcus epidermidis</i>	12	-	-	[80]
Ethanol extract	<i>S. aureus</i>	19.5	10% (w/v)	-	[82]
(C) Fungi					
Aqueous extract	<i>Candida albicans</i>	5	-	-	[55]
Ethanol extract	<i>C. albicans</i>	-	718.33 µg/mL	-	[74]
Nanoparticles loaded to extract	<i>C. albicans</i>	75	-	-	[74]
Methanol pod extract	<i>Colletotrichum</i> sp.	14	-	-	[76]
Ethanol extract	<i>C. albicans</i>	1.87 cm	-	-	[63]
Aqueous extract		1.87 cm	-	-	
Ethyl acetate extract	<i>Microsporium gypsum</i>	9.67	1.56	-	[26]
	<i>Rhizopus stolonifer</i>	8.67	6.25	-	
Methanol extract	<i>R. stolonifer</i>	9.66	1.56	-	[26]

Note: - (not tested).

30

The antiviral activities of *M. oleifera* extracts against several viruses are shown in Table 3.

30

Table 3. Antiviral activity of *M. oleifera* against several viruses.

<i>M. oleifera</i>	Viral	IC ₅₀ (µg/mL)	CC ₅₀ (µg/mL)	EC ₅₀ (µg/mL)	References
Leaf extract	SARS-CoV-2 "NRC-03-nhCoV"	52.79	111.54	-	[27]
Crude ethanol extract	SARS-CoV-2	12.29	7277	-	[28]
Seed extract	IAVs	-	-	1.27	[29]
Seed extract	H1N1	0.26	-	-	[84]
Aqueous extract	HSV-1	43.2%	-	-	[30]
	HSV-2	21.4%	-	-	
Leaf ethanol extract	H9	-	100	-	[33]
Methanol extract	HSV-1F	-	724.5	74.8	[34]
	VU-09	-	-	79.6	
Aqueous leaf extract	AqMOL	-	697.8	721.8	[35]
	ACV	-	>30	0.48	

Note: - (not tested).

3.4. Anthelmintic

Parasitic worm infections can infect various parts of the body, which could lead to health issues for the host. This could lead to the economic loss of livestock. To prevent these losses, the development of anthelmintic medicine has gained interest due to parasitic worm that affect not only affect livestock but also human health. Utilizing earthworms 3–5 cm in length and 0.1–0.2 cm in width, Nilani et al. evaluated the anthelmintic properties of the seed oil *M. oleifera*. The seed oil was divided into two concentrations, 25 and 50 mg/mL, they exhibit anthelmintic properties, with paralysis times of 21 and 16 min respectively while the death time 30 and 24 min, respectively. The study also reported that oleic acid (57) at a concentration of 25 mg/mL contained in seed oil showed a paralysis time 23 min and a death time 33 min [36].

3.5. Antihypertensive

Hypertension is a cardiovascular disease that causes sustained blood pressure levels. It could lead to health complications, including heart disease, kidney, and stroke. Randriamboajonvy et al. utilizing spontaneous hypertensive rats (SHR) as experiment model to demonstrate the effect of *M. oleifera* seed oil. The result showed a significant reduction in nocturnal heart rate without a change in diurnal heart rate after ten days of treatment. The use of seed oil in SHR increased the capacity of the left ventricle during diastole, which was substantially lower in SHR rats as in comparison with WKY (con-

trol) rats. Ejection fraction, a measure of systolic ventricular function, was substantially reduced in both SHR groups (control and seed oil-treated) in comparison with to WKY rats. This suggests that seed oil treatment did not have a positive effect on systolic ventricular function in SHR. The increased isovolumic relaxation time, indicative of diastolic function impairment in SHR, was completely reversed by seed oil treatment. *M. oleifera* seed oil treatment also led to a reduction in cardiomyocyte size in SHR seed oil-treated hearts compared to those in SHR control hearts. Furthermore, the study explored the potential involvement of peroxisome proliferator-activated receptor (PPAR) signaling pathways in seed oil's protective effect against cardiac fibrosis in SHR. The expression of PPAR α and PPAR δ in cardiac tissue was assessed, revealing increased staining in the left ventricle of SHR seed oil-treated rats compared to SHR controls. These findings collectively suggest a beneficial impact of *M. oleifera* seed oil on cardiac structure and function in SHR, accompanied by an upregulation of PPAR- α and δ signaling pathways [37].

Acuram et al. studied the antihypertensive properties of methanol and ethyl acetate extracts related to inhibition of angiotensin converting enzyme (ACE), furthermore, blood pressure was also investigated. The hypertension was induced in mice with N $^{\omega}$ -nitro-L-arginine methyl ester (L-name). The result demonstrated that compared to methanol extract, ethyl acetate showed more significant inhibition of ACE and lowering blood pressure on the last day [85].

3.6. Antileishmanial

Infection from the genus Leishmanial affecting health issues in tropical and subtropical regions such as Asia, Africa, America, and Mediterranean. This infection is transmitted from sandflies to humans. Kaur et al. studied the anti-leishmanial properties of *M. oleifera* extract against promastigotes of *Leishmania donovani*. The roots were extracted with 70% ethanol and the leaves were extracted with methanol. The roots ethanolic extract and the leaves' methanolic extract exhibited moderate inhibitory activity, with IC₅₀ values of 83.0 and 47.5 μ g/mL, respectively. Upon fractionation, the methanolic extract of leaves showed enhanced antileishmanial activity, particularly in its ethyl acetate fraction, which displayed increased potency with an IC₅₀ value of 27.5 mg/mL. Niazin was isolated from ethyl acetate fraction gave antileishmanial properties with IC₅₀ value of 5.25 mM [41].

3.7. Wound Healing

Tofiq et al. macerated the leaves of *M. oleifera* with 70% ethanol. The experiment was conducted in 7 groups and observed wound healing properties. The result demonstrated that ointment with 10% concentration of extract formulation showed a better effect, representing less scarring, brighter skin, and more regenerated hair follicles compared to gentamicin ointment. Ramadhany et al. made *M. oleifera* leaves extract by soxhlet with ethanol. The extract was made into 4 and 15% gel and investigated their wound healing properties on gingival wounds. The study analyzes the neutrophils, fibroblasts, angiogenesis, and epithelial thickness for seven days. It resulted in 15% *M. oleifera* gel extract having a better effect in reducing neutrophils, increasing the number fibroblasts and angiogenesis. However, 4% *M. oleifera* gel extract was better at increasing epithelial thickness [86].

3.8. Antioxidant

Antioxidant properties are used to decrease oxidative stress, which could lead to damaging tissues. Antioxidants function as electron donors to free radicals and neutralize them. Thus, made antioxidant properties become one of most researched topics. Antioxidant activities of *M. oleifera* by several bio-assay methods are shown in Table 4.

Table 4. Antioxidant activity of *M. oleifera* by several bio-assay methods.

<i>M. oleifera</i>	Bio-Assay	IC ₅₀	EC ₅₀ (mg/mL)	References	
Roots extract	Xanthine oxidase	16 µL	-	[44]	
Leaf extract		30 µL	-		
Stem bark extract		38 µL	-		
Roots extract	2-deoxyguanosine	40 µL	-	[44]	
Leaf extract		58 µL	-		
Stem bark extract		72 µL	-		
<i>n</i> -Butanol extract	DPPH	92.62%	0.07	[45]	
Ethyl acetate extract		90.27%	0.08		
Petroleum ether extract		-	0.35		
Aqueous extract	ABTS	-	0.44	[45]	
<i>n</i> -Butanol extract		99.46%	0.01		
Ethyl acetate extract		97.49%	0.04		
Crude extract	ABTS	77.82%	-	[45]	
Petroleum ether extract		-	0.18		
Aqueous extract		-	0.29		
<i>n</i> -Butanol extract	Hydroxy radical-scavenging	94.46%	-	[45]	
Ethyl acetate extract		80.68%	-		
Leaf extract		1.87 mg/mL	-		
Leaf extract	FRAP	0.99 mM Fe ²⁺ /g	-	[46]	
Root extract		1.24 mg/mL	-		
Ethyl acetate extract		526.7 µMol	-		
Acetone extract	DPPH	435.7 µMol	-	[87]	
Ethanol extract		0.44 mg/mL	-		
Ethanol extract		Hydroxy peroxide free radical scavenging	0.54 mg/mL		-
Ethanol extract	FRAP		0.25 mg/mL	-	
Ethyl acetate extract	DPPH		71.9 µg/mL	-	
Ethyl acetate extract	ABTS	54.79 µg/mL	-	[89]	

Note: - (not tested).

3.9. Anti-diarrheal

Misra et al. evaluated the anti-diarrheal potential of *M. oleifera*. Leaves of *M. oleifera* were extracted with petroleum ether and then subjected to ethanol for seven days. The animal models were divided into six groups, as control and as doses of extract, and castor oil was used to induce diarrhea. The study showed that the ethanol extract successfully acted as an anti-diarrheal within 52 min, with an extract dose 150 mg/kg, and showed total stools of 0.130 mg [90].

3.10. Hepatoprotective

Pari and Kumar conducted an evaluation of the hepatoprotective properties of an ethanol extract obtained from *Moringa oleifera* leaves in rats with liver damage caused by anti-tubercular medications such as isoniazid (INH), rifampicin (RMP), and pyrazinamide (PZA). This extract had considerable protective effects when administered orally, as indicated by its impact on numerous parameters. This included the serum levels of glutamic pyruvic transaminase (alanine aminotransferase), glutamic oxaloacetic transaminase (aspartate aminotransferase), bilirubin, and alkaline phosphatase, as well as the levels of lipids and lipid peroxidation in the liver [91].

Khalid et al. assessed the potential protective effects of *M. oleifera* leaf powder and a 70% ethanol extract of *M. oleifera* leaves in alleviating liver and kidney dysfunction induced by polycystic ovary syndrome (PCOS) in female albino mice. PCOS was induced by administering intramuscular injections of testosterone enanthate at a dose of 1.0 mg/100 g body weight for a duration of thirty-five days. The study conducted assessments of renal function (RFT), liver function (LFT), and the oxidative stress biomarker malondialdehyde (MDA) in the serum at intervals of 0, 7, and 14 days. The mice that received treatments of *M. oleifera* exhibited significant reductions in the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin, urea, and creatinine compared to the PCOS-induced controls. Conversely,

25
there was a notable increase in the levels of total protein, albumin, globulin, and the albumin/globulin (A/G) ratio. Furthermore, oxidative stress levels exhibited significant reductions in response to treatments, exposure duration, and their combined effect. The findings of this study suggest that both *Moringa oleifera* leaf powder and extract have the potential to reduce oxidative stress and improve renal and hepatic activity in female albino mice with PCOS-induced dysfunction [58].

3.11. Anti-Inflammatory

Inflammation is a recognized physiological reaction that serves to safeguard the body against infections and promote the healing of tissue injuries. However, persistent or chronic inflammation can potentially support the growth of various disorders and diseases associated with inflammation. Sulaiman et al. assessed the anti-inflammatory potential of an *M. oleifera* aqueous extract. The assay was conducted by carrageenan-induced paw edema. The extract was made at different doses and showed inhibitory effects in a dose-dependent manner. At dose 100 mg/kg, after five hours, the inhibition showed a value of 50%. The suggested anti-inflammatory mechanism was the extract which contained flavonoids with an inhibitory action against NF-k [64].

Fard et al. studied the anti-inflammatory potential of an *M. oleifera* extract on macrophages stimulated with lipopolysaccharide (LPS) in RAW264.7 macrophages. The anti-inflammatory properties of ethanol extracts derived from *M. oleifera*'s bioactive leaves were assessed by examining their ability to inhibit nitric oxide (NO) production using the Griess reaction and to modulate the expression of pro-inflammatory mediators in macrophages. The ethanol leaf extract exhibited a significant inhibition of various inflammatory markers, including NO production, as well as prostaglandin E2, TNF- α , IL-6, and IL-1 β secretion. Concurrently, the bioactive extract dose-dependently stimulated the production of IL-10. Furthermore, the ethanol extract effectively suppressed the protein expression of inflammatory markers such as inducible NO synthase, cyclooxygenase-2, and NF-kB p65, also in a dose-dependent manner [65].

Previously, Xu et al. investigated the antioxidant properties of *M. oleifera*, and also investigated its anti-inflammatory properties. The study was conducted by determining the NO production of RAW264.7 macrophages. The study revealed that the leaf extract gave a lower NO production, at 100 μ g/mL, while the seed extract presented higher NO production. It concluded that the leaf extract had better anti-inflammatory properties compared to the seed extract [46].

An ethyl acetate fraction of *M. oleifera* was assessed to have anti-inflammatory potential against LPS-induced macrophages. The study showed that macrophages which were treated with the ethyl acetate fraction exhibited a reduction in the production of pro-inflammatory mediators. This reduction was observed between the mRNA and protein levels. The study findings indicated that the fraction downregulated the mRNA expression of various inflammatory markers, including IL-1, IL-6, TNF- α , PTGS2, NF-kB P50, and RelA. Furthermore, the fraction effectively inhibited the expression of inflammatory mediators such as IL-6, TNF- α , and cyclooxygenase-2. Notably, the fraction effects included the inhibition of I κ B- α phosphorylation and the ability to decrease the expression of nuclear factor NF-kB p65, thereby impeding its nuclear translocation [52].

3.12. Anti-Diabetic

24
One of the traditional usages of *M. oleifera* was as a diabetic medicine. Gupta et al., and Al-Malki and El Rabey studied the proper effects of *M. oleifera* as an anti-diabetic medicine. Pod and seed powders of *M. oleifera* were used in various doses. The animal model used was a streptozotocin-induced diabetic male rat. The parameters used were the determination of IL-6, immunoglobulin A, immunoglobulin G, fasting blood sugar, glycosylated hemoglobin, albumin, potassium, sodium, creatinine, and uric acid. Both studies showed that *M. oleifera* extracts could restore the abnormalities to a slightly normal

level; however, a higher dose was suspected to be more effective. The water consumption of all subject groups also returned to normal after treatment [59,60].

Previously, Hamed et al. examined the antioxidant properties of *M. oleifera* leaf extracts. Furthermore, they also investigated the anti-diabetic activity of purified flavonoids from crude extracts by determining their α -glucosidase inhibitory effects. The results showed that purified flavonoids inhibited α -glucosidase by 54.41% at 100 $\mu\text{g}/\text{mL}$ and 99.01% at 800 $\mu\text{g}/\text{mL}$ in an uncompetitive manner [48]. Chen et al. reported that the ethanol leaf extracts of *M. oleifera* could be used as anti-diabetic medicine. They investigated the activity by determining the α -glucosidase value. The study showed an IC_{50} value of 123 $\mu\text{g}/\text{mL}$ [61].

3.13. Anticancer

Jung evaluated the anticancer properties of *M. oleifera* leaf extracts against A549 human lung cancer cells. The evaluation was conducted by MTT assay, and the changes and apoptotic effects were observed. The observation revealed that *M. oleifera* extract treatment resulted in a dose-dependent downregulation of caspase-3 and an upregulation of cleaved caspase-3, indicating an induction of apoptosis. There was a significant dose-dependent downregulation of Akt, p-IkB, NF-kB, p-Erk, β -catenin, and cyclin D1, all of which play roles in cell survival and proliferation. Treatment with soluble *M. oleifera* extracts for 48 h resulted in a significantly reduced release of reactive oxygen species (ROS) in comparison to the untreated control group. This implies a decrease in oxidative stress. In summary, the study concluded that MOL treatment induced apoptosis, inhibited the growth of tumor cells, and reduced the levels of internal reactive oxygen species (ROS) in human lung cancer cells. These outcomes emphasize the potential of *M. oleifera* leaf extracts as a promising candidate for further research and development in the context of lung cancer therapy [66]. The anticancer activities of *M. oleifera* against several cancer cell types are shown in Table 5.

Table 5. Anticancer activity of *M. oleifera* against several cancer cell types.

<i>M. oleifera</i>	Bio-Assay	IC_{50} ($\mu\text{g}/\text{mL}$)	Other Values	References
Seed essential oil	HeLa	442.8	23.9%	[67,68]
	HepG2	751.9	34.93%	
	MCF-7	226.1	40.48%	
	CACO-2	1000	50.28%	
Aqueous extract	L929	1000	42.99%	[67,68]
	HeLa	70	70 $\mu\text{g}/\text{mL}$	
Aqueous extract	A375	-	36.40%	[69]
Aqueous extract	Bcl-2	-	0.68 to 0.53-fold	[69]
Aqueous extract	Bax	-	2.62-fold increase at the m-RNA level;	[69]
Aqueous extract	MOE activation of Caspase-3/7	-	1.85-fold increase at the protein level	[69]
Aqueous extract	MOE activation of Caspase-9	-	Increase 1.75-fold	[69]
Aqueous extract	MCF-7	100	-	[92]
	HTC116	125	-	
	AsPC-1	240	-	
Leaf extract	Urethane-induced lung cancer in rats	-	Induced in glutathione 3.8 mg/g, superoxide dismutase 900.6 U/g, and malondialdehyde 172 nmol/g	[93]
Leaf extract	Urethane-induced lung cancer in rats	-	Increase 50% EGFR-mRNA, 10.8% improvements of mucin level and the presence of PCNA-positive cells in lung	[93]
CO ₂ root extract	MCF-7	-	Spanning 100 to 500 $\mu\text{g}/\text{mL}$	[94]
<i>n</i> -Hexane extract		180.6	-	[95]
Chloroform extract		190.2	-	
Ethyl acetate extract	Hep-2	40.2	-	[96]
Methanol extract		170.1	-	
Crude extract	HCT116	9.5 (24 h)	-	[96]
Crude extract	CYP3A4	52.50	-	[54]

Table 5. Cont.

<i>M. oleifera</i>	Bio-Assay	IC ₅₀ (µg/mL)	Other Values	References
Chloroform extract	MCF-7	6.25		
Dichloromethane extract	MCF-7	5	1.87-fold increase in p53 expression, 1.47-fold increase in Bax expression 1.05-fold increase in cytochrome C levels, 2.21-fold increase in caspase 8 expression	[97]
Ethyl acetate extract	MDA-MB-231	233.5	Increase 44.2% of late apoptotic cells; increased level of cleaved caspase 3 protein, Bax mRNA, and p53 mRNA; decreased anti-apoptotic Bcl-2 protein	[98]

Note: - (not tested).

Based on the data attained by Do et al., as shown in Table 3, this study demonstrated that *M. oleifera* extract induced apoptosis in A375 cells, as evidenced by chromatin condensation and the externalization of phosphatidylserine (PS), which are characteristic features of apoptotic cell death. The apoptosis process was initiated by the activation of caspase-9 and caspase-3/7, the cleavage of PARP, and the translocation of apoptosis-inducing factor into the nucleus. These findings provide insights into the apoptotic mechanisms triggered by *M. oleifera* extract in A375 cells [69]. Meanwhile, Pappas et al. assessed the gene expression of *M. oleifera* aqueous wild and cultivated leaf extracts against human pancreas cancer cells AsPC-1, MCF-7, and HCT-116 colon cancer cells. The aqueous extract exerted its effects by down-regulating p53 expression in all tested cell lines and by down-regulating c-myc in AsPC-1 cells. Additionally, specific marker genes associated with each cell line, such as BRCA-1 in MCF-7, mta-1 in AsPC-1, and Ki-67 in HTC116 cells, were down-regulated. Furthermore, the survivin (BIRC5) gene, an inhibitor of apoptosis, was down-regulated in all three cell lines, suggesting a shared target mechanism of Moringa constituents across these cell lines [92].

Kumar et al. discovered that an extract of *M. oleifera* leaves demonstrated effective inhibition of Dalton lymphoma (DL) cell proliferation. This inhibition was characterized by alterations in mitochondrial membrane potential ($\Delta\Psi_m$) and noticeable changes in overall cell morphology. Notably, DL cells treated with the extract experienced cell cycle arrest at the G2/M phase and a significant upregulation in the expression of p53 and p21. Furthermore, the treatment resulted in increased levels of pro-apoptotic markers, including Bax, Cytochrome-c (Cyt-c), and caspase-3, while reducing the expression levels of the anti-apoptotic Bcl-2 protein. These changes strongly suggest the induction of apoptosis in DL cells. Mechanistically, the anticancer efficacy of *M. oleifera* extract was attributed to the inactivation of the MEK/ERK-mediated pathway in DL cells. Additionally, it is noteworthy that the inhibition of DL growth by MOML was accompanied by apoptosis induction and improvements in hematological parameters in DL-induced mice [99].

4. Utilization of *M. oleifera* in Dental Health

Research on several bacteria that are pathogenic to dental health has been carried out, such as *Streptococcus mutans*, *Enterococcus faecalis*, *Staphylococcus aureus*, and others. Table 6 shows some data on the antibacterial activity of *M. oleifera* against oral pathogenic bacteria.

Table 6. Antibacterial activity of *M. oleifera* to some oral pathogenic bacteria.

<i>M. oleifera</i>	Microorganism	Inhibition Zone (mm)	MIC (µg/mL)	MBC	References
Ethanol extract	<i>P. aeruginosa</i>	21.21	458	-	[100]
Ethanol extract	<i>S. aureus</i>	20.55	>1	-	[101]
Aqueous extract	<i>S. aureus</i>	12	58.75 mg/mL	-	[100]
Methanol extract	<i>E. faecalis</i>	44.83	-	-	[102]

Table 6. Cont.

<i>M. oleifera</i>	Microorganism	Inhibition Zone (mm)	MIC (µg/mL)	MBC	References
Leaves ethanolic extract	<i>S. aureus</i>	19.25	-	-	[103]
	<i>S. mutans</i>	13	-	-	
Roots ethanolic extract	<i>S. aureus</i>	9.25	-	-	[103]
	<i>S. mutans</i>	10.50	-	-	
Seed ethanolic extract	<i>S. aureus</i>	3.25	-	-	[103]
	<i>S. mutans</i>	4.75	-	-	
Bark ethyl acetate extract	<i>S. aureus</i>	16.33	-	-	[104]
Root bark methanolic extract	<i>S. aureus</i>	19	12.5 mg/mL	-	[105]
Leaf extract	<i>S. mutans</i> biofilm	0.20/(OD 520 nm)	-	-	[106]
Diethyl ether, <i>n</i> -Hexane, and Ethyl acetate extract	<i>S. aureus</i>	-	15.6	-	[107]
Diethyl ether extract	<i>E. faecalis</i>	-	15.6	-	[107]
	<i>S. aureus</i>	-	15.6	-	[107]
Leaf extract	<i>E. faecalis</i>	11.89 (at 100 µg/mL)	-	-	[108]
Leaf extract	<i>E. faecalis</i>	35.5 (at 24 h) 48.83 (at 48 h)	75	-	[102]

Note: - (not tested).

Jwa evaluated the aqueous and ethanol extracts of *M. oleifera* against *S. mutans*, which were found in the cariogenic biofilm of dental caries. Both extracts reduced the bacteria's growth at concentrations of 25 and 6.25 µg/mL, respectively. At the same concentration, heated ethanol extract exhibited inhibitory activity better than non-heated extracts. This study showed that the ethanol extract was more effective than the aqueous extract against *S. mutans* [109]. Soraya et al. investigated the anti-bacterial properties of *M. oleifera* gel in inhibiting the growth of *S. mutans*, which were involved in the pathogenesis of dental caries. After 48 h, it was observed that the 12.5% concentration exhibited the highest effectiveness in reducing *S. mutans* growth. Within 24 h, the 6.25 and 3.125% concentrations displayed remarkable capabilities in suppressing *S. mutans* growth. Notably, the 6.25% concentration showed superior efficacy in reducing the formation of *S. mutans* biofilms. The application of *M. oleifera* gel extract created conditions in which *S. mutans*, a commensal bacterium, struggled to form a biofilm, with inhibition levels surpassing 70%. This was evidenced by the absence of substantial biofilm development. It is worth mentioning that at all tested concentrations, *M. oleifera* exhibited a toxic effect on *S. mutans* cells. The ethanol extract gel of *M. oleifera* demonstrated the ability to curtail both the growth and biofilm formation of *S. mutans* on tooth surfaces while concurrently exerting toxicity on *S. mutans* cells, potentially due to the presence of anti-bacterial compounds [110]. The anti-bacterial properties of herbal toothpaste, formulated with *M. oleifera* root essential oil, were assessed against bacteria commonly associated with tooth plaque, namely *S. mutans* and *S. aureus*. The Muller Hinton agar well diffusion method was used for this evaluation. The findings of this study demonstrated that *S. mutans* exhibited susceptibility to the herbal toothpaste, as indicated by a significant inhibition zone measuring 31 mm [111].

Alharbi et al. examined the antimicrobial efficacy of *M. oleifera* leaf extract, octenidine dihydrochloride (OCT), sodium hypochlorite (NaOCl), and their combinations as an intracanal irrigant against *E. faecalis*. Decoronation and root canal preparation were performed on single-rooted mandibular premolars. After autoclaving, each root specimen was inoculated with *E. faecalis* and incubated at 37 °C for 48 h. Subsequently, based on the irrigation solution used, the specimens were split into six groups: 2.5% NaOCl (Group 1), 0.1% OCT (Group 2), *M. oleifera* leaf extract (Group 3), a combination of *M. oleifera* extract and 1.25% NaOCl (Group 4), a combination of *M. oleifera* extract and OCT (Group 5), and

normal saline (Group 6). Both *M. oleifera* extract and 0.1% OCT demonstrated antibacterial effects against *E. faecalis* comparable to 2.5% NaOCl and could be considered as potential root canal irrigants. Furthermore, combination groups exhibited superior anti-microbial activity compared to individual irrigants [112].

Rochyani investigated the inhibitory potential of *M. oleifera* leaf extract on the biofilm formation of *E. faecalis* bacteria. The experiment was divided into several groups, including a negative control group (CMC solvent 0.1%), a positive control group (ChKM), and four test groups extracts of 20, 40, 60, and 80%, respectively. The results indicate that the *M. oleifera* leaf extract demonstrates a significant inhibitory effect on the biofilm formation of *E. faecalis* bacteria. Notably, the inhibitory effect observed in the 80% extract was found to be substantially greater than that achieved by the positive control group using ChKM [113].

Shanmugapriya et al. investigated the antimicrobial effects of *M. oleifera* extracts on pooled plaque collected from orthodontic patients. To achieve this, *M. oleifera* extracts were prepared through maceration. Subgingival plaque samples were collected, and the microorganisms present were cultured under anaerobic conditions. The microorganisms were subsequently subjected to treatment with the extracts, and their MIC and MBC were determined. Additionally, the cytotoxic effects of the extracts were assessed using a brine shrimp assay. The results of the study revealed that the 5% aqueous extract of *M. oleifera* exhibited a dose-dependent antimicrobial activity against oral anaerobic organisms. Notably, this anti-microbial effect became more pronounced with longer exposure times of the treated samples. Furthermore, in the cytotoxicity assay, the aqueous extract showed superior performance in lower concentrations in comparison to the ethanol extract. This was evident from the higher number of live nauplii observed in the aqueous extract group, indicating its lower cytotoxicity [114].

Sopandani et al. evaluated the antibacterial efficacy of *M. oleifera* extract at various concentrations (25, 50, 75, and 100%) when used as an irrigation solution against *E. faecalis* within the root canal ex vivo. Quantitative polymerase chain reaction (qPCR) was employed to assess the population of *E. faecalis* within the root canal following treatment with *M. oleifera* extract. The results indicated that *M. oleifera* extract solutions at concentrations of 75 and 100% exhibited comparable effectiveness to a 5.25% sodium hypochlorite (NaOCl) solution as a positive control [114].

Rieuwpassa et al. assessed the effectiveness of *M. oleifera* leaf extract in modulating the anti-inflammatory cytokine IL-1 of the bacteria *Porphyromonas gingivalis*, a key contributor to chronic periodontitis. The study revealed a significant variation in IL-1 levels across different observation days. Administration of the extract led to a reduction in pro-inflammatory cytokine IL-1 levels, as evident from the observations on days D0, D1, D3, D5, and D7 in the experimental Wistar rats induced with *Porphyromonas gingivalis* bacteria [115].

Kumar et al. evaluated the antibacterial effectiveness of a 5% *M. oleifera* mouthwash enhanced with silver nanoparticles against oral aerobic microorganisms. The mouthwash was prepared by utilizing a 5% *M. oleifera* aqueous extract for the synthesis of silver nanoparticles. The characterization of the mouthwash was performed through scanning electron microscopy analysis and energy dispersive X-ray analysis. To assess its anti-bacterial properties, the mouthwash was tested against *S. mutans*, *S. aureus*, *E. faecalis*, and *C. albicans* using the agar well diffusion assay. The results indicated that the 5% *Moringa oleifera*-silver nanoparticle mouthwash exhibited a pronounced effect on *S. aureus* and a comparable impact on *S. mutans* [114].

5. Conclusions

M. oleifera has a variety of pharmacological effects, such as anti-hemorrhage, anti-allergic, antimicrobial, anthelmintic, antihypertensive, antileukemia, antioxidant, anti-diabetic, hepatoprotection, anti-inflammatory, and anticancer effects. This plant is effective against dental infections. Antimicrobial research against microbes that cause dental infections has been carried out on the leaves of *M. oleifera* both in aqueous and ethanol extracts. This plant is reported to be active in vitro to inhibit several oral bacteria such as

E. faecalis, *S. mutans*, *P. gingivalis*, *S. aureus*, and *C. albicans*, and has been tested ex vivo. The chemical components contained in *M. oleifera* are phenolics, glucosinolates, flavonoids, fatty acids, esters, alkaloids, sterols, terpenes, and several other compounds. Based on the pharmacological effects and chemical components contained in *M. oleifera*, this plant has the potential to be further developed to produce an antibacterial agent product, especially for dental health. The search for bioactive compounds in *M. oleifera* that have a major role as antibacterials in oral pathogens can be carried out through isolation. Furthermore, both extracts and isolated compounds from *M. oleifera* can be further traced for their activity through in vitro, in vivo, and clinical trials.

Author Contributions: Conceptualization, M.F.A.; methodology, M.F.A.; software, S.A.P.; validation, T.A. and S.A.P.; formal analysis, M.F.A. and T.A.; investigation, T.A.; resources, M.F.A. and S.A.P.; data curation, S.A.P. and D.K.; writing—original draft preparation, M.F.A. and T.A.; writing—review and editing, M.F.A., D.K. and S.A.P.; visualization, S.A.P. and M.F.A.; supervision, M.F.A. and D.K.; project administration, S.A.P. and T.A.; funding acquisition, M.F.A. and T.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The author is grateful to Trisakti University for all research facilities.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Granella, S.J.; Bechlin, T.R.; Christ, D.; Coelho, S.R.M.; de Oliveira Paz, C.H. An approach to recent applications of *Moringa oleifera* in the agricultural and biofuel industries. *S. Afr. J. Bot.* **2021**, *137*, 110–116. [\[CrossRef\]](#)
2. Leone, A.; Spada, A.; Battezzati, A.; Schiraldi, A.; Aristil, J.; Bertoli, S. Cultivation, genetic, ethnopharmacology, phytochemistry and pharmacology of *Moringa oleifera* leaves: An overview. *Int. J. Mol. Sci.* **2015**, *16*, 12791–12835. [\[CrossRef\]](#)
3. Matic, I.; Guidi, A.; Kenzo, M.; Mattei, M.; Galgani, A. Investigation of medicinal plants traditionally used as dietary supplements: A review on *Moringa oleifera*. *J. Public Health Afr.* **2018**, *9*, 191–199. [\[CrossRef\]](#)
4. Mishra, G.; Singh, P.; Verma, R.; Kumar, S.; Srivastav, S.; Jha, K.; Khosa, R. Traditional uses, phytochemistry and pharmacological properties of *Moringa oleifera* plant: An overview. *Der Pharm. Lett.* **2011**, *3*, 141–164.
5. Padayachee, B.; Baijnath, H. An updated comprehensive review of the medicinal, phytochemical and pharmacological properties of *Moringa oleifera*. *S. Afr. J. Bot.* **2020**, *129*, 304–316. [\[CrossRef\]](#)
6. Valdiviéo-Navarro, M.; Martínez-Aguilar, Y.; Mesa-Fleitas, O.; Botello-León, A.; Hurtado, C.B.; Velázquez-Martí, B. Review of *Moringa oleifera* as forage meal (leaves plus stems) intended for the feeding of non-ruminant animals. *Anim. Feed. Sci. Technol.* **2020**, *260*, 114338. [\[CrossRef\]](#)
7. Brilhante, R.S.N.; Sales, J.A.; Pereira, V.S.; Castelo, D.d.S.C.M.; de Aguiar Cordeiro, R.; de Souza Sampaio, C.M.; Paiva, M.d.A.N.; Dos Santos, J.B.F.; Sidrim, J.J.C.; Rocha, M.F.G. Research advances on the multiple uses of *Moringa oleifera*: A sustainable alternative for socially neglected population. *Asian Pac. J. Trop. Med.* **2017**, *10*, 621–630. [\[CrossRef\]](#) [\[PubMed\]](#)
8. Gopalakrishnan, L.; Doriya, K.; Kumar, D.S. *Moringa oleifera*: A review on nutritive importance and its medicinal application. *Food Sci. Hum. Wellness* **2016**, *5*, 49–56. [\[CrossRef\]](#)
9. Trigo, C.; Castello, M.L.; Ortola, M.D.; Garcia-Mares, F.J.; Desamparados Soriano, M. *Moringa oleifera*: An unknown crop in developed countries with great potential for industry and adapted to climate change. *Foods* **2020**, *10*, 31. [\[CrossRef\]](#)
10. Hastuty, Y.D. Ekstrak daun kelor dan efeknya pada kadar hemoglobin remaja putri. *J. Kesehat. Poltekkes Plb.* **2022**, *17*, 121–127. [\[CrossRef\]](#)
11. Yuliasuti, S.; Kurnia, H. Pengaruh pemberian serbuk halus daun kelor (*Moringa oleifera*) terhadap kadar hb ibu hamil trimester iii dengan anemia di wilayah kerja puskesmas mangunreja kab. Tasikmalaya the influence of *Moringa oleifera* fine powder. *Media Inf.* **2021**, *17*, 122–127. [\[CrossRef\]](#)
12. Ferraz, C.C.R.; Henry, M.A.; Hargreaves, K.M.; Diogenes, A. Lipopolysaccharide from *Porphyromonas gingivalis* sensitizes capsaicin-sensitive nociceptors. *J. Endod.* **2011**, *37*, 45–48. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Gao, Y.; Jiang, X.; Lin, D.; Chen, Y.; Tong, Z. The starvation resistance and biofilm formation of *Enterococcus faecalis* in coexistence with *Candida albicans*, *Streptococcus gordonii*, *Actinomyces viscosus*, or *Lactobacillus acidophilus*. *J. Endod.* **2016**, *42*, 1233–1238. [\[CrossRef\]](#) [\[PubMed\]](#)

14. Miranda, T.T.; Vianna, C.R.; Rodrigues, L.; Rosa, C.A.; Corrêa Jr, A. Differential proteinase patterns among *Candida albicans* strains isolated from root canal and lingual dorsum: Possible roles in periapical disease. *J. Endod.* **2015**, *41*, 841–845. [[CrossRef](#)]
15. Salem, A.S.; Tompkins, G.R.; Cathro, P.R. Alkaline tolerance and biofilm formation of Root Canal isolates of *Enterococcus faecalis*: An in Vitro Study. *J. Endod.* **2022**, *48*, 542–547.e544. [[CrossRef](#)] [[PubMed](#)]
16. Gomes, B.P.; Montagner, F.; Jacinto, R.C.; Zaia, A.A.; Ferraz, C.C.R.; Souza-Filho, F.J. Polymerase chain reaction of *Porphyromonas gingivalis*, *Treponema denticola*, and *Tannerella forsythia* in primary endodontic infections. *J. Endod.* **2007**, *33*, 1049–1052. [[CrossRef](#)]
17. Senges, C.; Wrbas, K.-T.; Altenburger, M.; Follo, M.; Spitzmüller, B.; Wittmer, A.; Hellwig, E.; Al-Ahmad, A. Bacterial and *Candida albicans* adhesion on different root canal filling materials and sealers. *J. Endod.* **2011**, *37*, 1247–1252. [[CrossRef](#)]
18. Montagner, F.; Jacinto, R.C.; Signoretti, F.G.C.; de Mattos, V.S.; Grecca, F.S.; de Almeida Gomes, B.P.F. Beta-lactamic resistance profiles in *Porphyromonas*, *Prevotella*, and *Parvimonas* species isolated from acute endodontic infections. *J. Endod.* **2014**, *40*, 339–344. [[CrossRef](#)] [[PubMed](#)]
19. Putri, S.A.; Nur Shadrina, A.A.; Julaha, E.; Kurnia, D. Potential Nevadensin from *Ocimum basilicum* as Antibacterial Agent against *Streptococcus mutans*: In Vitro and In Silico Studies. *Comb. Chem. High Throughput Screen.* **2023**, *26*, 1746–1754. [[CrossRef](#)]
20. Madhloom, F. Antimicrobial Effect of *Moringa oleifera* L. and Red Pomegranate against Clinically Isolated *Porphyromonas gingivalis*: In vitro Study. *Arch. Razi Inst.* **2022**, *77*, 1405. [[CrossRef](#)]
21. Nugraha, A.P.; Triwardhani, A.; Sitalaksmi, R.M.; Ramadhani, N.F.; Luthfi, M.; Ulfa, N.M. Phytochemical, antioxidant, and antibacterial activity of *Moringa oleifera* nanosuspension against peri-implantitis bacteria: An in vitro study. *J. Oral Biol. Craniofacial Res.* **2023**, *13*, 720–726. [[CrossRef](#)] [[PubMed](#)]
22. Bhattacharya, A.; Tiwari, P.; Sahu, P.K.; Kumar, S. A review of the phytochemical and pharmacological characteristics of *Moringa oleifera*. *J. Pharm. Bioallied Sci.* **2018**, *10*, 181.
23. Özcan, M. *Moringa* spp: Composition and bioactive properties. *S. Afr. J. Bot.* **2020**, *129*, 25–31. [[CrossRef](#)]
24. Cheenpracha, S.; Park, E.-J.; Yoshida, W.Y.; Barit, C.; Wall, M.; Pezzuto, J.M.; Chang, L.C. Potential anti-inflammatory phenolic glycosides from the medicinal plant *Moringa oleifera* fruits. *Bioorg. Med. Chem.* **2010**, *18*, 6598–6602. [[CrossRef](#)]
25. Lar, P.; Ojile, E.; Dashe, E.; Oluoma, J. Antibacterial activity on *Moringa oleifera* seed extracts on some gram negative bacterial isolates. *Afr. J. Nat. Sci.* **2011**, *14*, 57–62.
26. Zaffer, M.; Ganie, S.A.; Gulia, S.S.; Yadav, S.S.; Singh, R.; Ganguly, S. Antifungal efficacy of *Moringa oleifera* Lam. *AJPCT* **2015**, *3*, 28–33.
27. El-Meidany, W.M.; Abdel-Gawad, F.K.; Mahmoud, S.H.; Ali, M.A. In vitro antiviral effect of cinnamon oil, *Moringa oleifera* extract, Manuka honey, and *Nigella sativa* oil against SARS-CoV-2 compared to remdesivir. *Bull. Natl. Res. Cent.* **2023**, *47*, 156. [[CrossRef](#)]
28. Allam, O.G.; Kutkat, O.; Gaballah, M.; El-Halawany, A.M.; Mostafa, A.; Shouman, S.; Ali, M.A.; El Farouk, O. Virucidal effect of *Moringa oleifera* against SARS-CoV-2 and Influenza A/H1N1. *Afr. J. Biol. Sci.* **2023**, *19*, 69–78. [[CrossRef](#)]
29. Xiong, Y.; Rajoka, M.S.R.; Mehwish, H.M.; Zhang, M.; Liang, N.; Li, C.; He, Z. Virucidal activity of *Moringa A* from *Moringa oleifera* seeds against Influenza A Viruses by regulating TFEB. *Int. Immunopharmacol.* **2021**, *95*, 107561. [[CrossRef](#)] [[PubMed](#)]
30. Nasr-Eldin, M.A.; Abdelhamid, A.; Baraka, D. Antibiofilm and antiviral potential of leaf extracts from *Moringa oleifera* and rosemary (*Rosmarinus officinalis* Lam.). *Egypt. J. Microbiol.* **2017**, *52*, 129–139. [[CrossRef](#)]
31. Mahbub, K.R.; Hoq, M.M.; Ahmed, M.M.; Sarker, A. In vitro antibacterial activity of *Crescentia cujete* and *Moringa oleifera*. *Bangladesh Res. Publ. J.* **2011**, *5*, 337–343.
32. Effendi, D.N.; Yuliawati, K.M.; Patricia, V.M. Uji Aktivitas Antibakteri Ekstrak Daun Kelor (*Moringa oleifera* L.) Terhadap Bakteri *Staphylococcus epidermidis*. *Proc. Bdg. Conf. Ser. Pharm.* **2023**, *3*, 528–533.
33. Ashraf, M.; Alam, S.S.; Fatima, M.; Altaf, I.; Khan, F.; Afzal, A. Comparative anti-influenza potential of *Moringa oleifera* leaves and amantadine in vitro. *Pak. Postgrad. Med. J.* **2017**, *28*, 127–131. [[CrossRef](#)]
34. Goswami, D.; Mukherjee, P.K.; Kar, A.; Ojha, D.; Roy, S.; Chattopadhyay, D. *Screening of Ethnomedicinal Plants of Diverse Culture for Antiviral Potentials*; NISCAIR-CSIR: New Delhi, India, 2016.
35. Kurokawa, M.; Wadhvani, A.; Kai, H.; Hidaka, M.; Yoshida, H.; Sugita, C.; Watanabe, W.; Matsuno, K.; Hagiwara, A. Activation of cellular immunity in herpes simplex virus type 1-infected mice by the oral administration of aqueous extract of *Moringa oleifera* Lam. leaves. *Phytother. Res.* **2016**, *30*, 797–804. [[CrossRef](#)]
36. Nilani, P.; Pinaka, M.K.; Duraisamy, B.; Dharmodaran, P.; Jeyaprakash, M. Anthelmintic activity of *Moringa oleifera* seed oil-validation of traditional use. *J. Adv. Sci. Res.* **2012**, *3*, 65–66.
37. Randriamboavonjy, J.I.; Loirand, G.; Vaillant, N.; Lauzier, B.; Derbré, S.; Michalet, S.; Pacaud, P.; Tesse, A. Cardiac protective effects of *Moringa oleifera* seeds in spontaneous hypertensive rats. *Am. J. Hypertens.* **2016**, *29*, 873–881. [[CrossRef](#)]
38. Bennett, R.N.; Mellon, F.A.; Foidl, N.; Pratt, J.H.; Dupont, M.S.; Perkins, L.; Kroon, P.A. Profiling glucosinolates and phenolics in vegetative and reproductive tissues of the multi-purpose trees *Moringa oleifera* L. (horseradish tree) and *Moringa stenopetala* L. *J. Agric. Food Chem.* **2003**, *51*, 3546–3553. [[CrossRef](#)]
39. Huang, L.; Yuan, C.; Wang, Y. Bioactivity-guided identification of anti-adipogenic isothiocyanates in the moringa (*Moringa oleifera*) seed and investigation of the structure-activity relationship. *Molecules* **2020**, *25*, 2504. [[CrossRef](#)]
40. Ragasa, C.Y.; Ng, V.A.S.; Shen, C.-C. Chemical constituents of *Moringa oleifera* Lam. seeds. *Int. J. Pharmacogn. Phytochem. Res.* **2016**, *8*, 495–498.
41. Kaur, A.; Kaur, P.K.; Singh, S.; Singh, I.P. Antileishmanial compounds from *Moringa oleifera* Lam. *Z. Für Naturforschung C* **2014**, *69*, 110–116. [[CrossRef](#)]

42. Jiang, M.-Y.; Lu, H.; Pu, X.-Y.; Li, Y.-H.; Tian, K.; Xiong, Y.; Wang, W.; Huang, X.-Z. Laxative Metabolites from the Leaves of *Moringa oleifera*. *J. Agric. Food Chem.* **2020**, *68*, 7850–7860. [[CrossRef](#)] [[PubMed](#)]
43. Adeyemi, S.; Larayetan, R.; Onoja, A.; Ajayi, A.; Yahaya, A.; Ogunmola, O.O.; Adeyi, A.; Chijioko, O. Anti-hemorrhagic activity of ethanol extract of *Moringa oleifera* leaf on envenomed albino rats. *Sci. Afr.* **2021**, *12*, e00742. [[CrossRef](#)]
44. Atawodi, S.E.; Atawodi, J.C.; Idakwo, G.A.; Pfundstein, B.; Haubner, R.; Wurtele, G.; Bartsch, H.; Owen, R.W. Evaluation of the polyphenol content and antioxidant properties of methanol extracts of the leaves, stem, and root barks of *Moringa oleifera* Lam. *J. Med. Food* **2010**, *13*, 710–716. [[CrossRef](#)] [[PubMed](#)]
45. Zhao, B.; Deng, J.; Li, H.; He, Y.; Lan, T.; Wu, D.; Gong, H.; Zhang, Y.; Chen, Z. Optimization of phenolic compound extraction from Chinese *Moringa oleifera* leaves and antioxidant activities. *J. Food Qual.* **2019**, *2019*, 5346279. [[CrossRef](#)]
46. Xu, Y.-B.; Chen, G.-L.; Guo, M.-Q. Antioxidant and anti-inflammatory activities of the crude extracts of *Moringa oleifera* from Kenya and their correlations with flavonoids. *Antioxidants* **2019**, *8*, 296. [[CrossRef](#)]
47. Sahakitpichan, P.; Mahidol, C.; Disadee, W.; Ruchirawat, S.; Kanchanapoom, T. Unusual glycosides of pyrrole alkaloid and 4'-hydroxyphenylethanamide from leaves of *Moringa oleifera*. *Phytochemistry* **2011**, *72*, 791–795. [[CrossRef](#)] [[PubMed](#)]
48. Karthivashan, G.; Tangestani Fard, M.; Arulselvan, P.; Abas, F.; Fakurazi, S. Identification of bioactive candidate compounds responsible for oxidative challenge from hydro-ethanolic extract of *Moringa oleifera* leaves. *J. Food Sci.* **2013**, *78*, C1368–C1375. [[CrossRef](#)]
49. Guevara, A.P.; Vargas, C.; Sakurai, H.; Fujiwara, Y.; Hashimoto, K.; Maoka, T.; Kozuka, M.; Ito, Y.; Tokuda, H.; Nishino, H. An antitumor promoter from *Moringa oleifera* Lam. *Mutat. Res/Genet. Toxicol. Environ. Mutagen.* **1999**, *440*, 181–188. [[CrossRef](#)] [[PubMed](#)]
50. Abd Rani, N.Z.; Kumolosasi, E.; Jasamai, M.; Jamal, J.A.; Lam, K.W.; Husain, K. In vitro anti-allergic activity of *Moringa oleifera* Lam. extracts and their isolated compounds. *BMC Complement. Altern. Med.* **2019**, *19*, 361. [[CrossRef](#)]
51. Igbo, U.E.; Igoli, J.O.; Onyiriuka, S.O.; Ogukwe, C.E.; Ayuk, A.A.; Gray, A.I. Isolation and characterization of Pyropheophorbide-a from *Moringa oleifera* Lam. *Trop. J. Nat. Prod. Res.* **2019**, *3*, 314–318. [[CrossRef](#)]
52. Luetragoon, T.; Pankla Sranujit, R.; Noysang, C.; Thongsri, Y.; Potup, P.; Suphrom, N.; Nuengchamng, N.; Usuwanthim, K. Bioactive compounds in *Moringa oleifera* Lam. leaves inhibit the pro-inflammatory mediators in lipopolysaccharide-induced human monocyte-derived macrophages. *Molecules* **2020**, *25*, 191. [[CrossRef](#)]
53. Punia, J.; Singh, R. Antioxidant potential and nutritional content of stem, bark and pod of Drumstick tree (*Moringa oleifera* Lam.) from semi-arid region of Haryana. *J. Indian Chem. Soc.* **2017**, *94*, 103–110.
54. Fantoukh, O.I.; Albady, M.A.; Parveen, A.; Hawwal, M.F.; Majrashi, T.; Ali, Z.; Khan, S.I.; Chittiboyina, A.G.; Khan, I.A. Isolation, synthesis, and drug interaction potential of secondary metabolites derived from the leaves of miracle tree (*Moringa oleifera*) against CYP3A4 and CYP2D6 isozymes. *Phytomedicine* **2019**, *60*, 153010. [[CrossRef](#)]
55. Oluduro, O.; Aderiyi, B.; Connolly, J.; Akintayo, E.; Famurewa, O. Characterization and antimicrobial activity of 4-([beta]-d-glucopyranosyl-1 [arrow right] 4-[alpha]-l-rhamnopyranosyloxy)-benzyl thiocarboxamide; a novel bioactive compound from *Moringa oleifera* seed extract. *Folia Microbiol.* **2010**, *55*, 422. [[CrossRef](#)]
56. Li, F.-H.; Wang, H.-Q.; Su, X.-M.; Li, C.-K.; Li, B.-M.; Chen, R.-Y.; Kang, J. Constituents isolated from n-butanol extract of leaves of *Moringa oleifera*. *Zhongguo Zhong Yao Za Zhi/Zhongguo Zhongyao Zazhi/China J. Chin. Mater. Medica* **2018**, *43*, 114–118.
57. Sashidhara, K.V.; Singh, S.P.; Kant, R.; Maulik, P.R.; Sarkar, J.; Kanojiya, S.; Kumar, K.R. Cytotoxic cycloartane triterpene and rare isomeric bisclerodane diterpenes from the leaves of *Polyalthia longifolia* var. *pendula*. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 5767–5771. [[CrossRef](#)]
58. Khalid, S.; Arshad, M.; Raza, K.; Mahmood, S.; Siddique, F.; Aziz, N.; Khan, S.; Khalid, W.; AL-Farga, A.; Aqlan, F. Assessment of hepatoprotective, nephroprotective efficacy, and antioxidative potential of *Moringa oleifera* leaf powder and ethanolic extract against PCOS-induced female albino mice (*Mus Musculus*). *Food Sci. Nutr.* **2023**, *11*, 7206–7217. [[CrossRef](#)]
59. Al-Malki, A.L.; El Rabey, H.A. The antidiabetic effect of low doses of *Moringa oleifera* Lam. seeds on streptozotocin induced diabetes and diabetic nephropathy in male rats. *BioMed Res. Int.* **2015**, *2015*, 381040. [[CrossRef](#)]
60. Gupta, R.; Mathur, M.; Bajaj, V.K.; Katariya, P.; Yadav, S.; Kamal, R.; Gupta, R.S. Evaluation of antidiabetic and antioxidant activity of *Moringa oleifera* in experimental diabetes. *J. Diabetes* **2012**, *4*, 164–171. [[CrossRef](#)]
61. Chen, G.-L.; Xu, Y.-B.; Wu, J.-L.; Li, N.; Guo, M.-Q. Hypoglycemic and hypolipidemic effects of *Moringa oleifera* leaves and their functional chemical constituents. *Food Chem.* **2020**, *333*, 127478. [[CrossRef](#)]
62. Vasanth, K.; Minakshi, G.C.; Velu, K.; Priya, T.; Kumar, R.M.; Kaliappan, I.; Dubey, G.P. Anti-adipogenic β -sitosterol and lupeol from *Moringa oleifera* suppress adipocyte differentiation through regulation of cell cycle progression. *J. Food Biochem.* **2022**, *46*, e14170. [[CrossRef](#)] [[PubMed](#)]
63. Abbas, H.H.; Atiyah, M.M. Anti-fungal activities of aqueous and alcoholic leaf extracts of *Moringa oleifera* Lam. on *Candida albicans* isolated from diabetic foot infections. In *Proceedings of the AIP Conference Proceedings*; AIP Publishing: New York, NY, USA, 2023.
64. Sulaiman, M.R.; Zakaria, Z.; Bujarimin, A.; Somchit, M.; Israf, D.; Moin, S. Evaluation of *Moringa oleifera* aqueous extract for antinociceptive and anti-inflammatory activities in animal models. *Pharm. Biol.* **2008**, *46*, 838–845. [[CrossRef](#)]
65. Ariyani, F.; Amin, I.; Fardiaz, D. Ekstrak Air Daun Sirih (Piper betle Linn) sebagai Antioksidan Alami pada Pengolahan Ikan Patin (*Pangasius hypophthalmus*) Asin Kering. *J. Pascapanen Dan Bioteknol. Kelaut. Dan Perikan.* **2015**, *10*, 45–59. [[CrossRef](#)]
66. Jung, I.L. Soluble extract from *Moringa oleifera* leaves with a new anticancer activity. *PLoS ONE* **2014**, *9*, e95492. [[CrossRef](#)] [[PubMed](#)]
67. Elsayed, E.A.; Sharaf-Eldin, M.A.; Wadaan, M. In vitro evaluation of cytotoxic activities of essential oil from *Moringa oleifera* seeds on HeLa, HepG2, MCF-7, CACO-2 and L929 cell lines. *Asian Pac. J. Cancer Prev* **2015**, *16*, 4671–4675. [[CrossRef](#)]

68. Nair, S.; Varalakshmi, K. Anticancer, cytotoxic potential of *Moringa oleifera* extracts on HeLa cell line. *J. Nat. Pharm.* **2011**, *2*, 138–142.
69. Do, B.H.; Nguyen, T.P.T.; Ho, N.Q.C.; Le, T.L.; Hoang, N.S.; Doan, C.C. Mitochondria-mediated Caspase-dependent and Caspase-independent apoptosis induced by aqueous extract from *Moringa oleifera* leaves in human melanoma cells. *Mol. Biol. Rep.* **2020**, *47*, 3675–3689. [[CrossRef](#)] [[PubMed](#)]
70. Dodiya, B.; Amin, B.; Kamlaben, S.; Patel, P. Antibacterial activity and phytochemical screening of different parts of *Moringa oleifera* against selected gram positive and gram negative bacteria. *J. Pharm. Chem. Biol. Sci.* **2015**, *3*, 421–425.
71. Abadallah, M.; Ali, M. Antibacterial activity of *Moringa oleifera* leaf extracts against bacteria isolated from patients attending general Sani Abacha specialist hospital damaturu. *J. Allied Pharm. Sci.* **2019**, *1*, 61–66.
72. Brilhante, R.S.N.; Sales, J.A.; de Souza Sampaio, C.M.; Barbosa, F.G.; Paiva, M.d.A.N.; de Melo Guedes, G.M.; de Alencar, L.P.; de Ponte, Y.B.; Bandeira, T.d.J.P.G.; Moreira, J.L.B. *Vibrio* spp. from Macrobrachium amazonicum prawn farming are inhibited by *Moringa oleifera* extracts. *Asian Pac. J. Trop. Med.* **2015**, *8*, 919–922. [[CrossRef](#)]
73. Morgan, C.; Opio, C.; Migabo, S. Chemical composition of *Moringa (Moringa oleifera)* root powder solution and effects of *Moringa* root powder on *E. coli* growth in contaminated water. *S. Afr. J. Bot.* **2020**, *129*, 243–248. [[CrossRef](#)]
74. Zahran, E.M.; Mohamad, S.A.; Yahia, R.; Badawi, A.M.; Sayed, A.M.; Abdelmohsen, U.R. Anti-otomycotic potential of nanoparticles of *Moringa oleifera* leaf extract: An integrated in vitro, in silico and phase 0 clinical study. *Food Funct.* **2022**, *13*, 11083–11096. [[CrossRef](#)] [[PubMed](#)]
75. Peixoto, J.R.O.; Silva, G.C.; Costa, R.A.; Vieira, G.H.F.; Fonteles Filho, A.A.; dos Fernandes Vieira, R.H.S. In vitro antibacterial effect of aqueous and ethanolic *Moringa* leaf extracts. *Asian Pac. J. Trop. Med.* **2011**, *4*, 201–204. [[CrossRef](#)] [[PubMed](#)]
76. Sayeed, M.A.; Hossain, M.S.; Chowdhury, M.E.H.; Haque, M. In vitro antimicrobial activity of methanolic extract of *Moringa oleifera* lam. fruits. *J. Pharmacogn. Phytochem.* **2012**, *1*, 94–98.
77. Moyo, B.; Masika, P.J.; Muchenje, V. Antimicrobial activities of *Moringa oleifera* Lam leaf extracts. *Afr. J. Biotechnol.* **2012**, *11*, 2797–2802. [[CrossRef](#)]
78. Kumar, V.; Pandey, N.; Mohan, N.; Singh, R.P. Antibacterial & antioxidant activity of different extract of *Moringa oleifera* Leaves—an in vitro study. *Int. J. Pharm. Sci. Rev. Res.* **2012**, *12*, 89–94.
79. Fouad, E.A.; Elnaga, A.S.A.; Kandil, M.M. Antibacterial efficacy of *Moringa oleifera* leaf extract against pyogenic bacteria isolated from a dromedary camel (*Camelus dromedarius*) abscess. *Vet. World* **2019**, *12*, 802. [[CrossRef](#)]
80. Syeda, A.M.; Riazunnisa, K. Data on GC-MS analysis, in vitro anti-oxidant and anti-microbial activity of the *Catharanthus roseus* and *Moringa oleifera* leaf extracts. *Data Brief* **2020**, *29*, 105258. [[CrossRef](#)] [[PubMed](#)]
81. Aboud, A.S.; Jazar, Z.H.; Mansoor, R.F.; Zboon, H.A. Effect of ethanol and aqueous extract of *Moringa oleifera* on bacteria isolated from wound infection. *Int. J. Sci. Res. Arch.* **2023**, *9*, 941–949. [[CrossRef](#)]
82. Cahyani, D.E.; Rusdi, B.; Mulqie, L. Antibacterial activity and klt-bioautography analysys of ethanol extract of kelor leaves (*Moringa oleifera* L.) against *Staphylococcus aureus* dan *Escherichia coli* Bacteria. *Proc. Bdg. Conf.Ser. Pharm.* **2023**, *3*, 168–176.
83. Doughari, J.; Pukuma, M.; De, N. Antibacterial effects of *Balanites aegyptiaca* L. Drel. and *Moringa oleifera* Lam. on *Salmonella typhi*. *Afr. J. Biotechnol.* **2007**, *6*, 2212–2215. [[CrossRef](#)]
84. Xiong, Y.; Riaz Rajoka, M.S.; Zhang, M.; He, Z. Isolation and identification of two new compounds from the seeds of *Moringa oleifera* and their antiviral and anti-inflammatory activities. *Nat. Prod. Res.* **2022**, *36*, 974–983. [[CrossRef](#)]
85. Lovely, K.A.; Hernandez, C.L.C. Anti-hypertensive effect of *Moringa oleifera* Lam. *Cogent Biol.* **2019**, *5*, 1596526.
86. Ramadhany, E.P.; Ambarawati, I.G.A.D.; Musyaffa, M.R. Effect of 4% and 15% moringa leaf extract gel on gingival wound healing in rats. *Maj. Kedokt. Gigi Indones.* **2022**, *8*, 192–199. [[CrossRef](#)]
87. Oldoni, T.L.C.; Merlin, N.; Bicas, T.C.; Prasniewski, A.; Carpes, S.T.; Ascari, J.; de Alencar, S.M.; Massarioli, A.P.; Bagatini, M.D.; Morales, R. Antihyperglycemic activity of crude extract and isolation of phenolic compounds with antioxidant activity from *Moringa oleifera* Lam. leaves grown in Southern Brazil. *Food Res. Int.* **2021**, *141*, 110082. [[CrossRef](#)]
88. Segwatibe, M.K.; Cosa, S.; Bassey, K. Antioxidant and Antimicrobial Evaluations of *Moringa oleifera* Lam Leaves Extract and Isolated Compounds. *Molecules* **2023**, *28*, 899. [[CrossRef](#)]
89. Hamed, Y.S.; Abdin, M.; Rayan, A.M.; Akhtar, H.M.S.; Zeng, X. Synergistic inhibition of isolated flavonoids from *Moringa oleifera* leaf on α -glucosidase activity. *Lwt* **2021**, *141*, 111081. [[CrossRef](#)]
90. Misra, A.; Srivastava, S.; Srivastava, M. Evaluation of anti diarrheal potential of *Moringa oleifera* (Lam.) leaves. *J. Pharmacogn. Phytochem.* **2014**, *2*, 43–46.
91. Pari, L.; Kumar, N.A. Hepatoprotective activity of *Moringa oleifera* on antitubercular drug-induced liver damage in rats. *J. Med. Food* **2002**, *5*, 171–177. [[CrossRef](#)]
92. Pappas, I.S.; Siomou, S.; Bozinou, E.; Lalas, S.I. *Moringa oleifera* leaves crude aqueous extract down-regulates of BRCA1, mta-1 and oncogenes c-myc and p53 in AsPC-1, MCF-7 and HTC-116 cells. *Food Biosci.* **2021**, *43*, 101221. [[CrossRef](#)]
93. Ibrahim, M.A.; Mohamed, S.R.; Dkhil, M.A.; Thagfan, F.A.; Abdel-Gaber, R.; Soliman, D. The effect of *Moringa oleifera* leaf extracts against urethane-induced lung cancer in rat model. *Environ. Sci. Pollut. Res.* **2023**, *30*, 37280–37294. [[CrossRef](#)] [[PubMed](#)]
94. Panchaware, P.S.; Shekokar, S.S.; Pachpor, A.G. Study of cytotoxic effects of CO₂ extract of shigru (*Moringa oleifera* lam.) Root, in MCF-7 cell line of breast cancer. *World J. Biol. Pharm. Health Sci.* **2023**, *15*, 128–137. [[CrossRef](#)]
95. Krishnamurthy, P.T.; Vardarajalu, A.; Wadhvani, A.; Patel, V. Identification and characterization of a potent anticancer fraction from the leaf extracts of *Moringa oleifera* L. *Indian J. Exp. Biol.* **2015**, *53*, 98–103.

96. Tragulpakseerojn, J.; Yamaguchi, N.; Pamonsinlapatham, P.; Wetwitayaklung, P.; Yoneyama, T.; Ishikawa, N.; Ishibashi, M.; Apirakaramwong, A. Anti-proliferative effect of *Moringa oleifera* Lam (Moringaceae) leaf extract on human colon cancer HCT116 cell line. *Trop. J. Pharm. Res.* **2017**, *16*, 371–378. [[CrossRef](#)]
97. Mohd Fisall, U.F.; Ismail, N.Z.; Adebayo, I.A.; Arsad, H. Dichloromethane fraction of *Moringa oleifera* leaf methanolic extract selectively inhibits breast cancer cells (MCF7) by induction of apoptosis via upregulation of Bax, p53 and caspase 8 expressions. *Mol. Biol. Rep.* **2021**, *48*, 4465–4475. [[CrossRef](#)] [[PubMed](#)]
98. Wisitpongpun, P.; Suphrom, N.; Potup, P.; Nuengchamng, N.; Calder, P.C.; Usuwanthim, K. In vitro bioassay-guided identification of anticancer properties from *Moringa oleifera* Lam. leaf against the MDA-MB-231 cell line. *Pharmaceuticals* **2020**, *13*, 464. [[CrossRef](#)]
99. Kumar, S.; Verma, P.K.; Shukla, A.; Singh, R.K.; Patel, A.K.; Yadav, L.; Kumar, S.; Kumar, N.; Acharya, A. *Moringa oleifera* L. leaf extract induces cell cycle arrest and mitochondrial apoptosis in Dalton's Lymphoma: An in vitro and in vivo study. *J. Ethnopharmacol.* **2023**, *302*, 115849. [[CrossRef](#)] [[PubMed](#)]
100. Rahman, M.M.; Sheikh, M.M.I.; Sharmin, S.A.; Islam, M.S.; Rahman, M.A.; Rahman, M.M.; Alam, M. Antibacterial activity of leaf juice and extracts of *Moringa oleifera* Lam. against some human pathogenic bacteria. *CMU J. Nat. Sci.* **2009**, *8*, 219.
101. Angestia, W.; Ningrum, V.; Lee, T.L.; Lee, S.-C.; Bakar, A. Antibacterial activities of moringa oliifera freeze dried extract on staphylococcus aureus. *J. Dentomaxillofacial Sci.* **2020**, *5*, 154–157. [[CrossRef](#)]
102. Arévalo-Híjar, L.; Aguilar-Luis, M.A.; Caballero-García, S.; González-Soto, N.; Valle-Mendoza, D. Antibacterial and cytotoxic effects of *Moringa oleifera* (Moringa) and *Azadirachta indica* (Neem) methanolic extracts against strains of *Enterococcus faecalis*. *Int. J. Dent.* **2018**, *2018*, 1071676. [[CrossRef](#)]
103. Elgamily, H.; Moussa, A.; Elborae, A.; Hoda, E.-S.; Al-Moghazy, M.; Abdalla, A. Microbiological assessment of *Moringa oleifera* extracts and its incorporation in novel dental remedies against some oral pathogens. *Open Access Maced. J. Med. Sci.* **2016**, *4*, 585. [[CrossRef](#)]
104. Zaffer, M.; Ahmad, S.; Sharma, R.; Mahajan, S.; Gupta, A.; Agnihotri, R.K. Antibacterial activity of bark extracts of *Moringa oleifera* Lam. against some selected bacteria. *Pak. J. Pharm. Sci.* **2014**, *27*, 1857–1862. [[PubMed](#)]
105. Amanze, E.K.; Nwankpa, U.D.; Udekwo, C.E.; Ogbonna, H.N.; Nwokafor, C.V.; Udensi, C.G. Antibacterial activity of *Moringa oleifera* root bark extract against some pathogenic organisms. *Asian J. Immunol.* **2020**, *4*, 21–27.
106. Ichsan, M.; Soraya, C.; Mubarak, Z.; Nur, S.; Gani, B.A. The Potency of *Moringa oleifera* on the Biofilm Formation, Adhesion, and Growth of *Streptococcus Mutants* Based on Incubation Times. *J. Int. Dent. Med. Res.* **2023**, *16*, 943–949.
107. Marrufo, T.; Encarnação, S.; Silva, O.M.D.; Duarte, A.; Neto, F.F.; Barbosa, F.M.; Agostinho, A.B. Chemical characterization and determination of antioxidant and antimicrobial activities of the leaves of *Moringa oleifera*. *Int. Netw. Environ. Manag. Confl.* **2013**, *2*, 1–15.
108. Gulzar, R.A.; Ajitha, H.S. Comparative evaluation of antimicrobial efficacy of *Moringa oleifera* extract and calcium hydroxide against *E. faecalis*. *Int. J. Dent. Oral. Sci.* **2021**, *8*, 2605–2609. [[CrossRef](#)]
109. Jwa, S.-K. Efficacy of *Moringa oleifera* leaf extracts against cariogenic biofilm. *Prev. Nutr. Food Sci.* **2019**, *24*, 308. [[CrossRef](#)] [[PubMed](#)]
110. Soraya, C.; Syafriza, D.; Gani, B.A. Antibacterial effect of *Moringa oleifera* gel to prevent the growth, biofilm formation, and cytotoxicity of *Streptococcus mutans*. *J. Int. Dent. Med. Res.* **2022**, *15*, 1053–1061.
111. Amalunweze, A.; Ezumezu, C. Production of herbal toothpaste using *Moringa* root essential oil extract. *Int. J. Adv. Biochem. Res.* **2022**, *6*, 49–51.
112. Alharbi, A.M.; Alharbi, T.M.; Alqahtani, M.S.; Elfasakhany, F.M.; Afifi, I.K.; Rajeh, M.T.; Fattouh, M.; Kenawi, L.M.M. A Comparative Evaluation of Antibacterial Efficacy of *Moringa oleifera* Leaf Extract, Octenidine Dihydrochloride, and Sodium Hypochlorite as Intracanal Irrigants against *Enterococcus faecalis*: An In Vitro Study. *Int. J. Dent.* **2023**, *2023*, 7690497. [[CrossRef](#)]
113. Rochyani, L. The inhibition of leaf extract *Moringaoleifera* on the formation biofilm bacteria *Enterococcus faecalis*. *DENTA* **2020**, *14*, 44–50. [[CrossRef](#)]
114. Kumar, G.K.; Ramamurthy, S.; Ulaganathan, A.; Varghese, S.; Praveen, A.A.; Saranya, V. *Moringa oleifera* Mouthwash Reinforced with Silver Nanoparticles—Preparation, Characterization and its Efficacy Against Oral Aerobic Microorganisms—In Vitro Study. *Biomed. Pharmacol. J.* **2022**, *15*, 2051–2059. [[CrossRef](#)]
115. Rieuwpassa, I.E.; Ramadany, S.; Achmad, H.; Sitanaya, R.; Lesmana, H.; Djais, A.I.; Sesioria, A.; Inayah, N.H.; Mutmainnah, N. The Effectiveness of *Moringa* Leaf Extract (*Moringa oleifera*) Against *Porphyromonas gingivalis* Bacteria in Periodontitis Cases Through IL-1 Cytokine Analysis. *J. Int. Dent. Med. Res.* **2022**, *15*, 611–617.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Moringa oleifera: A Review of the Pharmacology, Chemical Constituents, and Application for Dental Health

ORIGINALITY REPORT

15%

SIMILARITY INDEX

14%

INTERNET SOURCES

14%

PUBLICATIONS

5%

STUDENT PAPERS

PRIMARY SOURCES

1	jrasb.com Internet Source	2%
2	doaj.org Internet Source	2%
3	downloads.hindawi.com Internet Source	1%
4	Ioannis S. Pappas, Stella Siomou, Eleni Bozinou, Stavros I. Lalas. "Moringa oleifera leaves crude aqueous extract down-regulates of BRCA1, mta-1 and oncogenes c-myc and p53 in AsPC-1, MCF-7 and HTC-116cells", Food Bioscience, 2021 Publication	1%
5	vdoc.pub Internet Source	1%
6	Alan Kelbis Oliveira Lima, Lucas Marcelino dos Santos Souza, Guilherme Fonseca Reis, Alberto Gomes Tavares Junior et al. "Synthesis of Silver Nanoparticles Using Extracts from	1%

Different Parts of the Paullinia cupana Kunth Plant: Characterization and In Vitro Antimicrobial Activity", Pharmaceuticals, 2024
Publication

7 Sandeep Kumar, Praveen Kumar Verma, Alok Shukla, Rishi Kant Singh et al. "Moringa oleifera L. leaf extract induces cell cycle arrest and mitochondrial apoptosis in Dalton's Lymphoma: An in vitro and in vivo study", Journal of Ethnopharmacology, 2022
Publication

8 Rocha, L.G.. "A review of natural products with antileishmanial activity", Phytomedicine, 20050615
Publication

9 docksci.com
Internet Source

10 researchonline.ljmu.ac.uk
Internet Source

11 link.springer.com
Internet Source

12 www2.mdpi.com
Internet Source

13 "Anti-Viral Metabolites from Medicinal Plants", Springer Science and Business Media LLC, 2024
Publication

14

www.editorialmanager.in

Internet Source

<1 %

15

T. Pullaiah, Maddi Ramaiah. "Handbook of Research on Herbal Liver Protection - Hepatoprotective Plants", CRC Press, 2021

Publication

<1 %

16

www.science.gov

Internet Source

<1 %

17

Kaushal H. Shah, Manisha J. Oza. "Comprehensive Review of Bioactive and Molecular Aspects of Lam ", Food Reviews International, 2020

Publication

<1 %

18

www.karyailmiah.trisakti.ac.id

Internet Source

<1 %

19

oaji.net

Internet Source

<1 %

20

Qazi Mohammad Sajid Jamal, Varish Ahmad. "Identification of Metabolites from Catharanthus roseus Leaves and Stem Extract, and In Vitro and In Silico Antibacterial Activity against Food Pathogens", Pharmaceuticals, 2024

Publication

<1 %

21

V. Kuete. "Moringa oleifera", Elsevier BV, 2017

Publication

<1 %

22

Leny Heliawati, Seftiana Lestari, Uswatun Hasanah, Dwipa Ajiati, Dikdik Kurnia.
"Phytochemical Profile of Antibacterial Agents from Red Betel Leaf (*Piper crocatum* Ruiz and Pav) against Bacteria in Dental Caries",
Molecules, 2022

Publication

<1 %

23

Joseph I. Randriamboavonjy, Gervaise Loirand, Nathalie Vaillant, Benjamin Lauzier et al. " Cardiac Protective Effects of Seeds in Spontaneous Hypertensive Rats ", *American Journal of Hypertension*, 2016

Publication

<1 %

24

Saurav Ghimire, Lalita Subedi, Namrata Acharya, Bhakta Prasad Gaire. " : A Tree of Life as a Promising Medicinal Plant for Neurodegenerative Diseases ", *Journal of Agricultural and Food Chemistry*, 2021

Publication

<1 %

25

pesquisa.bvsalud.org

Internet Source

<1 %

26

ouci.dntb.gov.ua

Internet Source

<1 %

27

O.I. Adeniran, M.A. Mogale. " In vitro inhibitory effect of selected parts of against the formation of major types of advanced

<1 %

glycation end-products ", Acta Horticulturae,
2021

Publication

28

"Plant and Human Health, Volume 3",
Springer Nature, 2019

Publication

<1 %

29

Marwah M. Alfeqy, Seham S. El-Hawary, Ali M.
El-Halawany, Mohamed A. Rabeh et al.

"Biosynthesis and Characterization of
Aeonium arboreum-Derived Silver
Nanoparticles: Antimicrobial Activity, Biofilm
Inhibition, Antihemolytic Activity, and In Silico
Studies", International Journal of Molecular
Sciences, 2024

Publication

<1 %

30

Rosa Giugliano, Valeria Ferraro, Annalisa
Chianese, Roberta Della Marca et al. "Antiviral
Properties of Moringa oleifera Leaf Extracts
against Respiratory Viruses", Viruses, 2024

Publication

<1 %

Exclude quotes On

Exclude matches < 20 words

Exclude bibliography On